2021-01-24 03:24:42 | INFO | fairseq_cli.generate | Namespace(all_gather_list_size=16384, beam=5, bf16=False, bpe=None, broadcast_buffers=False, bucket_cap_mb=25, checkpoint_suffix='', cpu=False, criterion='cross_entropy', data='../../../data-bin/custom_EMEA/middle_EMEA', data_buffer_size=10, dataset_impl=None, ddp_backend='c10d', decoding_format=None, device_id=0, distributed_backend='nccl', distributed_init_method=None, distributed_no_spawn=False, distributed_port=-1, distributed_rank=0, distributed_world_size=1, distributed_wrapper='DDP', diverse_beam_groups=-1, diverse_beam_strength=0.5, diversity_rate=-1.0, empty_cache_freq=0, eval_bleu=True, eval_bleu_args=None, eval_bleu_detok='space', eval_bleu_detok_args=None, eval_bleu_print_samples=False, eval_bleu_remove_bpe=None, eval_tokenized_bleu=False, fast_stat_sync=False, find_unused_parameters=False, fix_batches_to_gpus=False, force_anneal=None, fp16=True, fp16_init_scale=128, fp16_no_flatten_grads=False, fp16_scale_tolerance=0.0, fp16_scale_window=None, gen_subset='test', iter_decode_eos_penalty=0.0, iter_decode_force_max_iter=False, iter_decode_max_iter=10, iter_decode_with_beam=1, iter_decode_with_external_reranker=False, left_pad_source='True', left_pad_target='False', lenpen=1, load_alignments=False, localsgd_frequency=3, log_format=None, log_interval=100, lr_scheduler='fixed', lr_shrink=0.1, match_source_len=False, max_len_a=0, max_len_b=200, max_sentences=128, max_source_positions=1024, max_target_positions=1024, max_tokens=None, memory_efficient_bf16=False, memory_efficient_fp16=False, min_len=1, min_loss_scale=0.0001, model_overrides='{}', model_parallel_size=1, momentum=0.99, nbest=1, no_beamable_mm=False, no_early_stop=False, no_progress_bar=False, no_repeat_ngram_size=0, no_seed_provided=True, nprocs_per_node=1, num_batch_buckets=0, num_shards=1, num_workers=1, optimizer='nag', path='../checkpoints/EMEA_15/checkpoint_best.pt', prefix_size=0, print_alignment=False, print_step=False, profile=False, quantization_config_path=None, quiet=False, remove_bpe='@@ ', replace_unk=None, required_batch_size_multiple=8, results_path=None, retain_dropout=False, retain_dropout_modules=None, retain_iter_history=False, sacrebleu=False, sampling=False, sampling_topk=-1, sampling_topp=-1.0, score_reference=False, scoring='sacrebleu', seed=1, shard_id=0, skip_invalid_size_inputs_valid_test=False, slowmo_algorithm='LocalSGD', slowmo_momentum=None, source_lang=None, target_lang=None, task='translation', temperature=1.0, tensorboard_logdir='', threshold_loss_scale=None, tokenizer=None, tpu=False, truncate_source=False, unkpen=0, unnormalized=False, upsample_primary=1, user_dir=None, warmup_updates=0, weight_decay=0.0)
2021-01-24 03:24:42 | INFO | fairseq.tasks.translation | [de] dictionary: 42024 types
2021-01-24 03:24:42 | INFO | fairseq.tasks.translation | [en] dictionary: 42024 types
2021-01-24 03:24:42 | INFO | fairseq.data.data_utils | loaded 859 examples from: ../../../data-bin/custom_EMEA/middle_EMEA/test.de-en.de
2021-01-24 03:24:42 | INFO | fairseq.data.data_utils | loaded 859 examples from: ../../../data-bin/custom_EMEA/middle_EMEA/test.de-en.en
2021-01-24 03:24:42 | INFO | fairseq.tasks.translation | ../../../data-bin/custom_EMEA/middle_EMEA test de-en 859 examples
2021-01-24 03:24:42 | INFO | fairseq_cli.generate | loading model(s) from ../checkpoints/EMEA_15/checkpoint_best.pt
S-692	Name und Anschrift des Herstellers , der für die Chargenfreigabe verantwortlich ist
T-692	Name and address of the manufacturer responsible for batch release
H-692	-0.1415547877550125	Name and address of the manufacturer responsible for batch release
D-692	-0.1415547877550125	Name and address of the manufacturer responsible for batch release
P-692	-0.4433 -0.1298 -0.0999 -0.1475 -0.1400 -0.1241 -0.0733 -0.1176 -0.0260 -0.1019 -0.1166 -0.1787
S-392	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-392	4.7 Effects on ability to drive and use machines
H-392	-0.11435195058584213	4.7 Effects on ability to drive and use machines
D-392	-0.11435195058584213	4.7 Effects on ability to drive and use machines
P-392	-0.1843 -0.1428 -0.0496 -0.0898 -0.1216 -0.0263 -0.1301 -0.0474 -0.1720 -0.1370 -0.0999 -0.1714
S-635	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-635	4.7 Effects on ability to drive and use machines
H-635	-0.11435195058584213	4.7 Effects on ability to drive and use machines
D-635	-0.11435195058584213	4.7 Effects on ability to drive and use machines
P-635	-0.1843 -0.1428 -0.0496 -0.0898 -0.1216 -0.0263 -0.1301 -0.0474 -0.1720 -0.1370 -0.0999 -0.1714
S-4	Die empfohlene Dosis von Adenuric beträgt 80 mg einmal täglich .
T-4	The recommended dose of Adenuric is 80 mg once a day .
H-4	-0.23584195971488953	The recommended dose of Adenuric is 80 mg once a day .
D-4	-0.23584195971488953	The recommended dose of Adenuric is 80 mg once a day .
P-4	-0.1555 -0.1283 -0.0719 -0.1304 -0.1434 -0.1631 -0.0598 -0.1140 -0.1324 -0.1333 -0.0446 -1.7497 -0.3315 -0.1183 -0.1474 -0.1500
S-17	Den vollständigen Wortlaut des EPAR für Adenuric finden Sie hier .
T-17	The full EPAR for Adenuric can be found here .
H-17	-0.20346970856189728	The full EPAR for Adenuric can be found here .
D-17	-0.20346970856189728	The full EPAR for Adenuric can be found here .
P-17	-0.2249 -0.1556 -0.0382 -0.0700 -0.1098 -0.1043 -0.1417 -0.0671 -0.1121 -0.9830 -0.1511 -0.2452 -0.1291 -0.3602 -0.1599
S-855	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-855	4.7 Effects on ability to drive and use machines
H-855	-0.11435195058584213	4.7 Effects on ability to drive and use machines
D-855	-0.11435195058584213	4.7 Effects on ability to drive and use machines
P-855	-0.1843 -0.1428 -0.0496 -0.0898 -0.1216 -0.0263 -0.1301 -0.0474 -0.1720 -0.1370 -0.0999 -0.1714
S-378	Gelenkblutung im Frühstadium , Muskelblutungen oder Blutungen im Mund .
T-378	Early haemarthrosis , muscle bleeding or oral bleeding .
H-378	-0.3484300374984741	Early joint haemorrhage , muscle haemorrhage or mouth haemorrhage .
D-378	-0.3484300374984741	Early joint haemorrhage , muscle haemorrhage or mouth haemorrhage .
P-378	-0.0636 -0.2759 -0.5797 -0.1246 -0.0270 -0.2231 -0.1654 -1.2566 -0.6252 -0.1131 -0.0167 -0.6483 -0.7204 -0.9437 -0.4823 -0.1126 -0.0224 -0.2379 -0.1747 -0.1555
S-554	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-554	4.7 Effects on ability to drive and use machines
H-554	-0.11435195058584213	4.7 Effects on ability to drive and use machines
D-554	-0.11435195058584213	4.7 Effects on ability to drive and use machines
P-554	-0.1843 -0.1428 -0.0496 -0.0898 -0.1216 -0.0263 -0.1301 -0.0474 -0.1720 -0.1370 -0.0999 -0.1714
S-459	Gelenkblutung im Frühstadium , Muskelblutungen oder Blutungen im Mund .
T-459	Early haemarthrosis , muscle bleeding or oral bleeding .
H-459	-0.3484300374984741	Early joint haemorrhage , muscle haemorrhage or mouth haemorrhage .
D-459	-0.3484300374984741	Early joint haemorrhage , muscle haemorrhage or mouth haemorrhage .
P-459	-0.0636 -0.2759 -0.5797 -0.1246 -0.0270 -0.2231 -0.1654 -1.2566 -0.6252 -0.1131 -0.0167 -0.6483 -0.7204 -0.9437 -0.4823 -0.1126 -0.0224 -0.2379 -0.1747 -0.1555
S-473	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-473	4.7 Effects on ability to drive and use machines
H-473	-0.11435195058584213	4.7 Effects on ability to drive and use machines
D-473	-0.11435195058584213	4.7 Effects on ability to drive and use machines
P-473	-0.1843 -0.1428 -0.0496 -0.0898 -0.1216 -0.0263 -0.1301 -0.0474 -0.1720 -0.1370 -0.0999 -0.1714
S-311	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-311	4.7 Effects on ability to drive and use machines
H-311	-0.11435195058584213	4.7 Effects on ability to drive and use machines
D-311	-0.11435195058584213	4.7 Effects on ability to drive and use machines
P-311	-0.1843 -0.1428 -0.0496 -0.0898 -0.1216 -0.0263 -0.1301 -0.0474 -0.1720 -0.1370 -0.0999 -0.1714
S-233	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-233	4.7 Effects on ability to drive and use machines
H-233	-0.11435195058584213	4.7 Effects on ability to drive and use machines
D-233	-0.11435195058584213	4.7 Effects on ability to drive and use machines
P-233	-0.1843 -0.1428 -0.0496 -0.0898 -0.1216 -0.0263 -0.1301 -0.0474 -0.1720 -0.1370 -0.0999 -0.1714
S-63	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-63	4.7 Effects on ability to drive and use machines
H-63	-0.11435195058584213	4.7 Effects on ability to drive and use machines
D-63	-0.11435195058584213	4.7 Effects on ability to drive and use machines
P-63	-0.1843 -0.1428 -0.0496 -0.0898 -0.1216 -0.0263 -0.1301 -0.0474 -0.1720 -0.1370 -0.0999 -0.1714
S-297	Gelenkblutung im Frühstadium , Muskelblutungen oder Blutungen im Mund .
T-297	Early haemarthrosis , muscle bleeding or oral bleeding .
H-297	-0.3484300374984741	Early joint haemorrhage , muscle haemorrhage or mouth haemorrhage .
D-297	-0.3484300374984741	Early joint haemorrhage , muscle haemorrhage or mouth haemorrhage .
P-297	-0.0636 -0.2759 -0.5797 -0.1246 -0.0270 -0.2231 -0.1654 -1.2566 -0.6252 -0.1131 -0.0167 -0.6483 -0.7204 -0.9437 -0.4823 -0.1126 -0.0224 -0.2379 -0.1747 -0.1555
S-316	Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-316	Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-316	-0.25522392988204956	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-316	-0.25522392988204956	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-316	-0.1837 -0.1900 -0.3433 -0.0701 -0.1766 -0.1510 -1.6530 -0.0215 -0.6109 -0.0532 -0.1520 -0.0917 -0.1426 -0.1226 -0.1484 -0.1175 -0.0549 -0.1610 -0.4055
S-219	Gelenkblutung im Frühstadium , Muskelblutungen oder Blutungen im Mund .
T-219	Early haemarthrosis , muscle bleeding or oral bleeding .
H-219	-0.3484300374984741	Early joint haemorrhage , muscle haemorrhage or mouth haemorrhage .
D-219	-0.3484300374984741	Early joint haemorrhage , muscle haemorrhage or mouth haemorrhage .
P-219	-0.0636 -0.2759 -0.5797 -0.1246 -0.0270 -0.2231 -0.1654 -1.2566 -0.6252 -0.1131 -0.0167 -0.6483 -0.7204 -0.9437 -0.4823 -0.1126 -0.0224 -0.2379 -0.1747 -0.1555
S-103	Jede Tablette enthält 63 mg Lactose und 16 mg Sucrose .
T-103	Each tablet contains 63 mg lactose anhydrous and 16 mg sucrose .
H-103	-0.1192922592163086	Each tablet contains 63 mg lactose and 16 mg sucrose .
D-103	-0.1192922592163086	Each tablet contains 63 mg lactose and 16 mg sucrose .
P-103	-0.0326 -0.1118 -0.0943 -0.0614 -0.1123 -0.0890 -0.5327 -0.0260 -0.1125 -0.1431 -0.1351 -0.0562 -0.0763 -0.0754 -0.0576 -0.1582 -0.1533
S-93	Ein kleiner Anteil Vitamin D3 wird vor Ausscheidung glukuronidiert .
T-93	A small percentage of vitamin D3 undergoes glucuronidation prior to elimination .
H-93	-0.3721315264701843	A small proportion of vitamin D3 is glucuronised prior to excretion .
D-93	-0.3721315264701843	A small proportion of vitamin D3 is glucuronised prior to excretion .
P-93	-0.1269 -0.0731 -1.7571 -0.1442 -0.1403 -0.0957 -0.1437 -0.1536 -0.1631 -0.2443 -0.3716 -1.2741 -0.8703 -0.7279 -0.1381 -0.4955 -0.0641 -0.1626 -0.1458 -0.1506
S-305	In solchen Fällen wird die Kontaktaufnahme mit einem Hämophilie- Zentrum empfohlen .
T-305	In such cases , it is recommended that a specialised haemophilia centre be contacted .
H-305	-0.34182238578796387	In such cases , contact with a haemophilia centre is recommended .
D-305	-0.34182238578796387	In such cases , contact with a haemophilia centre is recommended .
P-305	-0.8041 -0.5087 -0.3074 -1.1240 -0.6191 -0.1532 -0.1159 -0.3952 -0.0652 -0.1717 -0.2354 -0.3811 -0.1282 -0.1533 -0.1568 -0.1499
S-238	Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-238	Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-238	-0.25522392988204956	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-238	-0.25522392988204956	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-238	-0.1837 -0.1900 -0.3433 -0.0701 -0.1766 -0.1510 -1.6530 -0.0215 -0.6109 -0.0532 -0.1520 -0.0917 -0.1426 -0.1226 -0.1484 -0.1175 -0.0549 -0.1610 -0.4055
S-227	In solchen Fällen wird die Kontaktaufnahme mit einem Hämophilie- Zentrum empfohlen .
T-227	In such cases , it is recommended that a specialised haemophilia centre be contacted .
H-227	-0.34182238578796387	In such cases , contact with a haemophilia centre is recommended .
D-227	-0.34182238578796387	In such cases , contact with a haemophilia centre is recommended .
P-227	-0.8041 -0.5087 -0.3074 -1.1240 -0.6191 -0.1532 -0.1159 -0.3952 -0.0652 -0.1717 -0.2354 -0.3811 -0.1282 -0.1533 -0.1568 -0.1499
S-173	Ein kleiner Anteil Vitamin D3 wird vor Ausscheidung glukuronidiert .
T-173	A small percentage of vitamin D3 undergoes glucuronidation prior to elimination .
H-173	-0.3721315264701843	A small proportion of vitamin D3 is glucuronised prior to excretion .
D-173	-0.3721315264701843	A small proportion of vitamin D3 is glucuronised prior to excretion .
P-173	-0.1269 -0.0731 -1.7571 -0.1442 -0.1403 -0.0957 -0.1437 -0.1536 -0.1631 -0.2443 -0.3716 -1.2741 -0.8703 -0.7279 -0.1381 -0.4955 -0.0641 -0.1626 -0.1458 -0.1506
S-540	Gelenkblutung im Frühstadium , Muskelblutungen oder Blutungen im Mund .
T-540	Early haemarthrosis , muscle bleeding or oral bleeding .
H-540	-0.3484300374984741	Early joint haemorrhage , muscle haemorrhage or mouth haemorrhage .
D-540	-0.3484300374984741	Early joint haemorrhage , muscle haemorrhage or mouth haemorrhage .
P-540	-0.0636 -0.2759 -0.5797 -0.1246 -0.0270 -0.2231 -0.1654 -1.2566 -0.6252 -0.1131 -0.0167 -0.6483 -0.7204 -0.9437 -0.4823 -0.1126 -0.0224 -0.2379 -0.1747 -0.1555
S-621	Gelenkblutung im Frühstadium , Muskelblutungen oder Blutungen im Mund .
T-621	Early haemarthrosis , muscle bleeding or oral bleeding .
H-621	-0.3484300374984741	Early joint haemorrhage , muscle haemorrhage or mouth haemorrhage .
D-621	-0.3484300374984741	Early joint haemorrhage , muscle haemorrhage or mouth haemorrhage .
P-621	-0.0636 -0.2759 -0.5797 -0.1246 -0.0270 -0.2231 -0.1654 -1.2566 -0.6252 -0.1131 -0.0167 -0.6483 -0.7204 -0.9437 -0.4823 -0.1126 -0.0224 -0.2379 -0.1747 -0.1555
S-28	Jede Tablette enthält 62 mg Lactose und 8 mg Sucrose .
T-28	Each tablet contains 62 mg lactose anhydrous and 8 mg sucrose .
H-28	-0.11856985837221146	Each tablet contains 62 mg lactose and 8 mg sucrose .
D-28	-0.11856985837221146	Each tablet contains 62 mg lactose and 8 mg sucrose .
P-28	-0.0363 -0.1133 -0.0922 -0.0641 -0.1392 -0.0790 -0.4878 -0.0272 -0.1136 -0.1484 -0.1294 -0.0572 -0.0788 -0.0759 -0.0592 -0.1600 -0.1541
S-117	Viele dieser Patienten erhielten auch eine Chemotherapie und Kortikosteroide .
T-117	Many of these patients were also receiving chemotherapy and corticosteroids .
H-117	-0.1475197672843933	Many of these patients were also receiving chemotherapy and corticosteroids .
D-117	-0.1475197672843933	Many of these patients were also receiving chemotherapy and corticosteroids .
P-117	-0.1032 -0.1607 -0.1506 -0.0804 -0.5696 -0.0644 -0.3386 -0.1415 -0.0534 -0.0864 -0.1359 -0.1485 -0.1105 -0.0780 -0.1368 -0.1045 -0.0451 -0.1476 -0.1473
S-41	Viele dieser Patienten erhielten auch eine Chemotherapie und Kortikosteroide .
T-41	Many of these patients were also receiving chemotherapy and corticosteroids .
H-41	-0.1475197672843933	Many of these patients were also receiving chemotherapy and corticosteroids .
D-41	-0.1475197672843933	Many of these patients were also receiving chemotherapy and corticosteroids .
P-41	-0.1032 -0.1607 -0.1506 -0.0804 -0.5696 -0.0644 -0.3386 -0.1415 -0.0534 -0.0864 -0.1359 -0.1485 -0.1105 -0.0780 -0.1368 -0.1045 -0.0451 -0.1476 -0.1473
S-127	Bei diesen Patienten sind Urin und Serum-Calcium zu überwachen .
T-127	Urine and serum calcium should be monitored in these patients .
H-127	-0.1979369819164276	Urine and serum calcium should be monitored in these patients .
D-127	-0.1979369819164276	Urine and serum calcium should be monitored in these patients .
P-127	-1.0134 -0.0850 -0.1459 -0.0265 -0.1097 -0.0727 -0.0710 -0.1042 -0.5004 -0.2160 -0.1774 -0.1093 -0.1754 -0.1688 -0.0866 -0.1505 -0.1522
S-51	Bei diesen Patienten sind Urin und Serum-Calcium zu überwachen .
T-51	Urine and serum calcium should be monitored in these patients .
H-51	-0.1979369819164276	Urine and serum calcium should be monitored in these patients .
D-51	-0.1979369819164276	Urine and serum calcium should be monitored in these patients .
P-51	-1.0134 -0.0850 -0.1459 -0.0265 -0.1097 -0.0727 -0.0710 -0.1042 -0.5004 -0.2160 -0.1774 -0.1093 -0.1754 -0.1688 -0.0866 -0.1505 -0.1522
S-739	- wenn Sie allergisch gegen Maus- oder Hamsterprotein sind .
T-739	- if you are allergic to mouse or hamster proteins
H-739	-0.18732251226902008	- if you are allergic to mouse or hamster protein .
D-739	-0.18732251226902008	- if you are allergic to mouse or hamster protein .
P-739	-0.1696 -0.2061 -0.1251 -0.1385 -0.0284 -0.0871 -0.1655 -0.6661 -0.0893 -0.1466 -0.0549 -0.0650 -0.5468 -0.1602 -0.1605
S-134	Eine zusätzliche Ergänzung mit Vitamin D sollte individuell erwogen werden .
T-134	Additional vitamin D supplements may be considered on an individual basis .
H-134	-0.30776965618133545	Additional vitamin D supplementation should be considered on an individual basis .
D-134	-0.30776965618133545	Additional vitamin D supplementation should be considered on an individual basis .
P-134	-2.0505 -0.6528 -0.0758 -0.1043 -0.0505 -0.3037 -0.1213 -0.1405 -0.1713 -0.2470 -0.1976 -0.1389 -0.1089 -0.2728 -0.1388 -0.1495
S-129	Andere klinisch relevante Wechselwirkungen mit Arzneimitteln sind nicht zu erwarten .
T-129	No other clinically significant interactions with medicinal products are anticipated .
H-129	-0.3225325047969818	No other clinically relevant interactions with medicinal products are expected .
D-129	-0.3225325047969818	No other clinically relevant interactions with medicinal products are expected .
P-129	-1.4947 -0.0607 -0.0749 -0.1161 -0.2089 -1.2472 -0.3912 -0.0981 -0.0934 -0.0597 -0.0979 -0.2305 -0.3347 -0.1780 -0.1519
S-104	Die vollständige Auflistung der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-104	For a full list of excipients , see section 6.1 .
H-104	-0.1236543208360672	For a full list of excipients , see section 6.1 .
D-104	-0.1236543208360672	For a full list of excipients , see section 6.1 .
P-104	-0.1136 -0.1203 -0.1081 -0.0995 -0.1388 -0.0719 -0.0343 -0.1225 -0.0987 -0.1341 -0.1402 -0.2182 -0.1105 -0.1466 -0.1665 -0.1546
S-58	Eine zusätzliche Ergänzung mit Vitamin D sollte individuell erwogen werden .
T-58	Additional vitamin D supplements may be considered on an individual basis .
H-58	-0.30776965618133545	Additional vitamin D supplementation should be considered on an individual basis .
D-58	-0.30776965618133545	Additional vitamin D supplementation should be considered on an individual basis .
P-58	-2.0505 -0.6528 -0.0758 -0.1043 -0.0505 -0.3037 -0.1213 -0.1405 -0.1713 -0.2470 -0.1976 -0.1389 -0.1089 -0.2728 -0.1388 -0.1495
S-53	Andere klinisch relevante Wechselwirkungen mit Arzneimitteln sind nicht zu erwarten .
T-53	No other clinically significant interactions with medicinal products are anticipated .
H-53	-0.3225325047969818	No other clinically relevant interactions with medicinal products are expected .
D-53	-0.3225325047969818	No other clinically relevant interactions with medicinal products are expected .
P-53	-1.4947 -0.0607 -0.0749 -0.1161 -0.2089 -1.2472 -0.3912 -0.0981 -0.0934 -0.0597 -0.0979 -0.2305 -0.3347 -0.1780 -0.1519
S-773	Das Arzneimittel unmittelbar nach dem vollständigen Lösen des Pulvers verbrauchen .
T-773	Use the product immediately once the powder is completely dissolved .
H-773	-0.6127859950065613	Use immediately after dissolving the powder .
D-773	-0.6127859950065613	Use immediately after dissolving the powder .
P-773	-1.9425 -0.0483 -0.5053 -2.2104 -0.5521 -0.1809 -0.3087 -0.0839 -0.1336 -0.1621
S-29	Die vollständige Auflistung der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-29	For a full list of excipients , see section 6.1 .
H-29	-0.1236543208360672	For a full list of excipients , see section 6.1 .
D-29	-0.1236543208360672	For a full list of excipients , see section 6.1 .
P-29	-0.1136 -0.1203 -0.1081 -0.0995 -0.1388 -0.0719 -0.0343 -0.1225 -0.0987 -0.1341 -0.1402 -0.2182 -0.1105 -0.1466 -0.1665 -0.1546
S-754	99 Inhibitoren liegen . Dies wird von Ihrem Arzt abgeklärt werden .
T-754	This will be checked by your doctor .
H-754	-0.2446698099374771	This will be clarified by your doctor .
D-754	-0.2446698099374771	This will be clarified by your doctor .
P-754	-0.1357 -0.2286 -0.1418 -1.1166 -0.1350 -0.1356 -0.1470 -0.0981 -0.1493 -0.1588
S-830	Die vollständige Auflistung der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-830	For a full list of excipients , see section 6.1 .
H-830	-0.1236543208360672	For a full list of excipients , see section 6.1 .
D-830	-0.1236543208360672	For a full list of excipients , see section 6.1 .
P-830	-0.1136 -0.1203 -0.1081 -0.0995 -0.1388 -0.0719 -0.0343 -0.1225 -0.0987 -0.1341 -0.1402 -0.2182 -0.1105 -0.1466 -0.1665 -0.1546
S-810	Welche Unterlagen hat das Unternehmen dem CHMP zur Stützung seines Antrags vorgelegt ?
T-810	What documentation did the company present to support its application to the CHMP ?
H-810	-0.37158966064453125	What documents has the company submitted to the CHMP in support of its application ?
D-810	-0.37158966064453125	What documents has the company submitted to the CHMP in support of its application ?
P-810	-0.2814 -1.1413 -0.4755 -0.3485 -0.2767 -0.8229 -0.2697 -0.3943 -0.1507 -0.0548 -0.1389 -0.1473 -0.1521 -0.6912 -0.5873 -0.2281 -0.1563
S-21	Die Tablette darf nicht gekaut werden und nicht im Mund zergehen .
T-21	The tablet should not be chewed or allowed to dissolve in the mouth .
H-21	-0.33802902698516846	Do not chew or melt the tablet .
D-21	-0.33802902698516846	Do not chew or melt the tablet .
P-21	-0.7300 -0.1435 -0.0513 -0.1176 -0.2691 -0.9772 -0.2179 -0.2543 -0.0675 -0.1118 -0.9597 -0.1563
S-52	Patienten mit einer Malabsorption nehmen möglicherweise nicht ausreichend Vitamin D3 auf .
T-52	Patients with malabsorption may not adequately absorb vitamin D3 .
H-52	-0.30555644631385803	Malabsorbed patients may not be adequately absorbed with vitamin D3 .
D-52	-0.30555644631385803	Malabsorbed patients may not be adequately absorbed with vitamin D3 .
P-52	-0.4255 -0.1113 -0.0925 -0.0327 -0.0790 -0.1587 -0.4722 -0.9138 -0.0725 -1.2794 -0.1020 -0.8363 -0.2217 -0.0812 -0.1555 -0.1657 -0.1513 -0.1488
S-128	Patienten mit einer Malabsorption nehmen möglicherweise nicht ausreichend Vitamin D3 auf .
T-128	Patients with malabsorption may not adequately absorb vitamin D3 .
H-128	-0.30555644631385803	Malabsorbed patients may not be adequately absorbed with vitamin D3 .
D-128	-0.30555644631385803	Malabsorbed patients may not be adequately absorbed with vitamin D3 .
P-128	-0.4255 -0.1113 -0.0925 -0.0327 -0.0790 -0.1587 -0.4722 -0.9138 -0.0725 -1.2794 -0.1020 -0.8363 -0.2217 -0.0812 -0.1555 -0.1657 -0.1513 -0.1488
S-804	ADVATE darf nicht mit anderen Arzneimitteln oder Lösungen gemischt werden .
T-804	ADVATE must not be mixed with other medicinal products or solvents .
H-804	-0.2708398997783661	ADVATE must not be mixed with other medicinal products or solutions .
D-804	-0.2708398997783661	ADVATE must not be mixed with other medicinal products or solutions .
P-804	-0.1351 -0.1655 -0.0800 -0.0802 -1.0312 -0.1503 -0.1206 -0.9370 -0.1499 -0.6316 -0.1324 -0.1320 -0.0982 -0.1184 -0.3440 -0.1436 -0.1543
S-854	Deshalb sollte Aerinaze in der Stillzeit nicht angewendet werden .
T-854	Therefore Aerinaze should not be used in breast-feeding women .
H-854	-0.18478922545909882	Therefore , Aerinaze should not be administered to breast-feeding women .
D-854	-0.18478922545909882	Therefore , Aerinaze should not be administered to breast-feeding women .
P-854	-0.0802 -0.1043 -0.5502 -0.1606 -0.1216 -0.1271 -0.1304 -0.1000 -0.1279 -0.1251 -0.1218 -1.2518 -0.0984 -0.1521 -0.0737 -0.0432 -0.0603 -0.0513 -0.1019 -0.1443 -0.1546
S-146	Nach Markteinführung wurden folgende Reaktionen berichtet ( Häufigkeit nicht bekannt ) :
T-146	During post-marketing experience the following reactions have been reported ( frequency not known ) :
H-146	-0.2855781018733978	The following post-marketing reactions have been reported ( frequency unknown ) :
D-146	-0.2855781018733978	The following post-marketing reactions have been reported ( frequency unknown ) :
P-146	-0.5501 -0.1618 -1.6350 -0.2237 -0.0363 -0.1141 -0.0563 -0.2175 -0.1669 -0.1112 -0.1721 -0.1856 -0.0559 -0.7166 -0.1475 -0.1378 -0.1662
S-70	Nach Markteinführung wurden folgende Reaktionen berichtet ( Häufigkeit nicht bekannt ) :
T-70	During post-marketing experience the following reactions have been reported ( frequency not known ) :
H-70	-0.2855781018733978	The following post-marketing reactions have been reported ( frequency unknown ) :
D-70	-0.2855781018733978	The following post-marketing reactions have been reported ( frequency unknown ) :
P-70	-0.5501 -0.1618 -1.6350 -0.2237 -0.0363 -0.1141 -0.0563 -0.2175 -0.1669 -0.1112 -0.1721 -0.1856 -0.0559 -0.7166 -0.1475 -0.1378 -0.1662
S-730	Es kann anderen Menschen schaden , auch wenn diese die gleichen Beschwerden haben wie Sie .
T-730	if their symptoms are the same as yours .
H-730	-0.28204095363616943	It may harm them , even if their symptoms are the same as yours .
D-730	-0.28204095363616943	It may harm them , even if their symptoms are the same as yours .
P-730	-2.1198 -0.3830 -0.1680 -0.1737 -0.3294 -0.1083 -0.1162 -0.1909 -0.1153 -0.1396 -0.1667 -0.1287 -0.1510 -0.0741 -0.1154 -0.1600 -0.1547
S-508	- Nicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen
T-508	- Dispose any unused product or waste material in accordance with local requirements .
H-508	-0.3893873393535614	- Any unused product or waste material should be treated in accordance with local
D-508	-0.3893873393535614	- Any unused product or waste material should be treated in accordance with local
P-508	-0.1299 -0.5020 -0.1324 -0.1402 -0.1453 -0.1310 -0.1096 -0.1507 -1.2919 -0.1769 -1.6541 -0.1554 -0.0335 -0.1732 -0.1548 -1.0263 -0.5124
S-589	- Nicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen
T-589	- Dispose any unused product or waste material in accordance with local requirements .
H-589	-0.3893873393535614	- Any unused product or waste material should be treated in accordance with local
D-589	-0.3893873393535614	- Any unused product or waste material should be treated in accordance with local
P-589	-0.1299 -0.5020 -0.1324 -0.1402 -0.1453 -0.1310 -0.1096 -0.1507 -1.2919 -0.1769 -1.6541 -0.1554 -0.0335 -0.1732 -0.1548 -1.0263 -0.5124
S-772	Im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-772	Keep the vial in the outer carton in order to protect from light .
H-772	-0.1627786010503769	Keep in the outer carton in order to protect from light .
D-772	-0.1627786010503769	Keep in the outer carton in order to protect from light .
P-772	-0.8972 -0.2299 -0.1352 -0.0087 -0.1008 -0.0590 -0.0335 -0.1306 -0.0987 -0.1292 -0.1298 -0.1115 -0.0650 -0.1603 -0.1521
S-427	- Nicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen
T-427	- Dispose any unused product or waste material in accordance with local requirements .
H-427	-0.3893873393535614	- Any unused product or waste material should be treated in accordance with local
D-427	-0.3893873393535614	- Any unused product or waste material should be treated in accordance with local
P-427	-0.1299 -0.5020 -0.1324 -0.1402 -0.1453 -0.1310 -0.1096 -0.1507 -1.2919 -0.1769 -1.6541 -0.1554 -0.0335 -0.1732 -0.1548 -1.0263 -0.5124
S-346	- Nicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen
T-346	- Dispose any unused product or waste material in accordance with local requirements .
H-346	-0.3893873393535614	- Any unused product or waste material should be treated in accordance with local
D-346	-0.3893873393535614	- Any unused product or waste material should be treated in accordance with local
P-346	-0.1299 -0.5020 -0.1324 -0.1402 -0.1453 -0.1310 -0.1096 -0.1507 -1.2919 -0.1769 -1.6541 -0.1554 -0.0335 -0.1732 -0.1548 -1.0263 -0.5124
S-670	- Nicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen
T-670	- Dispose any unused product or waste material in accordance with local requirements .
H-670	-0.3893873393535614	- Any unused product or waste material should be treated in accordance with local
D-670	-0.3893873393535614	- Any unused product or waste material should be treated in accordance with local
P-670	-0.1299 -0.5020 -0.1324 -0.1402 -0.1453 -0.1310 -0.1096 -0.1507 -1.2919 -0.1769 -1.6541 -0.1554 -0.0335 -0.1732 -0.1548 -1.0263 -0.5124
S-850	Die Wechselwirkung zwischen Aerinaze und Alkohol wurde nicht untersucht .
T-850	The interaction with Aerinaze and alcohol has not been studied .
H-850	-0.2847144901752472	The interaction between Aerinaze and alcohol has not been studied .
D-850	-0.2847144901752472	The interaction between Aerinaze and alcohol has not been studied .
P-850	-0.2523 -1.0600 -0.1044 -0.5766 -0.2279 -0.1196 -0.1241 -0.1397 -0.0981 -0.1425 -0.1157 -0.1462 -0.1379 -0.1291 -1.1649 -0.1467 -0.1544
S-218	Häufigkeit der Dosierung ( Stunden ) / Behandlungsdauer ( Tage )
T-218	Frequency of doses ( hours<<unk>> / duration of therapy ( days )
H-218	-0.2654728591442108	Frequency of dosing ( hours ) / duration of treatment ( days )
D-218	-0.2654728591442108	Frequency of dosing ( hours ) / duration of treatment ( days )
P-218	-1.5512 -0.0629 -0.1110 -0.1655 -0.0859 -0.9041 -0.1112 -0.1163 -0.1525 -0.1919 -0.2302 -0.1272 -0.1927 -0.1468 -0.1396 -0.1335 -0.1446 -0.2115
S-296	Häufigkeit der Dosierung ( Stunden ) / Behandlungsdauer ( Tage )
T-296	Frequency of doses ( hours<<unk>> / duration of therapy ( days )
H-296	-0.2654728591442108	Frequency of dosing ( hours ) / duration of treatment ( days )
D-296	-0.2654728591442108	Frequency of dosing ( hours ) / duration of treatment ( days )
P-296	-1.5512 -0.0629 -0.1110 -0.1655 -0.0859 -0.9041 -0.1112 -0.1163 -0.1525 -0.1919 -0.2302 -0.1272 -0.1927 -0.1468 -0.1396 -0.1335 -0.1446 -0.2115
S-377	Häufigkeit der Dosierung ( Stunden ) / Behandlungsdauer ( Tage )
T-377	Frequency of doses ( hours<<unk>> / duration of therapy ( days )
H-377	-0.2654728591442108	Frequency of dosing ( hours ) / duration of treatment ( days )
D-377	-0.2654728591442108	Frequency of dosing ( hours ) / duration of treatment ( days )
P-377	-1.5512 -0.0629 -0.1110 -0.1655 -0.0859 -0.9041 -0.1112 -0.1163 -0.1525 -0.1919 -0.2302 -0.1272 -0.1927 -0.1468 -0.1396 -0.1335 -0.1446 -0.2115
S-458	Häufigkeit der Dosierung ( Stunden ) / Behandlungsdauer ( Tage )
T-458	Frequency of doses ( hours<<unk>> / duration of therapy ( days )
H-458	-0.2654728591442108	Frequency of dosing ( hours ) / duration of treatment ( days )
D-458	-0.2654728591442108	Frequency of dosing ( hours ) / duration of treatment ( days )
P-458	-1.5512 -0.0629 -0.1110 -0.1655 -0.0859 -0.9041 -0.1112 -0.1163 -0.1525 -0.1919 -0.2302 -0.1272 -0.1927 -0.1468 -0.1396 -0.1335 -0.1446 -0.2115
S-539	Häufigkeit der Dosierung ( Stunden ) / Behandlungsdauer ( Tage )
T-539	Frequency of doses ( hours<<unk>> / duration of therapy ( days )
H-539	-0.2654728591442108	Frequency of dosing ( hours ) / duration of treatment ( days )
D-539	-0.2654728591442108	Frequency of dosing ( hours ) / duration of treatment ( days )
P-539	-1.5512 -0.0629 -0.1110 -0.1655 -0.0859 -0.9041 -0.1112 -0.1163 -0.1525 -0.1919 -0.2302 -0.1272 -0.1927 -0.1468 -0.1396 -0.1335 -0.1446 -0.2115
S-620	Häufigkeit der Dosierung ( Stunden ) / Behandlungsdauer ( Tage )
T-620	Frequency of doses ( hours<<unk>> / duration of therapy ( days )
H-620	-0.2654728591442108	Frequency of dosing ( hours ) / duration of treatment ( days )
D-620	-0.2654728591442108	Frequency of dosing ( hours ) / duration of treatment ( days )
P-620	-1.5512 -0.0629 -0.1110 -0.1655 -0.0859 -0.9041 -0.1112 -0.1163 -0.1525 -0.1919 -0.2302 -0.1272 -0.1927 -0.1468 -0.1396 -0.1335 -0.1446 -0.2115
S-759	Am Ende der Packungsbeilage finden Sie genaue Informationen zur Selbstbehandlung .
T-759	Detailed instructions for self-administration are given at the end of this package leaflet .
H-759	-0.3619827926158905	Detailed information on self treatment can be found at the end of the leaflet .
D-759	-0.3619827926158905	Detailed information on self treatment can be found at the end of the leaflet .
P-759	-0.4969 -0.0532 -0.1631 -0.1177 -0.3137 -0.9509 -0.7201 -0.1508 -0.2325 -0.1933 -0.1312 -0.5295 -0.1458 -0.5304 -1.6986 -0.0384 -0.1013 -0.1572 -0.1530
S-265	- Nicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen
T-265	- Dispose any unused product or waste material in accordance with local requirements .
H-265	-0.3893873393535614	- Any unused product or waste material should be treated in accordance with local
D-265	-0.3893873393535614	- Any unused product or waste material should be treated in accordance with local
P-265	-0.1299 -0.5020 -0.1324 -0.1402 -0.1453 -0.1310 -0.1096 -0.1507 -1.2919 -0.1769 -1.6541 -0.1554 -0.0335 -0.1732 -0.1548 -1.0263 -0.5124
S-774	Arzneimittel dürfen nicht im Abwasser oder Haushaltsabfall entsorgt werden .
T-774	Medicines should not be disposed of via waste water or household waste .
H-774	-0.10926304757595062	Medicines should not be disposed of via wastewater or household waste .
D-774	-0.10926304757595062	Medicines should not be disposed of via wastewater or household waste .
P-774	-0.0517 -0.0375 -0.2406 -0.1391 -0.1506 -0.0645 -0.0591 -0.1463 -0.0711 -0.0847 -0.0372 -0.1261 -0.1481 -0.0911 -0.1137 -0.1465 -0.1495
S-803	Beim Auflösen und bei der Anwendung sind aseptische Techniken erforderlich .
T-803	Aseptic technique is required during preparation of the solution and administration .
H-803	-0.5398855805397034	Aseptic techniques are required for resolution and administration .
D-803	-0.5398855805397034	Aseptic techniques are required for resolution and administration .
P-803	-0.6145 -0.6294 -0.2630 -0.1124 -0.0937 -0.2686 -0.4095 -0.9075 -1.9654 -0.1241 -1.2846 -0.1931 -0.1527
S-430	Hände sorgfältig mit Seife und warmem Wasser waschen . .
T-430	Wash your hands thoroughly using soap and warm water .
H-430	-0.20763422548770905	Wash hands carefully with soap and warm water .
D-430	-0.20763422548770905	Wash hands carefully with soap and warm water .
P-430	-0.2383 -0.0394 -0.2109 -0.5850 -0.1360 -0.0808 -0.1333 -0.1870 -0.1018 -0.1533 -0.4181
S-268	Hände sorgfältig mit Seife und warmem Wasser waschen . .
T-268	Wash your hands thoroughly using soap and warm water .
H-268	-0.20763422548770905	Wash hands carefully with soap and warm water .
D-268	-0.20763422548770905	Wash hands carefully with soap and warm water .
P-268	-0.2383 -0.0394 -0.2109 -0.5850 -0.1360 -0.0808 -0.1333 -0.1870 -0.1018 -0.1533 -0.4181
S-82	Eine Ergänzung mit Vitamin D senkt diese Risiken und ihre Konsequenzen .
T-82	Supplemental vitamin D reduces these risks and their consequences .
H-82	-0.333897203207016	Taking vitamin D supplements reduces these risks and their consequences .
D-82	-0.333897203207016	Taking vitamin D supplements reduces these risks and their consequences .
P-82	-0.9085 -0.1837 -0.0901 -0.0969 -0.0535 -0.1543 -2.2164 -0.0938 -0.1866 -0.0828 -0.1373 -0.1120 -0.3925 -0.1499 -0.1501
S-673	Hände sorgfältig mit Seife und warmem Wasser waschen . .
T-673	Wash your hands thoroughly using soap and warm water .
H-673	-0.20763422548770905	Wash hands carefully with soap and warm water .
D-673	-0.20763422548770905	Wash hands carefully with soap and warm water .
P-673	-0.2383 -0.0394 -0.2109 -0.5850 -0.1360 -0.0808 -0.1333 -0.1870 -0.1018 -0.1533 -0.4181
S-511	Hände sorgfältig mit Seife und warmem Wasser waschen . .
T-511	Wash your hands thoroughly using soap and warm water .
H-511	-0.20763422548770905	Wash hands carefully with soap and warm water .
D-511	-0.20763422548770905	Wash hands carefully with soap and warm water .
P-511	-0.2383 -0.0394 -0.2109 -0.5850 -0.1360 -0.0808 -0.1333 -0.1870 -0.1018 -0.1533 -0.4181
S-349	Hände sorgfältig mit Seife und warmem Wasser waschen . .
T-349	Wash your hands thoroughly using soap and warm water .
H-349	-0.20763422548770905	Wash hands carefully with soap and warm water .
D-349	-0.20763422548770905	Wash hands carefully with soap and warm water .
P-349	-0.2383 -0.0394 -0.2109 -0.5850 -0.1360 -0.0808 -0.1333 -0.1870 -0.1018 -0.1533 -0.4181
S-159	Eine Ergänzung mit Vitamin D senkt diese Risiken und ihre Konsequenzen .
T-159	Supplemental vitamin D reduces these risks and their consequences .
H-159	-0.333897203207016	Taking vitamin D supplements reduces these risks and their consequences .
D-159	-0.333897203207016	Taking vitamin D supplements reduces these risks and their consequences .
P-159	-0.9085 -0.1837 -0.0901 -0.0969 -0.0535 -0.1543 -2.2164 -0.0938 -0.1866 -0.0828 -0.1373 -0.1120 -0.3925 -0.1499 -0.1501
S-123	Bei den meisten Patienten gingen die Beschwerden nach dem Absetzen der Therapie zurück .
T-123	Most patients had relief of symptoms after stopping treatment .
H-123	-0.40941303968429565	In most patients , symptoms decreased after discontinuation of therapy .
D-123	-0.40941303968429565	In most patients , symptoms decreased after discontinuation of therapy .
P-123	-0.4154 -0.2346 -0.2811 -1.0070 -0.3616 -2.0143 -0.1289 -0.4261 -0.0651 -0.0526 -0.1239 -0.3863 -0.3496 -0.1438 -0.1508
S-164	5,0 , 5,8 % ) in der Gruppe mit 10 mg täglich .
T-164	5.0 , 5.8 % ) in the 10 mg daily group .
H-164	-0.2036839723587036	5.0 , 5.8 % ) in the 10 mg daily group .
D-164	-0.2036839723587036	5.0 , 5.8 % ) in the 10 mg daily group .
P-164	-0.0996 -0.1094 -0.1732 -0.0872 -0.1187 -0.1455 -0.1432 -0.2015 -0.1443 -0.4978 -0.0512 -0.0842 -0.8692 -0.1741 -0.1561
S-194	Advate wird angewendet , um den fehlenden Faktor VIII zu ersetzen .
T-194	Advate is used to replace the missing factor VIII .
H-194	-0.23764649033546448	Advate is used to replace the missing factor VIII .
D-194	-0.23764649033546448	Advate is used to replace the missing factor VIII .
P-194	-0.4836 -0.1389 -0.2118 -0.2629 -0.1381 -0.4848 -0.1868 -0.2584 -0.3630 -0.1555 -0.0763 -0.1682 -0.1612
S-202	Den vollständigen Wortlaut des EPAR für Advate finden Sie hier .
T-202	The full EPAR for Advate is available here .
H-202	-0.22333621978759766	The full EPAR for Advate is available here .
D-202	-0.22333621978759766	The full EPAR for Advate is available here .
P-202	-0.2580 -0.1647 -0.0416 -0.0618 -0.1107 -0.3006 -0.1018 -0.7372 -0.1794 -0.1948 -0.3667 -0.1627
S-180	Es werden möglicherweise nicht alle Packungsgrößen in den Verkehr gebracht .
T-180	Not all pack sizes may be marketed .
H-180	-0.11160235852003098	Not all pack sizes may be marketed .
D-180	-0.11160235852003098	Not all pack sizes may be marketed .
P-180	-0.0780 -0.1240 -0.1539 -0.1229 -0.1020 -0.1064 -0.1382 -0.0369 -0.0680 -0.1380 -0.1592
S-101	Es werden möglicherweise nicht alle Packungsgrößen in den Verkehr gebracht .
T-101	Not all pack sizes may be marketed .
H-101	-0.11160235852003098	Not all pack sizes may be marketed .
D-101	-0.11160235852003098	Not all pack sizes may be marketed .
P-101	-0.0780 -0.1240 -0.1539 -0.1229 -0.1020 -0.1064 -0.1382 -0.0369 -0.0680 -0.1380 -0.1592
S-592	Hände sorgfältig mit Seife und warmem Wasser waschen . .
T-592	Wash your hands thoroughly using soap and warm water .
H-592	-0.20763422548770905	Wash hands carefully with soap and warm water .
D-592	-0.20763422548770905	Wash hands carefully with soap and warm water .
P-592	-0.2383 -0.0394 -0.2109 -0.5850 -0.1360 -0.0808 -0.1333 -0.1870 -0.1018 -0.1533 -0.4181
S-680	Das Produkt löst sich rasch ( üblicherweise in weniger als 1 Minute ) .
T-680	The product dissolves rapidly ( usually in less than 1 minute ) .
H-680	-0.3310675323009491	The product disperses rapidly ( usually in less than 1 minute ) .
D-680	-0.3310675323009491	The product disperses rapidly ( usually in less than 1 minute ) .
P-680	-0.9852 -0.0848 -1.6164 -0.0958 -0.1109 -0.7634 -0.1779 -0.1298 -0.2033 -0.1734 -0.1305 -0.2872 -0.0599 -0.1628 -0.1579 -0.1579
S-84	5,0 , 5,8 % ) in der Gruppe mit 10 mg täglich .
T-84	5.0 , 5.8 % ) in the 10 mg daily group .
H-84	-0.2036839723587036	5.0 , 5.8 % ) in the 10 mg daily group .
D-84	-0.2036839723587036	5.0 , 5.8 % ) in the 10 mg daily group .
P-84	-0.0996 -0.1094 -0.1732 -0.0872 -0.1187 -0.1455 -0.1432 -0.2015 -0.1443 -0.4978 -0.0512 -0.0842 -0.8692 -0.1741 -0.1561
S-275	Das Produkt löst sich rasch ( üblicherweise in weniger als 1 Minute ) .
T-275	The product dissolves rapidly ( usually in less than 1 minute ) .
H-275	-0.3310675323009491	The product disperses rapidly ( usually in less than 1 minute ) .
D-275	-0.3310675323009491	The product disperses rapidly ( usually in less than 1 minute ) .
P-275	-0.9852 -0.0848 -1.6164 -0.0958 -0.1109 -0.7634 -0.1779 -0.1298 -0.2033 -0.1734 -0.1305 -0.2872 -0.0599 -0.1628 -0.1579 -0.1579
S-189	Advate ist sowohl zur kurz- als auch zur langfristigen Anwendung angezeigt .
T-189	Advate is intended for either short-term or long-term use .
H-189	-0.48604196310043335	Advate is indicated for both short- and long-term use .
D-189	-0.48604196310043335	Advate is indicated for both short- and long-term use .
P-189	-1.8492 -0.1358 -0.1359 -0.0598 -0.1392 -0.6645 -0.0170 -0.4302 -0.1642 -2.2812 -0.8682 -0.0857 -0.1587 -0.1446 -0.1564
S-599	Das Produkt löst sich rasch ( üblicherweise in weniger als 1 Minute ) .
T-599	The product dissolves rapidly ( usually in less than 1 minute ) .
H-599	-0.3310675323009491	The product disperses rapidly ( usually in less than 1 minute ) .
D-599	-0.3310675323009491	The product disperses rapidly ( usually in less than 1 minute ) .
P-599	-0.9852 -0.0848 -1.6164 -0.0958 -0.1109 -0.7634 -0.1779 -0.1298 -0.2033 -0.1734 -0.1305 -0.2872 -0.0599 -0.1628 -0.1579 -0.1579
S-518	Das Produkt löst sich rasch ( üblicherweise in weniger als 1 Minute ) .
T-518	The product dissolves rapidly ( usually in less than 1 minute ) .
H-518	-0.3310675323009491	The product disperses rapidly ( usually in less than 1 minute ) .
D-518	-0.3310675323009491	The product disperses rapidly ( usually in less than 1 minute ) .
P-518	-0.9852 -0.0848 -1.6164 -0.0958 -0.1109 -0.7634 -0.1779 -0.1298 -0.2033 -0.1734 -0.1305 -0.2872 -0.0599 -0.1628 -0.1579 -0.1579
S-437	Das Produkt löst sich rasch ( üblicherweise in weniger als 1 Minute ) .
T-437	The product dissolves rapidly ( usually in less than 1 minute ) .
H-437	-0.3310675323009491	The product disperses rapidly ( usually in less than 1 minute ) .
D-437	-0.3310675323009491	The product disperses rapidly ( usually in less than 1 minute ) .
P-437	-0.9852 -0.0848 -1.6164 -0.0958 -0.1109 -0.7634 -0.1779 -0.1298 -0.2033 -0.1734 -0.1305 -0.2872 -0.0599 -0.1628 -0.1579 -0.1579
S-356	Das Produkt löst sich rasch ( üblicherweise in weniger als 1 Minute ) .
T-356	The product dissolves rapidly ( usually in less than 1 minute ) .
H-356	-0.3310675323009491	The product disperses rapidly ( usually in less than 1 minute ) .
D-356	-0.3310675323009491	The product disperses rapidly ( usually in less than 1 minute ) .
P-356	-0.9852 -0.0848 -1.6164 -0.0958 -0.1109 -0.7634 -0.1779 -0.1298 -0.2033 -0.1734 -0.1305 -0.2872 -0.0599 -0.1628 -0.1579 -0.1579
S-223	Angaben zur Rekonstitution vor der Verabreichung siehe Abschnitt 6.6 .
T-223	For instructions for reconstitution prior to administration , see section 6.6 .
H-223	-0.23356032371520996	For information on reconstitution prior to administration , see section 6.6 .
D-223	-0.23356032371520996	For information on reconstitution prior to administration , see section 6.6 .
P-223	-0.1257 -0.7003 -0.1892 -0.6072 -0.0606 -0.4485 -0.1360 -0.1336 -0.1466 -0.2096 -0.1400 -0.1111 -0.1593 -0.1807 -0.1550
S-301	Angaben zur Rekonstitution vor der Verabreichung siehe Abschnitt 6.6 .
T-301	For instructions for reconstitution prior to administration , see section 6.6 .
H-301	-0.23356032371520996	For information on reconstitution prior to administration , see section 6.6 .
D-301	-0.23356032371520996	For information on reconstitution prior to administration , see section 6.6 .
P-301	-0.1257 -0.7003 -0.1892 -0.6072 -0.0606 -0.4485 -0.1360 -0.1336 -0.1466 -0.2096 -0.1400 -0.1111 -0.1593 -0.1807 -0.1550
S-693	Arzneimittel auf eingeschränkte ärztliche Verschreibung ( siehe Anhang I :
T-693	Medicinal product subject to restricted medical prescription ( See Annex I :
H-693	-0.4283841550350189	Medicinal product subject to restricted medical prescription ( see Annex I :
D-693	-0.4283841550350189	Medicinal product subject to restricted medical prescription ( see Annex I :
P-693	-0.6935 -0.8659 -0.6959 -0.1614 -0.1520 -1.3025 -0.4211 -0.1896 -0.1598 -0.7680 -0.3552 -0.1096 -0.2046 -0.1570 -0.1896
S-625	Angaben zur Rekonstitution vor der Verabreichung siehe Abschnitt 6.6 .
T-625	For instructions for reconstitution prior to administration , see section 6.6 .
H-625	-0.23356032371520996	For information on reconstitution prior to administration , see section 6.6 .
D-625	-0.23356032371520996	For information on reconstitution prior to administration , see section 6.6 .
P-625	-0.1257 -0.7003 -0.1892 -0.6072 -0.0606 -0.4485 -0.1360 -0.1336 -0.1466 -0.2096 -0.1400 -0.1111 -0.1593 -0.1807 -0.1550
S-544	Angaben zur Rekonstitution vor der Verabreichung siehe Abschnitt 6.6 .
T-544	For instructions for reconstitution prior to administration , see section 6.6 .
H-544	-0.23356032371520996	For information on reconstitution prior to administration , see section 6.6 .
D-544	-0.23356032371520996	For information on reconstitution prior to administration , see section 6.6 .
P-544	-0.1257 -0.7003 -0.1892 -0.6072 -0.0606 -0.4485 -0.1360 -0.1336 -0.1466 -0.2096 -0.1400 -0.1111 -0.1593 -0.1807 -0.1550
S-463	Angaben zur Rekonstitution vor der Verabreichung siehe Abschnitt 6.6 .
T-463	For instructions for reconstitution prior to administration , see section 6.6 .
H-463	-0.23356032371520996	For information on reconstitution prior to administration , see section 6.6 .
D-463	-0.23356032371520996	For information on reconstitution prior to administration , see section 6.6 .
P-463	-0.1257 -0.7003 -0.1892 -0.6072 -0.0606 -0.4485 -0.1360 -0.1336 -0.1466 -0.2096 -0.1400 -0.1111 -0.1593 -0.1807 -0.1550
S-382	Angaben zur Rekonstitution vor der Verabreichung siehe Abschnitt 6.6 .
T-382	For instructions for reconstitution prior to administration , see section 6.6 .
H-382	-0.23356032371520996	For information on reconstitution prior to administration , see section 6.6 .
D-382	-0.23356032371520996	For information on reconstitution prior to administration , see section 6.6 .
P-382	-0.1257 -0.7003 -0.1892 -0.6072 -0.0606 -0.4485 -0.1360 -0.1336 -0.1466 -0.2096 -0.1400 -0.1111 -0.1593 -0.1807 -0.1550
S-47	Bei den meisten Patienten gingen die Beschwerden nach dem Absetzen der Therapie zurück .
T-47	Most patients had relief of symptoms after stopping treatment .
H-47	-0.40941303968429565	In most patients , symptoms decreased after discontinuation of therapy .
D-47	-0.40941303968429565	In most patients , symptoms decreased after discontinuation of therapy .
P-47	-0.4154 -0.2346 -0.2811 -1.0070 -0.3616 -2.0143 -0.1289 -0.4261 -0.0651 -0.0526 -0.1239 -0.3863 -0.3496 -0.1438 -0.1508
S-111	Daher ist eine Dosisanpassung bei älteren Menschen nicht erforderlich .
T-111	Therefore no dosage adjustment is necessary for the elderly .
H-111	-0.2560848295688629	Thus , no dosage adjustment is required in the elderly .
D-111	-0.2560848295688629	Thus , no dosage adjustment is required in the elderly .
P-111	-0.7073 -0.1418 -0.2540 -0.3710 -0.0331 -0.0993 -0.0799 -0.0750 -0.1264 -0.1365 -0.9688 -0.4207 -0.3277 -0.0406 -0.1664 -0.1490
S-288	Eine vollständige Liste der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-288	For a full list of excipients , see section 6.1 .
H-288	-0.12454218417406082	For a full list of excipients , see section 6.1 .
D-288	-0.12454218417406082	For a full list of excipients , see section 6.1 .
P-288	-0.1227 -0.1293 -0.1473 -0.0517 -0.1392 -0.0810 -0.0303 -0.1160 -0.0991 -0.1334 -0.1596 -0.1995 -0.1092 -0.1481 -0.1717 -0.1545
S-36	Daher ist eine Dosisanpassung bei älteren Menschen nicht erforderlich .
T-36	Therefore no dosage adjustment is necessary for the elderly .
H-36	-0.2560848295688629	Thus , no dosage adjustment is required in the elderly .
D-36	-0.2560848295688629	Thus , no dosage adjustment is required in the elderly .
P-36	-0.7073 -0.1418 -0.2540 -0.3710 -0.0331 -0.0993 -0.0799 -0.0750 -0.1264 -0.1365 -0.9688 -0.4207 -0.3277 -0.0406 -0.1664 -0.1490
S-694	Zusammenfassung der Merkmale des Arzneimittels , Abschnitt 4.2 ) .
T-694	Summary of Product Characteristics , section 4.2 )
H-694	-0.16984309256076813	Summary of Product Characteristics , section 4.2 ) .
D-694	-0.16984309256076813	Summary of Product Characteristics , section 4.2 ) .
P-694	-0.0509 -0.0772 -0.1497 -0.0731 -0.0254 -0.0578 -0.0546 -0.2024 -0.1130 -0.2863 -0.5277 -0.1379 -0.1455 -0.1464 -0.5040 -0.1656
S-208	Eine vollständige Liste der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-208	For a full list of excipients , see section 6.1 .
H-208	-0.12454218417406082	For a full list of excipients , see section 6.1 .
D-208	-0.12454218417406082	For a full list of excipients , see section 6.1 .
P-208	-0.1227 -0.1293 -0.1473 -0.0517 -0.1392 -0.0810 -0.0303 -0.1160 -0.0991 -0.1334 -0.1596 -0.1995 -0.1092 -0.1481 -0.1717 -0.1545
S-5	Sie kann mit oder unabhängig von den Mahlzeiten eingenommen werden .
T-5	It can be taken with or without food .
H-5	-0.2302434891462326	It can be taken with or without meals .
D-5	-0.2302434891462326	It can be taken with or without meals .
P-5	-0.9392 -0.2816 -0.1312 -0.0359 -0.1064 -0.1351 -0.0615 -0.3060 -0.1484 -0.1571
S-369	Eine vollständige Liste der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-369	For a full list of excipients , see section 6.1 .
H-369	-0.12454218417406082	For a full list of excipients , see section 6.1 .
D-369	-0.12454218417406082	For a full list of excipients , see section 6.1 .
P-369	-0.1227 -0.1293 -0.1473 -0.0517 -0.1392 -0.0810 -0.0303 -0.1160 -0.0991 -0.1334 -0.1596 -0.1995 -0.1092 -0.1481 -0.1717 -0.1545
S-450	Eine vollständige Liste der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-450	For a full list of excipients , see section 6.1 .
H-450	-0.12454218417406082	For a full list of excipients , see section 6.1 .
D-450	-0.12454218417406082	For a full list of excipients , see section 6.1 .
P-450	-0.1227 -0.1293 -0.1473 -0.0517 -0.1392 -0.0810 -0.0303 -0.1160 -0.0991 -0.1334 -0.1596 -0.1995 -0.1092 -0.1481 -0.1717 -0.1545
S-531	Eine vollständige Liste der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-531	For a full list of excipients , see section 6.1 .
H-531	-0.12454218417406082	For a full list of excipients , see section 6.1 .
D-531	-0.12454218417406082	For a full list of excipients , see section 6.1 .
P-531	-0.1227 -0.1293 -0.1473 -0.0517 -0.1392 -0.0810 -0.0303 -0.1160 -0.0991 -0.1334 -0.1596 -0.1995 -0.1092 -0.1481 -0.1717 -0.1545
S-612	Eine vollständige Liste der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-612	For a full list of excipients , see section 6.1 .
H-612	-0.12454218417406082	For a full list of excipients , see section 6.1 .
D-612	-0.12454218417406082	For a full list of excipients , see section 6.1 .
P-612	-0.1227 -0.1293 -0.1473 -0.0517 -0.1392 -0.0810 -0.0303 -0.1160 -0.0991 -0.1334 -0.1596 -0.1995 -0.1092 -0.1481 -0.1717 -0.1545
S-731	- Wenn eine der aufgeführten Nebenwirkungen Sie erheblich beeinträchtigt oder Sie
T-731	- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
H-731	-0.09064417332410812	- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
D-731	-0.09064417332410812	- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
P-731	-0.1418 -0.3152 -0.0481 -0.1330 -0.1513 -0.0538 -0.0902 -0.0201 -0.0165 -0.1364 -0.1118 -0.0750 -0.1537 -0.0434 -0.0371 -0.0134 -0.1423 -0.0539 -0.0075 -0.1220 -0.0736 -0.0041 -0.0217 -0.0721 -0.1079 -0.2111
S-729	- Wenn Sie weitere Fragen haben , wenden Sie sich an Ihren Arzt .
T-729	- If you have any further questions , ask your doctor .
H-729	-0.1881718933582306	- If you have any further questions , ask your doctor .
D-729	-0.1881718933582306	- If you have any further questions , ask your doctor .
P-729	-0.1254 -0.2996 -0.1405 -0.1464 -0.3422 -0.1426 -0.1704 -0.1294 -0.3771 -0.1646 -0.0916 -0.1514 -0.1651
S-591	seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-591	shows any sign of deterioration .
H-591	-0.5950458645820618	if its packaging is damaged or shows signs of tampering .
D-591	-0.5950458645820618	if its packaging is damaged or shows signs of tampering .
P-591	-3.1335 -0.8302 -0.5320 -0.1548 -0.1693 -0.2766 -0.1233 -1.9356 -0.2547 -0.1445 -1.2868 -0.0467 -0.0732 -0.1187 -0.2761 -0.1646
S-672	seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-672	shows any sign of deterioration .
H-672	-0.5950458645820618	if its packaging is damaged or shows signs of tampering .
D-672	-0.5950458645820618	if its packaging is damaged or shows signs of tampering .
P-672	-3.1335 -0.8302 -0.5320 -0.1548 -0.1693 -0.2766 -0.1233 -1.9356 -0.2547 -0.1445 -1.2868 -0.0467 -0.0732 -0.1187 -0.2761 -0.1646
S-769	Das Verfalldatum bezieht sich auf den letzten Tag des Monats .
T-769	The expiry date refers to the last day of that month .
H-769	-0.1414346843957901	The expiry date refers to the last day of the month .
D-769	-0.1414346843957901	The expiry date refers to the last day of the month .
P-769	-0.1735 -0.0256 -0.0628 -0.2128 -0.1798 -0.1032 -0.1480 -0.1421 -0.1630 -0.0963 -0.1915 -0.1948 -0.1206 -0.1520 -0.1554
S-510	seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-510	shows any sign of deterioration .
H-510	-0.5950458645820618	if its packaging is damaged or shows signs of tampering .
D-510	-0.5950458645820618	if its packaging is damaged or shows signs of tampering .
P-510	-3.1335 -0.8302 -0.5320 -0.1548 -0.1693 -0.2766 -0.1233 -1.9356 -0.2547 -0.1445 -1.2868 -0.0467 -0.0732 -0.1187 -0.2761 -0.1646
S-429	seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-429	shows any sign of deterioration .
H-429	-0.5950458645820618	if its packaging is damaged or shows signs of tampering .
D-429	-0.5950458645820618	if its packaging is damaged or shows signs of tampering .
P-429	-3.1335 -0.8302 -0.5320 -0.1548 -0.1693 -0.2766 -0.1233 -1.9356 -0.2547 -0.1445 -1.2868 -0.0467 -0.0732 -0.1187 -0.2761 -0.1646
S-753	Dies ist besonders bei größeren , chirurgischen Eingriffen wichtig .
T-753	This is particularly important if you are having major surgery .
H-753	-0.517304539680481	This is especially important during major surgical procedures .
D-753	-0.517304539680481	This is especially important during major surgical procedures .
P-753	-0.2483 -0.1207 -0.7977 -0.0914 -1.6705 -0.9498 -1.7019 -0.0587 -0.0838 -0.1715 -0.1578 -0.1558
S-267	seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-267	shows any sign of deterioration .
H-267	-0.5950458645820618	if its packaging is damaged or shows signs of tampering .
D-267	-0.5950458645820618	if its packaging is damaged or shows signs of tampering .
P-267	-3.1335 -0.8302 -0.5320 -0.1548 -0.1693 -0.2766 -0.1233 -1.9356 -0.2547 -0.1445 -1.2868 -0.0467 -0.0732 -0.1187 -0.2761 -0.1646
S-258	Im Kühlschrank lagern ( 2 <unk> C 8 <unk> C ) .
T-258	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-258	-0.17588433623313904	Store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
D-258	-0.17588433623313904	Store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
P-258	-0.5776 -0.1561 -0.1738 -0.1435 -0.0552 -0.0750 -0.1272 -0.1232 -0.5128 -0.1046 -0.1286 -0.1820 -0.0326 -0.1395 -0.1497 -0.1524 -0.1562
S-339	Im Kühlschrank lagern ( 2 <unk> C 8 <unk> C ) .
T-339	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-339	-0.17588433623313904	Store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
D-339	-0.17588433623313904	Store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
P-339	-0.5776 -0.1561 -0.1738 -0.1435 -0.0552 -0.0750 -0.1272 -0.1232 -0.5128 -0.1046 -0.1286 -0.1820 -0.0326 -0.1395 -0.1497 -0.1524 -0.1562
S-420	Im Kühlschrank lagern ( 2 <unk> C 8 <unk> C ) .
T-420	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-420	-0.17588433623313904	Store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
D-420	-0.17588433623313904	Store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
P-420	-0.5776 -0.1561 -0.1738 -0.1435 -0.0552 -0.0750 -0.1272 -0.1232 -0.5128 -0.1046 -0.1286 -0.1820 -0.0326 -0.1395 -0.1497 -0.1524 -0.1562
S-501	Im Kühlschrank lagern ( 2 <unk> C 8 <unk> C ) .
T-501	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-501	-0.17588433623313904	Store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
D-501	-0.17588433623313904	Store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
P-501	-0.5776 -0.1561 -0.1738 -0.1435 -0.0552 -0.0750 -0.1272 -0.1232 -0.5128 -0.1046 -0.1286 -0.1820 -0.0326 -0.1395 -0.1497 -0.1524 -0.1562
S-582	Im Kühlschrank lagern ( 2 <unk> C 8 <unk> C ) .
T-582	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-582	-0.17588433623313904	Store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
D-582	-0.17588433623313904	Store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
P-582	-0.5776 -0.1561 -0.1738 -0.1435 -0.0552 -0.0750 -0.1272 -0.1232 -0.5128 -0.1046 -0.1286 -0.1820 -0.0326 -0.1395 -0.1497 -0.1524 -0.1562
S-663	Im Kühlschrank lagern ( 2 <unk> C 8 <unk> C ) .
T-663	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-663	-0.17588433623313904	Store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
D-663	-0.17588433623313904	Store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
P-663	-0.5776 -0.1561 -0.1738 -0.1435 -0.0552 -0.0750 -0.1272 -0.1232 -0.5128 -0.1046 -0.1286 -0.1820 -0.0326 -0.1395 -0.1497 -0.1524 -0.1562
S-706	Nur zur einmaligen Anwendung Vor der Anwendung Gebrauchsinformation lesen .
T-706	Nur zur einmaligen Anwendung Vor der Anwendung Gebrauchsinformation lesen . Read the package leaflet before use .
H-706	-0.8232671618461609	For single use only Read instructions before use .
D-706	-0.8232671618461609	For single use only Read instructions before use .
P-706	-1.8580 -0.8639 -0.3296 -0.8842 -0.0560 -3.2001 -0.2872 -0.2105 -0.3842 -0.1589
S-348	seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-348	shows any sign of deterioration .
H-348	-0.5950458645820618	if its packaging is damaged or shows signs of tampering .
D-348	-0.5950458645820618	if its packaging is damaged or shows signs of tampering .
P-348	-3.1335 -0.8302 -0.5320 -0.1548 -0.1693 -0.2766 -0.1233 -1.9356 -0.2547 -0.1445 -1.2868 -0.0467 -0.0732 -0.1187 -0.2761 -0.1646
S-760	Fragen Sie Ihren Arzt , wenn Sie nicht ganz sicher sind .
T-760	You should check with your doctor if you are not sure .
H-760	-0.16713936626911163	Ask your doctor if you are not sure .
D-760	-0.16713936626911163	Ask your doctor if you are not sure .
P-760	-0.0981 -0.1091 -0.1498 -0.0866 -0.0828 -0.1278 -0.1765 -0.5306 -0.1648 -0.1549 -0.1577
S-14	Die zweite Studie erbrachte ähnliche Ergebnisse nach einem Jahr .
T-14	Similar results were seen in the second study after a year .
H-14	-0.4108887016773224	The second study produced similar results after one year .
D-14	-0.4108887016773224	The second study produced similar results after one year .
P-14	-0.1560 -0.1602 -1.3327 -0.7448 -0.0892 -0.2253 -1.2453 -0.1368 -0.1085 -0.1695 -0.1515
S-177	Die Bedeutung dieser Beobachtung für den Menschen ist nicht bekannt .
T-177	The relevance to humans is unknown .
H-177	-0.380014568567276	The significance of this observation for humans is unknown .
D-177	-0.380014568567276	The significance of this observation for humans is unknown .
P-177	-0.1509 -0.8494 -0.1708 -0.2916 -0.7535 -0.0396 -0.2594 -0.7515 -0.1598 -0.8220 -0.1592 -0.1525
S-818	Wie lautete die Empfehlung des CHMP zu diesem Zeitpunkt ?
T-818	What was the recommendation of the CHMP at that time ?
H-818	-0.3108910918235779	What was the CHMP recommendation at the time ?
D-818	-0.3108910918235779	What was the CHMP recommendation at the time ?
P-818	-0.1424 -0.1852 -0.1389 -0.1023 -0.0491 -0.5289 -0.1500 -0.1383 -1.8224 -0.1104 -0.2029 -0.1600
S-819	Aus welchen Gründen hat das Unternehmen den Antrag zurückgenommen ?
T-819	What were the reasons given by the company to withdraw the application ?
H-819	-0.24400360882282257	On what grounds has the company withdrawn the application ?
D-819	-0.24400360882282257	On what grounds has the company withdrawn the application ?
P-819	-0.9612 -0.2968 -0.0882 -0.1983 -0.2509 -0.2107 -0.0171 -0.1288 -0.2593 -0.1408 -0.2166 -0.1594
S-98	Die Bedeutung dieser Beobachtung für den Menschen ist nicht bekannt .
T-98	The relevance to humans is unknown .
H-98	-0.380014568567276	The significance of this observation for humans is unknown .
D-98	-0.380014568567276	The significance of this observation for humans is unknown .
P-98	-0.1509 -0.8494 -0.1708 -0.2916 -0.7535 -0.0396 -0.2594 -0.7515 -0.1598 -0.8220 -0.1592 -0.1525
S-805	Fragen und Antworten zur Rücknahme des Antrags auf Genehmigung für das Inverkehrbringen von Advexin
T-805	Questions and answers on the withdrawal of the marketing application for Advexin
H-805	-0.2722369134426117	Questions and Answers on the withdrawal of the Marketing Authorisation application for Advexin
D-805	-0.2722369134426117	Questions and Answers on the withdrawal of the Marketing Authorisation application for Advexin
P-805	-1.2386 -0.1659 -0.2019 -0.2897 -0.1358 -0.1010 -0.1760 -0.3831 -0.1396 -0.2842 -0.7288 -0.0609 -0.0604 -0.0569 -0.4737 -0.1431 -0.3190 -0.1571 -0.1465 -0.1825
S-551	Dies muss bei Patienten , die einer natriumkontrollierten Diät unterliegen , berücksichtigt werden .
T-551	To be taken into consideration by patients on a controlled sodium diet .
H-551	-0.39274343848228455	This has to be taken into account in patients on a sodium controlled diet .
D-551	-0.39274343848228455	This has to be taken into account in patients on a sodium controlled diet .
P-551	-0.3884 -1.5305 -0.1375 -0.1536 -0.9564 -0.0956 -0.1893 -1.2233 -0.0837 -0.2253 -0.1602 -0.1905 -0.8740 -0.1107 -0.0569 -0.1487 -0.1520
S-106	Die empfohlene Dosierung beträgt eine ADROVANCE Tablette einmal wöchentlich .
T-106	The recommended dosage is one ADROVANCE tablet once weekly .
H-106	-0.2881935238838196	The recommended dosage is one ADROVANCE tablet once a week .
D-106	-0.2881935238838196	The recommended dosage is one ADROVANCE tablet once a week .
P-106	-0.2188 -0.0781 -1.1468 -0.1311 -0.1078 -0.1736 -0.1895 -0.1208 -0.0757 -0.1463 -0.1006 -0.0874 -0.1281 -0.0878 -1.4955 -0.7804 -0.1065 -0.1492 -0.1516
S-306	In seltenen Fällen können sich Inhibitoren nach den ersten 100 Expositionstagen bilden .
T-306	Rarely , inhibitors may develop after the first 100 exposure days.
H-306	-0.18698598444461823	On rare occasions , inhibitors may form after the first 100 days of exposure .
D-306	-0.18698598444461823	On rare occasions , inhibitors may form after the first 100 days of exposure .
P-306	-0.9340 -0.0474 -0.1153 -0.2072 -0.1134 -0.0433 -0.0766 -0.1613 -0.1600 -0.5067 -0.2002 -0.1449 -0.0961 -0.0822 -0.1385 -0.1469 -0.0773 -0.1512 -0.1503
S-260	Die Durchstechflasche im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-260	Keep the vial in the outer carton in order to protect from light .
H-260	-0.10040736943483353	Keep the vial in the outer carton in order to protect from light .
D-260	-0.10040736943483353	Keep the vial in the outer carton in order to protect from light .
P-260	-0.0562 -0.1369 -0.0774 -0.0893 -0.1424 -0.1338 -0.0065 -0.1013 -0.0481 -0.0376 -0.1343 -0.0974 -0.1289 -0.1172 -0.1168 -0.0744 -0.1592 -0.1498
S-228	In seltenen Fällen können sich Inhibitoren nach den ersten 100 Expositionstagen bilden .
T-228	Rarely , inhibitors may develop after the first 100 exposure days.
H-228	-0.18698598444461823	On rare occasions , inhibitors may form after the first 100 days of exposure .
D-228	-0.18698598444461823	On rare occasions , inhibitors may form after the first 100 days of exposure .
P-228	-0.9340 -0.0474 -0.1153 -0.2072 -0.1134 -0.0433 -0.0766 -0.1613 -0.1600 -0.5067 -0.2002 -0.1449 -0.0961 -0.0822 -0.1385 -0.1469 -0.0773 -0.1512 -0.1503
S-148	Spezifische Erfahrungen zur Behandlung einer Überdosis mit Alendronat liegen nicht vor .
T-148	No specific information is available on the treatment of overdose with alendronate .
H-148	-0.26700475811958313	Specific experience in the treatment of overdose with alendronate is not available .
D-148	-0.26700475811958313	Specific experience in the treatment of overdose with alendronate is not available .
P-148	-0.8953 -0.1204 -0.3190 -0.4025 -0.6185 -0.2472 -0.1461 -0.3494 -0.0878 -0.1005 -0.1290 -0.1388 -0.1231 -0.1498 -0.6129 -0.2239 -0.1107 -0.1467 -0.1515
S-338	Aus mikrobiologischer Sicht sollte das Produkt unmittelbar nach der Rekonstitution verbraucht werden .
T-338	From a microbiological point of view , the product should be used immediately after reconstitution .
H-338	-0.2618006467819214	From a microbiological point of view , the product should be used immediately after reconstitution .
D-338	-0.2618006467819214	From a microbiological point of view , the product should be used immediately after reconstitution .
P-338	-0.3737 -0.2309 -0.1117 -0.0986 -0.1348 -0.5545 -0.1396 -0.0795 -0.2444 -0.7502 -0.0508 -0.0960 -0.1366 -0.9792 -0.1050 -0.5881 -0.1672 -0.0926 -0.1501 -0.1527
S-72	Spezifische Erfahrungen zur Behandlung einer Überdosis mit Alendronat liegen nicht vor .
T-72	No specific information is available on the treatment of overdose with alendronate .
H-72	-0.26700475811958313	Specific experience in the treatment of overdose with alendronate is not available .
D-72	-0.26700475811958313	Specific experience in the treatment of overdose with alendronate is not available .
P-72	-0.8953 -0.1204 -0.3190 -0.4025 -0.6185 -0.2472 -0.1461 -0.3494 -0.0878 -0.1005 -0.1290 -0.1388 -0.1231 -0.1498 -0.6129 -0.2239 -0.1107 -0.1467 -0.1515
S-31	Die empfohlene Dosierung beträgt eine ADROVANCE Tablette einmal wöchentlich .
T-31	The recommended dosage is one ADROVANCE tablet once weekly .
H-31	-0.2881935238838196	The recommended dosage is one ADROVANCE tablet once a week .
D-31	-0.2881935238838196	The recommended dosage is one ADROVANCE tablet once a week .
P-31	-0.2188 -0.0781 -1.1468 -0.1311 -0.1078 -0.1736 -0.1895 -0.1208 -0.0757 -0.1463 -0.1006 -0.0874 -0.1281 -0.0878 -1.4955 -0.7804 -0.1065 -0.1492 -0.1516
S-422	Die Durchstechflasche im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-422	Keep the vial in the outer carton in order to protect from light .
H-422	-0.10040736943483353	Keep the vial in the outer carton in order to protect from light .
D-422	-0.10040736943483353	Keep the vial in the outer carton in order to protect from light .
P-422	-0.0562 -0.1369 -0.0774 -0.0893 -0.1424 -0.1338 -0.0065 -0.1013 -0.0481 -0.0376 -0.1343 -0.0974 -0.1289 -0.1172 -0.1168 -0.0744 -0.1592 -0.1498
S-632	Dies muss bei Patienten , die einer natriumkontrollierten Diät unterliegen , berücksichtigt werden .
T-632	To be taken into consideration by patients on a controlled sodium diet .
H-632	-0.39274343848228455	This has to be taken into account in patients on a sodium controlled diet .
D-632	-0.39274343848228455	This has to be taken into account in patients on a sodium controlled diet .
P-632	-0.3884 -1.5305 -0.1375 -0.1536 -0.9564 -0.0956 -0.1893 -1.2233 -0.0837 -0.2253 -0.1602 -0.1905 -0.8740 -0.1107 -0.0569 -0.1487 -0.1520
S-503	Die Durchstechflasche im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-503	Keep the vial in the outer carton in order to protect from light .
H-503	-0.10040736943483353	Keep the vial in the outer carton in order to protect from light .
D-503	-0.10040736943483353	Keep the vial in the outer carton in order to protect from light .
P-503	-0.0562 -0.1369 -0.0774 -0.0893 -0.1424 -0.1338 -0.0065 -0.1013 -0.0481 -0.0376 -0.1343 -0.0974 -0.1289 -0.1172 -0.1168 -0.0744 -0.1592 -0.1498
S-470	Dies muss bei Patienten , die einer natriumkontrollierten Diät unterliegen , berücksichtigt werden .
T-470	To be taken into consideration by patients on a controlled sodium diet .
H-470	-0.39274343848228455	This has to be taken into account in patients on a sodium controlled diet .
D-470	-0.39274343848228455	This has to be taken into account in patients on a sodium controlled diet .
P-470	-0.3884 -1.5305 -0.1375 -0.1536 -0.9564 -0.0956 -0.1893 -1.2233 -0.0837 -0.2253 -0.1602 -0.1905 -0.8740 -0.1107 -0.0569 -0.1487 -0.1520
S-389	Dies muss bei Patienten , die einer natriumkontrollierten Diät unterliegen , berücksichtigt werden .
T-389	To be taken into consideration by patients on a controlled sodium diet .
H-389	-0.39274343848228455	This has to be taken into account in patients on a sodium controlled diet .
D-389	-0.39274343848228455	This has to be taken into account in patients on a sodium controlled diet .
P-389	-0.3884 -1.5305 -0.1375 -0.1536 -0.9564 -0.0956 -0.1893 -1.2233 -0.0837 -0.2253 -0.1602 -0.1905 -0.8740 -0.1107 -0.0569 -0.1487 -0.1520
S-308	Dies muss bei Patienten , die einer natriumkontrollierten Diät unterliegen , berücksichtigt werden .
T-308	To be taken into consideration by patients on a controlled sodium diet .
H-308	-0.39274343848228455	This has to be taken into account in patients on a sodium controlled diet .
D-308	-0.39274343848228455	This has to be taken into account in patients on a sodium controlled diet .
P-308	-0.3884 -1.5305 -0.1375 -0.1536 -0.9564 -0.0956 -0.1893 -1.2233 -0.0837 -0.2253 -0.1602 -0.1905 -0.8740 -0.1107 -0.0569 -0.1487 -0.1520
S-230	Dies muss bei Patienten , die einer natriumkontrollierten Diät unterliegen , berücksichtigt werden .
T-230	To be taken into consideration by patients on a controlled sodium diet .
H-230	-0.39274343848228455	This has to be taken into account in patients on a sodium controlled diet .
D-230	-0.39274343848228455	This has to be taken into account in patients on a sodium controlled diet .
P-230	-0.3884 -1.5305 -0.1375 -0.1536 -0.9564 -0.0956 -0.1893 -1.2233 -0.0837 -0.2253 -0.1602 -0.1905 -0.8740 -0.1107 -0.0569 -0.1487 -0.1520
S-504	6.6 Besondere Vorsichtsmaßnahmen für die Beseitigung und sonstige Hinweise zur Handhabung
T-504	39 6.6 Special precautions for disposal and other handling
H-504	-0.1548369824886322	6.6 Special precautions for disposal and other handling
D-504	-0.1548369824886322	6.6 Special precautions for disposal and other handling
P-504	-0.6618 -0.1562 -0.1174 -0.0650 -0.0936 -0.1265 -0.1247 -0.0923 -0.1232 -0.1254 -0.1031 -0.0729 -0.1507
S-423	6.6 Besondere Vorsichtsmaßnahmen für die Beseitigung und sonstige Hinweise zur Handhabung
T-423	29 6.6 Special precautions for disposal and other handling
H-423	-0.1548369824886322	6.6 Special precautions for disposal and other handling
D-423	-0.1548369824886322	6.6 Special precautions for disposal and other handling
P-423	-0.6618 -0.1562 -0.1174 -0.0650 -0.0936 -0.1265 -0.1247 -0.0923 -0.1232 -0.1254 -0.1031 -0.0729 -0.1507
S-342	6.6 Besondere Vorsichtsmaßnahmen für die Beseitigung und sonstige Hinweise zur Handhabung
T-342	19 6.6 Special precautions for disposal and other handling
H-342	-0.1548369824886322	6.6 Special precautions for disposal and other handling
D-342	-0.1548369824886322	6.6 Special precautions for disposal and other handling
P-342	-0.6618 -0.1562 -0.1174 -0.0650 -0.0936 -0.1265 -0.1247 -0.0923 -0.1232 -0.1254 -0.1031 -0.0729 -0.1507
S-666	6.6 Besondere Vorsichtsmaßnahmen für die Beseitigung und sonstige Hinweise zur Handhabung
T-666	6.6 Special precautions for disposal and other handling
H-666	-0.1548369824886322	6.6 Special precautions for disposal and other handling
D-666	-0.1548369824886322	6.6 Special precautions for disposal and other handling
P-666	-0.6618 -0.1562 -0.1174 -0.0650 -0.0936 -0.1265 -0.1247 -0.0923 -0.1232 -0.1254 -0.1031 -0.0729 -0.1507
S-387	In seltenen Fällen können sich Inhibitoren nach den ersten 100 Expositionstagen bilden .
T-387	Rarely , inhibitors may develop after the first 100 exposure days.
H-387	-0.18698598444461823	On rare occasions , inhibitors may form after the first 100 days of exposure .
D-387	-0.18698598444461823	On rare occasions , inhibitors may form after the first 100 days of exposure .
P-387	-0.9340 -0.0474 -0.1153 -0.2072 -0.1134 -0.0433 -0.0766 -0.1613 -0.1600 -0.5067 -0.2002 -0.1449 -0.0961 -0.0822 -0.1385 -0.1469 -0.0773 -0.1512 -0.1503
S-261	6.6 Besondere Vorsichtsmaßnahmen für die Beseitigung und sonstige Hinweise zur Handhabung
T-261	6.6 Special precautions for disposal and other handling
H-261	-0.1548369824886322	6.6 Special precautions for disposal and other handling
D-261	-0.1548369824886322	6.6 Special precautions for disposal and other handling
P-261	-0.6618 -0.1562 -0.1174 -0.0650 -0.0936 -0.1265 -0.1247 -0.0923 -0.1232 -0.1254 -0.1031 -0.0729 -0.1507
S-341	Die Durchstechflasche im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-341	Keep the vial in the outer carton in order to protect from light .
H-341	-0.10040736943483353	Keep the vial in the outer carton in order to protect from light .
D-341	-0.10040736943483353	Keep the vial in the outer carton in order to protect from light .
P-341	-0.0562 -0.1369 -0.0774 -0.0893 -0.1424 -0.1338 -0.0065 -0.1013 -0.0481 -0.0376 -0.1343 -0.0974 -0.1289 -0.1172 -0.1168 -0.0744 -0.1592 -0.1498
S-299	Die Patienten sollten regelmäßig auf die Bildung von Inhibitoren gegen Faktor VIII überwacht werden .
T-299	Patients should be monitored for the development of factor VIII inhibitors .
H-299	-0.34134042263031006	Patients should be monitored regularly for formation of inhibitors of factor VIII .
D-299	-0.34134042263031006	Patients should be monitored regularly for formation of inhibitors of factor VIII .
P-299	-0.0659 -0.0946 -0.1753 -0.1464 -0.5524 -0.1082 -0.8943 -0.1184 -1.1745 -0.1432 -1.2143 -0.0393 -0.0676 -0.1713 -0.5079 -0.8004 -0.1915 -0.0573 -0.1530 -0.1509
S-135	Es liegen keine geeigneten Daten zur Anwendung von ADROVANCE bei schwangeren Frauen vor .
T-135	There are no adequate data from the use of ADROVANCE in pregnant women .
H-135	-0.19423344731330872	There are no adequate data on the use of ADROVANCE in pregnant women .
D-135	-0.19423344731330872	There are no adequate data on the use of ADROVANCE in pregnant women .
P-135	-0.4397 -0.1774 -0.1206 -0.7974 -0.1117 -0.2251 -0.4066 -0.1109 -0.1472 -0.0976 -0.0766 -0.1463 -0.1047 -0.0760 -0.1283 -0.1285 -0.0939 -0.1465 -0.1551
S-257	Aus mikrobiologischer Sicht sollte das Produkt unmittelbar nach der Rekonstitution verbraucht werden .
T-257	From a microbiological point of view , the product should be used immediately after reconstitution .
H-257	-0.2618006467819214	From a microbiological point of view , the product should be used immediately after reconstitution .
D-257	-0.2618006467819214	From a microbiological point of view , the product should be used immediately after reconstitution .
P-257	-0.3737 -0.2309 -0.1117 -0.0986 -0.1348 -0.5545 -0.1396 -0.0795 -0.2444 -0.7502 -0.0508 -0.0960 -0.1366 -0.9792 -0.1050 -0.5881 -0.1672 -0.0926 -0.1501 -0.1527
S-24	Die Patienten erhielten einmal pro Woche entweder ADROVANCE oder nur Alendronat .
T-24	Patients received either ADROVANCE or alendronate only once a week .
H-24	-0.3183947801589966	Patients received either ADROVANCE or alendronate once a week .
D-24	-0.3183947801589966	Patients received either ADROVANCE or alendronate once a week .
P-24	-0.1831 -0.0926 -2.1473 -0.5029 -0.0524 -0.0743 -0.1407 -0.1057 -0.0662 -0.1767 -0.3329 -0.1459 -0.1232 -0.0884 -1.0102 -0.4070 -0.1011 -0.1487 -0.1503
S-836	Deshalb ist bei der Anwendung des Kombinationspräparats bei Patienten über 60 Jahren Vorsicht geboten .
T-836	Therefore the combination product should be used with caution in patients above 60 years of age .
H-836	-0.35715386271476746	Caution should therefore be exercised when administering the combination to patients over 60 years of age .
D-836	-0.35715386271476746	Caution should therefore be exercised when administering the combination to patients over 60 years of age .
P-836	-0.2730 -0.0722 -0.6510 -0.1750 -0.1568 -0.2484 -0.0891 -2.0357 -0.9809 -0.3332 -0.4218 -0.4791 -0.1884 -0.0503 -0.2127 -0.1354 -0.1661 -0.4105 -0.1180 -0.1535 -0.1491
S-771	Das Produkt darf nach der Lagerung bei Raumtemperatur nicht wieder gekühlt gelagert werden .
T-771	The product may not be returned to refrigerated storage after storage at room temperature .
H-771	-0.259311318397522	Do not store the product refrigerated after storage at room temperature .
D-771	-0.259311318397522	Do not store the product refrigerated after storage at room temperature .
P-771	-0.5168 -0.1308 -0.3396 -0.2711 -0.0872 -0.9971 -0.0946 -0.0834 -0.1560 -0.3095 -0.5116 -0.1585 -0.0857 -0.1103 -0.1433 -0.1535
S-623	Die Patienten sollten regelmäßig auf die Bildung von Inhibitoren gegen Faktor VIII überwacht werden .
T-623	Patients should be monitored for the development of factor VIII inhibitors .
H-623	-0.34134042263031006	Patients should be monitored regularly for formation of inhibitors of factor VIII .
D-623	-0.34134042263031006	Patients should be monitored regularly for formation of inhibitors of factor VIII .
P-623	-0.0659 -0.0946 -0.1753 -0.1464 -0.5524 -0.1082 -0.8943 -0.1184 -1.1745 -0.1432 -1.2143 -0.0393 -0.0676 -0.1713 -0.5079 -0.8004 -0.1915 -0.0573 -0.1530 -0.1509
S-542	Die Patienten sollten regelmäßig auf die Bildung von Inhibitoren gegen Faktor VIII überwacht werden .
T-542	Patients should be monitored for the development of factor VIII inhibitors .
H-542	-0.34134042263031006	Patients should be monitored regularly for formation of inhibitors of factor VIII .
D-542	-0.34134042263031006	Patients should be monitored regularly for formation of inhibitors of factor VIII .
P-542	-0.0659 -0.0946 -0.1753 -0.1464 -0.5524 -0.1082 -0.8943 -0.1184 -1.1745 -0.1432 -1.2143 -0.0393 -0.0676 -0.1713 -0.5079 -0.8004 -0.1915 -0.0573 -0.1530 -0.1509
S-461	Die Patienten sollten regelmäßig auf die Bildung von Inhibitoren gegen Faktor VIII überwacht werden .
T-461	Patients should be monitored for the development of factor VIII inhibitors .
H-461	-0.34134042263031006	Patients should be monitored regularly for formation of inhibitors of factor VIII .
D-461	-0.34134042263031006	Patients should be monitored regularly for formation of inhibitors of factor VIII .
P-461	-0.0659 -0.0946 -0.1753 -0.1464 -0.5524 -0.1082 -0.8943 -0.1184 -1.1745 -0.1432 -1.2143 -0.0393 -0.0676 -0.1713 -0.5079 -0.8004 -0.1915 -0.0573 -0.1530 -0.1509
S-380	Die Patienten sollten regelmäßig auf die Bildung von Inhibitoren gegen Faktor VIII überwacht werden .
T-380	Patients should be monitored for the development of factor VIII inhibitors .
H-380	-0.34134042263031006	Patients should be monitored regularly for formation of inhibitors of factor VIII .
D-380	-0.34134042263031006	Patients should be monitored regularly for formation of inhibitors of factor VIII .
P-380	-0.0659 -0.0946 -0.1753 -0.1464 -0.5524 -0.1082 -0.8943 -0.1184 -1.1745 -0.1432 -1.2143 -0.0393 -0.0676 -0.1713 -0.5079 -0.8004 -0.1915 -0.0573 -0.1530 -0.1509
S-468	In seltenen Fällen können sich Inhibitoren nach den ersten 100 Expositionstagen bilden .
T-468	Rarely , inhibitors may develop after the first 100 exposure days.
H-468	-0.18698598444461823	On rare occasions , inhibitors may form after the first 100 days of exposure .
D-468	-0.18698598444461823	On rare occasions , inhibitors may form after the first 100 days of exposure .
P-468	-0.9340 -0.0474 -0.1153 -0.2072 -0.1134 -0.0433 -0.0766 -0.1613 -0.1600 -0.5067 -0.2002 -0.1449 -0.0961 -0.0822 -0.1385 -0.1469 -0.0773 -0.1512 -0.1503
S-221	Die Patienten sollten regelmäßig auf die Bildung von Inhibitoren gegen Faktor VIII überwacht werden .
T-221	Patients should be monitored for the development of factor VIII inhibitors .
H-221	-0.34134042263031006	Patients should be monitored regularly for formation of inhibitors of factor VIII .
D-221	-0.34134042263031006	Patients should be monitored regularly for formation of inhibitors of factor VIII .
P-221	-0.0659 -0.0946 -0.1753 -0.1464 -0.5524 -0.1082 -0.8943 -0.1184 -1.1745 -0.1432 -1.2143 -0.0393 -0.0676 -0.1713 -0.5079 -0.8004 -0.1915 -0.0573 -0.1530 -0.1509
S-549	In seltenen Fällen können sich Inhibitoren nach den ersten 100 Expositionstagen bilden .
T-549	Rarely , inhibitors may develop after the first 100 exposure days.
H-549	-0.18698598444461823	On rare occasions , inhibitors may form after the first 100 days of exposure .
D-549	-0.18698598444461823	On rare occasions , inhibitors may form after the first 100 days of exposure .
P-549	-0.9340 -0.0474 -0.1153 -0.2072 -0.1134 -0.0433 -0.0766 -0.1613 -0.1600 -0.5067 -0.2002 -0.1449 -0.0961 -0.0822 -0.1385 -0.1469 -0.0773 -0.1512 -0.1503
S-61	5 Es ist nicht bekannt , ob Alendronat in die Muttermilch übergeht .
T-61	It is not known whether alendronate is excreted into human breast milk .
H-61	-0.45253196358680725	Alendronate is not known to be released into human milk .
D-61	-0.45253196358680725	Alendronate is not known to be released into human milk .
P-61	-0.9859 -0.1462 -0.1078 -0.0777 -0.1272 -0.6501 -0.1081 -0.1227 -0.2906 -3.1842 -0.2273 -0.2127 -0.2308 -0.1637 -0.1530
S-59	Es liegen keine geeigneten Daten zur Anwendung von ADROVANCE bei schwangeren Frauen vor .
T-59	There are no adequate data from the use of ADROVANCE in pregnant women .
H-59	-0.19423344731330872	There are no adequate data on the use of ADROVANCE in pregnant women .
D-59	-0.19423344731330872	There are no adequate data on the use of ADROVANCE in pregnant women .
P-59	-0.4397 -0.1774 -0.1206 -0.7974 -0.1117 -0.2251 -0.4066 -0.1109 -0.1472 -0.0976 -0.0766 -0.1463 -0.1047 -0.0760 -0.1283 -0.1285 -0.0939 -0.1465 -0.1551
S-0	Adenuric ist ein Arzneimittel , das den Wirkstoff Febuxostat enthält .
T-0	Adenuric is a medicine containing the active substance febuxostat .
H-0	-0.16614671051502228	Adenuric is a medicine containing the active substance Febuxostat .
D-0	-0.16614671051502228	Adenuric is a medicine containing the active substance Febuxostat .
P-0	-0.0957 -0.1335 -0.0646 -0.1124 -0.1415 -0.1632 -0.6199 -0.0754 -0.1339 -0.0696 -0.0479 -0.5841 -0.1308 -0.1138 -0.0881 -0.1116 -0.1503 -0.1544
S-833	Die empfohlene Dosierung von Aerinaze beträgt eine Tablette zweimal täglich .
T-833	The recommended dose of Aerinaze is one tablet twice a day .
H-833	-0.3039586842060089	The recommended dose of Aerinaze is one tablet 2 times daily .
D-833	-0.3039586842060089	The recommended dose of Aerinaze is one tablet 2 times daily .
P-833	-0.2111 -0.1585 -0.5885 -0.1762 -0.1504 -0.1253 -0.1326 -0.1316 -0.1023 -0.1305 -0.2728 -0.0598 -0.0895 -2.4854 -0.0932 -0.2562 -0.1558 -0.1516
S-735	Faktor VIII ist notwendig um im Blut Gerinnsel zu bilden und so Blutungen zu stoppen .
T-735	Factor VIII is necessary for the blood to form clots and stop bleedings .
H-735	-0.4964364767074585	Factor VIII is necessary to prevent clotting of the blood and to stop bleeding .
D-735	-0.4964364767074585	Factor VIII is necessary to prevent clotting of the blood and to stop bleeding .
P-735	-0.2952 -0.1592 -0.0663 -0.1267 -0.3854 -0.2518 -2.7862 -0.6990 -1.0456 -0.0815 -1.3316 -0.1344 -0.1544 -0.4486 -0.6745 -0.3768 -0.4689 -0.1345 -0.1549 -0.1533
S-665	Die Durchstechflasche im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-665	Keep the vial in the outer carton in order to protect from light .
H-665	-0.10040736943483353	Keep the vial in the outer carton in order to protect from light .
D-665	-0.10040736943483353	Keep the vial in the outer carton in order to protect from light .
P-665	-0.0562 -0.1369 -0.0774 -0.0893 -0.1424 -0.1338 -0.0065 -0.1013 -0.0481 -0.0376 -0.1343 -0.0974 -0.1289 -0.1172 -0.1168 -0.0744 -0.1592 -0.1498
S-630	In seltenen Fällen können sich Inhibitoren nach den ersten 100 Expositionstagen bilden .
T-630	Rarely , inhibitors may develop after the first 100 exposure days.
H-630	-0.18698598444461823	On rare occasions , inhibitors may form after the first 100 days of exposure .
D-630	-0.18698598444461823	On rare occasions , inhibitors may form after the first 100 days of exposure .
P-630	-0.9340 -0.0474 -0.1153 -0.2072 -0.1134 -0.0433 -0.0766 -0.1613 -0.1600 -0.5067 -0.2002 -0.1449 -0.0961 -0.0822 -0.1385 -0.1469 -0.0773 -0.1512 -0.1503
S-584	Die Durchstechflasche im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-584	Keep the vial in the outer carton in order to protect from light .
H-584	-0.10040736943483353	Keep the vial in the outer carton in order to protect from light .
D-584	-0.10040736943483353	Keep the vial in the outer carton in order to protect from light .
P-584	-0.0562 -0.1369 -0.0774 -0.0893 -0.1424 -0.1338 -0.0065 -0.1013 -0.0481 -0.0376 -0.1343 -0.0974 -0.1289 -0.1172 -0.1168 -0.0744 -0.1592 -0.1498
S-585	6.6 Besondere Vorsichtsmaßnahmen für die Beseitigung und sonstige Hinweise zur Handhabung
T-585	6.6 Special precautions for disposal and other handling
H-585	-0.1548369824886322	6.6 Special precautions for disposal and other handling
D-585	-0.1548369824886322	6.6 Special precautions for disposal and other handling
P-585	-0.6618 -0.1562 -0.1174 -0.0650 -0.0936 -0.1265 -0.1247 -0.0923 -0.1232 -0.1254 -0.1031 -0.0729 -0.1507
S-482	Nachfolgende Inhibitortests an diesem Patienten nach Ausschluss aus der Studie waren negativ .
T-482	Follow-up inhibitor tests in this patient after withdrawal from the study were negative .
H-482	-0.25578105449676514	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
D-482	-0.25578105449676514	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
P-482	-0.2175 -0.1894 -0.1230 -0.1044 -0.0572 -0.4336 -0.3594 -0.1220 -0.1381 -0.0635 -0.7996 -0.6693 -0.1039 -0.3509 -0.1432 -0.4207 -0.4009 -0.1229 -0.1454 -0.1505
S-563	Nachfolgende Inhibitortests an diesem Patienten nach Ausschluss aus der Studie waren negativ .
T-563	Follow-up inhibitor tests in this patient after withdrawal from the study were negative .
H-563	-0.25578105449676514	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
D-563	-0.25578105449676514	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
P-563	-0.2175 -0.1894 -0.1230 -0.1044 -0.0572 -0.4336 -0.3594 -0.1220 -0.1381 -0.0635 -0.7996 -0.6693 -0.1039 -0.3509 -0.1432 -0.4207 -0.4009 -0.1229 -0.1454 -0.1505
S-782	Pharmazeutischer Unternehmer Baxter AG Industriestrasse 67 A-1221 Wien , Österreich
T-782	95 Marketing Authorisation Holder Baxter AG Industriestrasse 67 A-1221 Vienna
H-782	-0.23270083963871002	Marketing Authorisation Holder Baxter AG Industriestrasse 67 A-1221 Vienna , Austria
D-782	-0.23270083963871002	Marketing Authorisation Holder Baxter AG Industriestrasse 67 A-1221 Vienna , Austria
P-782	-1.7061 -0.1605 -0.1531 -0.2007 -0.1814 -0.0534 -0.1528 -0.1342 -0.1734 -0.1262 -0.0382 -0.0795 -0.5438 -0.0774 -0.1357 -0.1333 -0.1203 -0.1395 -0.2731 -0.1661 -0.1473 -0.2236
S-401	Nachfolgende Inhibitortests an diesem Patienten nach Ausschluss aus der Studie waren negativ .
T-401	Follow-up inhibitor tests in this patient after withdrawal from the study were negative .
H-401	-0.25578105449676514	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
D-401	-0.25578105449676514	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
P-401	-0.2175 -0.1894 -0.1230 -0.1044 -0.0572 -0.4336 -0.3594 -0.1220 -0.1381 -0.0635 -0.7996 -0.6693 -0.1039 -0.3509 -0.1432 -0.4207 -0.4009 -0.1229 -0.1454 -0.1505
S-320	Nachfolgende Inhibitortests an diesem Patienten nach Ausschluss aus der Studie waren negativ .
T-320	Follow-up inhibitor tests in this patient after withdrawal from the study were negative .
H-320	-0.25578105449676514	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
D-320	-0.25578105449676514	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
P-320	-0.2175 -0.1894 -0.1230 -0.1044 -0.0572 -0.4336 -0.3594 -0.1220 -0.1381 -0.0635 -0.7996 -0.6693 -0.1039 -0.3509 -0.1432 -0.4207 -0.4009 -0.1229 -0.1454 -0.1505
S-241	Nachfolgende Inhibitortests an diesem Patienten nach Ausschluss aus der Studie waren negativ .
T-241	Follow-up inhibitor tests in this patient after withdrawal from the study were negative .
H-241	-0.25578105449676514	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
D-241	-0.25578105449676514	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
P-241	-0.2175 -0.1894 -0.1230 -0.1044 -0.0572 -0.4336 -0.3594 -0.1220 -0.1381 -0.0635 -0.7996 -0.6693 -0.1039 -0.3509 -0.1432 -0.4207 -0.4009 -0.1229 -0.1454 -0.1505
S-644	Nachfolgende Inhibitortests an diesem Patienten nach Ausschluss aus der Studie waren negativ .
T-644	Follow-up inhibitor tests in this patient after withdrawal from the study were negative .
H-644	-0.25578105449676514	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
D-644	-0.25578105449676514	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
P-644	-0.2175 -0.1894 -0.1230 -0.1044 -0.0572 -0.4336 -0.3594 -0.1220 -0.1381 -0.0635 -0.7996 -0.6693 -0.1039 -0.3509 -0.1432 -0.4207 -0.4009 -0.1229 -0.1454 -0.1505
S-137	Es ist nicht bekannt , ob Alendronat in die Muttermilch übergeht .
T-137	It is not known whether alendronate is excreted into human breast milk .
H-137	-0.427770733833313	It is not known whether alendronate is converted into human milk .
D-137	-0.427770733833313	It is not known whether alendronate is converted into human milk .
P-137	-0.8194 -0.1496 -0.3182 -0.0918 -0.3475 -0.1038 -0.1375 -0.0978 -0.0860 -0.2984 -2.6287 -0.3138 -0.9390 -0.2144 -0.1483 -0.1500
S-279	Das System umdrehen ( mit der Konzentrat-Durchstechflasche nach oben ) .
T-279	Invert the system ( the vial with the reconstituted solution has to be on top ) .
H-279	-0.5185602903366089	Turn the system upside down ( with the vial of concentrate facing up ) .
D-279	-0.5185602903366089	Turn the system upside down ( with the vial of concentrate facing up ) .
P-279	-0.1624 -0.1246 -0.4010 -0.2047 -1.4833 -1.7648 -0.1193 -0.1784 -0.6297 -0.1378 -0.5774 -0.0761 -0.9773 -1.1858 -0.7615 -0.6091 -0.1476 -0.1581 -0.1537
S-360	Das System umdrehen ( mit der Konzentrat-Durchstechflasche nach oben ) .
T-360	Invert the system ( the vial with the reconstituted solution has to be on top ) .
H-360	-0.5185602903366089	Turn the system upside down ( with the vial of concentrate facing up ) .
D-360	-0.5185602903366089	Turn the system upside down ( with the vial of concentrate facing up ) .
P-360	-0.1624 -0.1246 -0.4010 -0.2047 -1.4833 -1.7648 -0.1193 -0.1784 -0.6297 -0.1378 -0.5774 -0.0761 -0.9773 -1.1858 -0.7615 -0.6091 -0.1476 -0.1581 -0.1537
S-441	Das System umdrehen ( mit der Konzentrat-Durchstechflasche nach oben ) .
T-441	Invert the system ( the vial with the reconstituted solution has to be on top ) .
H-441	-0.5185602903366089	Turn the system upside down ( with the vial of concentrate facing up ) .
D-441	-0.5185602903366089	Turn the system upside down ( with the vial of concentrate facing up ) .
P-441	-0.1624 -0.1246 -0.4010 -0.2047 -1.4833 -1.7648 -0.1193 -0.1784 -0.6297 -0.1378 -0.5774 -0.0761 -0.9773 -1.1858 -0.7615 -0.6091 -0.1476 -0.1581 -0.1537
S-522	Das System umdrehen ( mit der Konzentrat-Durchstechflasche nach oben ) .
T-522	Invert the system ( the vial with the reconstituted solution has to be on top ) .
H-522	-0.5185602903366089	Turn the system upside down ( with the vial of concentrate facing up ) .
D-522	-0.5185602903366089	Turn the system upside down ( with the vial of concentrate facing up ) .
P-522	-0.1624 -0.1246 -0.4010 -0.2047 -1.4833 -1.7648 -0.1193 -0.1784 -0.6297 -0.1378 -0.5774 -0.0761 -0.9773 -1.1858 -0.7615 -0.6091 -0.1476 -0.1581 -0.1537
S-603	Das System umdrehen ( mit der Konzentrat-Durchstechflasche nach oben ) .
T-603	Invert the system ( the vial with the reconstituted solution has to be on top ) .
H-603	-0.5185602903366089	Turn the system upside down ( with the vial of concentrate facing up ) .
D-603	-0.5185602903366089	Turn the system upside down ( with the vial of concentrate facing up ) .
P-603	-0.1624 -0.1246 -0.4010 -0.2047 -1.4833 -1.7648 -0.1193 -0.1784 -0.6297 -0.1378 -0.5774 -0.0761 -0.9773 -1.1858 -0.7615 -0.6091 -0.1476 -0.1581 -0.1537
S-684	Das System umdrehen ( mit der Konzentrat-Durchstechflasche nach oben ) .
T-684	Invert the system ( the vial with the reconstituted solution has to be on top ) .
H-684	-0.5185602903366089	Turn the system upside down ( with the vial of concentrate facing up ) .
D-684	-0.5185602903366089	Turn the system upside down ( with the vial of concentrate facing up ) .
P-684	-0.1624 -0.1246 -0.4010 -0.2047 -1.4833 -1.7648 -0.1193 -0.1784 -0.6297 -0.1378 -0.5774 -0.0761 -0.9773 -1.1858 -0.7615 -0.6091 -0.1476 -0.1581 -0.1537
S-778	Trometamol , Polysorbat 80 , Glutathion ( reduziert ) .
T-778	trometamol , polysorbate 80 , and glutathione ( reduced ) .
H-778	-0.1600269377231598	Trometamol , polysorbate 80 , glutathione ( reduced ) .
D-778	-0.1600269377231598	Trometamol , polysorbate 80 , glutathione ( reduced ) .
P-778	-0.7534 -0.0986 -0.1673 -0.1546 -0.1536 -0.0929 -0.0367 -0.1189 -0.1665 -0.0877 -0.1499 -0.1441 -0.0866 -0.0793 -0.1269 -0.1901 -0.1448 -0.0922 -0.1556 -0.1936 -0.1672
S-109	Vitamin D3 einmal pro Woche in ADROVANCE und von 800 I.E.
T-109	Patients should receive supplemental calcium if intake from diet is inadequate ( see section 4.4 ) .
H-109	-0.17772886157035828	Vitamin D3 once a week in ADROVANCE and from 800 IU .
D-109	-0.17772886157035828	Vitamin D3 once a week in ADROVANCE and from 800 IU .
P-109	-0.6231 -0.0945 -0.1404 -0.1579 -0.3587 -0.3035 -0.1043 -0.1318 -0.0639 -0.0868 -0.1490 -0.0901 -0.0793 -0.1599 -0.3476 -0.0845 -0.1091 -0.1214 -0.1898 -0.1590
S-841	Ebenfalls zur Vorsicht geraten wird bei Patienten , die mit anderen Sympathomimetika behandelt werden .
T-841	Caution should also be exercised in patients being treated with other sympathomimetics .
H-841	-0.25615930557250977	Caution is also advised in patients treated with other sympathomimetics .
D-841	-0.25615930557250977	Caution is also advised in patients treated with other sympathomimetics .
P-841	-0.1383 -0.0625 -0.1556 -0.0879 -1.6854 -0.3279 -0.1173 -0.4381 -0.1348 -0.1576 -0.1319 -0.0759 -0.0901 -0.1927 -0.1533 -0.1493
S-55	Unerwünschte Reaktionen , die auf diese kombinierte Anwendung zurückzuführen waren , wurden nicht beobachtet .
T-55	No adverse reactions attributable to their concomitant use were identified .
H-55	-0.44619977474212646	Adverse reactions attributable to this combined use have not been observed .
D-55	-0.44619977474212646	Adverse reactions attributable to this combined use have not been observed .
P-55	-0.8153 -0.0263 -0.0353 -0.0375 -1.0530 -0.0773 -0.1250 -0.1463 -0.1658 -1.1868 -2.4545 -0.4120 -0.1150 -0.0941 -0.5348 -0.1501 -0.1565
S-131	Unerwünschte Reaktionen , die auf diese kombinierte Anwendung zurückzuführen waren , wurden nicht beobachtet .
T-131	No adverse reactions attributable to their concomitant use were identified .
H-131	-0.44619977474212646	Adverse reactions attributable to this combined use have not been observed .
D-131	-0.44619977474212646	Adverse reactions attributable to this combined use have not been observed .
P-131	-0.8153 -0.0263 -0.0353 -0.0375 -1.0530 -0.0773 -0.1250 -0.1463 -0.1658 -1.1868 -2.4545 -0.4120 -0.1150 -0.0941 -0.5348 -0.1501 -0.1565
S-814	Als das Unternehmen seinen Antrag zurücknahm , war in dem Antragsverfahren Tag 179 erreicht .
T-814	The application was at day 179 when the company withdrew .
H-814	-0.41136401891708374	When the company withdrew its application , day 179 of the application procedure had been reached .
D-814	-0.41136401891708374	When the company withdrew its application , day 179 of the application procedure had been reached .
P-814	-0.3776 -0.3214 -0.1807 -0.0170 -0.0732 -0.5170 -0.2107 -0.2630 -1.7345 -0.0952 -0.1707 -1.0442 -0.1454 -0.4888 -0.6446 -0.7713 -0.1043 -0.7711 -0.1443 -0.1523
S-119	Während der Behandlung sollten diese Patienten kieferchirurgische Eingriffe soweit möglich vermeiden .
T-119	While on treatment , these patients should avoid invasive dental procedures if possible .
H-119	-0.4420403838157654	While on treatment , patients should avoid maxillofacial surgery as much as possible .
D-119	-0.4420403838157654	While on treatment , patients should avoid maxillofacial surgery as much as possible .
P-119	-1.4612 -0.4254 -0.2568 -0.1916 -0.9537 -0.0711 -0.0842 -1.7371 -0.2115 -0.4378 -0.0967 -0.0989 -0.6152 -0.4938 -0.7277 -0.1338 -0.1089 -0.1432 -0.1500
S-64	Es wurden keine Studien zur Verkehrstüchtigkeit oder zur Fähigkeit zum Bedienen von Maschinen durchgeführt .
T-64	No studies on the effects on the ability to drive and use machines have been performed .
H-64	-0.24414804577827454	No studies on the ability to drive or use machines have been performed .
D-64	-0.24414804577827454	No studies on the ability to drive or use machines have been performed .
P-64	-0.3569 -0.0647 -0.4890 -0.8253 -0.0838 -0.1353 -0.0434 -0.1842 -0.1687 -0.1078 -0.2372 -0.1379 -0.5233 -0.1474 -0.1574
S-820	Sobald die Nase wieder frei ist , können die Patienten Desloratadin allein einnehmen .
T-820	Once the nose has cleared , patients can use desloratadine alone .
H-820	-0.38103100657463074	Once the nose is clear , patients can take desloratadine on their own .
D-820	-0.38103100657463074	Once the nose is clear , patients can take desloratadine on their own .
P-820	-1.4725 -0.2438 -0.5097 -0.1482 -1.1560 -0.4955 -0.0711 -1.0224 -0.2006 -0.3597 -0.0447 -0.1192 -0.2470 -0.2591 -0.2364 -0.2318 -0.1221 -0.1492 -0.1508
S-815	Zur Beurteilung eines neuen Antrags benötigt der CHMP in der Regel bis zu 210 Tage .
T-815	The CHMP normally takes up to 210 days to evaluate a new application .
H-815	-0.29470354318618774	The CHMP usually takes up to 210 days to assess a new application .
D-815	-0.29470354318618774	The CHMP usually takes up to 210 days to assess a new application .
P-815	-0.8766 -0.3187 -0.0545 -0.9411 -0.4456 -0.0673 -0.1332 -0.0584 -0.1571 -0.1298 -0.6315 -0.1431 -0.1942 -0.2689 -0.1442 -0.1512
S-76	Der unter Therapie mit Alendronat gebildete Knochen ist von normaler Qualität .
T-76	The bone formed during treatment with alendronate is of normal quality .
H-76	-0.2668444812297821	The bone formed during therapy with alendronate is of normal quality .
D-76	-0.2668444812297821	The bone formed during therapy with alendronate is of normal quality .
P-76	-0.5322 -0.1144 -0.6785 -0.5355 -0.9499 -0.1296 -0.1624 -0.1353 -0.1472 -0.1210 -0.1391 -0.1288 -0.0921 -0.0944 -0.1547 -0.1544
S-43	Während der Behandlung sollten diese Patienten kieferchirurgische Eingriffe soweit möglich vermeiden .
T-43	While on treatment , these patients should avoid invasive dental procedures if possible .
H-43	-0.4420403838157654	While on treatment , patients should avoid maxillofacial surgery as much as possible .
D-43	-0.4420403838157654	While on treatment , patients should avoid maxillofacial surgery as much as possible .
P-43	-1.4612 -0.4254 -0.2568 -0.1916 -0.9537 -0.0711 -0.0842 -1.7371 -0.2115 -0.4378 -0.0967 -0.0989 -0.6152 -0.4938 -0.7277 -0.1338 -0.1089 -0.1432 -0.1500
S-153	Der unter Therapie mit Alendronat gebildete Knochen ist von normaler Qualität .
T-153	The bone formed during treatment with alendronate is of normal quality .
H-153	-0.2668444812297821	The bone formed during therapy with alendronate is of normal quality .
D-153	-0.2668444812297821	The bone formed during therapy with alendronate is of normal quality .
P-153	-0.5322 -0.1144 -0.6785 -0.5355 -0.9499 -0.1296 -0.1624 -0.1353 -0.1472 -0.1210 -0.1391 -0.1288 -0.0921 -0.0944 -0.1547 -0.1544
S-140	Es wurden keine Studien zur Verkehrstüchtigkeit oder zur Fähigkeit zum Bedienen von Maschinen durchgeführt .
T-140	No studies on the effects on the ability to drive and use machines have been performed .
H-140	-0.24414804577827454	No studies on the ability to drive or use machines have been performed .
D-140	-0.24414804577827454	No studies on the ability to drive or use machines have been performed .
P-140	-0.3569 -0.0647 -0.4890 -0.8253 -0.0838 -0.1353 -0.0434 -0.1842 -0.1687 -0.1078 -0.2372 -0.1379 -0.5233 -0.1474 -0.1574
S-390	Es wurden keine Untersuchungen zur Wechselwirkung von ADVATE mit anderen Arzneimitteln durchgeführt .
T-390	24 No interaction studies have been performed with ADVATE .
H-390	-0.28080686926841736	No studies on the interaction of ADVATE with other medicinal products have been performed .
D-390	-0.28080686926841736	No studies on the interaction of ADVATE with other medicinal products have been performed .
P-390	-0.9695 -0.7578 -0.7201 -0.3195 -0.2952 -0.1259 -0.1675 -0.1369 -0.1575 -0.0782 -0.0801 -0.1209 -0.6338 -0.0463 -0.0583 -0.0722 -0.2135 -0.1322 -0.5100 -0.1467 -0.1549
S-27	Den vollständigen Wortlaut des EPAR für ADROVANCE finden Sie hier .
T-27	The full EPAR for ADROVANCE is available here .
H-27	-0.20661987364292145	The full EPAR for ADROVANCE can be found here .
D-27	-0.20661987364292145	The full EPAR for ADROVANCE can be found here .
P-27	-0.3125 -0.1953 -0.0392 -0.0807 -0.1081 -0.1213 -0.0766 -0.1495 -0.0969 -0.0785 -1.0106 -0.1393 -0.2705 -0.1426 -0.3194 -0.1649
S-309	Es wurden keine Untersuchungen zur Wechselwirkung von ADVATE mit anderen Arzneimitteln durchgeführt .
T-309	14 No interaction studies have been performed with ADVATE .
H-309	-0.28080686926841736	No studies on the interaction of ADVATE with other medicinal products have been performed .
D-309	-0.28080686926841736	No studies on the interaction of ADVATE with other medicinal products have been performed .
P-309	-0.9695 -0.7578 -0.7201 -0.3195 -0.2952 -0.1259 -0.1675 -0.1369 -0.1575 -0.0782 -0.0801 -0.1209 -0.6338 -0.0463 -0.0583 -0.0722 -0.2135 -0.1322 -0.5100 -0.1467 -0.1549
S-231	Es wurden keine Untersuchungen zur Wechselwirkung von ADVATE mit anderen Arzneimitteln durchgeführt .
T-231	No interaction studies have been performed with ADVATE. .
H-231	-0.28080686926841736	No studies on the interaction of ADVATE with other medicinal products have been performed .
D-231	-0.28080686926841736	No studies on the interaction of ADVATE with other medicinal products have been performed .
P-231	-0.9695 -0.7578 -0.7201 -0.3195 -0.2952 -0.1259 -0.1675 -0.1369 -0.1575 -0.0782 -0.0801 -0.1209 -0.6338 -0.0463 -0.0583 -0.0722 -0.2135 -0.1322 -0.5100 -0.1467 -0.1549
S-471	Es wurden keine Untersuchungen zur Wechselwirkung von ADVATE mit anderen Arzneimitteln durchgeführt .
T-471	34 No interaction studies have been performed with ADVATE .
H-471	-0.28080686926841736	No studies on the interaction of ADVATE with other medicinal products have been performed .
D-471	-0.28080686926841736	No studies on the interaction of ADVATE with other medicinal products have been performed .
P-471	-0.9695 -0.7578 -0.7201 -0.3195 -0.2952 -0.1259 -0.1675 -0.1369 -0.1575 -0.0782 -0.0801 -0.1209 -0.6338 -0.0463 -0.0583 -0.0722 -0.2135 -0.1322 -0.5100 -0.1467 -0.1549
S-552	Es wurden keine Untersuchungen zur Wechselwirkung von ADVATE mit anderen Arzneimitteln durchgeführt .
T-552	44 No interaction studies have been performed with ADVATE .
H-552	-0.28080686926841736	No studies on the interaction of ADVATE with other medicinal products have been performed .
D-552	-0.28080686926841736	No studies on the interaction of ADVATE with other medicinal products have been performed .
P-552	-0.9695 -0.7578 -0.7201 -0.3195 -0.2952 -0.1259 -0.1675 -0.1369 -0.1575 -0.0782 -0.0801 -0.1209 -0.6338 -0.0463 -0.0583 -0.0722 -0.2135 -0.1322 -0.5100 -0.1467 -0.1549
S-350	Schutzkappen von den Durchstechflaschen mit Pulver und Lösungsmittel entfernen .
T-350	Remove caps from powder and solvent vials .
H-350	-0.2965630888938904	Remove the protective caps from the vials with powder and solvent .
D-350	-0.2965630888938904	Remove the protective caps from the vials with powder and solvent .
P-350	-0.1710 -0.0470 -0.1149 -0.6689 -0.2473 -0.2953 -0.1469 -0.2303 -0.0507 -0.1183 -0.4599 -0.5095 -0.1490 -0.1492 -1.3901 -0.1399 -0.1532
S-16	Der Inhaber der Genehmigung für das Inverkehrbringen ist Beaufour Ipsen Pharma .
T-16	The marketing authorisation holder is Beaufour Ipsen Pharma .
H-16	-0.2712559103965759	The MAH is held by Beaufour Ipsen Pharma .
D-16	-0.2712559103965759	The MAH is held by Beaufour Ipsen Pharma .
P-16	-0.3070 -0.3985 -0.0158 -0.1513 -1.9805 -0.1429 -0.1316 -0.0755 -0.1489 -0.0866 -0.1579 -0.0588 -0.0881 -0.1716 -0.1538
S-247	Der aktivierte Faktor X wandelt Prothrombin in Thrombin um .
T-247	Activated Factor X converts prothrombin to thrombin .
H-247	-0.2822253108024597	The activated factor X converts prothrombin to thrombin .
D-247	-0.2822253108024597	The activated factor X converts prothrombin to thrombin .
P-247	-1.6586 -0.1936 -0.1285 -0.0882 -0.0819 -0.1513 -0.1647 -0.2286 -0.0246 -0.1565 -0.1253 -1.1759 -0.0452 -0.1359 -0.1196 -0.1611 -0.1583
S-674	Schutzkappen von den Durchstechflaschen mit Pulver und Lösungsmittel entfernen .
T-674	Remove caps from powder and solvent vials .
H-674	-0.2965630888938904	Remove the protective caps from the vials with powder and solvent .
D-674	-0.2965630888938904	Remove the protective caps from the vials with powder and solvent .
P-674	-0.1710 -0.0470 -0.1149 -0.6689 -0.2473 -0.2953 -0.1469 -0.2303 -0.0507 -0.1183 -0.4599 -0.5095 -0.1490 -0.1492 -1.3901 -0.1399 -0.1532
S-593	Schutzkappen von den Durchstechflaschen mit Pulver und Lösungsmittel entfernen .
T-593	Remove caps from powder and solvent vials .
H-593	-0.2965630888938904	Remove the protective caps from the vials with powder and solvent .
D-593	-0.2965630888938904	Remove the protective caps from the vials with powder and solvent .
P-593	-0.1710 -0.0470 -0.1149 -0.6689 -0.2473 -0.2953 -0.1469 -0.2303 -0.0507 -0.1183 -0.4599 -0.5095 -0.1490 -0.1492 -1.3901 -0.1399 -0.1532
S-512	Schutzkappen von den Durchstechflaschen mit Pulver und Lösungsmittel entfernen .
T-512	Remove caps from powder and solvent vials .
H-512	-0.2965630888938904	Remove the protective caps from the vials with powder and solvent .
D-512	-0.2965630888938904	Remove the protective caps from the vials with powder and solvent .
P-512	-0.1710 -0.0470 -0.1149 -0.6689 -0.2473 -0.2953 -0.1469 -0.2303 -0.0507 -0.1183 -0.4599 -0.5095 -0.1490 -0.1492 -1.3901 -0.1399 -0.1532
S-431	Schutzkappen von den Durchstechflaschen mit Pulver und Lösungsmittel entfernen .
T-431	Remove caps from powder and solvent vials .
H-431	-0.2965630888938904	Remove the protective caps from the vials with powder and solvent .
D-431	-0.2965630888938904	Remove the protective caps from the vials with powder and solvent .
P-431	-0.1710 -0.0470 -0.1149 -0.6689 -0.2473 -0.2953 -0.1469 -0.2303 -0.0507 -0.1183 -0.4599 -0.5095 -0.1490 -0.1492 -1.3901 -0.1399 -0.1532
S-766	- Atembeschwerden , pfeifendes Atmen , Engegefühl in der Brust ,
T-766	- difficulty in breathing , wheezing , tightness in the chest ,
H-766	-0.6176184415817261	- difficulty in breathing , whistling , tightness in the chest ,
D-766	-0.6176184415817261	- difficulty in breathing , whistling , tightness in the chest ,
P-766	-0.1191 -2.7411 -0.3755 -0.1198 -0.1715 -0.8480 -0.2437 -0.3983 -1.4142 -0.1363 -0.0748 -0.2605 -0.1849 -0.0801 -0.1955 -2.5183
S-269	Schutzkappen von den Durchstechflaschen mit Pulver und Lösungsmittel entfernen .
T-269	Remove caps from powder and solvent vials .
H-269	-0.2965630888938904	Remove the protective caps from the vials with powder and solvent .
D-269	-0.2965630888938904	Remove the protective caps from the vials with powder and solvent .
P-269	-0.1710 -0.0470 -0.1149 -0.6689 -0.2473 -0.2953 -0.1469 -0.2303 -0.0507 -0.1183 -0.4599 -0.5095 -0.1490 -0.1492 -1.3901 -0.1399 -0.1532
S-200	Falls sich Antikörper entwickeln , ist die Wirksamkeit von Advate nicht gewährleistet .
T-200	If antibodies develop , Advate will not work effectively .
H-200	-0.35728079080581665	If antibodies develop , the effectiveness of Advate is not assured .
D-200	-0.35728079080581665	If antibodies develop , the effectiveness of Advate is not assured .
P-200	-0.6238 -0.0902 -0.0813 -1.7641 -0.1304 -0.4752 -0.5053 -0.1397 -0.1383 -0.4246 -0.1234 -0.3173 -0.1439 -0.4590 -0.1466 -0.1533
S-108	Hinweise , um eine ausreichende Resorption von Alendronat zu gewährleisten :
T-108	To permit adequate absorption of alendronate :
H-108	-0.3972814679145813	Notes on how to ensure adequate absorption of alendronate :
D-108	-0.3972814679145813	Notes on how to ensure adequate absorption of alendronate :
P-108	-1.9705 -0.1456 -1.6156 -0.4089 -0.1646 -0.1807 -0.2362 -0.1866 -0.0739 -0.1534 -0.1477 -0.1474 -0.1290 -0.0747 -0.5490 -0.1729
S-827	Den vollständigen Wortlaut des EPAR für Aerinaze finden Sie hier .
T-827	The full EPAR for Aerinaze can be found here .
H-827	-0.213105246424675	The full EPAR for Aerinaze can be found here .
D-827	-0.213105246424675	The full EPAR for Aerinaze can be found here .
P-827	-0.2603 -0.1725 -0.0370 -0.0644 -0.1096 -0.1577 -0.1130 -0.1290 -0.1248 -0.1025 -1.1012 -0.1465 -0.2447 -0.1363 -0.3482 -0.1617
S-139	16 4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-139	4.7 Effects on ability to drive and use machines
H-139	-0.10679309070110321	4.7 Effects on ability to drive and use machines
D-139	-0.10679309070110321	4.7 Effects on ability to drive and use machines
P-139	-0.1110 -0.1366 -0.0451 -0.0920 -0.1275 -0.0193 -0.1280 -0.0448 -0.1704 -0.1409 -0.0985 -0.1675
S-327	Der aktivierte Faktor X wandelt Prothrombin in Thrombin um .
T-327	Activated Factor X converts prothrombin to thrombin .
H-327	-0.2822253108024597	The activated factor X converts prothrombin to thrombin .
D-327	-0.2822253108024597	The activated factor X converts prothrombin to thrombin .
P-327	-1.6586 -0.1936 -0.1285 -0.0882 -0.0819 -0.1513 -0.1647 -0.2286 -0.0246 -0.1565 -0.1253 -1.1759 -0.0452 -0.1359 -0.1196 -0.1611 -0.1583
S-558	Folgende Tabelle 2 gibt die Häufigkeit der Nebenwirkungen in klinischen Studien an :
T-558	The following table 2 provides the frequency of adverse drug reactions in clinical trials :
H-558	-0.38688424229621887	The following table 2 indicates the frequency of adverse reactions in clinical trials :
D-558	-0.38688424229621887	The following table 2 indicates the frequency of adverse reactions in clinical trials :
P-558	-0.3341 -0.3035 -0.3075 -0.5822 -2.3093 -0.1381 -0.2231 -0.5289 -0.0928 -0.1581 -1.0123 -0.0218 -0.6349 -0.0422 -0.1639 -0.0507 -0.1573 -0.1278 -0.1624
S-477	Folgende Tabelle 2 gibt die Häufigkeit der Nebenwirkungen in klinischen Studien an :
T-477	The following table 2 provides the frequency of adverse drug reactions in clinical trials :
H-477	-0.38688424229621887	The following table 2 indicates the frequency of adverse reactions in clinical trials :
D-477	-0.38688424229621887	The following table 2 indicates the frequency of adverse reactions in clinical trials :
P-477	-0.3341 -0.3035 -0.3075 -0.5822 -2.3093 -0.1381 -0.2231 -0.5289 -0.0928 -0.1581 -1.0123 -0.0218 -0.6349 -0.0422 -0.1639 -0.0507 -0.1573 -0.1278 -0.1624
S-816	Sobald das Unternehmen Antworten auf diese Fragen übermittelt hat , werden diese vom CHMP geprüft .
T-816	Once the company has supplied responses to the questions , the CHMP reviews them and may , before giving an opinion , ask any remaining questions at day 180.
H-816	-0.6210132837295532	Once the company has submitted answers to these questions , the CHMP will review them .
D-816	-0.6210132837295532	Once the company has submitted answers to these questions , the CHMP will review them .
P-816	-1.1888 -0.9642 -0.3883 -1.3537 -0.9323 -2.1316 -0.2272 -0.2293 -0.1533 -0.1938 -1.5333 -0.1983 -0.0564 -0.1176 -0.7227 -0.4857 -0.1478 -0.1539
S-641	60 Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-641	55 Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-641	-0.248408704996109	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-641	-0.248408704996109	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-641	-0.1564 -0.1876 -0.3112 -0.0718 -0.2113 -0.1483 -1.5388 -0.0205 -0.6769 -0.0551 -0.1548 -0.0949 -0.1382 -0.1229 -0.1483 -0.1135 -0.0535 -0.1904 -0.3254
S-560	49 Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-560	45 Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-560	-0.2537410259246826	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-560	-0.2537410259246826	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-560	-0.1678 -0.1783 -0.3685 -0.0694 -0.2088 -0.1507 -1.4931 -0.0211 -0.6241 -0.0492 -0.1520 -0.0941 -0.1353 -0.1247 -0.1487 -0.1142 -0.0530 -0.1885 -0.4795
S-479	38 Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-479	35 Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-479	-0.26343852281570435	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-479	-0.26343852281570435	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-479	-0.1515 -0.1883 -0.3759 -0.0745 -0.2129 -0.1493 -1.6556 -0.0206 -0.7024 -0.0547 -0.1521 -0.0933 -0.1372 -0.1231 -0.1484 -0.1126 -0.0521 -0.1965 -0.4042
S-398	27 Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-398	25 Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-398	-0.24892064929008484	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-398	-0.24892064929008484	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-398	-0.1924 -0.1978 -0.3173 -0.0733 -0.2169 -0.1491 -1.4786 -0.0210 -0.6350 -0.0509 -0.1526 -0.0956 -0.1368 -0.1239 -0.1488 -0.1127 -0.0545 -0.1993 -0.3727
S-317	16 Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-317	15 Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-317	-0.24594815075397491	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-317	-0.24594815075397491	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-317	-0.1621 -0.1880 -0.3300 -0.0689 -0.2136 -0.1500 -1.4563 -0.0218 -0.6730 -0.0546 -0.1551 -0.0950 -0.1358 -0.1241 -0.1483 -0.1126 -0.0542 -0.1882 -0.3413
S-639	Folgende Tabelle 2 gibt die Häufigkeit der Nebenwirkungen in klinischen Studien an :
T-639	The following table 2 provides the frequency of adverse drug reactions in clinical trials :
H-639	-0.38688424229621887	The following table 2 indicates the frequency of adverse reactions in clinical trials :
D-639	-0.38688424229621887	The following table 2 indicates the frequency of adverse reactions in clinical trials :
P-639	-0.3341 -0.3035 -0.3075 -0.5822 -2.3093 -0.1381 -0.2231 -0.5289 -0.0928 -0.1581 -1.0123 -0.0218 -0.6349 -0.0422 -0.1639 -0.0507 -0.1573 -0.1278 -0.1624
S-408	Der aktivierte Faktor X wandelt Prothrombin in Thrombin um .
T-408	Activated Factor X converts prothrombin to thrombin .
H-408	-0.2822253108024597	The activated factor X converts prothrombin to thrombin .
D-408	-0.2822253108024597	The activated factor X converts prothrombin to thrombin .
P-408	-1.6586 -0.1936 -0.1285 -0.0882 -0.0819 -0.1513 -0.1647 -0.2286 -0.0246 -0.1565 -0.1253 -1.1759 -0.0452 -0.1359 -0.1196 -0.1611 -0.1583
S-633	Es wurden keine Untersuchungen zur Wechselwirkung von ADVATE mit anderen Arzneimitteln durchgeführt .
T-633	54 No interaction studies have been performed with ADVATE .
H-633	-0.28080686926841736	No studies on the interaction of ADVATE with other medicinal products have been performed .
D-633	-0.28080686926841736	No studies on the interaction of ADVATE with other medicinal products have been performed .
P-633	-0.9695 -0.7578 -0.7201 -0.3195 -0.2952 -0.1259 -0.1675 -0.1369 -0.1575 -0.0782 -0.0801 -0.1209 -0.6338 -0.0463 -0.0583 -0.0722 -0.2135 -0.1322 -0.5100 -0.1467 -0.1549
S-396	Folgende Tabelle 2 gibt die Häufigkeit der Nebenwirkungen in klinischen Studien an :
T-396	The following table 2 provides the frequency of adverse drug reactions in clinical trials :
H-396	-0.38688424229621887	The following table 2 indicates the frequency of adverse reactions in clinical trials :
D-396	-0.38688424229621887	The following table 2 indicates the frequency of adverse reactions in clinical trials :
P-396	-0.3341 -0.3035 -0.3075 -0.5822 -2.3093 -0.1381 -0.2231 -0.5289 -0.0928 -0.1581 -1.0123 -0.0218 -0.6349 -0.0422 -0.1639 -0.0507 -0.1573 -0.1278 -0.1624
S-315	Folgende Tabelle 2 gibt die Häufigkeit der Nebenwirkungen in klinischen Studien an :
T-315	The following table 2 provides the frequency of adverse drug reactions in clinical trials :
H-315	-0.38688424229621887	The following table 2 indicates the frequency of adverse reactions in clinical trials :
D-315	-0.38688424229621887	The following table 2 indicates the frequency of adverse reactions in clinical trials :
P-315	-0.3341 -0.3035 -0.3075 -0.5822 -2.3093 -0.1381 -0.2231 -0.5289 -0.0928 -0.1581 -1.0123 -0.0218 -0.6349 -0.0422 -0.1639 -0.0507 -0.1573 -0.1278 -0.1624
S-237	Folgende Tabelle 2 gibt die Häufigkeit der Nebenwirkungen in klinischen Studien an :
T-237	The following table 2 provides the frequency of adverse drug reactions in clinical trials :
H-237	-0.38688424229621887	The following table 2 indicates the frequency of adverse reactions in clinical trials :
D-237	-0.38688424229621887	The following table 2 indicates the frequency of adverse reactions in clinical trials :
P-237	-0.3341 -0.3035 -0.3075 -0.5822 -2.3093 -0.1381 -0.2231 -0.5289 -0.0928 -0.1581 -1.0123 -0.0218 -0.6349 -0.0422 -0.1639 -0.0507 -0.1573 -0.1278 -0.1624
S-763	Sollten Sie weitere Fragen zur Anwendung dieses Arzneimittels haben , wenden Sie sich an Ihren Arzt .
T-763	If you have any further questions on the use of this product , ask your doctor .
H-763	-0.2560684084892273	If you have any further questions on the use of this product , contact your doctor .
D-763	-0.2560684084892273	If you have any further questions on the use of this product , contact your doctor .
P-763	-0.1106 -0.1438 -0.1943 -0.2540 -0.1438 -0.1144 -0.1738 -0.1422 -0.1160 -0.1338 -0.1057 -0.8876 -0.1139 -1.3828 -0.1899 -0.0980 -0.1528 -0.1518
S-651	Der aktivierte Faktor X wandelt Prothrombin in Thrombin um .
T-651	Activated Factor X converts prothrombin to thrombin .
H-651	-0.2822253108024597	The activated factor X converts prothrombin to thrombin .
D-651	-0.2822253108024597	The activated factor X converts prothrombin to thrombin .
P-651	-1.6586 -0.1936 -0.1285 -0.0882 -0.0819 -0.1513 -0.1647 -0.2286 -0.0246 -0.1565 -0.1253 -1.1759 -0.0452 -0.1359 -0.1196 -0.1611 -0.1583
S-489	Der aktivierte Faktor X wandelt Prothrombin in Thrombin um .
T-489	Activated Factor X converts prothrombin to thrombin .
H-489	-0.2822253108024597	The activated factor X converts prothrombin to thrombin .
D-489	-0.2822253108024597	The activated factor X converts prothrombin to thrombin .
P-489	-1.6586 -0.1936 -0.1285 -0.0882 -0.0819 -0.1513 -0.1647 -0.2286 -0.0246 -0.1565 -0.1253 -1.1759 -0.0452 -0.1359 -0.1196 -0.1611 -0.1583
S-570	Der aktivierte Faktor X wandelt Prothrombin in Thrombin um .
T-570	Activated Factor X converts prothrombin to thrombin .
H-570	-0.2822253108024597	The activated factor X converts prothrombin to thrombin .
D-570	-0.2822253108024597	The activated factor X converts prothrombin to thrombin .
P-570	-1.6586 -0.1936 -0.1285 -0.0882 -0.0819 -0.1513 -0.1647 -0.2286 -0.0246 -0.1565 -0.1253 -1.1759 -0.0452 -0.1359 -0.1196 -0.1611 -0.1583
S-33	Hinweise , um eine ausreichende Resorption von Alendronat zu gewährleisten :
T-33	To permit adequate absorption of alendronate :
H-33	-0.3972814679145813	Notes on how to ensure adequate absorption of alendronate :
D-33	-0.3972814679145813	Notes on how to ensure adequate absorption of alendronate :
P-33	-1.9705 -0.1456 -1.6156 -0.4089 -0.1646 -0.1807 -0.2362 -0.1866 -0.0739 -0.1534 -0.1477 -0.1474 -0.1290 -0.0747 -0.5490 -0.1729
S-548	In solchen Fällen wird die Kontaktaufnahme mit einem Hämophilie- Zentrum empfohlen .
T-548	In such cases , it is recommended that a specialised haemophilia centre be contacted .
H-548	-0.34191328287124634	In such cases , contact with a haemophilia centre is recommended .
D-548	-0.34191328287124634	In such cases , contact with a haemophilia centre is recommended .
P-548	-0.8065 -0.5086 -0.3074 -1.1242 -0.6191 -0.1533 -0.1158 -0.3951 -0.0650 -0.1718 -0.2343 -0.3809 -0.1282 -0.1534 -0.1571 -0.1499
S-559	Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-559	Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-559	-0.25511181354522705	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-559	-0.25511181354522705	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-559	-0.1837 -0.1900 -0.3413 -0.0701 -0.1763 -0.1510 -1.6515 -0.0218 -0.6140 -0.0527 -0.1520 -0.0915 -0.1415 -0.1227 -0.1494 -0.1175 -0.0549 -0.1594 -0.4057
S-640	Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-640	Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-640	-0.25511181354522705	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-640	-0.25511181354522705	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-640	-0.1837 -0.1900 -0.3413 -0.0701 -0.1763 -0.1510 -1.6515 -0.0218 -0.6140 -0.0527 -0.1520 -0.0915 -0.1415 -0.1227 -0.1494 -0.1175 -0.0549 -0.1594 -0.4057
S-478	Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-478	Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-478	-0.25511181354522705	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-478	-0.25511181354522705	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-478	-0.1837 -0.1900 -0.3413 -0.0701 -0.1763 -0.1510 -1.6515 -0.0218 -0.6140 -0.0527 -0.1520 -0.0915 -0.1415 -0.1227 -0.1494 -0.1175 -0.0549 -0.1594 -0.4057
S-467	In solchen Fällen wird die Kontaktaufnahme mit einem Hämophilie- Zentrum empfohlen .
T-467	In such cases , it is recommended that a specialised haemophilia centre be contacted .
H-467	-0.34191328287124634	In such cases , contact with a haemophilia centre is recommended .
D-467	-0.34191328287124634	In such cases , contact with a haemophilia centre is recommended .
P-467	-0.8065 -0.5086 -0.3074 -1.1242 -0.6191 -0.1533 -0.1158 -0.3951 -0.0650 -0.1718 -0.2343 -0.3809 -0.1282 -0.1534 -0.1571 -0.1499
S-629	In solchen Fällen wird die Kontaktaufnahme mit einem Hämophilie- Zentrum empfohlen .
T-629	In such cases , it is recommended that a specialised haemophilia centre be contacted .
H-629	-0.34191328287124634	In such cases , contact with a haemophilia centre is recommended .
D-629	-0.34191328287124634	In such cases , contact with a haemophilia centre is recommended .
P-629	-0.8065 -0.5086 -0.3074 -1.1242 -0.6191 -0.1533 -0.1158 -0.3951 -0.0650 -0.1718 -0.2343 -0.3809 -0.1282 -0.1534 -0.1571 -0.1499
S-397	Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-397	Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-397	-0.25511181354522705	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-397	-0.25511181354522705	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-397	-0.1837 -0.1900 -0.3413 -0.0701 -0.1763 -0.1510 -1.6515 -0.0218 -0.6140 -0.0527 -0.1520 -0.0915 -0.1415 -0.1227 -0.1494 -0.1175 -0.0549 -0.1594 -0.4057
S-762	Fahren Sie sofort mit der nächsten vorgesehenen Anwendung fort , wie von Ihrem Arzt angewiesen .
T-762	Proceed with the next injection as scheduled immediately and continue as advised by your doctor .
H-762	-0.5130266547203064	Continue with the next scheduled dose immediately as instructed by your doctor .
D-762	-0.5130266547203064	Continue with the next scheduled dose immediately as instructed by your doctor .
P-762	-0.3703 -0.1002 -1.3183 -0.1501 -0.1552 -1.1270 -1.8864 -0.7112 -0.1361 -1.4710 -0.1066 -0.1242 -0.1150 -0.1359 -0.1499 -0.1511
S-236	Innerhalb der Häufigkeiten sind die Nebenwirkungen nach absteigender Schwere aufgeführt .
T-236	Within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
H-236	-0.35736462473869324	Within the frequencies , undesirable effects are listed in descending order of severity .
D-236	-0.35736462473869324	Within the frequencies , undesirable effects are listed in descending order of severity .
P-236	-0.5868 -0.9870 -0.1047 -0.2629 -0.1098 -1.5248 -0.2010 -0.0521 -0.0584 -0.0657 -0.1288 -0.6517 -0.1545 -0.9624 -0.2284 -0.1187 -0.1544 -0.7166 -0.1349 -0.1503 -0.1507
S-314	Innerhalb der Häufigkeiten sind die Nebenwirkungen nach absteigender Schwere aufgeführt .
T-314	Within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
H-314	-0.35736462473869324	Within the frequencies , undesirable effects are listed in descending order of severity .
D-314	-0.35736462473869324	Within the frequencies , undesirable effects are listed in descending order of severity .
P-314	-0.5868 -0.9870 -0.1047 -0.2629 -0.1098 -1.5248 -0.2010 -0.0521 -0.0584 -0.0657 -0.1288 -0.6517 -0.1545 -0.9624 -0.2284 -0.1187 -0.1544 -0.7166 -0.1349 -0.1503 -0.1507
S-395	Innerhalb der Häufigkeiten sind die Nebenwirkungen nach absteigender Schwere aufgeführt .
T-395	Within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
H-395	-0.35736462473869324	Within the frequencies , undesirable effects are listed in descending order of severity .
D-395	-0.35736462473869324	Within the frequencies , undesirable effects are listed in descending order of severity .
P-395	-0.5868 -0.9870 -0.1047 -0.2629 -0.1098 -1.5248 -0.2010 -0.0521 -0.0584 -0.0657 -0.1288 -0.6517 -0.1545 -0.9624 -0.2284 -0.1187 -0.1544 -0.7166 -0.1349 -0.1503 -0.1507
S-476	Innerhalb der Häufigkeiten sind die Nebenwirkungen nach absteigender Schwere aufgeführt .
T-476	Within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
H-476	-0.35736462473869324	Within the frequencies , undesirable effects are listed in descending order of severity .
D-476	-0.35736462473869324	Within the frequencies , undesirable effects are listed in descending order of severity .
P-476	-0.5868 -0.9870 -0.1047 -0.2629 -0.1098 -1.5248 -0.2010 -0.0521 -0.0584 -0.0657 -0.1288 -0.6517 -0.1545 -0.9624 -0.2284 -0.1187 -0.1544 -0.7166 -0.1349 -0.1503 -0.1507
S-557	Innerhalb der Häufigkeiten sind die Nebenwirkungen nach absteigender Schwere aufgeführt .
T-557	Within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
H-557	-0.35736462473869324	Within the frequencies , undesirable effects are listed in descending order of severity .
D-557	-0.35736462473869324	Within the frequencies , undesirable effects are listed in descending order of severity .
P-557	-0.5868 -0.9870 -0.1047 -0.2629 -0.1098 -1.5248 -0.2010 -0.0521 -0.0584 -0.0657 -0.1288 -0.6517 -0.1545 -0.9624 -0.2284 -0.1187 -0.1544 -0.7166 -0.1349 -0.1503 -0.1507
S-638	Innerhalb der Häufigkeiten sind die Nebenwirkungen nach absteigender Schwere aufgeführt .
T-638	Within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
H-638	-0.35736462473869324	Within the frequencies , undesirable effects are listed in descending order of severity .
D-638	-0.35736462473869324	Within the frequencies , undesirable effects are listed in descending order of severity .
P-638	-0.5868 -0.9870 -0.1047 -0.2629 -0.1098 -1.5248 -0.2010 -0.0521 -0.0584 -0.0657 -0.1288 -0.6517 -0.1545 -0.9624 -0.2284 -0.1187 -0.1544 -0.7166 -0.1349 -0.1503 -0.1507
S-386	In solchen Fällen wird die Kontaktaufnahme mit einem Hämophilie- Zentrum empfohlen .
T-386	In such cases , it is recommended that a specialised haemophilia centre be contacted .
H-386	-0.34191328287124634	In such cases , contact with a haemophilia centre is recommended .
D-386	-0.34191328287124634	In such cases , contact with a haemophilia centre is recommended .
P-386	-0.8065 -0.5086 -0.3074 -1.1242 -0.6191 -0.1533 -0.1158 -0.3951 -0.0650 -0.1718 -0.2343 -0.3809 -0.1282 -0.1534 -0.1571 -0.1499
S-46	Der Zeitpunkt des Auftretens dieser Symptome variierte von einem Tag bis zu mehreren Monaten nach Therapiebeginn .
T-46	The time to onset of symptoms varied from one day to several months after starting treatment .
H-46	-0.2667308449745178	The timing of onset of these symptoms varied from one day to several months after initiation of therapy .
D-46	-0.2667308449745178	The timing of onset of these symptoms varied from one day to several months after initiation of therapy .
P-46	-0.2858 -0.2813 -0.1845 -1.7879 -0.1507 -0.1352 -0.1127 -0.1180 -0.0803 -0.1592 -0.2164 -0.1969 -0.1109 -0.1404 -0.0827 -0.1420 -0.5396 -0.2364 -0.3488 -0.2983 -0.2259 -0.1524 -0.1486
S-636	ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen .
T-636	ADVATE has no influence on the ability to drive and use machines .
H-636	-0.16398607194423676	ADVATE has no effect on the ability to drive and use machines .
D-636	-0.16398607194423676	ADVATE has no effect on the ability to drive and use machines .
P-636	-0.2098 -0.1694 -0.0809 -0.0892 -0.1835 -0.1668 -0.6192 -0.1241 -0.1263 -0.0705 -0.1369 -0.0547 -0.2277 -0.1287 -0.0963 -0.1469 -0.1569
S-357	Nach der Rekonstitution sollte die Lösung klar , farblos und frei von Fremdpartikeln sein .
T-357	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-357	-0.26802858710289	After reconstitution , the solution should be clear , colourless and free of foreign particles .
D-357	-0.26802858710289	After reconstitution , the solution should be clear , colourless and free of foreign particles .
P-357	-0.5208 -0.1394 -0.1075 -0.8939 -0.1431 -0.1141 -0.1055 -0.1168 -0.1084 -0.1490 -0.1640 -0.0958 -0.0757 -0.2039 -0.1234 -0.8197 -1.1607 -0.1770 -0.1133 -0.1471 -0.1494
S-555	ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen .
T-555	ADVATE has no influence on the ability to drive and use machines .
H-555	-0.16398607194423676	ADVATE has no effect on the ability to drive and use machines .
D-555	-0.16398607194423676	ADVATE has no effect on the ability to drive and use machines .
P-555	-0.2098 -0.1694 -0.0809 -0.0892 -0.1835 -0.1668 -0.6192 -0.1241 -0.1263 -0.0705 -0.1369 -0.0547 -0.2277 -0.1287 -0.0963 -0.1469 -0.1569
S-122	Der Zeitpunkt des Auftretens dieser Symptome variierte von einem Tag bis zu mehreren Monaten nach Therapiebeginn .
T-122	The time to onset of symptoms varied from one day to several months after starting treatment .
H-122	-0.2667308449745178	The timing of onset of these symptoms varied from one day to several months after initiation of therapy .
D-122	-0.2667308449745178	The timing of onset of these symptoms varied from one day to several months after initiation of therapy .
P-122	-0.2858 -0.2813 -0.1845 -1.7879 -0.1507 -0.1352 -0.1127 -0.1180 -0.0803 -0.1592 -0.2164 -0.1969 -0.1109 -0.1404 -0.0827 -0.1420 -0.5396 -0.2364 -0.3488 -0.2983 -0.2259 -0.1524 -0.1486
S-276	Nach der Rekonstitution sollte die Lösung klar , farblos und frei von Fremdpartikeln sein .
T-276	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-276	-0.26802858710289	After reconstitution , the solution should be clear , colourless and free of foreign particles .
D-276	-0.26802858710289	After reconstitution , the solution should be clear , colourless and free of foreign particles .
P-276	-0.5208 -0.1394 -0.1075 -0.8939 -0.1431 -0.1141 -0.1055 -0.1168 -0.1084 -0.1490 -0.1640 -0.0958 -0.0757 -0.2039 -0.1234 -0.8197 -1.1607 -0.1770 -0.1133 -0.1471 -0.1494
S-843	Eine fortgesetzte Anwendung kann zu einer Toleranz führen , die ein erhöhtes Risiko für eine Überdosierung bedingt .
T-843	Continuous use can lead to tolerance resulting in an increased risk of overdosing .
H-843	-0.39379096031188965	Continuous use may lead to a tolerance associated with an increased risk of overdose .
D-843	-0.39379096031188965	Continuous use may lead to a tolerance associated with an increased risk of overdose .
P-843	-0.4795 -0.8010 -0.2010 -0.0805 -0.5207 -0.1411 -2.0826 -0.2074 -0.1242 -1.7323 -0.1130 -0.1362 -0.0619 -0.0872 -0.1426 -0.0797 -0.1839 -0.1571 -0.1501
S-600	Nach der Rekonstitution sollte die Lösung klar , farblos und frei von Fremdpartikeln sein .
T-600	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-600	-0.26802858710289	After reconstitution , the solution should be clear , colourless and free of foreign particles .
D-600	-0.26802858710289	After reconstitution , the solution should be clear , colourless and free of foreign particles .
P-600	-0.5208 -0.1394 -0.1075 -0.8939 -0.1431 -0.1141 -0.1055 -0.1168 -0.1084 -0.1490 -0.1640 -0.0958 -0.0757 -0.2039 -0.1234 -0.8197 -1.1607 -0.1770 -0.1133 -0.1471 -0.1494
S-683	Die Spritze an den BAXJECT II anschließen . ( Abb.d ) .
T-683	Connect the syringe to BAXJECT II ( Fig . d ) .
H-683	-0.28995880484580994	Connect the syringe to BAXJECT II ( fig.d ) .
D-683	-0.28995880484580994	Connect the syringe to BAXJECT II ( fig.d ) .
P-683	-0.3989 -0.1039 -0.1082 -0.1347 -0.1303 -0.0275 -0.0216 -0.1427 -0.8074 -0.1294 -0.2614 -0.0977 -0.1127 -0.1683 -0.7714 -1.6483 -0.4830 -0.0844 -0.1452 -0.1557 -0.1566
S-474	ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen .
T-474	ADVATE has no influence on the ability to drive and use machines .
H-474	-0.16398607194423676	ADVATE has no effect on the ability to drive and use machines .
D-474	-0.16398607194423676	ADVATE has no effect on the ability to drive and use machines .
P-474	-0.2098 -0.1694 -0.0809 -0.0892 -0.1835 -0.1668 -0.6192 -0.1241 -0.1263 -0.0705 -0.1369 -0.0547 -0.2277 -0.1287 -0.0963 -0.1469 -0.1569
S-393	ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen .
T-393	ADVATE has no influence on the ability to drive and use machines .
H-393	-0.16398607194423676	ADVATE has no effect on the ability to drive and use machines .
D-393	-0.16398607194423676	ADVATE has no effect on the ability to drive and use machines .
P-393	-0.2098 -0.1694 -0.0809 -0.0892 -0.1835 -0.1668 -0.6192 -0.1241 -0.1263 -0.0705 -0.1369 -0.0547 -0.2277 -0.1287 -0.0963 -0.1469 -0.1569
S-438	Nach der Rekonstitution sollte die Lösung klar , farblos und frei von Fremdpartikeln sein .
T-438	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-438	-0.26802858710289	After reconstitution , the solution should be clear , colourless and free of foreign particles .
D-438	-0.26802858710289	After reconstitution , the solution should be clear , colourless and free of foreign particles .
P-438	-0.5208 -0.1394 -0.1075 -0.8939 -0.1431 -0.1141 -0.1055 -0.1168 -0.1084 -0.1490 -0.1640 -0.0958 -0.0757 -0.2039 -0.1234 -0.8197 -1.1607 -0.1770 -0.1133 -0.1471 -0.1494
S-234	ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen .
T-234	ADVATE has no influence on the ability to drive and use machines .
H-234	-0.16398607194423676	ADVATE has no effect on the ability to drive and use machines .
D-234	-0.16398607194423676	ADVATE has no effect on the ability to drive and use machines .
P-234	-0.2098 -0.1694 -0.0809 -0.0892 -0.1835 -0.1668 -0.6192 -0.1241 -0.1263 -0.0705 -0.1369 -0.0547 -0.2277 -0.1287 -0.0963 -0.1469 -0.1569
S-359	Die Spritze an den BAXJECT II anschließen . ( Abb.d ) .
T-359	Connect the syringe to BAXJECT II ( Fig . d ) .
H-359	-0.28995880484580994	Connect the syringe to BAXJECT II ( fig.d ) .
D-359	-0.28995880484580994	Connect the syringe to BAXJECT II ( fig.d ) .
P-359	-0.3989 -0.1039 -0.1082 -0.1347 -0.1303 -0.0275 -0.0216 -0.1427 -0.8074 -0.1294 -0.2614 -0.0977 -0.1127 -0.1683 -0.7714 -1.6483 -0.4830 -0.0844 -0.1452 -0.1557 -0.1566
S-85	8 Behandlungsgruppen waren auch hinsichtlich der BMD-Zunahmen an anderen Skelettstellen vergleichbar .
T-85	The two treatment groups were also similar with regard to BMD increases at other skeletal sites .
H-85	-0.4369976222515106	Treatment groups were also comparable in BMD increases at other skeletal sites .
D-85	-0.4369976222515106	Treatment groups were also comparable in BMD increases at other skeletal sites .
P-85	-0.9478 -0.0607 -0.1099 -0.1708 -0.1649 -0.0939 -1.4982 -0.1885 -1.0563 -0.7032 -0.1534 -1.0812 -0.5105 -0.5809 -1.1463 -0.0813 -0.0750 -0.1175 -0.1331 -0.1528 -0.1508
S-602	Die Spritze an den BAXJECT II anschließen . ( Abb.d ) .
T-602	Connect the syringe to BAXJECT II ( Fig . d ) .
H-602	-0.28995880484580994	Connect the syringe to BAXJECT II ( fig.d ) .
D-602	-0.28995880484580994	Connect the syringe to BAXJECT II ( fig.d ) .
P-602	-0.3989 -0.1039 -0.1082 -0.1347 -0.1303 -0.0275 -0.0216 -0.1427 -0.8074 -0.1294 -0.2614 -0.0977 -0.1127 -0.1683 -0.7714 -1.6483 -0.4830 -0.0844 -0.1452 -0.1557 -0.1566
S-521	Die Spritze an den BAXJECT II anschließen . ( Abb.d ) .
T-521	Connect the syringe to BAXJECT II ( Fig . d ) .
H-521	-0.28995880484580994	Connect the syringe to BAXJECT II ( fig.d ) .
D-521	-0.28995880484580994	Connect the syringe to BAXJECT II ( fig.d ) .
P-521	-0.3989 -0.1039 -0.1082 -0.1347 -0.1303 -0.0275 -0.0216 -0.1427 -0.8074 -0.1294 -0.2614 -0.0977 -0.1127 -0.1683 -0.7714 -1.6483 -0.4830 -0.0844 -0.1452 -0.1557 -0.1566
S-440	Die Spritze an den BAXJECT II anschließen . ( Abb.d ) .
T-440	Connect the syringe to BAXJECT II ( Fig . d ) .
H-440	-0.28995880484580994	Connect the syringe to BAXJECT II ( fig.d ) .
D-440	-0.28995880484580994	Connect the syringe to BAXJECT II ( fig.d ) .
P-440	-0.3989 -0.1039 -0.1082 -0.1347 -0.1303 -0.0275 -0.0216 -0.1427 -0.8074 -0.1294 -0.2614 -0.0977 -0.1127 -0.1683 -0.7714 -1.6483 -0.4830 -0.0844 -0.1452 -0.1557 -0.1566
S-519	Nach der Rekonstitution sollte die Lösung klar , farblos und frei von Fremdpartikeln sein .
T-519	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-519	-0.26802858710289	After reconstitution , the solution should be clear , colourless and free of foreign particles .
D-519	-0.26802858710289	After reconstitution , the solution should be clear , colourless and free of foreign particles .
P-519	-0.5208 -0.1394 -0.1075 -0.8939 -0.1431 -0.1141 -0.1055 -0.1168 -0.1084 -0.1490 -0.1640 -0.0958 -0.0757 -0.2039 -0.1234 -0.8197 -1.1607 -0.1770 -0.1133 -0.1471 -0.1494
S-278	Die Spritze an den BAXJECT II anschließen . ( Abb.d ) .
T-278	Connect the syringe to BAXJECT II ( Fig . d ) .
H-278	-0.28995880484580994	Connect the syringe to BAXJECT II ( fig.d ) .
D-278	-0.28995880484580994	Connect the syringe to BAXJECT II ( fig.d ) .
P-278	-0.3989 -0.1039 -0.1082 -0.1347 -0.1303 -0.0275 -0.0216 -0.1427 -0.8074 -0.1294 -0.2614 -0.0977 -0.1127 -0.1683 -0.7714 -1.6483 -0.4830 -0.0844 -0.1452 -0.1557 -0.1566
S-681	Nach der Rekonstitution sollte die Lösung klar , farblos und frei von Fremdpartikeln sein .
T-681	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-681	-0.26802858710289	After reconstitution , the solution should be clear , colourless and free of foreign particles .
D-681	-0.26802858710289	After reconstitution , the solution should be clear , colourless and free of foreign particles .
P-681	-0.5208 -0.1394 -0.1075 -0.8939 -0.1431 -0.1141 -0.1055 -0.1168 -0.1084 -0.1490 -0.1640 -0.0958 -0.0757 -0.2039 -0.1234 -0.8197 -1.1607 -0.1770 -0.1133 -0.1471 -0.1494
S-744	Ihr Arzt wird entscheiden , ob Sie ADVATE in der Schwangerschaft und Stillzeit anwenden können .
T-744	Your doctor will decide if ADVATE may be used during pregnancy and breast-feeding .
H-744	-0.2570761442184448	Your doctor will decide whether you can use ADVATE in pregnancy and breast-feeding women .
D-744	-0.2570761442184448	Your doctor will decide whether you can use ADVATE in pregnancy and breast-feeding women .
P-744	-0.2385 -0.1182 -0.2514 -0.0631 -0.9586 -0.6901 -0.2490 -0.2281 -0.1216 -0.1763 -0.0967 -0.0826 -0.4412 -0.1175 -0.2494 -0.5732 -0.0364 -0.0970 -0.0452 -0.5185 -0.1458 -0.1574
S-195	Es korrigiert den Faktor VIII-Mangel und ermöglicht eine vorübergehende Kontrolle der Blutungsstörung .
T-195	It corrects the factor VIII deficiency and gives temporary control of the bleeding disorder .
H-195	-0.5500038862228394	It corrects factor VIIII deficiency and enables temporary control of impaired bleeding .
D-195	-0.5500038862228394	It corrects factor VIIII deficiency and enables temporary control of impaired bleeding .
P-195	-0.7624 -0.1115 -0.2617 -1.0682 -0.4489 -1.4764 -0.0116 -0.0718 -0.1199 -0.1477 -2.1133 -0.1066 -0.2270 -0.3007 -0.1548 -2.4340 -0.3674 -0.9364 -0.1184 -0.1555 -0.1558
S-750	Der erforderliche Faktor VIII-Spiegel hängt von der Schwere und dem Ort der Blutung ab .
T-750	The target factor VIII levels will depend on the severity and location of the bleeding .
H-750	-0.5308995842933655	The required Factor VIII level will vary with the severity and site of haemorrhage .
D-750	-0.5308995842933655	The required Factor VIII level will vary with the severity and site of haemorrhage .
P-750	-0.3033 -0.8921 -1.0145 -0.7677 -1.5119 -0.2319 -1.1194 -0.7352 -0.0869 -0.2391 -0.1467 -0.4574 -0.1260 -0.2016 -0.7456 -0.1384 -2.0372 -0.4117 -0.0531 -0.1477 -0.1623 -0.1502
S-312	ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen .
T-312	ADVATE has no influence on the ability to drive and use machines .
H-312	-0.16398607194423676	ADVATE has no effect on the ability to drive and use machines .
D-312	-0.16398607194423676	ADVATE has no effect on the ability to drive and use machines .
P-312	-0.2098 -0.1694 -0.0809 -0.0892 -0.1835 -0.1668 -0.6192 -0.1241 -0.1263 -0.0705 -0.1369 -0.0547 -0.2277 -0.1287 -0.0963 -0.1469 -0.1569
S-344	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-344	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-344	-0.29019325971603394	After reconstitution , the solution is clear , colourless and free of foreign particles .
D-344	-0.29019325971603394	After reconstitution , the solution is clear , colourless and free of foreign particles .
P-344	-0.4688 -0.1317 -0.0795 -1.1901 -0.1422 -0.1333 -0.1572 -0.1098 -0.1537 -0.1155 -0.1001 -0.0775 -0.1806 -0.1265 -0.7857 -1.2471 -0.1893 -0.1140 -0.1504 -0.1509
S-263	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-263	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-263	-0.29019325971603394	After reconstitution , the solution is clear , colourless and free of foreign particles .
D-263	-0.29019325971603394	After reconstitution , the solution is clear , colourless and free of foreign particles .
P-263	-0.4688 -0.1317 -0.0795 -1.1901 -0.1422 -0.1333 -0.1572 -0.1098 -0.1537 -0.1155 -0.1001 -0.0775 -0.1806 -0.1265 -0.7857 -1.2471 -0.1893 -0.1140 -0.1504 -0.1509
S-62	Colecalciferol und einige seiner aktiven Metaboliten gehen in die Muttermilch über .
T-62	Colecalciferol and some of its active metabolites pass into breast milk .
H-62	-0.24728445708751678	Colecalciferol and some of its active metabolites are released into human milk .
D-62	-0.24728445708751678	Colecalciferol and some of its active metabolites are released into human milk .
P-62	-0.1892 -0.0956 -0.1849 -0.1125 -0.1044 -0.1479 -0.1381 -0.1004 -0.1424 -0.1076 -0.0963 -0.0874 -0.0404 -0.0656 -0.1622 -2.2394 -0.3722 -0.2989 -0.2022 -0.1557 -0.1496
S-425	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-425	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-425	-0.29019325971603394	After reconstitution , the solution is clear , colourless and free of foreign particles .
D-425	-0.29019325971603394	After reconstitution , the solution is clear , colourless and free of foreign particles .
P-425	-0.4688 -0.1317 -0.0795 -1.1901 -0.1422 -0.1333 -0.1572 -0.1098 -0.1537 -0.1155 -0.1001 -0.0775 -0.1806 -0.1265 -0.7857 -1.2471 -0.1893 -0.1140 -0.1504 -0.1509
S-506	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-506	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-506	-0.29019325971603394	After reconstitution , the solution is clear , colourless and free of foreign particles .
D-506	-0.29019325971603394	After reconstitution , the solution is clear , colourless and free of foreign particles .
P-506	-0.4688 -0.1317 -0.0795 -1.1901 -0.1422 -0.1333 -0.1572 -0.1098 -0.1537 -0.1155 -0.1001 -0.0775 -0.1806 -0.1265 -0.7857 -1.2471 -0.1893 -0.1140 -0.1504 -0.1509
S-587	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-587	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-587	-0.29019325971603394	After reconstitution , the solution is clear , colourless and free of foreign particles .
D-587	-0.29019325971603394	After reconstitution , the solution is clear , colourless and free of foreign particles .
P-587	-0.4688 -0.1317 -0.0795 -1.1901 -0.1422 -0.1333 -0.1572 -0.1098 -0.1537 -0.1155 -0.1001 -0.0775 -0.1806 -0.1265 -0.7857 -1.2471 -0.1893 -0.1140 -0.1504 -0.1509
S-668	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-668	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-668	-0.29019325971603394	After reconstitution , the solution is clear , colourless and free of foreign particles .
D-668	-0.29019325971603394	After reconstitution , the solution is clear , colourless and free of foreign particles .
P-668	-0.4688 -0.1317 -0.0795 -1.1901 -0.1422 -0.1333 -0.1572 -0.1098 -0.1537 -0.1155 -0.1001 -0.0775 -0.1806 -0.1265 -0.7857 -1.2471 -0.1893 -0.1140 -0.1504 -0.1509
S-138	Colecalciferol und einige seiner aktiven Metaboliten gehen in die Muttermilch über .
T-138	Colecalciferol and some of its active metabolites pass into breast milk .
H-138	-0.24728445708751678	Colecalciferol and some of its active metabolites are released into human milk .
D-138	-0.24728445708751678	Colecalciferol and some of its active metabolites are released into human milk .
P-138	-0.1892 -0.0956 -0.1849 -0.1125 -0.1044 -0.1479 -0.1381 -0.1004 -0.1424 -0.1076 -0.0963 -0.0874 -0.0404 -0.0656 -0.1622 -2.2394 -0.3722 -0.2989 -0.2022 -0.1557 -0.1496
S-780	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-780	After reconstitution , the solution is clear , colourless and free from foreign particles .
H-780	-0.29019325971603394	After reconstitution , the solution is clear , colourless and free of foreign particles .
D-780	-0.29019325971603394	After reconstitution , the solution is clear , colourless and free of foreign particles .
P-780	-0.4688 -0.1317 -0.0795 -1.1901 -0.1422 -0.1333 -0.1572 -0.1098 -0.1537 -0.1155 -0.1001 -0.0775 -0.1806 -0.1265 -0.7857 -1.2471 -0.1893 -0.1140 -0.1504 -0.1509
S-741	Falls Ihre Blutungen mit ADVATE nicht kontrolliert werden können , wenden Sie sich umgehend an Ihren Arzt
T-741	If your bleeding is not controlled with ADVATE , tell your doctor immediately .
H-741	-0.39161059260368347	If your bleeding cannot be controlled with ADVATE , contact your doctor immediately .
D-741	-0.39161059260368347	If your bleeding cannot be controlled with ADVATE , contact your doctor immediately .
P-741	-0.2245 -0.4981 -2.1259 -0.1926 -0.0844 -0.1170 -0.3344 -0.2814 -0.1387 -0.1731 -0.0835 -0.0766 -0.1635 -1.3302 -0.1491 -0.1076 -0.8611 -0.3383 -0.1606
S-608	ADVATE 3000 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
T-608	ADVATE 3000 IU powder and solvent for solution for injection .
H-608	-0.3313223719596863	ADVATE 3000 IU powder and solvents for solution for injection
D-608	-0.3313223719596863	ADVATE 3000 IU powder and solvents for solution for injection
P-608	-0.0812 -0.1650 -0.0846 -0.0859 -0.0731 -0.1113 -0.1283 -0.9845 -0.1522 -0.0949 -0.8856 -0.1125 -0.2796 -2.1811 -0.1485 -0.1475 -0.0945 -0.1535
S-527	ADVATE 2000 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
T-527	ADVATE 2000 IU powder and solvent for solution for injection .
H-527	-0.34797731041908264	ADVATE 2000 IU powder and solvents for solution for injection
D-527	-0.34797731041908264	ADVATE 2000 IU powder and solvents for solution for injection
P-527	-0.0796 -0.1654 -0.0831 -0.0874 -0.1232 -0.1223 -0.1180 -1.2835 -0.1531 -0.0926 -0.9783 -0.1150 -0.2295 -2.1022 -0.1327 -0.1441 -0.0972 -0.1563
S-525	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden .
T-525	The pulse rate should be determined before and during administration of ADVATE .
H-525	-0.428939551115036	The patient s pulse should be measured before and during ADVATE administration .
D-525	-0.428939551115036	The patient s pulse should be measured before and during ADVATE administration .
P-525	-1.3601 -0.0651 -1.2420 -0.7339 -0.0875 -0.1465 -0.1681 -0.1669 -0.9161 -0.1518 -0.4676 -1.5103 -0.1786 -0.0828 -0.0838 -0.0564 -0.1510 -0.1526
S-446	ADVATE 1500 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
T-446	ADVATE 1500 IU powder and solvent for solution for injection .
H-446	-0.33732372522354126	ADVATE 1500 IU powder and solvents for solution for injection
D-446	-0.33732372522354126	ADVATE 1500 IU powder and solvents for solution for injection
P-446	-0.0778 -0.1636 -0.0838 -0.0859 -0.0771 -0.1119 -0.1170 -0.9788 -0.1531 -0.0919 -0.9033 -0.1136 -0.2584 -2.3232 -0.1365 -0.1449 -0.0973 -0.1539
S-444	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden .
T-444	The pulse rate should be determined before and during administration of ADVATE .
H-444	-0.428939551115036	The patient s pulse should be measured before and during ADVATE administration .
D-444	-0.428939551115036	The patient s pulse should be measured before and during ADVATE administration .
P-444	-1.3601 -0.0651 -1.2420 -0.7339 -0.0875 -0.1465 -0.1681 -0.1669 -0.9161 -0.1518 -0.4676 -1.5103 -0.1786 -0.0828 -0.0838 -0.0564 -0.1510 -0.1526
S-365	ADVATE 1000 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
T-365	ADVATE 1000 IU powder and solvent for solution for injection .
H-365	-0.3306048512458801	ADVATE 1000 IU powder and solvents for solution for injection
D-365	-0.3306048512458801	ADVATE 1000 IU powder and solvents for solution for injection
P-365	-0.0875 -0.1654 -0.0824 -0.0849 -0.0810 -0.1130 -0.1128 -0.9301 -0.1544 -0.0924 -0.9484 -0.1131 -0.2594 -2.1787 -0.1471 -0.1487 -0.0956 -0.1560
S-708	Kann einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) gelagert werden .
T-708	Can be stored at room temperature ( up to 25<<unk>> C ) for a single period up to 2 months .
H-708	-0.31912651658058167	Can be stored once for up to 2 months at room temperature ( up to 25<unk> C ) .
D-708	-0.31912651658058167	Can be stored once for up to 2 months at room temperature ( up to 25<unk> C ) .
P-708	-1.1312 -0.1806 -0.2923 -0.1301 -1.1282 -0.3956 -0.9304 -0.1309 -0.1697 -0.1667 -0.1383 -0.0841 -0.1054 -0.1625 -0.1431 -0.1252 -0.9282 -0.0578 -0.1669 -0.1453 -0.1513 -0.1573
S-748	Die Einnahmehäufigkeit hängt davon ab , wie gut ADVATE bei Ihnen wirkt .
T-748	The frequency of administration will depend on how well ADVATE is working for you .
H-748	-0.34112703800201416	The frequency of doses depends on how well ADVATE works for you .
D-748	-0.34112703800201416	The frequency of doses depends on how well ADVATE works for you .
P-748	-0.3566 -0.0340 -0.0849 -0.3654 -1.5603 -0.6242 -0.7227 -0.1355 -0.1207 -0.4597 -0.0479 -0.1661 -0.0811 -0.0786 -0.7693 -0.4172 -0.1537 -0.1503 -0.1533
S-284	ADVATE 500 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
T-284	ADVATE 500 IU powder and solvent for solution for injection .
H-284	-0.34300053119659424	ADVATE 500 IU powder and solvents for preparation of solution for injection
D-284	-0.34300053119659424	ADVATE 500 IU powder and solvents for preparation of solution for injection
P-284	-0.0820 -0.1622 -0.0837 -0.0853 -0.1059 -0.1127 -0.1229 -1.0798 -0.1513 -0.0938 -0.8583 -0.1117 -0.2501 -2.4020 -0.1420 -0.5475 -0.1096 -0.1121 -0.0924 -0.1547
S-216	Die folgende Tabelle 1 enthält Richtwerte für die Dosierung bei Blutungen und chirurgischen Eingriffen :
T-216	The followingtable 1 can be used to guide dosing in bleeding episodes and surgery :
H-216	-0.4743271470069885	The following table 1 provides guidance on dosage for haemorrhage and surgery :
D-216	-0.4743271470069885	The following table 1 provides guidance on dosage for haemorrhage and surgery :
P-216	-0.3992 -0.1724 -0.4121 -0.2466 -0.8954 -1.5243 -1.0084 -0.6535 -0.8989 -0.1409 -0.3917 -0.1376 -0.3894 -0.0403 -0.6258 -0.1329 -0.6637 -0.1176 -0.1615
S-697	Kann einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) gelagert werden .
T-697	Can be stored at room temperature ( up to 25<<unk>> C ) for a single period up to 2 months .
H-697	-0.31912651658058167	Can be stored once for up to 2 months at room temperature ( up to 25<unk> C ) .
D-697	-0.31912651658058167	Can be stored once for up to 2 months at room temperature ( up to 25<unk> C ) .
P-697	-1.1312 -0.1806 -0.2923 -0.1301 -1.1282 -0.3956 -0.9304 -0.1309 -0.1697 -0.1667 -0.1383 -0.0841 -0.1054 -0.1625 -0.1431 -0.1252 -0.9282 -0.0578 -0.1669 -0.1453 -0.1513 -0.1573
S-801	29-1 LT-09129 Vilnius Tel : <unk> 370 5 269 16 91
T-801	29-1 LT-09129 Vilnius Tel : <<unk>> 370 5 269 16 91
H-801	-0.1573272943496704	29-1 LT-09129 Vilnius Tel : <unk> 370 5 269 16 91
D-801	-0.1573272943496704	29-1 LT-09129 Vilnius Tel : <unk> 370 5 269 16 91
P-801	-0.8773 -0.1639 -0.1382 -0.1480 -0.1978 -0.1941 -0.0741 -0.0834 -0.1249 -0.1889 -0.1526 -0.1397 -0.0668 -0.1451 -0.0249 -0.0575 -0.1216 -0.0840 -0.1274 -0.1145 -0.0699 -0.1664
S-687	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden .
T-687	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden . The pulse rate should be determined before and during administration of ADVATE .
H-687	-0.428939551115036	The patient s pulse should be measured before and during ADVATE administration .
D-687	-0.428939551115036	The patient s pulse should be measured before and during ADVATE administration .
P-687	-1.3601 -0.0651 -1.2420 -0.7339 -0.0875 -0.1465 -0.1681 -0.1669 -0.9161 -0.1518 -0.4676 -1.5103 -0.1786 -0.0828 -0.0838 -0.0564 -0.1510 -0.1526
S-606	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden .
T-606	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden . The pulse rate should be determined before and during administration of ADVATE .
H-606	-0.428939551115036	The patient s pulse should be measured before and during ADVATE administration .
D-606	-0.428939551115036	The patient s pulse should be measured before and during ADVATE administration .
P-606	-1.3601 -0.0651 -1.2420 -0.7339 -0.0875 -0.1465 -0.1681 -0.1669 -0.9161 -0.1518 -0.4676 -1.5103 -0.1786 -0.0828 -0.0838 -0.0564 -0.1510 -0.1526
S-723	Kann einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) gelagert werden .
T-723	Can be stored at room temperature ( up to 25<<unk>> C ) for a single period up to 2 months .
H-723	-0.31912651658058167	Can be stored once for up to 2 months at room temperature ( up to 25<unk> C ) .
D-723	-0.31912651658058167	Can be stored once for up to 2 months at room temperature ( up to 25<unk> C ) .
P-723	-1.1312 -0.1806 -0.2923 -0.1301 -1.1282 -0.3956 -0.9304 -0.1309 -0.1697 -0.1667 -0.1383 -0.0841 -0.1054 -0.1625 -0.1431 -0.1252 -0.9282 -0.0578 -0.1669 -0.1453 -0.1513 -0.1573
S-718	Kann einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) gelagert werden .
T-718	Can be stored at room temperature ( up to 25<<unk>> C ) for a single period up to 2 months .
H-718	-0.31912651658058167	Can be stored once for up to 2 months at room temperature ( up to 25<unk> C ) .
D-718	-0.31912651658058167	Can be stored once for up to 2 months at room temperature ( up to 25<unk> C ) .
P-718	-1.1312 -0.1806 -0.2923 -0.1301 -1.1282 -0.3956 -0.9304 -0.1309 -0.1697 -0.1667 -0.1383 -0.0841 -0.1054 -0.1625 -0.1431 -0.1252 -0.9282 -0.0578 -0.1669 -0.1453 -0.1513 -0.1573
S-713	Kann einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) gelagert werden .
T-713	Can be stored at room temperature ( up to 25<<unk>> C ) for a single period up to 2 months .
H-713	-0.31912651658058167	Can be stored once for up to 2 months at room temperature ( up to 25<unk> C ) .
D-713	-0.31912651658058167	Can be stored once for up to 2 months at room temperature ( up to 25<unk> C ) .
P-713	-1.1312 -0.1806 -0.2923 -0.1301 -1.1282 -0.3956 -0.9304 -0.1309 -0.1697 -0.1667 -0.1383 -0.0841 -0.1054 -0.1625 -0.1431 -0.1252 -0.9282 -0.0578 -0.1669 -0.1453 -0.1513 -0.1573
S-702	Kann einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) gelagert werden .
T-702	Can be stored at room temperature ( up to 25<<unk>> C ) for a single period up to 2 months .
H-702	-0.31912651658058167	Can be stored once for up to 2 months at room temperature ( up to 25<unk> C ) .
D-702	-0.31912651658058167	Can be stored once for up to 2 months at room temperature ( up to 25<unk> C ) .
P-702	-1.1312 -0.1806 -0.2923 -0.1301 -1.1282 -0.3956 -0.9304 -0.1309 -0.1697 -0.1667 -0.1383 -0.0841 -0.1054 -0.1625 -0.1431 -0.1252 -0.9282 -0.0578 -0.1669 -0.1453 -0.1513 -0.1573
S-294	Die folgende Tabelle 1 enthält Richtwerte für die Dosierung bei Blutungen und chirurgischen Eingriffen :
T-294	The followingtable 1 can be used to guide dosing in bleeding episodes and surgery :
H-294	-0.4743271470069885	The following table 1 provides guidance on dosage for haemorrhage and surgery :
D-294	-0.4743271470069885	The following table 1 provides guidance on dosage for haemorrhage and surgery :
P-294	-0.3992 -0.1724 -0.4121 -0.2466 -0.8954 -1.5243 -1.0084 -0.6535 -0.8989 -0.1409 -0.3917 -0.1376 -0.3894 -0.0403 -0.6258 -0.1329 -0.6637 -0.1176 -0.1615
S-743	Schwangerschaft und Stillzeit Informieren Sie Ihren Arzt , wenn Sie schwanger sind oder stillen .
T-743	Pregnancy and breast-feeding Tell your doctor if you are pregnant or breast-feeding .
H-743	-0.1489054411649704	Pregnancy and breast-feeding Tell your doctor if you are pregnant or breast-feeding .
D-743	-0.1489054411649704	Pregnancy and breast-feeding Tell your doctor if you are pregnant or breast-feeding .
P-743	-0.1326 -0.0427 -0.1251 -0.1444 -0.1665 -0.0384 -0.0853 -0.0330 -1.0724 -0.0677 -0.1528 -0.1190 -0.1364 -0.1430 -0.1210 -0.1399 -0.1300 -0.1141 -0.0338 -0.0526 -0.0410 -0.1768 -0.1561
S-375	Die folgende Tabelle 1 enthält Richtwerte für die Dosierung bei Blutungen und chirurgischen Eingriffen :
T-375	The followingtable 1 can be used to guide dosing in bleeding episodes and surgery :
H-375	-0.4743271470069885	The following table 1 provides guidance on dosage for haemorrhage and surgery :
D-375	-0.4743271470069885	The following table 1 provides guidance on dosage for haemorrhage and surgery :
P-375	-0.3992 -0.1724 -0.4121 -0.2466 -0.8954 -1.5243 -1.0084 -0.6535 -0.8989 -0.1409 -0.3917 -0.1376 -0.3894 -0.0403 -0.6258 -0.1329 -0.6637 -0.1176 -0.1615
S-742	B. Atembeschwerden und ( Beinahe<unk> -Ohnmacht benötigen eine sofortige Notfallbehandlung .
T-742	Severe symptoms , including difficulty in breathing and ( near ) fainting , require prompt emergency treatment .
H-742	-0.5889223217964172	Difficulty breathing and ( near ) fainting require immediate emergency treatment .
D-742	-0.5889223217964172	Difficulty breathing and ( near ) fainting require immediate emergency treatment .
P-742	-2.7519 -0.2872 -0.2253 -0.6984 -0.3327 -0.9917 -0.1910 -0.5899 -0.1003 -1.1134 -0.1482 -0.3039 -0.1543 -1.5637 -0.8557 -0.2322 -0.3509 -0.1451 -0.1536
S-764	Wie alle Arzneimittel kann ADVATE Nebenwirkungen haben , die aber nicht bei jedem auftreten müssen .
T-764	Like all medicines , ADVATE can cause side effects , although not everybody gets them .
H-764	-0.1333855539560318	Like all medicines , ADVATE can cause side effects , although not everybody gets them .
D-764	-0.1333855539560318	Like all medicines , ADVATE can cause side effects , although not everybody gets them .
P-764	-0.1194 -0.0862 -0.1098 -0.1177 -0.1220 -0.1418 -0.1640 -0.0977 -0.0847 -0.1624 -0.0778 -0.1062 -0.0839 -0.1273 -0.2669 -0.0984 -0.4319 -0.0243 -0.0724 -0.1558 -0.1504
S-740	Die Entwicklung von Inhibitoren ist eine bekannte Komplikation der Hämophilie A Behandlung .
T-740	Development of inhibitors is a known complication in the treatment of haemophilia A.
H-740	-0.3354933559894562	The development of inhibitors is a known complication of haemophilia A treatment .
D-740	-0.3354933559894562	The development of inhibitors is a known complication of haemophilia A treatment .
P-740	-2.4881 -0.0881 -0.1433 -0.1421 -0.0470 -0.0876 -0.1445 -0.1516 -0.1730 -0.9139 -0.0944 -0.1480 -0.1691 -1.3895 -0.1502 -0.0715 -0.0961 -0.1408 -0.1072 -0.1491 -0.1504
S-618	Die folgende Tabelle 1 enthält Richtwerte für die Dosierung bei Blutungen und chirurgischen Eingriffen :
T-618	The followingtable 1 can be used to guide dosing in bleeding episodes and surgery :
H-618	-0.4743271470069885	The following table 1 provides guidance on dosage for haemorrhage and surgery :
D-618	-0.4743271470069885	The following table 1 provides guidance on dosage for haemorrhage and surgery :
P-618	-0.3992 -0.1724 -0.4121 -0.2466 -0.8954 -1.5243 -1.0084 -0.6535 -0.8989 -0.1409 -0.3917 -0.1376 -0.3894 -0.0403 -0.6258 -0.1329 -0.6637 -0.1176 -0.1615
S-537	Die folgende Tabelle 1 enthält Richtwerte für die Dosierung bei Blutungen und chirurgischen Eingriffen :
T-537	The followingtable 1 can be used to guide dosing in bleeding episodes and surgery :
H-537	-0.4743271470069885	The following table 1 provides guidance on dosage for haemorrhage and surgery :
D-537	-0.4743271470069885	The following table 1 provides guidance on dosage for haemorrhage and surgery :
P-537	-0.3992 -0.1724 -0.4121 -0.2466 -0.8954 -1.5243 -1.0084 -0.6535 -0.8989 -0.1409 -0.3917 -0.1376 -0.3894 -0.0403 -0.6258 -0.1329 -0.6637 -0.1176 -0.1615
S-456	Die folgende Tabelle 1 enthält Richtwerte für die Dosierung bei Blutungen und chirurgischen Eingriffen :
T-456	The followingtable 1 can be used to guide dosing in bleeding episodes and surgery :
H-456	-0.4743271470069885	The following table 1 provides guidance on dosage for haemorrhage and surgery :
D-456	-0.4743271470069885	The following table 1 provides guidance on dosage for haemorrhage and surgery :
P-456	-0.3992 -0.1724 -0.4121 -0.2466 -0.8954 -1.5243 -1.0084 -0.6535 -0.8989 -0.1409 -0.3917 -0.1376 -0.3894 -0.0403 -0.6258 -0.1329 -0.6637 -0.1176 -0.1615
S-363	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden .
T-363	The pulse rate should be determined before and during administration of ADVATE .
H-363	-0.428939551115036	The patient s pulse should be measured before and during ADVATE administration .
D-363	-0.428939551115036	The patient s pulse should be measured before and during ADVATE administration .
P-363	-1.3601 -0.0651 -1.2420 -0.7339 -0.0875 -0.1465 -0.1681 -0.1669 -0.9161 -0.1518 -0.4676 -1.5103 -0.1786 -0.0828 -0.0838 -0.0564 -0.1510 -0.1526
S-775	Fragen Sie Ihren Apotheker wie das Arzneimittel zu entsorgen ist , wenn Sie es nicht mehr benötigen .
T-775	Ask your pharmacist how to dispose of medicines no longer required .
H-775	-0.10841526836156845	Ask your pharmacist how to dispose of medicines no longer required .
D-775	-0.10841526836156845	Ask your pharmacist how to dispose of medicines no longer required .
P-775	-0.0666 -0.0962 -0.1692 -0.0629 -0.1280 -0.1366 -0.1547 -0.0838 -0.0376 -0.1434 -0.0541 -0.0727 -0.0575 -0.1247 -0.1679 -0.1305 -0.1566
S-282	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden .
T-282	The pulse rate should be determined before and during administration of ADVATE .
H-282	-0.428939551115036	The patient s pulse should be measured before and during ADVATE administration .
D-282	-0.428939551115036	The patient s pulse should be measured before and during ADVATE administration .
P-282	-1.3601 -0.0651 -1.2420 -0.7339 -0.0875 -0.1465 -0.1681 -0.1669 -0.9161 -0.1518 -0.4676 -1.5103 -0.1786 -0.0828 -0.0838 -0.0564 -0.1510 -0.1526
S-724	Das Behältnis in der Originalverpackung aufbewahren , um den Inhalt vor Licht zu schützen .
T-724	Store in the original package in order to protect from light .
H-724	-0.19393175840377808	Store in the original package in order to protect from light .
D-724	-0.19393175840377808	Store in the original package in order to protect from light .
P-724	-0.5984 -0.5620 -0.1336 -0.1051 -0.1565 -0.1264 -0.0866 -0.1298 -0.1226 -0.1056 -0.0763 -0.1600 -0.1582
S-719	Das Behältnis in der Originalverpackung aufbewahren , um den Inhalt vor Licht zu schützen .
T-719	Store in the original package in order to protect from light .
H-719	-0.19393175840377808	Store in the original package in order to protect from light .
D-719	-0.19393175840377808	Store in the original package in order to protect from light .
P-719	-0.5984 -0.5620 -0.1336 -0.1051 -0.1565 -0.1264 -0.0866 -0.1298 -0.1226 -0.1056 -0.0763 -0.1600 -0.1582
S-207	0,45 mmol Natriumchlorid ( 10 mg ) pro Durchstechflasche .
T-207	0.45 mmol sodium ( 10 mg ) per vial .
H-207	-0.1299930214881897	0.45 mmol sodium chloride ( 10 mg ) per vial .
D-207	-0.1299930214881897	0.45 mmol sodium chloride ( 10 mg ) per vial .
P-207	-0.1276 -0.1399 -0.1118 -0.1324 -0.1008 -0.0593 -0.0596 -0.1237 -0.1051 -0.0495 -0.0985 -0.1472 -0.1332 -0.0471 -0.1547 -0.0927 -0.0264 -0.0557 -0.6837 -0.1511
S-300	Wenn es nicht durch medizinisches Personal verabreicht werden soll , ist vorher ein entsprechendes Training erforderlich .
T-300	In case of administration by a non health care professional appropriate training is needed .
H-300	-0.4348464012145996	If it is not to be administered by medical staff , appropriate training is required beforehand .
D-300	-0.4348464012145996	If it is not to be administered by medical staff , appropriate training is required beforehand .
P-300	-0.9834 -0.4337 -0.3012 -0.1794 -0.1440 -0.1174 -0.0361 -0.0956 -0.1239 -0.6794 -0.4186 -0.3165 -0.3570 -0.5264 -1.1756 -0.3477 -2.0534 -0.1088 -0.1493 -0.1493
S-287	0,45 mmol Natriumchlorid ( 10 mg ) pro Durchstechflasche .
T-287	0.45 mmol sodium ( 10 mg ) per vial .
H-287	-0.1299930214881897	0.45 mmol sodium chloride ( 10 mg ) per vial .
D-287	-0.1299930214881897	0.45 mmol sodium chloride ( 10 mg ) per vial .
P-287	-0.1276 -0.1399 -0.1118 -0.1324 -0.1008 -0.0593 -0.0596 -0.1237 -0.1051 -0.0495 -0.0985 -0.1472 -0.1332 -0.0471 -0.1547 -0.0927 -0.0264 -0.0557 -0.6837 -0.1511
S-222	Wenn es nicht durch medizinisches Personal verabreicht werden soll , ist vorher ein entsprechendes Training erforderlich .
T-222	In case of administration by a non health care professional appropriate training is needed .
H-222	-0.4348464012145996	If it is not to be administered by medical staff , appropriate training is required beforehand .
D-222	-0.4348464012145996	If it is not to be administered by medical staff , appropriate training is required beforehand .
P-222	-0.9834 -0.4337 -0.3012 -0.1794 -0.1440 -0.1174 -0.0361 -0.0956 -0.1239 -0.6794 -0.4186 -0.3165 -0.3570 -0.5264 -1.1756 -0.3477 -2.0534 -0.1088 -0.1493 -0.1493
S-6	Die Behandlung mit Adenuric darf nicht abgesetzt werden , wenn ein Gichtanfall auftritt .
T-6	Adenuric treatment should not be stopped if an attack happens .
H-6	-0.28384238481521606	Treatment with Adenuric should not be discontinued if an attack of gout occurs .
D-6	-0.28384238481521606	Treatment with Adenuric should not be discontinued if an attack of gout occurs .
P-6	-1.4347 -0.0656 -0.1197 -0.1283 -0.3877 -0.1925 -0.0639 -0.1142 -0.5470 -0.1285 -0.1047 -0.0763 -0.0865 -0.6600 -1.4081 -0.1407 -0.1329 -0.0561 -0.1414 -0.1613 -0.0781 -0.1519 -0.1482
S-449	0,45 mmol Natriumchlorid ( 10 mg ) pro Durchstechflasche .
T-449	0.45 mmol sodium ( 10 mg ) per vial .
H-449	-0.1299930214881897	0.45 mmol sodium chloride ( 10 mg ) per vial .
D-449	-0.1299930214881897	0.45 mmol sodium chloride ( 10 mg ) per vial .
P-449	-0.1276 -0.1399 -0.1118 -0.1324 -0.1008 -0.0593 -0.0596 -0.1237 -0.1051 -0.0495 -0.0985 -0.1472 -0.1332 -0.0471 -0.1547 -0.0927 -0.0264 -0.0557 -0.6837 -0.1511
S-462	Wenn es nicht durch medizinisches Personal verabreicht werden soll , ist vorher ein entsprechendes Training erforderlich .
T-462	In case of administration by a non health care professional appropriate training is needed .
H-462	-0.4348464012145996	If it is not to be administered by medical staff , appropriate training is required beforehand .
D-462	-0.4348464012145996	If it is not to be administered by medical staff , appropriate training is required beforehand .
P-462	-0.9834 -0.4337 -0.3012 -0.1794 -0.1440 -0.1174 -0.0361 -0.0956 -0.1239 -0.6794 -0.4186 -0.3165 -0.3570 -0.5264 -1.1756 -0.3477 -2.0534 -0.1088 -0.1493 -0.1493
S-714	Das Behältnis in der Originalverpackung aufbewahren , um den Inhalt vor Licht zu schützen .
T-714	Store in the original package in order to protect from light .
H-714	-0.19393175840377808	Store in the original package in order to protect from light .
D-714	-0.19393175840377808	Store in the original package in order to protect from light .
P-714	-0.5984 -0.5620 -0.1336 -0.1051 -0.1565 -0.1264 -0.0866 -0.1298 -0.1226 -0.1056 -0.0763 -0.1600 -0.1582
S-709	Das Behältnis in der Originalverpackung aufbewahren , um den Inhalt vor Licht zu schützen .
T-709	Store in the original package in order to protect from light .
H-709	-0.19393175840377808	Store in the original package in order to protect from light .
D-709	-0.19393175840377808	Store in the original package in order to protect from light .
P-709	-0.5984 -0.5620 -0.1336 -0.1051 -0.1565 -0.1264 -0.0866 -0.1298 -0.1226 -0.1056 -0.0763 -0.1600 -0.1582
S-703	Das Behältnis in der Originalverpackung aufbewahren , um den Inhalt vor Licht zu schützen .
T-703	Store in the original package in order to protect from light .
H-703	-0.19393175840377808	Store in the original package in order to protect from light .
D-703	-0.19393175840377808	Store in the original package in order to protect from light .
P-703	-0.5984 -0.5620 -0.1336 -0.1051 -0.1565 -0.1264 -0.0866 -0.1298 -0.1226 -0.1056 -0.0763 -0.1600 -0.1582
S-698	Das Behältnis in der Originalverpackung aufbewahren , um den Inhalt vor Licht zu schützen .
T-698	Store in the original package in order to protect from light .
H-698	-0.19393175840377808	Store in the original package in order to protect from light .
D-698	-0.19393175840377808	Store in the original package in order to protect from light .
P-698	-0.5984 -0.5620 -0.1336 -0.1051 -0.1565 -0.1264 -0.0866 -0.1298 -0.1226 -0.1056 -0.0763 -0.1600 -0.1582
S-732	Nebenwirkungen bemerken , die nicht in dieser Gebrauchsinformation angegeben sind , informieren Sie bitte Ihren Arzt .
T-732	please tell your doctor .
H-732	-0.2871929109096527	please tell you doctor .
D-732	-0.2871929109096527	please tell you doctor .
P-732	-0.0315 -0.2164 -0.9847 -0.1323 -0.1635 -0.1947
S-381	Wenn es nicht durch medizinisches Personal verabreicht werden soll , ist vorher ein entsprechendes Training erforderlich .
T-381	In case of administration by a non health care professional appropriate training is needed .
H-381	-0.4348464012145996	If it is not to be administered by medical staff , appropriate training is required beforehand .
D-381	-0.4348464012145996	If it is not to be administered by medical staff , appropriate training is required beforehand .
P-381	-0.9834 -0.4337 -0.3012 -0.1794 -0.1440 -0.1174 -0.0361 -0.0956 -0.1239 -0.6794 -0.4186 -0.3165 -0.3570 -0.5264 -1.1756 -0.3477 -2.0534 -0.1088 -0.1493 -0.1493
S-664	Der Beginn und das Ende der Raumtemperaturlagerung sollten auf dem Umkarton vermerkt werden .
T-664	The beginning of storage at room temperature should be recorded on the product carton .
H-664	-0.2292061597108841	The start and end of room temperature storage should be noted on the outer carton .
D-664	-0.2292061597108841	The start and end of room temperature storage should be noted on the outer carton .
P-664	-0.1827 -0.5729 -0.1441 -0.2319 -0.1502 -0.3979 -0.0923 -0.1123 -0.1423 -0.1442 -1.3648 -0.1188 -0.1347 -0.0336 -0.1196 -0.0641 -0.0457 -0.1541 -0.1487
S-204	ADVATE 250 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
T-204	ADVATE 250 IU powder and solvent for solution for injection
H-204	-0.3458680510520935	ADVATE 250 IU powder and solvents for preparation of solution for injection
D-204	-0.3458680510520935	ADVATE 250 IU powder and solvents for preparation of solution for injection
P-204	-0.0768 -0.1623 -0.0839 -0.0872 -0.0932 -0.1069 -0.1144 -1.2463 -0.1517 -0.0924 -0.9008 -0.1120 -0.2431 -2.2878 -0.1430 -0.5495 -0.1116 -0.1089 -0.0925 -0.1530
S-770	Bitte notieren Sie den Beginn und das Ende der Raumtemperaturlagerung auf dem Umkarton .
T-770	Please record the beginning of storage at room temperature on the product carton .
H-770	-0.2704591751098633	Please note the start and end of room temperature storage on the outer carton .
D-770	-0.2704591751098633	Please note the start and end of room temperature storage on the outer carton .
P-770	-1.0080 -0.8721 -0.1520 -0.6382 -0.1481 -0.3001 -0.1576 -0.5404 -0.1001 -0.1059 -0.1498 -0.1352 -0.0421 -0.1218 -0.0576 -0.0389 -0.1459 -0.1544
S-583	Der Beginn und das Ende der Raumtemperaturlagerung sollten auf dem Umkarton vermerkt werden .
T-583	The beginning of storage at room temperature should be recorded on the product carton .
H-583	-0.2292061597108841	The start and end of room temperature storage should be noted on the outer carton .
D-583	-0.2292061597108841	The start and end of room temperature storage should be noted on the outer carton .
P-583	-0.1827 -0.5729 -0.1441 -0.2319 -0.1502 -0.3979 -0.0923 -0.1123 -0.1423 -0.1442 -1.3648 -0.1188 -0.1347 -0.0336 -0.1196 -0.0641 -0.0457 -0.1541 -0.1487
S-502	Der Beginn und das Ende der Raumtemperaturlagerung sollten auf dem Umkarton vermerkt werden .
T-502	The beginning of storage at room temperature should be recorded on the product carton .
H-502	-0.2292061597108841	The start and end of room temperature storage should be noted on the outer carton .
D-502	-0.2292061597108841	The start and end of room temperature storage should be noted on the outer carton .
P-502	-0.1827 -0.5729 -0.1441 -0.2319 -0.1502 -0.3979 -0.0923 -0.1123 -0.1423 -0.1442 -1.3648 -0.1188 -0.1347 -0.0336 -0.1196 -0.0641 -0.0457 -0.1541 -0.1487
S-421	Der Beginn und das Ende der Raumtemperaturlagerung sollten auf dem Umkarton vermerkt werden .
T-421	The beginning of storage at room temperature should be recorded on the product carton .
H-421	-0.2292061597108841	The start and end of room temperature storage should be noted on the outer carton .
D-421	-0.2292061597108841	The start and end of room temperature storage should be noted on the outer carton .
P-421	-0.1827 -0.5729 -0.1441 -0.2319 -0.1502 -0.3979 -0.0923 -0.1123 -0.1423 -0.1442 -1.3648 -0.1188 -0.1347 -0.0336 -0.1196 -0.0641 -0.0457 -0.1541 -0.1487
S-340	Der Beginn und das Ende der Raumtemperaturlagerung sollten auf dem Umkarton vermerkt werden .
T-340	The beginning of storage at room temperature should be recorded on the product carton .
H-340	-0.2292061597108841	The start and end of room temperature storage should be noted on the outer carton .
D-340	-0.2292061597108841	The start and end of room temperature storage should be noted on the outer carton .
P-340	-0.1827 -0.5729 -0.1441 -0.2319 -0.1502 -0.3979 -0.0923 -0.1123 -0.1423 -0.1442 -1.3648 -0.1188 -0.1347 -0.0336 -0.1196 -0.0641 -0.0457 -0.1541 -0.1487
S-259	Der Beginn und das Ende der Raumtemperaturlagerung sollten auf dem Umkarton vermerkt werden .
T-259	The beginning of storage at room temperature should be recorded on the product carton .
H-259	-0.2292061597108841	The start and end of room temperature storage should be noted on the outer carton .
D-259	-0.2292061597108841	The start and end of room temperature storage should be noted on the outer carton .
P-259	-0.1827 -0.5729 -0.1441 -0.2319 -0.1502 -0.3979 -0.0923 -0.1123 -0.1423 -0.1442 -1.3648 -0.1188 -0.1347 -0.0336 -0.1196 -0.0641 -0.0457 -0.1541 -0.1487
S-368	0,45 mmol Natriumchlorid ( 10 mg ) pro Durchstechflasche .
T-368	0.45 mmol sodium ( 10 mg ) per vial .
H-368	-0.1299930214881897	0.45 mmol sodium chloride ( 10 mg ) per vial .
D-368	-0.1299930214881897	0.45 mmol sodium chloride ( 10 mg ) per vial .
P-368	-0.1276 -0.1399 -0.1118 -0.1324 -0.1008 -0.0593 -0.0596 -0.1237 -0.1051 -0.0495 -0.0985 -0.1472 -0.1332 -0.0471 -0.1547 -0.0927 -0.0264 -0.0557 -0.6837 -0.1511
S-203	Pulver : Durchstechflasche ( Glas ) Lösungsmittel : Durchstechflasche ( Glas )
T-203	powder : vial ( glass ) ; solvent : vial ( glass )
H-203	-0.32746803760528564	Powder : Vial ( glass ) Solvent : vial ( glass )
D-203	-0.32746803760528564	Powder : Vial ( glass ) Solvent : vial ( glass )
P-203	-2.5821 -0.1119 -0.1799 -0.1472 -0.0838 -0.1285 -0.1318 -0.0453 -0.1434 -0.1603 -0.9986 -0.1435 -0.3534 -0.0918 -0.1357 -0.0608 -0.1437 -0.2526
S-530	0,45 mmol Natriumchlorid ( 10 mg ) pro Durchstechflasche .
T-530	0.45 mmol sodium ( 10 mg ) per vial .
H-530	-0.1299930214881897	0.45 mmol sodium chloride ( 10 mg ) per vial .
D-530	-0.1299930214881897	0.45 mmol sodium chloride ( 10 mg ) per vial .
P-530	-0.1276 -0.1399 -0.1118 -0.1324 -0.1008 -0.0593 -0.0596 -0.1237 -0.1051 -0.0495 -0.0985 -0.1472 -0.1332 -0.0471 -0.1547 -0.0927 -0.0264 -0.0557 -0.6837 -0.1511
S-765	- Hautrötung , Ausschlag , Quaddelbildung , Juckreiz am ganzen Körper ,
T-765	- rash , hives , wheals , generalised itching ,
H-765	-0.5709110498428345	- redness , rash , wheals , itching all over the body ,
D-765	-0.5709110498428345	- redness , rash , wheals , itching all over the body ,
P-765	-0.1366 -1.2246 -0.0546 -0.1736 -0.0847 -0.0464 -0.1570 -0.3999 -2.0347 -0.1969 -1.4888 -0.1637 -1.2033 -0.0767 -0.5562 -0.0824 -0.3133 -1.8830
S-624	Wenn es nicht durch medizinisches Personal verabreicht werden soll , ist vorher ein entsprechendes Training erforderlich .
T-624	In case of administration by a non health care professional appropriate training is needed .
H-624	-0.4348464012145996	If it is not to be administered by medical staff , appropriate training is required beforehand .
D-624	-0.4348464012145996	If it is not to be administered by medical staff , appropriate training is required beforehand .
P-624	-0.9834 -0.4337 -0.3012 -0.1794 -0.1440 -0.1174 -0.0361 -0.0956 -0.1239 -0.6794 -0.4186 -0.3165 -0.3570 -0.5264 -1.1756 -0.3477 -2.0534 -0.1088 -0.1493 -0.1493
S-611	0,45 mmol Natriumchlorid ( 10 mg ) pro Durchstechflasche .
T-611	0.45 mmol sodium ( 10 mg ) per vial .
H-611	-0.1299930214881897	0.45 mmol sodium chloride ( 10 mg ) per vial .
D-611	-0.1299930214881897	0.45 mmol sodium chloride ( 10 mg ) per vial .
P-611	-0.1276 -0.1399 -0.1118 -0.1324 -0.1008 -0.0593 -0.0596 -0.1237 -0.1051 -0.0495 -0.0985 -0.1472 -0.1332 -0.0471 -0.1547 -0.0927 -0.0264 -0.0557 -0.6837 -0.1511
S-543	Wenn es nicht durch medizinisches Personal verabreicht werden soll , ist vorher ein entsprechendes Training erforderlich .
T-543	In case of administration by a non health care professional appropriate training is needed .
H-543	-0.4348464012145996	If it is not to be administered by medical staff , appropriate training is required beforehand .
D-543	-0.4348464012145996	If it is not to be administered by medical staff , appropriate training is required beforehand .
P-543	-0.9834 -0.4337 -0.3012 -0.1794 -0.1440 -0.1174 -0.0361 -0.0956 -0.1239 -0.6794 -0.4186 -0.3165 -0.3570 -0.5264 -1.1756 -0.3477 -2.0534 -0.1088 -0.1493 -0.1493
S-465	Wie bei allen intravenösen Proteinen können allergische Überempfindlichkeitsreaktionen auftreten .
T-465	As with any intravenous protein product allergic type hypersensitivity reactions are possible .
H-465	-0.1912674456834793	As with all intravenous proteins , hypersensitivity reactions may occur .
D-465	-0.1912674456834793	As with all intravenous proteins , hypersensitivity reactions may occur .
P-465	-0.7292 -0.1744 -0.1372 -0.0896 -0.0982 -0.0959 -0.1056 -0.0429 -0.0626 -0.5455 -0.2751 -0.2029 -0.0379 -0.1994 -0.0600 -0.3885 -0.0762 -0.1627 -0.1504
S-546	Wie bei allen intravenösen Proteinen können allergische Überempfindlichkeitsreaktionen auftreten .
T-546	As with any intravenous protein product allergic type hypersensitivity reactions are possible .
H-546	-0.1912674456834793	As with all intravenous proteins , hypersensitivity reactions may occur .
D-546	-0.1912674456834793	As with all intravenous proteins , hypersensitivity reactions may occur .
P-546	-0.7292 -0.1744 -0.1372 -0.0896 -0.0982 -0.0959 -0.1056 -0.0429 -0.0626 -0.5455 -0.2751 -0.2029 -0.0379 -0.1994 -0.0600 -0.3885 -0.0762 -0.1627 -0.1504
S-303	Wie bei allen intravenösen Proteinen können allergische Überempfindlichkeitsreaktionen auftreten .
T-303	As with any intravenous protein product allergic type hypersensitivity reactions are possible .
H-303	-0.1912674456834793	As with all intravenous proteins , hypersensitivity reactions may occur .
D-303	-0.1912674456834793	As with all intravenous proteins , hypersensitivity reactions may occur .
P-303	-0.7292 -0.1744 -0.1372 -0.0896 -0.0982 -0.0959 -0.1056 -0.0429 -0.0626 -0.5455 -0.2751 -0.2029 -0.0379 -0.1994 -0.0600 -0.3885 -0.0762 -0.1627 -0.1504
S-627	Wie bei allen intravenösen Proteinen können allergische Überempfindlichkeitsreaktionen auftreten .
T-627	As with any intravenous protein product allergic type hypersensitivity reactions are possible .
H-627	-0.1912674456834793	As with all intravenous proteins , hypersensitivity reactions may occur .
D-627	-0.1912674456834793	As with all intravenous proteins , hypersensitivity reactions may occur .
P-627	-0.7292 -0.1744 -0.1372 -0.0896 -0.0982 -0.0959 -0.1056 -0.0429 -0.0626 -0.5455 -0.2751 -0.2029 -0.0379 -0.1994 -0.0600 -0.3885 -0.0762 -0.1627 -0.1504
S-761	Sollten Sie eine größere Menge angewendet haben , wenden Sie sich bitte schnellstmöglich an Ihren Arzt .
T-761	If you inject more ADVATE than recommended , tell your doctor as soon as possible .
H-761	-0.48294946551322937	If you take more doses , talk to your doctor as soon as possible .
D-761	-0.48294946551322937	If you take more doses , talk to your doctor as soon as possible .
P-761	-0.2290 -0.1472 -2.8265 -0.5934 -1.7073 -0.1102 -0.1972 -1.2205 -0.1574 -0.1455 -0.0954 -0.1590 -0.1016 -0.1322 -0.0846 -0.1470 -0.1562
S-248	Dieses setzt dann Fibrin aus Fibrinogen frei und die Gerinnselbildung kann erfolgen .
T-248	Thrombin then converts fibrinogen into fibrin and a clot can be formed .
H-248	-0.3535991311073303	This then releases fibrin from fibrinogen and clotting can occur .
D-248	-0.3535991311073303	This then releases fibrin from fibrinogen and clotting can occur .
P-248	-0.4401 -0.6565 -0.4322 -0.0637 -0.1036 -0.2697 -0.1274 -0.1528 -0.6892 -0.4005 -0.4700 -0.2229 -0.4227 -0.1442 -0.1400 -0.6796 -1.0068 -0.1453 -0.1511
S-384	Wie bei allen intravenösen Proteinen können allergische Überempfindlichkeitsreaktionen auftreten .
T-384	As with any intravenous protein product allergic type hypersensitivity reactions are possible .
H-384	-0.1912674456834793	As with all intravenous proteins , hypersensitivity reactions may occur .
D-384	-0.1912674456834793	As with all intravenous proteins , hypersensitivity reactions may occur .
P-384	-0.7292 -0.1744 -0.1372 -0.0896 -0.0982 -0.0959 -0.1056 -0.0429 -0.0626 -0.5455 -0.2751 -0.2029 -0.0379 -0.1994 -0.0600 -0.3885 -0.0762 -0.1627 -0.1504
S-409	Dieses setzt dann Fibrin aus Fibrinogen frei und die Gerinnselbildung kann erfolgen .
T-409	Thrombin then converts fibrinogen into fibrin and a clot can be formed .
H-409	-0.3535991311073303	This then releases fibrin from fibrinogen and clotting can occur .
D-409	-0.3535991311073303	This then releases fibrin from fibrinogen and clotting can occur .
P-409	-0.4401 -0.6565 -0.4322 -0.0637 -0.1036 -0.2697 -0.1274 -0.1528 -0.6892 -0.4005 -0.4700 -0.2229 -0.4227 -0.1442 -0.1400 -0.6796 -1.0068 -0.1453 -0.1511
S-225	Wie bei allen intravenösen Proteinen können allergische Überempfindlichkeitsreaktionen auftreten .
T-225	As with any intravenous protein product allergic type hypersensitivity reactions are possible .
H-225	-0.1912674456834793	As with all intravenous proteins , hypersensitivity reactions may occur .
D-225	-0.1912674456834793	As with all intravenous proteins , hypersensitivity reactions may occur .
P-225	-0.7292 -0.1744 -0.1372 -0.0896 -0.0982 -0.0959 -0.1056 -0.0429 -0.0626 -0.5455 -0.2751 -0.2029 -0.0379 -0.1994 -0.0600 -0.3885 -0.0762 -0.1627 -0.1504
S-1	Es ist als gelbe , kapselförmige Tabletten ( 80 und 120 mg ) erhältlich .
T-1	It is available as yellow , capsule- shaped tablets ( 80 and 120 mg ) .
H-1	-0.35972708463668823	It is supplied as yellow capsular tablets ( 80 and 120 mg ) .
D-1	-0.35972708463668823	It is supplied as yellow capsular tablets ( 80 and 120 mg ) .
P-1	-0.1310 -0.1666 -1.0194 -0.0607 -0.5987 -0.1024 -0.7016 -0.1637 -2.4226 -0.1372 -0.2043 -0.1274 -0.1935 -0.1592 -0.1208 -0.0599 -0.1576 -0.1540 -0.1544
S-846	Die gleichzeitige Anwendung von Sympathomimetika kann zu kritischen hypertonen Reaktionen führen .
T-846	Concurrent administration with sympathomimetic medicines may result in critical hypertension reactions .
H-846	-0.24289345741271973	Co-administration of sympathomimetics may lead to critical hypertonic reactions .
D-846	-0.24289345741271973	Co-administration of sympathomimetics may lead to critical hypertonic reactions .
P-846	-0.6402 -0.3341 -0.0133 -0.1685 -0.0502 -0.0535 -0.0718 -0.1330 -0.1031 -1.2378 -0.1319 -0.5882 -0.0285 -0.3824 -0.2542 -0.0682 -0.0447 -0.1590 -0.1524
S-806	Advexin wurde am 23 . Oktober 2006 als Arzneimittel für seltene Leiden ausgewiesen .
T-806	Advexin was designated as an orphan medicinal product on 23 October 2006.
H-806	-0.30972820520401	Advexin was designated an orphan medicinal product on 23 October 2006 .
D-806	-0.30972820520401	Advexin was designated an orphan medicinal product on 23 October 2006 .
P-806	-0.8840 -0.1504 -0.1416 -0.1547 -0.6830 -0.1501 -0.5511 -0.4697 -0.1807 -0.1798 -1.0521 -0.1596 -0.0949 -0.1131 -0.0996 -0.1580 -0.3542 -0.1585 -0.1498
S-662	Aus mikrobiologischer Sicht sollte das Produkt unmittelbar nach der Rekonstitution verbraucht werden .
T-662	From a microbiological point of view , the product should be used immediately after reconstitution .
H-662	-0.2617441713809967	From a microbiological point of view , the product should be used immediately after reconstitution .
D-662	-0.2617441713809967	From a microbiological point of view , the product should be used immediately after reconstitution .
P-662	-0.3737 -0.2309 -0.1125 -0.0992 -0.1348 -0.5545 -0.1397 -0.0796 -0.2444 -0.7485 -0.0508 -0.0959 -0.1376 -0.9753 -0.1041 -0.5900 -0.1672 -0.0925 -0.1513 -0.1525
S-581	Aus mikrobiologischer Sicht sollte das Produkt unmittelbar nach der Rekonstitution verbraucht werden .
T-581	From a microbiological point of view , the product should be used immediately after reconstitution .
H-581	-0.2617441713809967	From a microbiological point of view , the product should be used immediately after reconstitution .
D-581	-0.2617441713809967	From a microbiological point of view , the product should be used immediately after reconstitution .
P-581	-0.3737 -0.2309 -0.1125 -0.0992 -0.1348 -0.5545 -0.1397 -0.0796 -0.2444 -0.7485 -0.0508 -0.0959 -0.1376 -0.9753 -0.1041 -0.5900 -0.1672 -0.0925 -0.1513 -0.1525
S-676	Nun die Verpackung vom BAXJECT II abnehmen ( Abb . B ) .
T-676	Grip the package at its edge and pull the package off BAXJECT II ( Fig . b ) .
H-676	-0.24443668127059937	Remove the package from BAXJECT II ( Fig . B ) .
D-676	-0.24443668127059937	Remove the package from BAXJECT II ( Fig . B ) .
P-676	-0.5432 -0.0324 -0.1330 -0.1843 -0.4192 -0.1178 -1.1883 -0.1267 -0.2574 -0.0814 -0.1132 -0.1226 -0.1555 -0.4921 -0.1621 -0.1480 -0.1571 -0.1422 -0.1572 -0.1551
S-328	Dieses setzt dann Fibrin aus Fibrinogen frei und die Gerinnselbildung kann erfolgen .
T-328	Thrombin then converts fibrinogen into fibrin and a clot can be formed .
H-328	-0.3535991311073303	This then releases fibrin from fibrinogen and clotting can occur .
D-328	-0.3535991311073303	This then releases fibrin from fibrinogen and clotting can occur .
P-328	-0.4401 -0.6565 -0.4322 -0.0637 -0.1036 -0.2697 -0.1274 -0.1528 -0.6892 -0.4005 -0.4700 -0.2229 -0.4227 -0.1442 -0.1400 -0.6796 -1.0068 -0.1453 -0.1511
S-500	Aus mikrobiologischer Sicht sollte das Produkt unmittelbar nach der Rekonstitution verbraucht werden .
T-500	From a microbiological point of view , the product should be used immediately after reconstitution .
H-500	-0.2617441713809967	From a microbiological point of view , the product should be used immediately after reconstitution .
D-500	-0.2617441713809967	From a microbiological point of view , the product should be used immediately after reconstitution .
P-500	-0.3737 -0.2309 -0.1125 -0.0992 -0.1348 -0.5545 -0.1397 -0.0796 -0.2444 -0.7485 -0.0508 -0.0959 -0.1376 -0.9753 -0.1041 -0.5900 -0.1672 -0.0925 -0.1513 -0.1525
S-628	Wenn diese Symptome auftreten , sollen die Patienten die Behandlung sofort abbrechen und ihren Arzt kontaktieren .
T-628	If these symptoms occur , they should be advised to discontinue use of the product immediately and contact their physicians .
H-628	-0.2831156551837921	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
D-628	-0.2831156551837921	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
P-628	-0.5051 -0.2234 -0.1904 -1.2289 -0.2768 -0.0880 -0.0916 -0.2921 -0.0922 -0.2279 -0.0632 -0.1338 -0.0943 -0.1199 -0.8928 -0.1401 -0.1526
S-466	Wenn diese Symptome auftreten , sollen die Patienten die Behandlung sofort abbrechen und ihren Arzt kontaktieren .
T-466	If these symptoms occur , they should be advised to discontinue use of the product immediately and contact their physicians .
H-466	-0.2831156551837921	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
D-466	-0.2831156551837921	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
P-466	-0.5051 -0.2234 -0.1904 -1.2289 -0.2768 -0.0880 -0.0916 -0.2921 -0.0922 -0.2279 -0.0632 -0.1338 -0.0943 -0.1199 -0.8928 -0.1401 -0.1526
S-595	Nun die Verpackung vom BAXJECT II abnehmen ( Abb . B ) .
T-595	Grip the package at its edge and pull the package off BAXJECT II ( Fig . b ) .
H-595	-0.24443668127059937	Remove the package from BAXJECT II ( Fig . B ) .
D-595	-0.24443668127059937	Remove the package from BAXJECT II ( Fig . B ) .
P-595	-0.5432 -0.0324 -0.1330 -0.1843 -0.4192 -0.1178 -1.1883 -0.1267 -0.2574 -0.0814 -0.1132 -0.1226 -0.1555 -0.4921 -0.1621 -0.1480 -0.1571 -0.1422 -0.1572 -0.1551
S-514	Nun die Verpackung vom BAXJECT II abnehmen ( Abb . B ) .
T-514	Grip the package at its edge and pull the package off BAXJECT II ( Fig . b ) .
H-514	-0.24443668127059937	Remove the package from BAXJECT II ( Fig . B ) .
D-514	-0.24443668127059937	Remove the package from BAXJECT II ( Fig . B ) .
P-514	-0.5432 -0.0324 -0.1330 -0.1843 -0.4192 -0.1178 -1.1883 -0.1267 -0.2574 -0.0814 -0.1132 -0.1226 -0.1555 -0.4921 -0.1621 -0.1480 -0.1571 -0.1422 -0.1572 -0.1551
S-433	Nun die Verpackung vom BAXJECT II abnehmen ( Abb . B ) .
T-433	Grip the package at its edge and pull the package off BAXJECT II ( Fig . b ) .
H-433	-0.24443668127059937	Remove the package from BAXJECT II ( Fig . B ) .
D-433	-0.24443668127059937	Remove the package from BAXJECT II ( Fig . B ) .
P-433	-0.5432 -0.0324 -0.1330 -0.1843 -0.4192 -0.1178 -1.1883 -0.1267 -0.2574 -0.0814 -0.1132 -0.1226 -0.1555 -0.4921 -0.1621 -0.1480 -0.1571 -0.1422 -0.1572 -0.1551
S-352	Nun die Verpackung vom BAXJECT II abnehmen ( Abb . B ) .
T-352	Grip the package at its edge and pull the package off BAXJECT II ( Fig . b ) .
H-352	-0.24443668127059937	Remove the package from BAXJECT II ( Fig . B ) .
D-352	-0.24443668127059937	Remove the package from BAXJECT II ( Fig . B ) .
P-352	-0.5432 -0.0324 -0.1330 -0.1843 -0.4192 -0.1178 -1.1883 -0.1267 -0.2574 -0.0814 -0.1132 -0.1226 -0.1555 -0.4921 -0.1621 -0.1480 -0.1571 -0.1422 -0.1572 -0.1551
S-271	Nun die Verpackung vom BAXJECT II abnehmen ( Abb . B ) .
T-271	Grip the package at its edge and pull the package off BAXJECT II ( Fig . b ) .
H-271	-0.24443668127059937	Remove the package from BAXJECT II ( Fig . B ) .
D-271	-0.24443668127059937	Remove the package from BAXJECT II ( Fig . B ) .
P-271	-0.5432 -0.0324 -0.1330 -0.1843 -0.4192 -0.1178 -1.1883 -0.1267 -0.2574 -0.0814 -0.1132 -0.1226 -0.1555 -0.4921 -0.1621 -0.1480 -0.1571 -0.1422 -0.1572 -0.1551
S-490	Dieses setzt dann Fibrin aus Fibrinogen frei und die Gerinnselbildung kann erfolgen .
T-490	Thrombin then converts fibrinogen into fibrin and a clot can be formed .
H-490	-0.3535991311073303	This then releases fibrin from fibrinogen and clotting can occur .
D-490	-0.3535991311073303	This then releases fibrin from fibrinogen and clotting can occur .
P-490	-0.4401 -0.6565 -0.4322 -0.0637 -0.1036 -0.2697 -0.1274 -0.1528 -0.6892 -0.4005 -0.4700 -0.2229 -0.4227 -0.1442 -0.1400 -0.6796 -1.0068 -0.1453 -0.1511
S-547	Wenn diese Symptome auftreten , sollen die Patienten die Behandlung sofort abbrechen und ihren Arzt kontaktieren .
T-547	If these symptoms occur , they should be advised to discontinue use of the product immediately and contact their physicians .
H-547	-0.2831156551837921	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
D-547	-0.2831156551837921	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
P-547	-0.5051 -0.2234 -0.1904 -1.2289 -0.2768 -0.0880 -0.0916 -0.2921 -0.0922 -0.2279 -0.0632 -0.1338 -0.0943 -0.1199 -0.8928 -0.1401 -0.1526
S-571	Dieses setzt dann Fibrin aus Fibrinogen frei und die Gerinnselbildung kann erfolgen .
T-571	Thrombin then converts fibrinogen into fibrin and a clot can be formed .
H-571	-0.3535991311073303	This then releases fibrin from fibrinogen and clotting can occur .
D-571	-0.3535991311073303	This then releases fibrin from fibrinogen and clotting can occur .
P-571	-0.4401 -0.6565 -0.4322 -0.0637 -0.1036 -0.2697 -0.1274 -0.1528 -0.6892 -0.4005 -0.4700 -0.2229 -0.4227 -0.1442 -0.1400 -0.6796 -1.0068 -0.1453 -0.1511
S-385	Wenn diese Symptome auftreten , sollen die Patienten die Behandlung sofort abbrechen und ihren Arzt kontaktieren .
T-385	If these symptoms occur , they should be advised to discontinue use of the product immediately and contact their physicians .
H-385	-0.2831156551837921	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
D-385	-0.2831156551837921	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
P-385	-0.5051 -0.2234 -0.1904 -1.2289 -0.2768 -0.0880 -0.0916 -0.2921 -0.0922 -0.2279 -0.0632 -0.1338 -0.0943 -0.1199 -0.8928 -0.1401 -0.1526
S-304	Wenn diese Symptome auftreten , sollen die Patienten die Behandlung sofort abbrechen und ihren Arzt kontaktieren .
T-304	If these symptoms occur , they should be advised to discontinue use of the product immediately and contact their physicians .
H-304	-0.2831156551837921	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
D-304	-0.2831156551837921	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
P-304	-0.5051 -0.2234 -0.1904 -1.2289 -0.2768 -0.0880 -0.0916 -0.2921 -0.0922 -0.2279 -0.0632 -0.1338 -0.0943 -0.1199 -0.8928 -0.1401 -0.1526
S-226	Wenn diese Symptome auftreten , sollen die Patienten die Behandlung sofort abbrechen und ihren Arzt kontaktieren .
T-226	If these symptoms occur , they should be advised to discontinue use of the product immediately and contact their physicians .
H-226	-0.2831156551837921	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
D-226	-0.2831156551837921	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
P-226	-0.5051 -0.2234 -0.1904 -1.2289 -0.2768 -0.0880 -0.0916 -0.2921 -0.0922 -0.2279 -0.0632 -0.1338 -0.0943 -0.1199 -0.8928 -0.1401 -0.1526
S-825	Aerinaze linderte die Symptome wirksamer als die beiden Wirkstoffe jeweils allein .
T-825	Aerinaze was more effective in reducing symptoms than either of the two active substances taken alone .
H-825	-0.4981704354286194	Aerinaze was more effective at relieving symptoms than the two agents alone .
D-825	-0.4981704354286194	Aerinaze was more effective at relieving symptoms than the two agents alone .
P-825	-0.1708 -0.1135 -0.1217 -0.1433 -0.1091 -1.1654 -0.1086 -0.0774 -0.6182 -1.3907 -0.1620 -0.4318 -0.1201 -0.9133 -0.4522 -2.1299 -0.9332 -0.1528 -0.1514
S-652	Dieses setzt dann Fibrin aus Fibrinogen frei und die Gerinnselbildung kann erfolgen .
T-652	Thrombin then converts fibrinogen into fibrin and a clot can be formed .
H-652	-0.3535991311073303	This then releases fibrin from fibrinogen and clotting can occur .
D-652	-0.3535991311073303	This then releases fibrin from fibrinogen and clotting can occur .
P-652	-0.4401 -0.6565 -0.4322 -0.0637 -0.1036 -0.2697 -0.1274 -0.1528 -0.6892 -0.4005 -0.4700 -0.2229 -0.4227 -0.1442 -0.1400 -0.6796 -1.0068 -0.1453 -0.1511
S-419	Aus mikrobiologischer Sicht sollte das Produkt unmittelbar nach der Rekonstitution verbraucht werden .
T-419	From a microbiological point of view , the product should be used immediately after reconstitution .
H-419	-0.2617441713809967	From a microbiological point of view , the product should be used immediately after reconstitution .
D-419	-0.2617441713809967	From a microbiological point of view , the product should be used immediately after reconstitution .
P-419	-0.3737 -0.2309 -0.1125 -0.0992 -0.1348 -0.5545 -0.1397 -0.0796 -0.2444 -0.7485 -0.0508 -0.0959 -0.1376 -0.9753 -0.1041 -0.5900 -0.1672 -0.0925 -0.1513 -0.1525
S-25	Hauptindikator der Wirksamkeit war der Prozentsatz der Patienten mit geringem Vitamin-D-Spiegel .
T-25	The main measure of effectiveness was the percentage of patients with low vitamin D levels .
H-25	-0.28871482610702515	The main measure of efficacy was the percentage of patients with low vitamin D levels .
D-25	-0.28871482610702515	The main measure of efficacy was the percentage of patients with low vitamin D levels .
P-25	-0.1541 -0.7158 -0.5132 -0.1407 -0.7235 -0.0755 -0.0963 -0.1855 -0.1837 -0.2694 -0.1505 -0.0874 -0.2186 -0.2110 -0.7330 -0.0977 -0.0968 -0.8145 -0.1573 -0.1498
S-418	Nach der Rekonstitution Die chemischen und physikalischen Daten zeigen eine Stabilität von über 3 Stunden bei 25 <unk> C .
T-418	After reconstitution Chemical and physical in-use stability has been demonstrated for 3 hours at 25<<unk>> C .
H-418	-0.4102131128311157	After reconstitution Chemical and physical data show a stability of over 3 hours at 25<unk> C .
D-418	-0.4102131128311157	After reconstitution Chemical and physical data show a stability of over 3 hours at 25<unk> C .
P-418	-1.1485 -0.2082 -0.1094 -0.2519 -0.0903 -0.1489 -0.1597 -0.1872 -0.3582 -1.3501 -0.3547 -0.3355 -1.2731 -0.1752 -0.1625 -0.1486 -1.2745 -0.0748 -0.1542 -0.4880 -0.1612
S-172	Verteilung Nach der Resorption geht Vitamin D3 als Bestandteil von Chylomikronen ins Blut über .
T-172	Distribution Following absorption , vitamin D3 enters the blood as part of chylomicrons .
H-172	-0.24451997876167297	Distribution After absorption , vitamin D3 is absorbed by the blood as a component of chylomicrons .
D-172	-0.24451997876167297	Distribution After absorption , vitamin D3 is absorbed by the blood as a component of chylomicrons .
P-172	-0.2719 -0.0983 -0.5590 -0.0530 -0.1295 -0.3179 -0.1161 -0.1000 -0.1431 -0.1600 -0.1737 -1.0490 -0.0693 -0.9268 -0.1259 -0.0466 -0.1300 -0.3807 -0.3895 -0.0984 -0.1735 -0.1881 -0.1510 -0.1154 -0.1275 -0.1227 -0.5640 -0.1599 -0.1504
S-92	Verteilung Nach der Resorption geht Vitamin D3 als Bestandteil von Chylomikronen ins Blut über .
T-92	Distribution Following absorption , vitamin D3 enters the blood as part of chylomicrons .
H-92	-0.24451997876167297	Distribution After absorption , vitamin D3 is absorbed by the blood as a component of chylomicrons .
D-92	-0.24451997876167297	Distribution After absorption , vitamin D3 is absorbed by the blood as a component of chylomicrons .
P-92	-0.2719 -0.0983 -0.5590 -0.0530 -0.1295 -0.3179 -0.1161 -0.1000 -0.1431 -0.1600 -0.1737 -1.0490 -0.0693 -0.9268 -0.1259 -0.0466 -0.1300 -0.3807 -0.3895 -0.0984 -0.1735 -0.1881 -0.1510 -0.1154 -0.1275 -0.1227 -0.5640 -0.1599 -0.1504
S-751	Wenn Sie den Eindruck haben , dass die Wirkung von ADVATE unzureichend ist , informieren Sie Ihren Arzt .
T-751	If you have the impression that the effect of ADVATE is insufficient , talk to your doctor .
H-751	-0.18960562348365784	If you have the impression that the effect of ADVATE is insufficient , tell your doctor .
D-751	-0.18960562348365784	If you have the impression that the effect of ADVATE is insufficient , tell your doctor .
P-751	-0.1471 -0.1453 -0.1895 -0.1594 -0.0762 -0.1432 -0.1950 -0.0765 -0.1397 -0.1404 -0.1640 -0.0794 -0.0806 -0.1454 -0.2210 -0.4913 -0.1422 -0.8472 -0.1722 -0.1079 -0.1503 -0.1576
S-187	Advate besteht aus einem Pulver und einem Lösungsmittel , die zur Herstellung einer Injektionslösung gemischt werden .
T-187	Advate is a powder and solvent that are mixed together to make a solution for injection .
H-187	-0.30759966373443604	Advate consists of a powder and a solvent mixed to make a solution for injection .
D-187	-0.30759966373443604	Advate consists of a powder and a solvent mixed to make a solution for injection .
P-187	-0.5417 -0.1412 -0.0816 -0.1267 -0.1507 -0.1467 -0.0973 -0.1537 -0.1616 -0.0977 -0.5452 -1.6172 -0.4010 -1.2771 -0.2022 -0.0935 -0.1242 -0.1054 -0.0880 -0.1549 -0.1519
S-580	Nach der Rekonstitution Die chemischen und physikalischen Daten zeigen eine Stabilität von über 3 Stunden bei 25 <unk> C .
T-580	After reconstitution Chemical and physical in-use stability has been demonstrated for 3 hours at 25<<unk>> C .
H-580	-0.4102131128311157	After reconstitution Chemical and physical data show a stability of over 3 hours at 25<unk> C .
D-580	-0.4102131128311157	After reconstitution Chemical and physical data show a stability of over 3 hours at 25<unk> C .
P-580	-1.1485 -0.2082 -0.1094 -0.2519 -0.0903 -0.1489 -0.1597 -0.1872 -0.3582 -1.3501 -0.3547 -0.3355 -1.2731 -0.1752 -0.1625 -0.1486 -1.2745 -0.0748 -0.1542 -0.4880 -0.1612
S-7	Die Wirksamkeit und Sicherheit von Adenuric wurden bei Patienten mit schweren Nieren- oder Leberproblemen nicht untersucht .
T-7	The safety and effectiveness of Adenuric have not been studied in patients with severe kidney or liver problems .
H-7	-0.2316494733095169	The efficacy and safety of Adenuric have not been evaluated in patients with severe renal or liver problems .
D-7	-0.2316494733095169	The efficacy and safety of Adenuric have not been evaluated in patients with severe renal or liver problems .
P-7	-0.0807 -0.3396 -0.0528 -0.0783 -0.1761 -0.0588 -0.1476 -0.1168 -0.1814 -0.0642 -0.1126 -0.2026 -0.1191 -0.1067 -1.1144 -0.1647 -0.1403 -0.1007 -0.1751 -0.0934 -0.4620 -0.1028 -0.1415 -0.7118 -0.9110 -0.1508 -0.1491
S-499	Nach der Rekonstitution Die chemischen und physikalischen Daten zeigen eine Stabilität von über 3 Stunden bei 25 <unk> C .
T-499	After reconstitution Chemical and physical in-use stability has been demonstrated for 3 hours at 25<<unk>> C .
H-499	-0.4102131128311157	After reconstitution Chemical and physical data show a stability of over 3 hours at 25<unk> C .
D-499	-0.4102131128311157	After reconstitution Chemical and physical data show a stability of over 3 hours at 25<unk> C .
P-499	-1.1485 -0.2082 -0.1094 -0.2519 -0.0903 -0.1489 -0.1597 -0.1872 -0.3582 -1.3501 -0.3547 -0.3355 -1.2731 -0.1752 -0.1625 -0.1486 -1.2745 -0.0748 -0.1542 -0.4880 -0.1612
S-337	Nach der Rekonstitution Die chemischen und physikalischen Daten zeigen eine Stabilität von über 3 Stunden bei 25 <unk> C .
T-337	After reconstitution Chemical and physical in-use stability has been demonstrated for 3 hours at 25<<unk>> C .
H-337	-0.4102131128311157	After reconstitution Chemical and physical data show a stability of over 3 hours at 25<unk> C .
D-337	-0.4102131128311157	After reconstitution Chemical and physical data show a stability of over 3 hours at 25<unk> C .
P-337	-1.1485 -0.2082 -0.1094 -0.2519 -0.0903 -0.1489 -0.1597 -0.1872 -0.3582 -1.3501 -0.3547 -0.3355 -1.2731 -0.1752 -0.1625 -0.1486 -1.2745 -0.0748 -0.1542 -0.4880 -0.1612
S-256	Nach der Rekonstitution Die chemischen und physikalischen Daten zeigen eine Stabilität von über 3 Stunden bei 25 <unk> C .
T-256	After reconstitution Chemical and physical in-use stability has been demonstrated for 3 hours at 25<<unk>> C .
H-256	-0.4102131128311157	After reconstitution Chemical and physical data show a stability of over 3 hours at 25<unk> C .
D-256	-0.4102131128311157	After reconstitution Chemical and physical data show a stability of over 3 hours at 25<unk> C .
P-256	-1.1485 -0.2082 -0.1094 -0.2519 -0.0903 -0.1489 -0.1597 -0.1872 -0.3582 -1.3501 -0.3547 -0.3355 -1.2731 -0.1752 -0.1625 -0.1486 -1.2745 -0.0748 -0.1542 -0.4880 -0.1612
S-755	Möglicherweise werden Sie höhere ADVATE-Dosen oder sogar ein anderes Produkt benötigen , um die Blutungen zu kontrollieren .
T-755	You might need a higher dose of ADVATE or even a different product to control bleedings .
H-755	-0.3219785690307617	You may need higher doses of ADVATE , or even another product , to control the haemorrhage .
D-755	-0.3219785690307617	You may need higher doses of ADVATE , or even another product , to control the haemorrhage .
P-755	-0.4487 -0.1439 -0.1999 -0.1564 -0.1484 -0.1256 -0.1514 -0.1119 -0.1780 -0.1166 -0.1285 -0.8285 -0.1161 -0.1757 -0.8840 -0.1189 -0.3803 -0.1418 -0.5888 -1.0913 -1.0973 -0.2307 -0.0372 -0.4769 -0.1439 -0.1505
S-201	Die vollständige Auflistung der im Zusammenhang mit Advate berichteten Nebenwirkungen ist der Packungsbeilage zu entnehmen .
T-201	For the full list of all side effects reported with Advate , see the Package Leaflet .
H-201	-0.17858873307704926	For the full list of all side effects reported with Advate , see the Package Leaflet .
D-201	-0.17858873307704926	For the full list of all side effects reported with Advate , see the Package Leaflet .
P-201	-0.2204 -0.2001 -0.1242 -0.1134 -0.1370 -0.7700 -0.3075 -0.1011 -0.0758 -0.1461 -0.4193 -0.1226 -0.1332 -0.2260 -0.1476 -0.0297 -0.1239 -0.0385 -0.0441 -0.1206 -0.1755 -0.1523
S-240	Inhibitorentwicklung Die Neoantigenität von ADVATE wurde an zuvor behandelten Patienten beurteilt .
T-240	6 The immunogenicity of ADVATE was evaluated in previously treated patients .
H-240	-0.21192559599876404	Inhibitor development ADVATE neoantigenicity has been evaluated in previously treated patients .
D-240	-0.21192559599876404	Inhibitor development ADVATE neoantigenicity has been evaluated in previously treated patients .
P-240	-0.0776 -0.0491 -0.1487 -0.1543 -0.4097 -1.4390 -0.1766 -0.0851 -0.0841 -0.2648 -0.1902 -0.1576 -0.0692 -0.1015 -0.1519 -0.2292 -0.1762 -0.2482 -0.1376 -0.1220 -0.1752 -0.2277 -0.0956 -0.1734 -0.1537
S-661	Nach der Rekonstitution Die chemischen und physikalischen Daten zeigen eine Stabilität von über 3 Stunden bei 25 <unk> C .
T-661	After reconstitution Chemical and physical in-use stability has been demonstrated for 3 hours at 25<<unk>> C .
H-661	-0.4102131128311157	After reconstitution Chemical and physical data show a stability of over 3 hours at 25<unk> C .
D-661	-0.4102131128311157	After reconstitution Chemical and physical data show a stability of over 3 hours at 25<unk> C .
P-661	-1.1485 -0.2082 -0.1094 -0.2519 -0.0903 -0.1489 -0.1597 -0.1872 -0.3582 -1.3501 -0.3547 -0.3355 -1.2731 -0.1752 -0.1625 -0.1486 -1.2745 -0.0748 -0.1542 -0.4880 -0.1612
S-11	Die Wirkungen von Adenuric wurden zunächst in Versuchsmodellen getestet , bevor sie an Menschen untersucht wurden .
T-11	The effects of Adenuric were first tested in experimental models before being studied in humans .
H-11	-0.15878303349018097	The effects of Adenuric were first tested in experimental models before being studied in humans .
D-11	-0.15878303349018097	The effects of Adenuric were first tested in experimental models before being studied in humans .
P-11	-0.1571 -0.1232 -0.1435 -0.1188 -0.1655 -0.0594 -0.1125 -0.1778 -0.3345 -0.2713 -0.1338 -0.2063 -0.0645 -0.1452 -0.3459 -0.0635 -0.0805 -0.1331 -0.1965 -0.1496 -0.1519
S-857	Es wird nicht erwartet , dass Pseudoephedrinsulfat die psychomotorische Leistungsfähigkeit beeinträchtigt .
T-857	It is not expected that pseudoephedrine sulphate impairs psychomotor performance .
H-857	-0.2827221751213074	Pseudoephedrine sulphate is not expected to impair psychomotor function .
D-857	-0.2827221751213074	Pseudoephedrine sulphate is not expected to impair psychomotor function .
P-857	-0.3325 -0.2113 -0.1709 -0.2607 -0.1493 -0.0908 -0.1363 -0.1207 -0.2671 -0.1508 -0.1464 -0.2482 -0.0630 -0.1264 -0.4672 -0.0544 -1.1497 -0.1894 -0.2508 -0.3891 -1.2239 -0.1531 -0.1507
S-347	- Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen ,
T-347	- Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-347	-0.31487590074539185	- Do not use the BAXJECT II unit set if its sterile barrier has been broken .
D-347	-0.31487590074539185	- Do not use the BAXJECT II unit set if its sterile barrier has been broken .
P-347	-0.1301 -0.1234 -0.1322 -0.0888 -0.4229 -0.1226 -0.1223 -0.2672 -0.0980 -0.1079 -0.2610 -0.5155 -0.1349 -0.6516 -0.2039 -0.1867 -0.0589 -0.0608 -1.0131 -0.1921 -0.8036 -1.3657 -0.1791
S-266	- Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen ,
T-266	- Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-266	-0.31487590074539185	- Do not use the BAXJECT II unit set if its sterile barrier has been broken .
D-266	-0.31487590074539185	- Do not use the BAXJECT II unit set if its sterile barrier has been broken .
P-266	-0.1301 -0.1234 -0.1322 -0.0888 -0.4229 -0.1226 -0.1223 -0.2672 -0.0980 -0.1079 -0.2610 -0.5155 -0.1349 -0.6516 -0.2039 -0.1867 -0.0589 -0.0608 -1.0131 -0.1921 -0.8036 -1.3657 -0.1791
S-738	- wenn Sie allergisch ( überempfindlich ) gegen Octocog alfa oder einem der sonstigen Bestandteile
T-738	- if you are allergic ( hypersensitive ) to octocog alfa or any of the other ingredients of ADVATE
H-738	-0.2400527000427246	- if you are allergic ( hypersensitive ) to Octocog alfa or any of the other ingredients
D-738	-0.2400527000427246	- if you are allergic ( hypersensitive ) to Octocog alfa or any of the other ingredients
P-738	-0.1419 -0.2773 -0.1325 -0.1469 -0.0406 -0.0506 -0.1336 -0.0895 -0.0620 -0.1473 -0.1446 -0.2938 -0.1123 -0.1136 -0.1456 -0.1161 -0.0581 -0.1533 -0.2508 -0.1414 -0.1345 -0.2935 -0.0439 -2.5376
S-671	- Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen ,
T-671	- Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-671	-0.31487590074539185	- Do not use the BAXJECT II unit set if its sterile barrier has been broken .
D-671	-0.31487590074539185	- Do not use the BAXJECT II unit set if its sterile barrier has been broken .
P-671	-0.1301 -0.1234 -0.1322 -0.0888 -0.4229 -0.1226 -0.1223 -0.2672 -0.0980 -0.1079 -0.2610 -0.5155 -0.1349 -0.6516 -0.2039 -0.1867 -0.0589 -0.0608 -1.0131 -0.1921 -0.8036 -1.3657 -0.1791
S-590	- Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen ,
T-590	- Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-590	-0.31487590074539185	- Do not use the BAXJECT II unit set if its sterile barrier has been broken .
D-590	-0.31487590074539185	- Do not use the BAXJECT II unit set if its sterile barrier has been broken .
P-590	-0.1301 -0.1234 -0.1322 -0.0888 -0.4229 -0.1226 -0.1223 -0.2672 -0.0980 -0.1079 -0.2610 -0.5155 -0.1349 -0.6516 -0.2039 -0.1867 -0.0589 -0.0608 -1.0131 -0.1921 -0.8036 -1.3657 -0.1791
S-509	- Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen ,
T-509	- Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-509	-0.31487590074539185	- Do not use the BAXJECT II unit set if its sterile barrier has been broken .
D-509	-0.31487590074539185	- Do not use the BAXJECT II unit set if its sterile barrier has been broken .
P-509	-0.1301 -0.1234 -0.1322 -0.0888 -0.4229 -0.1226 -0.1223 -0.2672 -0.0980 -0.1079 -0.2610 -0.5155 -0.1349 -0.6516 -0.2039 -0.1867 -0.0589 -0.0608 -1.0131 -0.1921 -0.8036 -1.3657 -0.1791
S-428	- Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen ,
T-428	- Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-428	-0.31487590074539185	- Do not use the BAXJECT II unit set if its sterile barrier has been broken .
D-428	-0.31487590074539185	- Do not use the BAXJECT II unit set if its sterile barrier has been broken .
P-428	-0.1301 -0.1234 -0.1322 -0.0888 -0.4229 -0.1226 -0.1223 -0.2672 -0.0980 -0.1079 -0.2610 -0.5155 -0.1349 -0.6516 -0.2039 -0.1867 -0.0589 -0.0608 -1.0131 -0.1921 -0.8036 -1.3657 -0.1791
S-808	Der Wirkstoff in Advexin , Contusugene Ladenovec , ist ein viraler Vektor .
T-808	The active substance in Advexin , contusugene ladenovec , is a viral vector .
H-808	-0.20237015187740326	The active substance in Advexin , Contusugene Ladenovec , is a viral vector .
D-808	-0.20237015187740326	The active substance in Advexin , Contusugene Ladenovec , is a viral vector .
P-808	-0.1460 -0.1271 -0.1112 -0.1563 -0.6868 -0.1330 -0.1522 -0.1531 -0.1619 -0.3179 -0.1058 -0.0706 -0.7766 -0.1476 -0.1084 -0.1182 -0.1589 -0.1374 -0.1213 -0.4365 -0.1133 -0.1052 -0.1577 -0.1540
S-319	Inhibitorentwicklung Die Neoantigenität von ADVATE wurde an zuvor behandelten Patienten beurteilt .
T-319	16 Inhibitor Development The immunogenicity of ADVATE was evaluated in previously treated patients .
H-319	-0.21192559599876404	Inhibitor development ADVATE neoantigenicity has been evaluated in previously treated patients .
D-319	-0.21192559599876404	Inhibitor development ADVATE neoantigenicity has been evaluated in previously treated patients .
P-319	-0.0776 -0.0491 -0.1487 -0.1543 -0.4097 -1.4390 -0.1766 -0.0851 -0.0841 -0.2648 -0.1902 -0.1576 -0.0692 -0.1015 -0.1519 -0.2292 -0.1762 -0.2482 -0.1376 -0.1220 -0.1752 -0.2277 -0.0956 -0.1734 -0.1537
S-796	elezna cesta 14 SI-1000 Ljubljana Tel . : <unk> 386 1 420 16 80
T-796	elezna cesta 14 SI-1000 Ljubljana Tel . : <<unk>> 386 1 420 16 80
H-796	-0.11395010352134705	elezna cesta 14 SI-1000 Ljubljana Tel . : <unk> 386 1 420 16 80
D-796	-0.11395010352134705	elezna cesta 14 SI-1000 Ljubljana Tel . : <unk> 386 1 420 16 80
P-796	-0.0914 -0.1147 -0.0640 -0.1318 -0.0903 -0.1362 -0.1224 -0.1254 -0.1210 -0.0599 -0.1202 -0.1137 -0.1105 -0.1173 -0.0565 -0.1588 -0.1384 -0.0405 -0.1015 -0.1451 -0.1397 -0.1376 -0.1281 -0.1126 -0.1077 -0.1774
S-643	Inhibitorentwicklung Die Neoantigenität von ADVATE wurde an zuvor behandelten Patienten beurteilt .
T-643	56 Inhibitor Development The immunogenicity of ADVATE was evaluated in previously treated patients .
H-643	-0.21192559599876404	Inhibitor development ADVATE neoantigenicity has been evaluated in previously treated patients .
D-643	-0.21192559599876404	Inhibitor development ADVATE neoantigenicity has been evaluated in previously treated patients .
P-643	-0.0776 -0.0491 -0.1487 -0.1543 -0.4097 -1.4390 -0.1766 -0.0851 -0.0841 -0.2648 -0.1902 -0.1576 -0.0692 -0.1015 -0.1519 -0.2292 -0.1762 -0.2482 -0.1376 -0.1220 -0.1752 -0.2277 -0.0956 -0.1734 -0.1537
S-562	Inhibitorentwicklung Die Neoantigenität von ADVATE wurde an zuvor behandelten Patienten beurteilt .
T-562	46 Inhibitor Development The immunogenicity of ADVATE was evaluated in previously treated patients .
H-562	-0.21192559599876404	Inhibitor development ADVATE neoantigenicity has been evaluated in previously treated patients .
D-562	-0.21192559599876404	Inhibitor development ADVATE neoantigenicity has been evaluated in previously treated patients .
P-562	-0.0776 -0.0491 -0.1487 -0.1543 -0.4097 -1.4390 -0.1766 -0.0851 -0.0841 -0.2648 -0.1902 -0.1576 -0.0692 -0.1015 -0.1519 -0.2292 -0.1762 -0.2482 -0.1376 -0.1220 -0.1752 -0.2277 -0.0956 -0.1734 -0.1537
S-481	Inhibitorentwicklung Die Neoantigenität von ADVATE wurde an zuvor behandelten Patienten beurteilt .
T-481	36 Inhibitor Development The immunogenicity of ADVATE was evaluated in previously treated patients .
H-481	-0.21192559599876404	Inhibitor development ADVATE neoantigenicity has been evaluated in previously treated patients .
D-481	-0.21192559599876404	Inhibitor development ADVATE neoantigenicity has been evaluated in previously treated patients .
P-481	-0.0776 -0.0491 -0.1487 -0.1543 -0.4097 -1.4390 -0.1766 -0.0851 -0.0841 -0.2648 -0.1902 -0.1576 -0.0692 -0.1015 -0.1519 -0.2292 -0.1762 -0.2482 -0.1376 -0.1220 -0.1752 -0.2277 -0.0956 -0.1734 -0.1537
S-400	Inhibitorentwicklung Die Neoantigenität von ADVATE wurde an zuvor behandelten Patienten beurteilt .
T-400	26 Inhibitor Development The immunogenicity of ADVATE was evaluated in previously treated patients .
H-400	-0.21192559599876404	Inhibitor development ADVATE neoantigenicity has been evaluated in previously treated patients .
D-400	-0.21192559599876404	Inhibitor development ADVATE neoantigenicity has been evaluated in previously treated patients .
P-400	-0.0776 -0.0491 -0.1487 -0.1543 -0.4097 -1.4390 -0.1766 -0.0851 -0.0841 -0.2648 -0.1902 -0.1576 -0.0692 -0.1015 -0.1519 -0.2292 -0.1762 -0.2482 -0.1376 -0.1220 -0.1752 -0.2277 -0.0956 -0.1734 -0.1537
S-151	Studien zur Präklinik zeigten , dass Alendronat sich bevorzugt an den Stellen der aktiven Resorption konzentriert .
T-151	Preclinical studies have shown preferential localisation of alendronate to sites of active resorption .
H-151	-0.3999200165271759	Preclinical studies have shown that alendronate is preferred to concentrate at sites of active absorption .
D-151	-0.3999200165271759	Preclinical studies have shown that alendronate is preferred to concentrate at sites of active absorption .
P-151	-1.8415 -1.3295 -0.0396 -0.4884 -0.0904 -0.6564 -0.0977 -0.1405 -0.1181 -0.1443 -0.1015 -0.0848 -2.1916 -0.3228 -0.2114 -0.0704 -0.2291 -0.7037 -0.1402 -0.0781 -0.1330 -0.0853 -0.1498 -0.1501
S-700	ADVATE 250 I.E. Pulver zur Herstellung einer Injektionslösung . Zur i.v. Anwendung .
T-700	ADVATE 250 IU powder for solution for injection Octocog alfa IV use
H-700	-0.4393811523914337	ADVATE 250 IU powder for preparation of solution for injection . I.V. use
D-700	-0.4393811523914337	ADVATE 250 IU powder for preparation of solution for injection . I.V. use
P-700	-0.1143 -0.1649 -0.0861 -0.0903 -0.1064 -0.1037 -0.1344 -0.0535 -0.1992 -1.1759 -0.1458 -0.4962 -0.1160 -0.0949 -0.0895 -1.7766 -0.7338 -1.9979 -0.3662 -0.3566 -0.8250
S-199	Patienten mit Hämophilie A können Antikörper ( Inhibitoren ) gegenüber Faktor VIII bilden .
T-199	Haemophilia A patients may develop antibodies ( inhibitors ) to factor VIII .
H-199	-0.22725123167037964	Patients with haemophilia A may develop antibodies ( inhibitors ) to factor VIII .
D-199	-0.22725123167037964	Patients with haemophilia A may develop antibodies ( inhibitors ) to factor VIII .
P-199	-0.4625 -0.1038 -0.1626 -0.2056 -0.0743 -0.0653 -0.0707 -0.1210 -0.1137 -1.2779 -0.0831 -0.0966 -0.1613 -0.1375 -0.0691 -0.0785 -0.1629 -0.1425 -0.3789 -0.9214 -0.1849 -0.0654 -0.1628 -0.1518
S-634	Deshalb sollte in der Schwangerschaft und Stillzeit Faktor VIII nur bei eindeutiger Indikationsstellung angewendet werden .
T-634	Therefore , factor VIII should be used during pregnancy and lactation only if clearly indicated .
H-634	-0.41763418912887573	Therefore , factor VIII should only be used in pregnancy and breast-feeding when there is a clear indication .
D-634	-0.41763418912887573	Therefore , factor VIII should only be used in pregnancy and breast-feeding when there is a clear indication .
P-634	-0.2971 -0.1056 -0.4328 -2.5118 -0.1749 -0.0627 -0.1577 -0.2167 -0.1638 -0.1629 -0.4005 -0.1178 -0.2139 -0.5964 -0.0355 -0.0798 -0.0285 -1.7567 -1.9340 -0.1298 -0.1896 -0.2587 -0.0759 -0.1860 -0.1518
S-705	ADVATE 500 I.E. Pulver zur Herstellung einer Injektionslösung . Zur i.v. Anwendung .
T-705	ADVATE 500 IU powder for solution for injection Octocog alfa IV use
H-705	-0.4362257719039917	ADVATE 500 IU powder for the preparation of a solution for injection .
D-705	-0.4362257719039917	ADVATE 500 IU powder for the preparation of a solution for injection .
P-705	-0.1104 -0.1646 -0.0853 -0.0896 -0.1157 -0.1061 -0.1411 -0.0458 -0.1940 -2.5630 -0.5599 -0.1451 -0.9708 -0.0546 -0.1208 -0.1020 -0.0908 -0.8782 -1.7505
S-711	ADVATE 1000 I.E. Pulver zur Herstellung einer Injektionslösung . Zur i.v. Anwendung .
T-711	ADVATE 1000 IU powder for solution for injection Octocog alfa IV use
H-711	-0.4325266480445862	ADVATE 1000 IU powder for the preparation of a solution for injection .
D-711	-0.4325266480445862	ADVATE 1000 IU powder for the preparation of a solution for injection .
P-711	-0.1204 -0.1666 -0.0840 -0.0878 -0.0833 -0.1102 -0.1213 -0.0540 -0.1870 -2.5700 -0.5375 -0.1455 -1.0463 -0.0573 -0.1199 -0.1021 -0.0921 -0.9989 -1.5341
S-647	Symptome durch Überdosierung mit rekombinantem Blutgerinnungsfaktor VIII vom Menschen sind nicht bekannt .
T-647	No symptoms of overdose with recombinant coagulation factor VIII have been reported .
H-647	-0.24216635525226593	Symptoms of overdose with human recombinant blood clotting factor VIII are not known .
D-647	-0.24216635525226593	Symptoms of overdose with human recombinant blood clotting factor VIII are not known .
P-647	-0.3983 -0.0284 -0.2046 -0.1255 -0.2264 -0.1193 -0.9601 -0.2000 -0.0873 -0.0811 -0.1365 -0.7307 -0.5022 -0.0126 -0.1153 -0.1048 -0.1690 -0.0716 -0.1696 -0.7540 -0.0620 -0.1624 -0.1481
S-721	ADVATE 2000 I.E. Pulver zur Herstellung einer Injektionslösung . Zur i.v. Anwendung .
T-721	ADVATE 2000 IU powder for solution for injection Octocog alfa IV use
H-721	-0.452050119638443	ADVATE 2000 IU powder for the preparation of a solution for injection .
D-721	-0.452050119638443	ADVATE 2000 IU powder for the preparation of a solution for injection .
P-721	-0.1154 -0.1668 -0.0851 -0.0901 -0.1169 -0.1174 -0.1550 -0.0650 -0.1836 -2.4654 -0.5840 -0.1447 -1.0556 -0.0548 -0.1192 -0.1011 -0.0907 -1.1771 -1.7010
S-566	Symptome durch Überdosierung mit rekombinantem Blutgerinnungsfaktor VIII vom Menschen sind nicht bekannt .
T-566	No symptoms of overdose with recombinant coagulation factor VIII have been reported .
H-566	-0.24216635525226593	Symptoms of overdose with human recombinant blood clotting factor VIII are not known .
D-566	-0.24216635525226593	Symptoms of overdose with human recombinant blood clotting factor VIII are not known .
P-566	-0.3983 -0.0284 -0.2046 -0.1255 -0.2264 -0.1193 -0.9601 -0.2000 -0.0873 -0.0811 -0.1365 -0.7307 -0.5022 -0.0126 -0.1153 -0.1048 -0.1690 -0.0716 -0.1696 -0.7540 -0.0620 -0.1624 -0.1481
S-553	Deshalb sollte in der Schwangerschaft und Stillzeit Faktor VIII nur bei eindeutiger Indikationsstellung angewendet werden .
T-553	Therefore , factor VIII should be used during pregnancy and lactation only if clearly indicated .
H-553	-0.41763418912887573	Therefore , factor VIII should only be used in pregnancy and breast-feeding when there is a clear indication .
D-553	-0.41763418912887573	Therefore , factor VIII should only be used in pregnancy and breast-feeding when there is a clear indication .
P-553	-0.2971 -0.1056 -0.4328 -2.5118 -0.1749 -0.0627 -0.1577 -0.2167 -0.1638 -0.1629 -0.4005 -0.1178 -0.2139 -0.5964 -0.0355 -0.0798 -0.0285 -1.7567 -1.9340 -0.1298 -0.1896 -0.2587 -0.0759 -0.1860 -0.1518
S-485	Symptome durch Überdosierung mit rekombinantem Blutgerinnungsfaktor VIII vom Menschen sind nicht bekannt .
T-485	No symptoms of overdose with recombinant coagulation factor VIII have been reported .
H-485	-0.24216635525226593	Symptoms of overdose with human recombinant blood clotting factor VIII are not known .
D-485	-0.24216635525226593	Symptoms of overdose with human recombinant blood clotting factor VIII are not known .
P-485	-0.3983 -0.0284 -0.2046 -0.1255 -0.2264 -0.1193 -0.9601 -0.2000 -0.0873 -0.0811 -0.1365 -0.7307 -0.5022 -0.0126 -0.1153 -0.1048 -0.1690 -0.0716 -0.1696 -0.7540 -0.0620 -0.1624 -0.1481
S-472	Deshalb sollte in der Schwangerschaft und Stillzeit Faktor VIII nur bei eindeutiger Indikationsstellung angewendet werden .
T-472	Therefore , factor VIII should be used during pregnancy and lactation only if clearly indicated .
H-472	-0.41763418912887573	Therefore , factor VIII should only be used in pregnancy and breast-feeding when there is a clear indication .
D-472	-0.41763418912887573	Therefore , factor VIII should only be used in pregnancy and breast-feeding when there is a clear indication .
P-472	-0.2971 -0.1056 -0.4328 -2.5118 -0.1749 -0.0627 -0.1577 -0.2167 -0.1638 -0.1629 -0.4005 -0.1178 -0.2139 -0.5964 -0.0355 -0.0798 -0.0285 -1.7567 -1.9340 -0.1298 -0.1896 -0.2587 -0.0759 -0.1860 -0.1518
S-404	Symptome durch Überdosierung mit rekombinantem Blutgerinnungsfaktor VIII vom Menschen sind nicht bekannt .
T-404	No symptoms of overdose with recombinant coagulation factor VIII have been reported .
H-404	-0.24216635525226593	Symptoms of overdose with human recombinant blood clotting factor VIII are not known .
D-404	-0.24216635525226593	Symptoms of overdose with human recombinant blood clotting factor VIII are not known .
P-404	-0.3983 -0.0284 -0.2046 -0.1255 -0.2264 -0.1193 -0.9601 -0.2000 -0.0873 -0.0811 -0.1365 -0.7307 -0.5022 -0.0126 -0.1153 -0.1048 -0.1690 -0.0716 -0.1696 -0.7540 -0.0620 -0.1624 -0.1481
S-391	Deshalb sollte in der Schwangerschaft und Stillzeit Faktor VIII nur bei eindeutiger Indikationsstellung angewendet werden .
T-391	Therefore , factor VIII should be used during pregnancy and lactation only if clearly indicated .
H-391	-0.41763418912887573	Therefore , factor VIII should only be used in pregnancy and breast-feeding when there is a clear indication .
D-391	-0.41763418912887573	Therefore , factor VIII should only be used in pregnancy and breast-feeding when there is a clear indication .
P-391	-0.2971 -0.1056 -0.4328 -2.5118 -0.1749 -0.0627 -0.1577 -0.2167 -0.1638 -0.1629 -0.4005 -0.1178 -0.2139 -0.5964 -0.0355 -0.0798 -0.0285 -1.7567 -1.9340 -0.1298 -0.1896 -0.2587 -0.0759 -0.1860 -0.1518
S-716	ADVATE 1500 I.E. Pulver zur Herstellung einer Injektionslösung . Zur i.v. Anwendung .
T-716	ADVATE 1500 IU powder for solution for injection Octocog alfa IV use
H-716	-0.4312325716018677	ADVATE 1500 IU powder for the preparation of a solution for injection .
D-716	-0.4312325716018677	ADVATE 1500 IU powder for the preparation of a solution for injection .
P-716	-0.1101 -0.1661 -0.0851 -0.0889 -0.0869 -0.1104 -0.1234 -0.0486 -0.1858 -2.4971 -0.5575 -0.1454 -1.0370 -0.0572 -0.1208 -0.1009 -0.0931 -0.8825 -1.6967
S-310	Deshalb sollte in der Schwangerschaft und Stillzeit Faktor VIII nur bei eindeutiger Indikationsstellung angewendet werden .
T-310	Therefore , factor VIII should be used during pregnancy and lactation only if clearly indicated .
H-310	-0.41763418912887573	Therefore , factor VIII should only be used in pregnancy and breast-feeding when there is a clear indication .
D-310	-0.41763418912887573	Therefore , factor VIII should only be used in pregnancy and breast-feeding when there is a clear indication .
P-310	-0.2971 -0.1056 -0.4328 -2.5118 -0.1749 -0.0627 -0.1577 -0.2167 -0.1638 -0.1629 -0.4005 -0.1178 -0.2139 -0.5964 -0.0355 -0.0798 -0.0285 -1.7567 -1.9340 -0.1298 -0.1896 -0.2587 -0.0759 -0.1860 -0.1518
S-726	ADVATE 3000 I.E. Pulver zur Herstellung einer Injektionslösung . Zur i.v. Anwendung .
T-726	ADVATE 3000 IU powder for solution for injection Octocog alfa IV use
H-726	-0.433330237865448	ADVATE 3000 IU powder for the preparation of a solution for injection .
D-726	-0.433330237865448	ADVATE 3000 IU powder for the preparation of a solution for injection .
P-726	-0.1203 -0.1666 -0.0864 -0.0887 -0.0723 -0.1123 -0.1341 -0.0598 -0.1908 -2.5258 -0.6037 -0.1452 -0.9782 -0.0581 -0.1189 -0.1012 -0.0927 -0.9990 -1.5793
S-141	Folgende Nebenwirkungen wurden während klinischer Studien und<unk> oder nach Markteinführung von Alendronat berichtet .
T-141	The following adverse reactions have been reported during clinical studies and/ or post-marketing use with alendronate .
H-141	-0.29489150643348694	The following undesirable effects have been reported during clinical trials and/ or after the launch of alendronate .
D-141	-0.29489150643348694	The following undesirable effects have been reported during clinical trials and/ or after the launch of alendronate .
P-141	-0.1306 -0.1036 -1.3541 -0.0532 -0.0793 -0.0554 -0.1671 -0.1665 -0.0731 -0.0889 -0.1147 -0.2686 -0.2002 -0.0706 -0.1383 -1.0963 -0.2323 -2.0520 -0.1503 -0.1891 -0.1399 -0.0907 -0.0519 -0.1529 -0.1528
S-65	Folgende Nebenwirkungen wurden während klinischer Studien und<unk> oder nach Markteinführung von Alendronat berichtet .
T-65	The following adverse reactions have been reported during clinical studies and/ or post-marketing use with alendronate .
H-65	-0.29489150643348694	The following undesirable effects have been reported during clinical trials and/ or after the launch of alendronate .
D-65	-0.29489150643348694	The following undesirable effects have been reported during clinical trials and/ or after the launch of alendronate .
P-65	-0.1306 -0.1036 -1.3541 -0.0532 -0.0793 -0.0554 -0.1671 -0.1665 -0.0731 -0.0889 -0.1147 -0.2686 -0.2002 -0.0706 -0.1383 -1.0963 -0.2323 -2.0520 -0.1503 -0.1891 -0.1399 -0.0907 -0.0519 -0.1529 -0.1528
S-132	B. Cholestyramin , Colestipol ) können die Resorption von Vitamin D beeinträchtigen .
T-132	Colecalciferol Olestra , mineral oils , orlistat , and bile acid sequestrants ( e. g. cholestyramine , colestipol ) may impair the absorption of vitamin D.
H-132	-0.3362019956111908	cholestyramine , colestipol ) may impair the absorption of vitamin D .
D-132	-0.3362019956111908	cholestyramine , colestipol ) may impair the absorption of vitamin D .
P-132	-3.3829 -0.0678 -0.1156 -0.0944 -0.1734 -0.2018 -0.1992 -0.1116 -0.7324 -0.1441 -0.1142 -0.4762 -0.0319 -0.4469 -0.0889 -0.0757 -0.1477 -0.1134 -0.0774 -0.2811 -0.1639 -0.1559
S-56	B. Cholestyramin , Colestipol ) können die Resorption von Vitamin D beeinträchtigen .
T-56	Colecalciferol Olestra , mineral oils , orlistat , and bile acid sequestrants ( e. g. cholestyramine , colestipol ) may impair the absorption of vitamin D.
H-56	-0.3362019956111908	cholestyramine , colestipol ) may impair the absorption of vitamin D .
D-56	-0.3362019956111908	cholestyramine , colestipol ) may impair the absorption of vitamin D .
P-56	-3.3829 -0.0678 -0.1156 -0.0944 -0.1734 -0.2018 -0.1992 -0.1116 -0.7324 -0.1441 -0.1142 -0.4762 -0.0319 -0.4469 -0.0889 -0.0757 -0.1477 -0.1134 -0.0774 -0.2811 -0.1639 -0.1559
S-812	Die 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel.
T-812	Die 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel. 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
H-812	-0.1482354998588562	Die 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
D-812	-0.1482354998588562	Die 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
P-812	-0.0664 -0.1035 -0.0659 -0.0686 -0.0837 -0.0783 -0.0479 -0.1459 -0.0889 -0.1336 -0.1266 -0.1173 -0.1122 -0.1492 -0.1077 -0.0968 -0.1114 -0.1450 -0.1488 -0.1121 -0.1515 -0.1308 -0.9479 -0.1439 -0.2218
S-747	Die Behandlung mit ADVATE wird von einem in der Behandlung von Hämophilie A erfahrenen Arzt eingeleitet .
T-747	Treatment with ADVATE will be started by a doctor who is experienced in the care of patients with haemophilia A.
H-747	-0.26408055424690247	ADVATE treatment is initiated by a physician experienced in the treatment of haemophilia A .
D-747	-0.26408055424690247	ADVATE treatment is initiated by a physician experienced in the treatment of haemophilia A .
P-747	-1.0752 -0.1930 -0.0912 -0.0857 -0.4070 -0.1360 -0.0615 -0.1354 -0.1313 -0.1423 -0.3441 -0.0793 -1.2141 -0.1241 -0.1630 -0.5736 -0.1482 -0.3245 -0.0864 -0.0583 -0.0999 -0.3365 -0.1763 -0.1514
S-193	Faktor VIII ist eine der Substanzen ( Faktoren ) im Körper , die an der Blutgerinnung beteiligt sind .
T-193	In the body , factor VIII is one of the substances ( factors ) involved in blood coagulation ( clotting ) .
H-193	-0.24550987780094147	Factor VIII is one of the substances ( factors ) in the body involved in blood clotting .
D-193	-0.24550987780094147	Factor VIII is one of the substances ( factors ) in the body involved in blood clotting .
P-193	-0.4309 -0.1688 -0.0687 -0.1408 -0.1373 -0.1503 -0.1536 -0.5013 -0.0900 -0.1775 -0.1622 -0.1455 -0.2506 -0.1465 -0.1104 -1.1340 -0.1290 -0.9106 -0.1612 -0.0166 -0.1415 -0.1655 -0.1539
S-837	Das Kombinationspräparat wird für die Anwendung bei Patienten mit eingeschränkter Nieren- oder Leberfunktion nicht empfohlen .
T-837	The combination product is not recommended for use in patients with impaired renal or hepatic function .
H-837	-0.23392048478126526	The combination preparation is not recommended for use in patients with impaired renal or hepatic function .
D-837	-0.23392048478126526	The combination preparation is not recommended for use in patients with impaired renal or hepatic function .
P-837	-0.2313 -0.1477 -0.4509 -0.1581 -0.1615 -0.0593 -0.1271 -0.0759 -0.1395 -0.0814 -0.1287 -0.3824 -0.3019 -0.2175 -0.1103 -0.1837 -0.2998 -0.0357 -0.0973 -1.4393 -0.1640 -0.1529
S-756	Steigern Sie die Dosierung von ADVATE zur Kontrolle Ihrer Blutung nicht ohne Ihren Arzt zu befragen .
T-756	Do not increase the total dose of ADVATE to control your bleeding without consulting your doctor .
H-756	-0.29718533158302307	Do not increase the dosage of ADVATE to control your bleeding without consulting your doctor .
D-756	-0.29718533158302307	Do not increase the dosage of ADVATE to control your bleeding without consulting your doctor .
P-756	-1.4106 -0.1470 -0.1254 -0.2073 -0.6925 -0.0772 -0.1110 -0.1480 -0.1260 -0.1708 -0.0897 -0.0785 -0.1491 -0.6774 -0.5802 -1.0977 -0.1422 -0.1579 -0.2431 -0.1357 -0.1630 -0.0973 -0.1519 -0.1531
S-794	78 sector 4 Bucure ti 041836-RO Tel . : <unk> 40-21-321 16 40
T-794	78 sector 4 Bucure ti 041836-RO Tel . : <<unk>> 40-21-321 16 40
H-794	-0.12292108684778214	78 sector 4 Bucure ti 041836-RO Tel . : <unk> 40-21-321 16 40
D-794	-0.12292108684778214	78 sector 4 Bucure ti 041836-RO Tel . : <unk> 40-21-321 16 40
P-794	-0.2090 -0.1613 -0.1311 -0.1358 -0.0618 -0.2032 -0.0448 -0.1126 -0.0727 -0.0724 -0.1457 -0.1202 -0.0600 -0.1593 -0.1355 -0.0342 -0.2721 -0.0829 -0.1111 -0.0972 -0.1376 -0.1040 -0.1107 -0.1212 -0.1767
S-786	Opletalova 55 CZ-110 00 Praha 1 Tel . : <unk> 420 225774111
T-786	Opletalova 55 CZ-110 00 Praha 1 Tel . : <<unk>> 420 225774111
H-786	-0.1401924341917038	Opletalova 55 CZ-110 00 Praha 1 Tel . : <unk> 420 225774111
D-786	-0.1401924341917038	Opletalova 55 CZ-110 00 Praha 1 Tel . : <unk> 420 225774111
P-786	-0.1734 -0.1012 -0.3972 -0.1416 -0.0905 -0.1592 -0.1539 -0.1363 -0.1014 -0.1165 -0.3155 -0.1719 -0.1474 -0.0549 -0.1614 -0.1399 -0.0245 -0.1678 -0.1323 -0.0964 -0.0851 -0.0817 -0.1285 -0.0557 -0.1708
S-124	Andere mögliche Ursachen einer Osteoporose neben Östrogen-Mangel und Alter sollten in Betracht gezogen werden .
T-124	Causes of osteoporosis other than oestrogen deficiency and ageing should be considered .
H-124	-0.1694767326116562	Other possible causes of osteoporosis besides oestrogen deficiency and age should be considered .
D-124	-0.1694767326116562	Other possible causes of osteoporosis besides oestrogen deficiency and age should be considered .
P-124	-0.2961 -0.4304 -0.0564 -0.1433 -0.1264 -0.1090 -0.1112 -0.1304 -0.1046 -0.0708 -1.0963 -0.0958 -0.0938 -0.0587 -0.0577 -0.0828 -0.0387 -0.0479 -0.1115 -0.1250 -0.2968 -0.1337 -0.1687 -0.1234 -0.1475 -0.1497
S-48	Andere mögliche Ursachen einer Osteoporose neben Östrogen-Mangel und Alter sollten in Betracht gezogen werden .
T-48	Causes of osteoporosis other than oestrogen deficiency and ageing should be considered .
H-48	-0.1694767326116562	Other possible causes of osteoporosis besides oestrogen deficiency and age should be considered .
D-48	-0.1694767326116562	Other possible causes of osteoporosis besides oestrogen deficiency and age should be considered .
P-48	-0.2961 -0.4304 -0.0564 -0.1433 -0.1264 -0.1090 -0.1112 -0.1304 -0.1046 -0.0708 -1.0963 -0.0958 -0.0938 -0.0587 -0.0577 -0.0828 -0.0387 -0.0479 -0.1115 -0.1250 -0.2968 -0.1337 -0.1687 -0.1234 -0.1475 -0.1497
S-817	Bevor der CHMP ein Gutachten abgibt , kann er dem Unternehmen an Tag 180 etwaig verbleibende Fragen stellen .
T-817	Following the CHMP s opinion , it usually takes around two months for the European Commission to grant a licence .
H-817	-0.438960462808609	Before the CHMP issues an opinion , it may ask the company any remaining questions on Day 180 .
D-817	-0.438960462808609	Before the CHMP issues an opinion , it may ask the company any remaining questions on Day 180 .
P-817	-0.3939 -1.2111 -0.0798 -0.0522 -1.9181 -0.4092 -0.3997 -0.4213 -0.2126 -0.3122 -0.1294 -0.6008 -1.0408 -0.0752 -0.1892 -0.1280 -0.1696 -1.0703 -0.0737 -0.1766 -0.1545
S-323	Symptome durch Überdosierung mit rekombinantem Blutgerinnungsfaktor VIII vom Menschen sind nicht bekannt .
T-323	No symptoms of overdose with recombinant coagulation factor VIII have been reported .
H-323	-0.24216635525226593	Symptoms of overdose with human recombinant blood clotting factor VIII are not known .
D-323	-0.24216635525226593	Symptoms of overdose with human recombinant blood clotting factor VIII are not known .
P-323	-0.3983 -0.0284 -0.2046 -0.1255 -0.2264 -0.1193 -0.9601 -0.2000 -0.0873 -0.0811 -0.1365 -0.7307 -0.5022 -0.0126 -0.1153 -0.1048 -0.1690 -0.0716 -0.1696 -0.7540 -0.0620 -0.1624 -0.1481
S-232	Deshalb sollte in der Schwangerschaft und Stillzeit Faktor VIII nur bei eindeutiger Indikationsstellung angewendet werden .
T-232	Therefore , factor VIII should be used during pregnancy and lactation only if clearly indicated .
H-232	-0.41763418912887573	Therefore , factor VIII should only be used in pregnancy and breast-feeding when there is a clear indication .
D-232	-0.41763418912887573	Therefore , factor VIII should only be used in pregnancy and breast-feeding when there is a clear indication .
P-232	-0.2971 -0.1056 -0.4328 -2.5118 -0.1749 -0.0627 -0.1577 -0.2167 -0.1638 -0.1629 -0.4005 -0.1178 -0.2139 -0.5964 -0.0355 -0.0798 -0.0285 -1.7567 -1.9340 -0.1298 -0.1896 -0.2587 -0.0759 -0.1860 -0.1518
S-244	Symptome durch Überdosierung mit rekombinantem Blutgerinnungsfaktor VIII vom Menschen sind nicht bekannt .
T-244	No symptoms of overdose with recombinant coagulation factor VIII have been reported .
H-244	-0.24216635525226593	Symptoms of overdose with human recombinant blood clotting factor VIII are not known .
D-244	-0.24216635525226593	Symptoms of overdose with human recombinant blood clotting factor VIII are not known .
P-244	-0.3983 -0.0284 -0.2046 -0.1255 -0.2264 -0.1193 -0.9601 -0.2000 -0.0873 -0.0811 -0.1365 -0.7307 -0.5022 -0.0126 -0.1153 -0.1048 -0.1690 -0.0716 -0.1696 -0.7540 -0.0620 -0.1624 -0.1481
S-858	Diese und andere unerwünschte Ereignisse , die in klinischen Prüfungen auftraten , sind in der nachfolgenden Tabelle aufgeführt .
T-858	These and other undesirable effects reported during the clinical trials are listed in the following table .
H-858	-0.21143996715545654	These and other adverse events that occurred in clinical trials are listed in the table below .
D-858	-0.21143996715545654	These and other adverse events that occurred in clinical trials are listed in the table below .
P-858	-0.0918 -0.1567 -0.1260 -0.2770 -0.0457 -0.0882 -0.9465 -0.3893 -0.2269 -0.1594 -0.0653 -0.1555 -0.1203 -0.1340 -0.1409 -0.4872 -0.0901 -0.1605 -0.1562
S-811	Die Wirkungen von Advexin wurden zunächst in Versuchsmodellen getestet , bevor sie an Menschen untersucht wurden .
T-811	The effects of Advexin were first tested in experimental models before being studied in humans .
H-811	-0.1894666850566864	The effects of Advexin were first tested in experimental models before being studied in humans .
D-811	-0.1894666850566864	The effects of Advexin were first tested in experimental models before being studied in humans .
P-811	-0.1859 -0.1112 -0.1428 -0.5945 -0.1417 -0.1459 -0.1747 -0.2983 -0.3189 -0.1333 -0.2773 -0.0674 -0.1499 -0.3353 -0.0608 -0.0690 -0.1332 -0.1464 -0.1513 -0.1515
S-733	2. Was müssen Sie vor der Anwendung von ADVATE beachten ? 3. Wie ist ADVATE anzuwenden ?
T-733	Before you use ADVATE 3.
H-733	-0.22521884739398956	Before you use ADVATE 3.
D-733	-0.22521884739398956	Before you use ADVATE 3.
P-733	-0.0998 -0.1548 -0.9436 -0.1653 -0.1628 -0.0827 -0.0869 -0.0565 -0.2746
S-191	Ausführliche Erläuterungen zur Berechnung der Dosierungen sind der Packungsbeilage zu entnehmen .
T-191	Full details on how to calculate the doses are included in the Package Leaflet .
H-191	-0.3480890393257141	For detailed information on how to calculate doses , see the Package Leaflet .
D-191	-0.3480890393257141	For detailed information on how to calculate doses , see the Package Leaflet .
P-191	-1.6313 -0.4538 -0.5129 -0.0873 -0.7267 -0.3161 -0.1517 -0.1262 -0.2763 -0.3399 -0.1674 -0.2997 -0.1343 -1.0532 -0.1152 -0.0732 -0.0464 -0.1387 -0.1613 -0.1499
S-94	In beiden Fällen wurde die Radioaktivität fast ausschließlich als Metaboliten der Ausgangssubstanz ausgeschieden .
T-94	In both cases , the excreted radioactivity was almost exclusively as metabolites of the parent .
H-94	-0.2369251251220703	In both cases , radioactivity was excreted almost exclusively as metabolites of the starting substance .
D-94	-0.2369251251220703	In both cases , radioactivity was excreted almost exclusively as metabolites of the starting substance .
P-94	-0.1807 -0.0931 -0.2569 -0.7514 -0.4154 -0.0717 -0.1544 -0.4412 -0.0232 -0.1005 -0.0891 -0.7289 -0.1253 -0.1280 -0.0461 -0.0764 -0.1792 -0.1344 -0.8064 -0.1108 -0.1483 -0.1508
S-44	Knochen- , Gelenk- und<unk> oder Muskelschmerzen wurden bei Patienten unter Bisphosphonaten berichtet .
T-44	Bone , joint , and/ or muscle pain has been reported in patients taking bisphosphonates .
H-44	-0.17461135983467102	Bone , joint and/ or muscle pain have been reported in patients receiving bisphosphonates .
D-44	-0.17461135983467102	Bone , joint and/ or muscle pain have been reported in patients receiving bisphosphonates .
P-44	-0.2297 -0.1558 -0.1627 -0.1152 -0.0683 -0.1035 -0.1342 -0.0530 -0.1386 -0.2106 -0.1703 -0.1180 -0.1640 -0.0660 -1.2976 -0.0749 -0.0337 -0.0387 -0.1486 -0.0594 -0.1471 -0.1518
S-588	- Zur Rekonstitution nur das beigepackte sterilisierte Wasser für Injektionszwecke und das
T-588	- For reconstitution use only the sterilised water for injections and the reconstitution device
H-588	-0.5273037552833557	- For reconstitution only the accompanying sterilised water for injections and the
D-588	-0.5273037552833557	- For reconstitution only the accompanying sterilised water for injections and the
P-588	-0.1251 -0.8768 -0.1722 -0.1238 -0.5416 -0.2580 -2.6056 -0.0731 -0.0974 -0.2127 -0.1390 -0.1988 -0.2205 -0.1102 -0.1910 -0.8370 -0.1956 -0.6807 -2.3596
S-426	- Zur Rekonstitution nur das beigepackte sterilisierte Wasser für Injektionszwecke und das
T-426	- For reconstitution use only the sterilised water for injections and the reconstitution device
H-426	-0.5273037552833557	- For reconstitution only the accompanying sterilised water for injections and the
D-426	-0.5273037552833557	- For reconstitution only the accompanying sterilised water for injections and the
P-426	-0.1251 -0.8768 -0.1722 -0.1238 -0.5416 -0.2580 -2.6056 -0.0731 -0.0974 -0.2127 -0.1390 -0.1988 -0.2205 -0.1102 -0.1910 -0.8370 -0.1956 -0.6807 -2.3596
S-165	Die zwei Behandlungsgruppen waren auch hinsichtlich der BMD-Zunahmen an anderen Skelettstellen vergleichbar .
T-165	The two treatment groups were also similar with regard to BMD increases at other skeletal sites .
H-165	-0.36989036202430725	The two treatment groups were also comparable in BMD increases at other skeletal sites .
D-165	-0.36989036202430725	The two treatment groups were also comparable in BMD increases at other skeletal sites .
P-165	-0.1672 -0.1677 -0.1163 -0.1898 -0.1593 -0.0816 -1.1360 -0.1819 -0.6094 -0.8788 -0.1538 -0.8462 -0.5255 -0.7235 -1.1071 -0.0823 -0.0731 -0.1163 -0.1487 -0.1542 -0.1493
S-174	In beiden Fällen wurde die Radioaktivität fast ausschließlich als Metaboliten der Ausgangssubstanz ausgeschieden .
T-174	In both cases , the excreted radioactivity was almost exclusively as metabolites of the parent .
H-174	-0.2369251251220703	In both cases , radioactivity was excreted almost exclusively as metabolites of the starting substance .
D-174	-0.2369251251220703	In both cases , radioactivity was excreted almost exclusively as metabolites of the starting substance .
P-174	-0.1807 -0.0931 -0.2569 -0.7514 -0.4154 -0.0717 -0.1544 -0.4412 -0.0232 -0.1005 -0.0891 -0.7289 -0.1253 -0.1280 -0.0461 -0.0764 -0.1792 -0.1344 -0.8064 -0.1108 -0.1483 -0.1508
S-198	Darüber hinaus war bei 81 % dieser Blutungsepisoden nur eine einzige Behandlung mit Advate erforderlich .
T-198	In addition , 81 % of these bleeding episodes required only a single treatment with Advate .
H-198	-0.4247085750102997	Moreover , in 81 % of these bleeding episodes , only one treatment of Advate was required .
D-198	-0.4247085750102997	Moreover , in 81 % of these bleeding episodes , only one treatment of Advate was required .
P-198	-0.6425 -0.1464 -1.6259 -0.1238 -0.1192 -0.1462 -0.2513 -1.5356 -0.2511 -0.0023 -0.2812 -0.5938 -0.5524 -0.1091 -0.6012 -0.5341 -0.1418 -0.0946 -0.8669 -0.1474 -0.1522
S-507	- Zur Rekonstitution nur das beigepackte sterilisierte Wasser für Injektionszwecke und das
T-507	- For reconstitution use only the sterilised water for injections and the reconstitution device
H-507	-0.5273037552833557	- For reconstitution only the accompanying sterilised water for injections and the
D-507	-0.5273037552833557	- For reconstitution only the accompanying sterilised water for injections and the
P-507	-0.1251 -0.8768 -0.1722 -0.1238 -0.5416 -0.2580 -2.6056 -0.0731 -0.0974 -0.2127 -0.1390 -0.1988 -0.2205 -0.1102 -0.1910 -0.8370 -0.1956 -0.6807 -2.3596
S-188	Advate enthält den Wirkstoff Octocog alfa ( menschlicher Gerinnungsfaktor VIII ) .
T-188	Advate contains the active substance octocog alfa ( human coagulation factor VIII ) .
H-188	-0.23229005932807922	Advate contains the active substance octocog alfa ( human coagulation factor VIII ) .
D-188	-0.23229005932807922	Advate contains the active substance octocog alfa ( human coagulation factor VIII ) .
P-188	-1.1263 -0.1455 -0.0485 -0.4287 -0.0523 -0.0536 -0.9345 -0.1116 -0.1162 -0.1582 -0.1205 -0.0768 -0.1401 -0.1052 -0.6691 -0.1630 -0.1451 -0.0431 -0.1782 -0.0661 -0.1511 -0.1556 -0.1536
S-345	- Zur Rekonstitution nur das beigepackte sterilisierte Wasser für Injektionszwecke und das
T-345	- For reconstitution use only the sterilised water for injections and the reconstitution device
H-345	-0.5273037552833557	- For reconstitution only the accompanying sterilised water for injections and the
D-345	-0.5273037552833557	- For reconstitution only the accompanying sterilised water for injections and the
P-345	-0.1251 -0.8768 -0.1722 -0.1238 -0.5416 -0.2580 -2.6056 -0.0731 -0.0974 -0.2127 -0.1390 -0.1988 -0.2205 -0.1102 -0.1910 -0.8370 -0.1956 -0.6807 -2.3596
S-264	- Zur Rekonstitution nur das beigepackte sterilisierte Wasser für Injektionszwecke und das
T-264	- For reconstitution use only the sterilised water for injections and the reconstitution device
H-264	-0.5273037552833557	- For reconstitution only the accompanying sterilised water for injections and the
D-264	-0.5273037552833557	- For reconstitution only the accompanying sterilised water for injections and the
P-264	-0.1251 -0.8768 -0.1722 -0.1238 -0.5416 -0.2580 -2.6056 -0.0731 -0.0974 -0.2127 -0.1390 -0.1988 -0.2205 -0.1102 -0.1910 -0.8370 -0.1956 -0.6807 -2.3596
S-19	Dieses Arzneimittel ist identisch mit FOSAVANCE , das bereits in der Europäischen Union zugelassen ist .
T-19	This medicine is the same as FOSAVANCE , which is already authorised in the European Union .
H-19	-0.27510741353034973	This medicine is identical to FOSAVANCE , which is already authorised in the European Union .
D-19	-0.27510741353034973	This medicine is identical to FOSAVANCE , which is already authorised in the European Union .
P-19	-0.1230 -1.5222 -0.1342 -0.1617 -0.1271 -0.1696 -0.4831 -0.1009 -0.1497 -0.1471 -0.1120 -0.0814 -0.7835 -0.2024 -0.1344 -0.2835 -0.8609 -0.1098 -0.1715 -0.1397 -0.1562 -0.1335 -0.1576 -0.1577
S-781	Jede Packung beinhaltet des Weiteren ein Gerät zur Rekonstitution ( BAXJECTII ) .
T-781	Each pack also contains a device for reconstitution ( BAXJECT II ) .
H-781	-0.3510727286338806	Each carton also contains a reconstitution device ( BAXJECTII ) .
D-781	-0.3510727286338806	Each carton also contains a reconstitution device ( BAXJECTII ) .
P-781	-0.1225 -0.8883 -0.0380 -0.2063 -0.6727 -0.3144 -0.9592 -0.0636 -1.6997 -0.1354 -0.3553 -0.1387 -0.2368 -0.1053 -0.1541 -0.1175 -0.1543 -0.1549 -0.1532
S-3	Wenn derartige Ablagerungen in den Gelenken entstehen und Schmerzen verursachen , spricht man von einer Gicht .
T-3	When this happens in the joints and causes pain , it is known as gout .
H-3	-0.42186209559440613	When such deposits appear in the joints and cause pain , this is called gout .
D-3	-0.42186209559440613	When such deposits appear in the joints and cause pain , this is called gout .
P-3	-0.6185 -1.0932 -1.4306 -0.1387 -1.9065 -0.1380 -0.1351 -0.1213 -0.0646 -0.3612 -0.1168 -0.0736 -0.1966 -0.5409 -0.1062 -0.9471 -0.0820 -0.0695 -0.1446 -0.1522
S-179	In der Original-Blisterpackung aufbewahren , um den Inhalt vor Feuchtigkeit und Licht zu schützen .
T-179	Store in the original blister in order to protect from moisture and light .
H-179	-0.1244351789355278	Store in the original blister in order to protect from moisture and light .
D-179	-0.1244351789355278	Store in the original blister in order to protect from moisture and light .
P-179	-0.0285 -0.1474 -0.1249 -0.1421 -0.2454 -0.1302 -0.1173 -0.1162 -0.1310 -0.0928 -0.1061 -0.1658 -0.0511 -0.0689 -0.1595 -0.0929 -0.1663 -0.1534
S-100	In der Original-Blisterpackung aufbewahren , um den Inhalt vor Feuchtigkeit und Licht zu schützen .
T-100	Store in the original blister in order to protect from moisture and light .
H-100	-0.1244351789355278	Store in the original blister in order to protect from moisture and light .
D-100	-0.1244351789355278	Store in the original blister in order to protect from moisture and light .
P-100	-0.0285 -0.1474 -0.1249 -0.1421 -0.2454 -0.1302 -0.1173 -0.1162 -0.1310 -0.0928 -0.1061 -0.1658 -0.0511 -0.0689 -0.1595 -0.0929 -0.1663 -0.1534
S-728	Lesen Sie die gesamte Packungsbeilage sorgfältig durch , bevor Sie mit der Anwendung dieses Arzneimittels beginnen .
T-728	Read all of this leaflet carefully before you start using this medicine .
H-728	-0.19123172760009766	Read all of this leaflet carefully before you start taking this medicine .
D-728	-0.19123172760009766	Read all of this leaflet carefully before you start taking this medicine .
P-728	-0.0642 -0.1547 -0.1480 -0.1344 -0.0554 -0.0519 -0.1312 -0.0817 -0.1749 -0.1151 -0.2360 -1.1803 -0.1235 -0.1167 -0.1412 -0.1505
S-746	Dies muss bei Patienten , die einer natriumkontollierten Diät unterliegen , berücksichtigt werden .
T-746	To be taken into consideration by patients on a controlled sodium diet .
H-746	-0.48693975806236267	This has to be taken into account in patients on a sodium controlled diet .
D-746	-0.48693975806236267	This has to be taken into account in patients on a sodium controlled diet .
P-746	-0.4826 -1.5348 -0.1336 -0.1473 -0.9249 -0.0912 -0.1688 -0.8225 -0.1142 -0.2026 -0.2082 -0.7051 -0.5272 -1.8611 -0.0489 -0.1525 -0.1526
S-669	- Zur Rekonstitution nur das beigepackte sterilisierte Wasser für Injektionszwecke und das
T-669	- For reconstitution use only the sterilised water for injections and the reconstitution device
H-669	-0.5273037552833557	- For reconstitution only the accompanying sterilised water for injections and the
D-669	-0.5273037552833557	- For reconstitution only the accompanying sterilised water for injections and the
P-669	-0.1251 -0.8768 -0.1722 -0.1238 -0.5416 -0.2580 -2.6056 -0.0731 -0.0974 -0.2127 -0.1390 -0.1988 -0.2205 -0.1102 -0.1910 -0.8370 -0.1956 -0.6807 -2.3596
S-66	Häufig : muskuloskelettale ( Knochen- , Muskel- oder Gelenk- ) Schmerzen .
T-66	Musculoskeletal and connective tissue disorders :
H-66	-0.19723275303840637	Common : musculoskeletal ( bone , muscle or joint ) pain .
D-66	-0.19723275303840637	Common : musculoskeletal ( bone , muscle or joint ) pain .
P-66	-0.7200 -0.1263 -0.2039 -0.0361 -0.4425 -0.0808 -0.0779 -0.1901 -0.1186 -0.2645 -0.0659 -0.1538 -0.1083 -0.4992 -0.0673 -0.1638 -0.0838 -0.1835 -0.1611
S-844	Sportler müssen darauf hingewiesen werden , dass unter der Therapie mit Pseudoephedrin positive Dopingtests möglich sind .
T-844	Athletes should be informed that treatment with pseudoephedrine could lead to positive doping tests .
H-844	-0.5026916265487671	Athletes should be advised that therapy with pseudoephedrine may allow positive doping tests .
D-844	-0.5026916265487671	Athletes should be advised that therapy with pseudoephedrine may allow positive doping tests .
P-844	-0.7213 -0.1158 -0.8164 -0.1297 -1.6173 -0.2089 -2.1610 -0.1240 -0.1618 -0.5066 -0.1690 -0.0831 -0.1806 -0.2076 -0.0927 -0.2073 -2.1726 -0.3441 -0.5735 -0.0556 -0.2609 -0.1497
S-615	Die Behandlung muss unter der Überwachung eines Arztes erfolgen , der mit der Behandlung der Hämophilie vertraut ist .
T-615	Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
H-615	-0.29920247197151184	Treatment should be given under the supervision of a physician familiar with the treatment of haemophilia .
D-615	-0.29920247197151184	Treatment should be given under the supervision of a physician familiar with the treatment of haemophilia .
P-615	-0.1067 -0.0467 -0.1201 -0.9744 -0.1149 -1.9533 -0.1816 -0.1325 -0.0958 -0.0590 -0.1430 -0.1023 -0.3176 -0.1671 -1.4648 -0.1242 -0.1702 -0.2812 -0.1402 -0.1812 -0.1041 -0.0641 -0.1386 -0.1449 -0.1516
S-453	Die Behandlung muss unter der Überwachung eines Arztes erfolgen , der mit der Behandlung der Hämophilie vertraut ist .
T-453	Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
H-453	-0.29920247197151184	Treatment should be given under the supervision of a physician familiar with the treatment of haemophilia .
D-453	-0.29920247197151184	Treatment should be given under the supervision of a physician familiar with the treatment of haemophilia .
P-453	-0.1067 -0.0467 -0.1201 -0.9744 -0.1149 -1.9533 -0.1816 -0.1325 -0.0958 -0.0590 -0.1430 -0.1023 -0.3176 -0.1671 -1.4648 -0.1242 -0.1702 -0.2812 -0.1402 -0.1812 -0.1041 -0.0641 -0.1386 -0.1449 -0.1516
S-610	Nach der Rekonstitution enthält jeder ml Lösung ungefähr 600 I.E.<unk> ml Octocog alfa .
T-610	After reconstitution , each ml solution for injection contains approximately 600 IU octocog alfa . * The potency ( International Units ) is determined using the chromogenic assay against an in-house standard that is referenced to the WHO standard .
H-610	-0.1958497166633606	After reconstitution , each ml of solution contains approximately 600 IU/ ml of Octocog alfa .
D-610	-0.1958497166633606	After reconstitution , each ml of solution contains approximately 600 IU/ ml of Octocog alfa .
P-610	-0.5150 -0.1534 -0.0991 -0.1674 -0.3704 -0.1010 -0.1460 -0.0840 -0.1037 -0.5026 -0.0960 -0.1343 -0.1273 -0.1739 -0.0603 -0.4960 -0.4901 -0.1116 -0.1190 -0.1429 -0.1319 -0.0755 -0.1513 -0.1477
S-529	Nach der Rekonstitution enthält jeder ml Lösung ungefähr 400 I.E.<unk> ml Octocog alfa .
T-529	After reconstitution , each ml solution for injection contains approximately 400 IU octocog alfa . * The potency ( International Units ) is determined using the chromogenic assay against an in-house standard that is referenced to the WHO standard .
H-529	-0.1947827935218811	After reconstitution , each ml of solution contains approximately 400 IU/ ml of Octocog alfa .
D-529	-0.1947827935218811	After reconstitution , each ml of solution contains approximately 400 IU/ ml of Octocog alfa .
P-529	-0.5305 -0.1540 -0.1006 -0.1700 -0.3736 -0.1011 -0.1465 -0.0870 -0.1081 -0.4424 -0.0894 -0.1275 -0.1233 -0.1731 -0.0603 -0.5293 -0.4803 -0.1108 -0.1190 -0.1416 -0.1326 -0.0746 -0.1500 -0.1492
S-448	Nach der Rekonstitution enthält jeder ml Lösung ungefähr 300 I.E.<unk> ml Octocog alfa .
T-448	After reconstitution , each ml solution for injection contains approximately 300 IU octocog alfa . * The potency ( International Units ) is determined using the chromogenic assay against an in-house standard that is referenced to the WHO standard .
H-448	-0.19193126261234283	After reconstitution , each ml of solution contains approximately 300 IU/ ml of Octocog alfa .
D-448	-0.19193126261234283	After reconstitution , each ml of solution contains approximately 300 IU/ ml of Octocog alfa .
P-448	-0.5383 -0.1554 -0.0994 -0.1686 -0.3757 -0.1016 -0.1467 -0.0889 -0.1061 -0.3919 -0.0938 -0.1266 -0.1258 -0.1748 -0.0576 -0.5377 -0.4390 -0.1116 -0.1192 -0.1419 -0.1325 -0.0745 -0.1508 -0.1480
S-367	Nach der Rekonstitution enthält jeder ml Lösung ungefähr 200 I.E.<unk> ml Octocog alfa .
T-367	After reconstitution , each ml solution for injection contains approximately 200 IU octocog alfa . * The potency ( International Units ) is determined using the chromogenic assay against an in-house standard that is referenced to the WHO standard .
H-367	-0.1953042447566986	After reconstitution , each ml of solution contains approximately 200 IU/ ml of Octocog alfa .
D-367	-0.1953042447566986	After reconstitution , each ml of solution contains approximately 200 IU/ ml of Octocog alfa .
P-367	-0.5223 -0.1565 -0.0967 -0.1698 -0.3872 -0.1015 -0.1476 -0.0876 -0.1058 -0.4756 -0.1064 -0.1248 -0.1192 -0.1700 -0.0594 -0.5176 -0.4576 -0.1122 -0.1189 -0.1417 -0.1327 -0.0745 -0.1524 -0.1492
S-286	Nach der Rekonstitution enthält jeder ml Lösung ungefähr 100 I.E.<unk> ml Octocog alfa .
T-286	After reconstitution , each ml solution for injection contains approximately 100 IU octocog alfa . * The potency ( International Units ) is determined using the chromogenic assay against an in-house standard that is referenced to the WHO standard .
H-286	-0.197362020611763	After reconstitution , each ml of solution contains approximately 100 IU/ ml of Octocog alfa .
D-286	-0.197362020611763	After reconstitution , each ml of solution contains approximately 100 IU/ ml of Octocog alfa .
P-286	-0.5253 -0.1522 -0.0984 -0.1668 -0.4115 -0.0991 -0.1448 -0.0865 -0.1083 -0.4069 -0.1436 -0.1278 -0.1191 -0.1665 -0.0551 -0.5888 -0.4575 -0.1114 -0.1200 -0.1417 -0.1315 -0.0743 -0.1511 -0.1483
S-206	Nach der Rekonstitution enthält jeder ml Lösung ungefähr 50 I.E.<unk> ml Octocog alfa .
T-206	After reconstitution , each ml solution for injection contains approximately 50 IU octocog alfa . * The potency ( International Units ) is determined using the chromogenic assay against an in-house standard that is referenced to the WHO standard .
H-206	-0.2040974348783493	After reconstitution , each ml of solution contains approximately 50 IU/ ml of Octocog alfa .
D-206	-0.2040974348783493	After reconstitution , each ml of solution contains approximately 50 IU/ ml of Octocog alfa .
P-206	-0.5359 -0.1522 -0.0970 -0.1686 -0.4094 -0.1011 -0.1443 -0.0849 -0.1130 -0.5205 -0.1803 -0.1287 -0.1244 -0.1758 -0.0591 -0.5103 -0.5122 -0.1114 -0.1196 -0.1436 -0.1323 -0.0738 -0.1519 -0.1483
S-196	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel.
T-196	The study went on to look at the number 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
H-196	-0.17089760303497314	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
D-196	-0.17089760303497314	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
P-196	-0.2226 -0.0687 -0.0746 -0.0915 -0.1016 -0.0574 -0.1458 -0.1063 -0.1300 -0.1294 -0.1209 -0.1261 -0.1500 -0.1050 -0.0997 -0.1211 -0.1426 -0.1496 -0.1190 -0.1525 -0.1074 -1.2610 -0.1471 -0.1718
S-120	Knochen- , Gelenk- und<unk> oder Muskelschmerzen wurden bei Patienten unter Bisphosphonaten berichtet .
T-120	Bone , joint , and/ or muscle pain has been reported in patients taking bisphosphonates .
H-120	-0.17461135983467102	Bone , joint and/ or muscle pain have been reported in patients receiving bisphosphonates .
D-120	-0.17461135983467102	Bone , joint and/ or muscle pain have been reported in patients receiving bisphosphonates .
P-120	-0.2297 -0.1558 -0.1627 -0.1152 -0.0683 -0.1035 -0.1342 -0.0530 -0.1386 -0.2106 -0.1703 -0.1180 -0.1640 -0.0660 -1.2976 -0.0749 -0.0337 -0.0387 -0.1486 -0.0594 -0.1471 -0.1518
S-534	Die Behandlung muss unter der Überwachung eines Arztes erfolgen , der mit der Behandlung der Hämophilie vertraut ist .
T-534	Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
H-534	-0.29920247197151184	Treatment should be given under the supervision of a physician familiar with the treatment of haemophilia .
D-534	-0.29920247197151184	Treatment should be given under the supervision of a physician familiar with the treatment of haemophilia .
P-534	-0.1067 -0.0467 -0.1201 -0.9744 -0.1149 -1.9533 -0.1816 -0.1325 -0.0958 -0.0590 -0.1430 -0.1023 -0.3176 -0.1671 -1.4648 -0.1242 -0.1702 -0.2812 -0.1402 -0.1812 -0.1041 -0.0641 -0.1386 -0.1449 -0.1516
S-9	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel.
T-9	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
H-9	-0.17089760303497314	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
D-9	-0.17089760303497314	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
P-9	-0.2226 -0.0687 -0.0746 -0.0915 -0.1016 -0.0574 -0.1458 -0.1063 -0.1300 -0.1294 -0.1209 -0.1261 -0.1500 -0.1050 -0.0997 -0.1211 -0.1426 -0.1496 -0.1190 -0.1525 -0.1074 -1.2610 -0.1471 -0.1718
S-372	Die Behandlung muss unter der Überwachung eines Arztes erfolgen , der mit der Behandlung der Hämophilie vertraut ist .
T-372	Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
H-372	-0.29920247197151184	Treatment should be given under the supervision of a physician familiar with the treatment of haemophilia .
D-372	-0.29920247197151184	Treatment should be given under the supervision of a physician familiar with the treatment of haemophilia .
P-372	-0.1067 -0.0467 -0.1201 -0.9744 -0.1149 -1.9533 -0.1816 -0.1325 -0.0958 -0.0590 -0.1430 -0.1023 -0.3176 -0.1671 -1.4648 -0.1242 -0.1702 -0.2812 -0.1402 -0.1812 -0.1041 -0.0641 -0.1386 -0.1449 -0.1516
S-291	Die Behandlung muss unter der Überwachung eines Arztes erfolgen , der mit der Behandlung der Hämophilie vertraut ist .
T-291	Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
H-291	-0.29920247197151184	Treatment should be given under the supervision of a physician familiar with the treatment of haemophilia .
D-291	-0.29920247197151184	Treatment should be given under the supervision of a physician familiar with the treatment of haemophilia .
P-291	-0.1067 -0.0467 -0.1201 -0.9744 -0.1149 -1.9533 -0.1816 -0.1325 -0.0958 -0.0590 -0.1430 -0.1023 -0.3176 -0.1671 -1.4648 -0.1242 -0.1702 -0.2812 -0.1402 -0.1812 -0.1041 -0.0641 -0.1386 -0.1449 -0.1516
S-211	Die Behandlung muss unter der Überwachung eines Arztes erfolgen , der mit der Behandlung der Hämophilie vertraut ist .
T-211	Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
H-211	-0.29920247197151184	Treatment should be given under the supervision of a physician familiar with the treatment of haemophilia .
D-211	-0.29920247197151184	Treatment should be given under the supervision of a physician familiar with the treatment of haemophilia .
P-211	-0.1067 -0.0467 -0.1201 -0.9744 -0.1149 -1.9533 -0.1816 -0.1325 -0.0958 -0.0590 -0.1430 -0.1023 -0.3176 -0.1671 -1.4648 -0.1242 -0.1702 -0.2812 -0.1402 -0.1812 -0.1041 -0.0641 -0.1386 -0.1449 -0.1516
S-75	Studien zur Präklinik zeigten , dass Alendronat sich bevorzugt an den Stellen der aktiven Resorption
T-75	Preclinical studies have shown preferential localisation of alendronate to sites of active resorption .
H-75	-0.5731649994850159	Preclinical studies have shown that alendronate is preferred at sites of active absorption
D-75	-0.5731649994850159	Preclinical studies have shown that alendronate is preferred at sites of active absorption
P-75	-2.1593 -0.9106 -0.0339 -0.4682 -0.0763 -0.7268 -0.0806 -0.1523 -0.1314 -0.1455 -0.1025 -0.0709 -1.4631 -0.2647 -1.0441 -0.7423 -0.1646 -0.1307 -0.2674 -0.0844 -2.8168
S-758	Wenn Sie selbst oder eine andere Person ADVATE verabreichen , darf dies nur nach einem entsprechenden Training geschehen .
T-758	You or someone else might also administer ADVATE as an injection , but only after receiving adequate training .
H-758	-0.5030390620231628	If you or someone else gives ADVATE , this should only be done after adequate training .
D-758	-0.5030390620231628	If you or someone else gives ADVATE , this should only be done after adequate training .
P-758	-0.2410 -0.2053 -0.1728 -0.3824 -0.1028 -1.1150 -0.0886 -0.1734 -0.0959 -0.0813 -0.7586 -2.6955 -0.6406 -0.2325 -0.2767 -0.3403 -0.1988 -2.0325 -0.2950 -0.2821 -0.1527
S-822	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel.
T-822	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
H-822	-0.17089760303497314	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
D-822	-0.17089760303497314	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
P-822	-0.2226 -0.0687 -0.0746 -0.0915 -0.1016 -0.0574 -0.1458 -0.1063 -0.1300 -0.1294 -0.1209 -0.1261 -0.1500 -0.1050 -0.0997 -0.1211 -0.1426 -0.1496 -0.1190 -0.1525 -0.1074 -1.2610 -0.1471 -0.1718
S-749	In einigen Fällen jedoch können , besonders bei jüngeren Patienten , häufigere Injektionen oder höhere Dosen erforderlich sein .
T-749	However , in some cases , especially in younger patients , more frequent injections or higher doses may be necessary .
H-749	-0.2947840988636017	In some cases , however , more frequent injections or higher doses may be required , especially in younger patients .
D-749	-0.2947840988636017	In some cases , however , more frequent injections or higher doses may be required , especially in younger patients .
P-749	-1.5891 -0.0941 -0.1840 -0.2749 -0.2669 -0.1461 -0.2177 -0.0733 -0.8333 -0.0604 -0.1262 -0.2949 -0.1516 -0.1032 -0.0527 -0.1567 -1.2726 -0.1411 -0.2662 -0.2423 -0.1313 -0.0845 -0.1635 -0.1482
S-142	Häufig : muskuloskelettale ( Knochen- , Muskel- oder Gelenk- ) Schmerzen .
T-142	Musculoskeletal and connective tissue disorders :
H-142	-0.19723275303840637	Common : musculoskeletal ( bone , muscle or joint ) pain .
D-142	-0.19723275303840637	Common : musculoskeletal ( bone , muscle or joint ) pain .
P-142	-0.7200 -0.1263 -0.2039 -0.0361 -0.4425 -0.0808 -0.0779 -0.1901 -0.1186 -0.2645 -0.0659 -0.1538 -0.1083 -0.4992 -0.0673 -0.1638 -0.0838 -0.1835 -0.1611
S-22	Die Patientinnen sollen außerdem zusätzlich Calcium einnehmen , falls über die Nahrung nicht genügend aufgenommen wird .
T-22	Patients should also take calcium supplements if they are not getting enough calcium from their diet .
H-22	-0.40698209404945374	Patients should also take additional calcium if insufficient is taken from food .
D-22	-0.40698209404945374	Patients should also take additional calcium if insufficient is taken from food .
P-22	-0.0909 -0.0986 -0.2166 -0.1043 -0.1094 -1.0374 -0.0543 -0.0740 -0.1176 -0.2136 -0.6053 -0.3818 -0.8366 -1.5964 -0.4332 -1.0635 -0.1428 -0.1496
S-39	ADROVANCE wurde bei Kindern und Jugendlichen nicht untersucht und sollte daher bei ihnen nicht angewendet werden .
T-39	ADROVANCE has not been studied in children and adolescents and therefore should not be given to them .
H-39	-0.1918153464794159	ADROVANCE has not been studied in children and adolescents and therefore should not be used in them .
D-39	-0.1918153464794159	ADROVANCE has not been studied in children and adolescents and therefore should not be used in them .
P-39	-0.1735 -0.0731 -0.1500 -0.1094 -0.0765 -0.1031 -0.1475 -0.0986 -0.5430 -0.1370 -0.2151 -0.2323 -0.0871 -0.0653 -0.0480 -0.1837 -0.9553 -0.1729 -0.1254 -0.1276 -0.2600 -0.2685 -0.1365 -0.1512 -0.1547
S-783	Hersteller Baxter S.A. Boulevard René Branquart 80 B-7860 Lessines , Belgien
T-783	Manufacturer Baxter SA Boulevard René Branquart 80 B-7860 Lessines Belgium
H-783	-0.14223775267601013	Manufacturer Baxter S.A. Boulevard René Branquart 80 B-7860 Lessines , Belgium
D-783	-0.14223775267601013	Manufacturer Baxter S.A. Boulevard René Branquart 80 B-7860 Lessines , Belgium
P-783	-0.0900 -0.0576 -0.0647 -0.1351 -0.1830 -0.1334 -0.1748 -0.4818 -0.0635 -0.2300 -0.0967 -0.2075 -0.0789 -0.1034 -0.1174 -0.0755 -0.1211 -0.1123 -0.0570 -0.1247 -0.1214 -0.0351 -0.1072 -0.1570 -0.3966 -0.1725
S-331	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery
T-331	AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-331	-0.2987237274646759	AUC0- ( IU h/ dl ) t 1/ 2 ( h ) Recovery
D-331	-0.2987237274646759	AUC0- ( IU h/ dl ) t 1/ 2 ( h ) Recovery
P-331	-0.1256 -0.1767 -0.1419 -0.1428 -0.1410 -0.1086 -2.0996 -0.2221 -0.5707 -0.0354 -0.1448 -0.1507 -0.0911 -0.5949 -0.1862 -0.1459 -0.2705 -0.1486 -0.5293 -0.1472 -0.0894 -0.3090
S-835	Die empfohlene Dosierung und die Dauer der Behandlung dürfen nicht überschritten werden ( siehe Abschnitt 4.2 ) .
T-835	Do not exceed the recommended dosage and the duration of treatment ( see section 4.2 ) .
H-835	-0.24434956908226013	Do not exceed the recommended dose and duration of treatment ( see section 4.2 ) .
D-835	-0.24434956908226013	Do not exceed the recommended dose and duration of treatment ( see section 4.2 ) .
P-835	-0.1130 -0.1348 -0.1697 -0.0968 -0.1299 -0.0635 -1.6839 -0.3068 -0.4897 -0.1255 -0.1479 -0.1883 -0.1467 -0.2390 -0.1371 -0.1204 -0.1340 -0.1535 -0.1500 -0.1564
S-798	Viale Tiziano , 25 I-00196 Roma Tel : <unk> 39 06 324911
T-798	Viale Tiziano , 25 I-00196 Roma Tel : <<unk>> 39 06 324911
H-798	-0.12596487998962402	Viale Tiziano , 25 I-00196 Roma Tel : <unk> 39 06 324911
D-798	-0.12596487998962402	Viale Tiziano , 25 I-00196 Roma Tel : <unk> 39 06 324911
P-798	-0.0826 -0.0686 -0.1500 -0.0412 -0.1450 -0.1546 -0.1185 -0.1352 -0.1104 -0.0831 -0.1248 -0.1572 -0.3747 -0.0473 -0.1445 -0.0201 -0.0888 -0.1045 -0.1264 -0.1122 -0.1777 -0.1653 -0.1642
S-788	Kobaltweg 49 NL-3542 CE Utrecht Tel : <unk> 31 30 2488911
T-788	Kobaltweg 49 NL-3542 CE Utrecht Tel : <<unk>> 31 30 2488911
H-788	-0.14980246126651764	Cobaltweg 49 NL-3542 CE Utrecht Tel : <unk> 31 30 2488911
D-788	-0.14980246126651764	Cobaltweg 49 NL-3542 CE Utrecht Tel : <unk> 31 30 2488911
P-788	-0.8166 -0.4358 -0.0828 -0.0746 -0.1160 -0.1805 -0.1124 -0.0996 -0.0804 -0.0369 -0.0956 -0.0789 -0.0679 -0.0402 -0.1445 -0.0191 -0.1128 -0.1186 -0.1181 -0.1083 -0.1764 -0.1624 -0.1672
S-114	ADROVANCE wurde bei Kindern und Jugendlichen nicht untersucht und sollte daher bei ihnen nicht angewendet werden .
T-114	ADROVANCE has not been studied in children and adolescents and therefore should not be given to them .
H-114	-0.1918153464794159	ADROVANCE has not been studied in children and adolescents and therefore should not be used in them .
D-114	-0.1918153464794159	ADROVANCE has not been studied in children and adolescents and therefore should not be used in them .
P-114	-0.1735 -0.0731 -0.1500 -0.1094 -0.0765 -0.1031 -0.1475 -0.0986 -0.5430 -0.1370 -0.2151 -0.2323 -0.0871 -0.0653 -0.0480 -0.1837 -0.9553 -0.1729 -0.1254 -0.1276 -0.2600 -0.2685 -0.1365 -0.1512 -0.1547
S-184	Via Complutense , 140 E-28805 Alcalá de Henares Madrid , Spain
T-184	Via Complutense , 140 ES-28805 Alcalá de Henares Madrid , Spain
H-184	-0.10650583356618881	Via Complutense , 140 E-28805 Alcalá de Henares Madrid , Spain
D-184	-0.10650583356618881	Via Complutense , 140 E-28805 Alcalá de Henares Madrid , Spain
P-184	-0.0913 -0.1324 -0.1580 -0.0867 -0.0964 -0.0407 -0.1548 -0.0952 -0.1077 -0.1175 -0.0853 -0.1459 -0.1005 -0.1009 -0.0785 -0.0699 -0.1152 -0.1150 -0.0715 -0.0660 -0.1536 -0.1004 -0.1664
S-412	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery
T-412	AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-412	-0.2987237274646759	AUC0- ( IU h/ dl ) t 1/ 2 ( h ) Recovery
D-412	-0.2987237274646759	AUC0- ( IU h/ dl ) t 1/ 2 ( h ) Recovery
P-412	-0.1256 -0.1767 -0.1419 -0.1428 -0.1410 -0.1086 -2.0996 -0.2221 -0.5707 -0.0354 -0.1448 -0.1507 -0.0911 -0.5949 -0.1862 -0.1459 -0.2705 -0.1486 -0.5293 -0.1472 -0.0894 -0.3090
S-493	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery
T-493	AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-493	-0.2987237274646759	AUC0- ( IU h/ dl ) t 1/ 2 ( h ) Recovery
D-493	-0.2987237274646759	AUC0- ( IU h/ dl ) t 1/ 2 ( h ) Recovery
P-493	-0.1256 -0.1767 -0.1419 -0.1428 -0.1410 -0.1086 -2.0996 -0.2221 -0.5707 -0.0354 -0.1448 -0.1507 -0.0911 -0.5949 -0.1862 -0.1459 -0.2705 -0.1486 -0.5293 -0.1472 -0.0894 -0.3090
S-574	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery
T-574	AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-574	-0.2987237274646759	AUC0- ( IU h/ dl ) t 1/ 2 ( h ) Recovery
D-574	-0.2987237274646759	AUC0- ( IU h/ dl ) t 1/ 2 ( h ) Recovery
P-574	-0.1256 -0.1767 -0.1419 -0.1428 -0.1410 -0.1086 -2.0996 -0.2221 -0.5707 -0.0354 -0.1448 -0.1507 -0.0911 -0.5949 -0.1862 -0.1459 -0.2705 -0.1486 -0.5293 -0.1472 -0.0894 -0.3090
S-655	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery
T-655	AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-655	-0.2987237274646759	AUC0- ( IU h/ dl ) t 1/ 2 ( h ) Recovery
D-655	-0.2987237274646759	AUC0- ( IU h/ dl ) t 1/ 2 ( h ) Recovery
P-655	-0.1256 -0.1767 -0.1419 -0.1428 -0.1410 -0.1086 -2.0996 -0.2221 -0.5707 -0.0354 -0.1448 -0.1507 -0.0911 -0.5949 -0.1862 -0.1459 -0.2705 -0.1486 -0.5293 -0.1472 -0.0894 -0.3090
S-838	Aerinaze darf nicht bei Kindern unter 12 Jahren angewendet werden ( siehe Abschnitt 4.2 ) .
T-838	Aerinaze should not be used in children below the age of 12 years ( see section 4.2 ) .
H-838	-0.23724903166294098	Aerinaze should not be used in children under 12 years of age ( see section 4.2 ) .
D-838	-0.23724903166294098	Aerinaze should not be used in children under 12 years of age ( see section 4.2 ) .
P-838	-0.5473 -0.1165 -0.1247 -0.1436 -0.0971 -0.5924 -0.1393 -0.1175 -0.2326 -0.3738 -0.4438 -0.5718 -0.1902 -0.1306 -0.4283 -0.1367 -0.1551 -0.3433 -0.0947 -0.1161 -0.1322 -0.1532 -0.1595 -0.1536
S-116	Es ist sehr wichtig , dass alle Dosierungsanweisungen an den Patienten weitergegeben werden und vom Patienten verstanden
T-116	It is very important that the full dosing instructions are provided to , and are understood by the patient ( see section 4.2 ) .
H-116	-0.30195364356040955	It is very important that all dosing instructions are passed on to the patient and understood by the patient .
D-116	-0.30195364356040955	It is very important that all dosing instructions are passed on to the patient and understood by the patient .
P-116	-0.1907 -0.1589 -0.7366 -0.1281 -0.1947 -0.1260 -0.2235 -0.4441 -0.3426 -0.1425 -1.7351 -0.1154 -0.1167 -0.1418 -0.0918 -0.1368 -0.6412 -0.1596 -0.1295 -0.0901 -0.4392 -0.1583
S-32	Angesichts des Krankheitsverlaufs bei Osteoporose ist ADROVANCE zur Langzeittherapie vorgesehen .
T-32	Due to the nature of the disease process in osteoporosis , ADROVANCE is intended for long-term use .
H-32	-0.3653988540172577	ADROVANCE is scheduled for long term therapy in view of the progression of osteoporosis .
D-32	-0.3653988540172577	ADROVANCE is scheduled for long term therapy in view of the progression of osteoporosis .
P-32	-1.0836 -0.0709 -0.1486 -0.0917 -0.0868 -0.2118 -1.3102 -0.3369 -0.8081 -0.5306 -1.2653 -0.2405 -0.0907 -0.1410 -0.1233 -1.7979 -0.0812 -0.1413 -0.1578 -0.1020 -0.1057 -0.1190 -0.0943 -0.0696 -0.1414 -0.1501
S-107	Angesichts des Krankheitsverlaufs bei Osteoporose ist ADROVANCE zur Langzeittherapie vorgesehen .
T-107	Due to the nature of the disease process in osteoporosis , ADROVANCE is intended for long-term use .
H-107	-0.3653988540172577	ADROVANCE is scheduled for long term therapy in view of the progression of osteoporosis .
D-107	-0.3653988540172577	ADROVANCE is scheduled for long term therapy in view of the progression of osteoporosis .
P-107	-1.0836 -0.0709 -0.1486 -0.0917 -0.0868 -0.2118 -1.3102 -0.3369 -0.8081 -0.5306 -1.2653 -0.2405 -0.0907 -0.1410 -0.1233 -1.7979 -0.0812 -0.1413 -0.1578 -0.1020 -0.1057 -0.1190 -0.0943 -0.0696 -0.1414 -0.1501
S-853	Verminderte Milchproduktion wurde von stillenden Müttern im Zusammenhang mit Pseudoephedrin berichtet .
T-853	Decreased milk production in nursing mothers has been reported with pseudoephedrine .
H-853	-0.3582283854484558	Decreased milk production has been reported by lactating mothers in association with pseudoephedrine .
D-853	-0.3582283854484558	Decreased milk production has been reported by lactating mothers in association with pseudoephedrine .
P-853	-2.0750 -0.0477 -0.0530 -0.0644 -0.2263 -0.1390 -0.1471 -0.0868 -1.2039 -1.6477 -0.0222 -0.1103 -0.5742 -0.2968 -0.6358 -0.1301 -0.1939 -0.3709 -0.1606 -0.0563 -0.1539 -0.1547 -0.1005 -0.1529 -0.1515
S-434	Zum Auflösen nur das beigepackte Wasser für Injektionszwecke und das beigepackte Rekonstitutionsset verwenden .
T-434	For reconstitution only the water for injections and the reconstitution device provided in the pack should be used .
H-434	-0.4725411534309387	Use only the enclosed water for injections and the enclosed reconstitution set to disperse .
D-434	-0.4725411534309387	Use only the enclosed water for injections and the enclosed reconstitution set to disperse .
P-434	-1.3548 -0.3419 -0.1329 -2.1051 -0.0786 -0.1099 -0.1654 -0.1677 -0.8139 -0.1739 -0.1328 -0.1033 -0.0689 -1.6711 -0.0608 -1.0588 -0.4424 -0.9479 -0.0231 -0.1433 -0.1462 -0.1531
S-272	Zum Auflösen nur das beigepackte Wasser für Injektionszwecke und das beigepackte Rekonstitutionsset verwenden .
T-272	For reconstitution only the water for injections and the reconstitution device provided in the pack should be used .
H-272	-0.4725411534309387	Use only the enclosed water for injections and the enclosed reconstitution set to disperse .
D-272	-0.4725411534309387	Use only the enclosed water for injections and the enclosed reconstitution set to disperse .
P-272	-1.3548 -0.3419 -0.1329 -2.1051 -0.0786 -0.1099 -0.1654 -0.1677 -0.8139 -0.1739 -0.1328 -0.1033 -0.0689 -1.6711 -0.0608 -1.0588 -0.4424 -0.9479 -0.0231 -0.1433 -0.1462 -0.1531
S-20	ADROVANCE vermindert das Risiko für Wirbel<unk> säulen<unk> - und Hüftfrakturen ( Brüche ) .
T-20	ADROVANCE reduces the risk of vertebral ( spine ) and hip fractures ( breaks ) .
H-20	-0.25776997208595276	ADROVANCE decreases the risk of spine and hip fractures ( fractures ) .
D-20	-0.25776997208595276	ADROVANCE decreases the risk of spine and hip fractures ( fractures ) .
P-20	-0.0868 -0.0727 -0.1447 -0.0977 -0.0839 -1.4412 -0.1126 -0.1527 -0.1227 -0.1943 -0.1988 -1.1248 -0.2868 -0.0444 -0.1899 -0.0783 -0.3417 -0.3595 -0.0598 -0.1433 -0.1748 -0.1595
S-677	Zum Auflösen nur das beigepackte Wasser für Injektionszwecke und das beigepackte Rekonstitutionsset verwenden .
T-677	For reconstitution only the water for injections and the reconstitution device provided in the pack should be used .
H-677	-0.4725411534309387	Use only the enclosed water for injections and the enclosed reconstitution set to disperse .
D-677	-0.4725411534309387	Use only the enclosed water for injections and the enclosed reconstitution set to disperse .
P-677	-1.3548 -0.3419 -0.1329 -2.1051 -0.0786 -0.1099 -0.1654 -0.1677 -0.8139 -0.1739 -0.1328 -0.1033 -0.0689 -1.6711 -0.0608 -1.0588 -0.4424 -0.9479 -0.0231 -0.1433 -0.1462 -0.1531
S-596	Zum Auflösen nur das beigepackte Wasser für Injektionszwecke und das beigepackte Rekonstitutionsset verwenden .
T-596	For reconstitution only the water for injections and the reconstitution device provided in the pack should be used .
H-596	-0.4725411534309387	Use only the enclosed water for injections and the enclosed reconstitution set to disperse .
D-596	-0.4725411534309387	Use only the enclosed water for injections and the enclosed reconstitution set to disperse .
P-596	-1.3548 -0.3419 -0.1329 -2.1051 -0.0786 -0.1099 -0.1654 -0.1677 -0.8139 -0.1739 -0.1328 -0.1033 -0.0689 -1.6711 -0.0608 -1.0588 -0.4424 -0.9479 -0.0231 -0.1433 -0.1462 -0.1531
S-125	Der Vitamin-D-Gehalt von ADROVANCE ist nicht zur Behandlung eines Vitamin-D-Mangels geeignet .
T-125	The content of vitamin D in ADROVANCE is not suitable for correction of vitamin D deficiency .
H-125	-0.27023300528526306	The vitamin D level of ADROVANCE is not suitable for the treatment of vitamin D deficiency .
D-125	-0.27023300528526306	The vitamin D level of ADROVANCE is not suitable for the treatment of vitamin D deficiency .
P-125	-0.5696 -1.6367 -0.0888 -0.1051 -1.3736 -0.3143 -0.0984 -0.0794 -0.1417 -0.0969 -0.0661 -0.1793 -0.2313 -0.3801 -0.3870 -0.1538 -0.1425 -0.1408 -0.0398 -0.1123 -0.0912 -0.0128 -0.0525 -0.2245 -0.1541 -0.1532
S-353	Zum Auflösen nur das beigepackte Wasser für Injektionszwecke und das beigepackte Rekonstitutionsset verwenden .
T-353	For reconstitution only the water for injections and the reconstitution device provided in the pack should be used .
H-353	-0.4725411534309387	Use only the enclosed water for injections and the enclosed reconstitution set to disperse .
D-353	-0.4725411534309387	Use only the enclosed water for injections and the enclosed reconstitution set to disperse .
P-353	-1.3548 -0.3419 -0.1329 -2.1051 -0.0786 -0.1099 -0.1654 -0.1677 -0.8139 -0.1739 -0.1328 -0.1033 -0.0689 -1.6711 -0.0608 -1.0588 -0.4424 -0.9479 -0.0231 -0.1433 -0.1462 -0.1531
S-49	Der Vitamin-D-Gehalt von ADROVANCE ist nicht zur Behandlung eines Vitamin-D-Mangels geeignet .
T-49	The content of vitamin D in ADROVANCE is not suitable for correction of vitamin D deficiency .
H-49	-0.27023300528526306	The vitamin D level of ADROVANCE is not suitable for the treatment of vitamin D deficiency .
D-49	-0.27023300528526306	The vitamin D level of ADROVANCE is not suitable for the treatment of vitamin D deficiency .
P-49	-0.5696 -1.6367 -0.0888 -0.1051 -1.3736 -0.3143 -0.0984 -0.0794 -0.1417 -0.0969 -0.0661 -0.1793 -0.2313 -0.3801 -0.3870 -0.1538 -0.1425 -0.1408 -0.0398 -0.1123 -0.0912 -0.0128 -0.0525 -0.2245 -0.1541 -0.1532
S-176	In Studien verursachten hohe Dosen bei Ratten ein vermehrtes Auftreten von unvollständiger Ossifikation bei den Feten .
T-176	In studies , rats given high doses showed an increased incidence of incomplete foetal ossification .
H-176	-0.3203606605529785	In studies , high doses in rats increased the occurrence of incomplete ossification in the foetus .
D-176	-0.3203606605529785	In studies , high doses in rats increased the occurrence of incomplete ossification in the foetus .
P-176	-0.3305 -0.1896 -0.2241 -0.3238 -0.0714 -0.1046 -0.1658 -0.0474 -2.9678 -0.1334 -1.0762 -0.0575 -0.0625 -0.1158 -0.1459 -0.1741 -0.2030 -0.1575 -0.1309 -0.1781 -0.3934 -0.3851 -0.0317 -0.3597 -0.1500 -0.1495
S-97	In Studien verursachten hohe Dosen bei Ratten ein vermehrtes Auftreten von unvollständiger Ossifikation bei den Feten .
T-97	In studies , rats given high doses showed an increased incidence of incomplete foetal ossification .
H-97	-0.3203606605529785	In studies , high doses in rats increased the occurrence of incomplete ossification in the foetus .
D-97	-0.3203606605529785	In studies , high doses in rats increased the occurrence of incomplete ossification in the foetus .
P-97	-0.3305 -0.1896 -0.2241 -0.3238 -0.0714 -0.1046 -0.1658 -0.0474 -2.9678 -0.1334 -1.0762 -0.0575 -0.0625 -0.1158 -0.1459 -0.1741 -0.2030 -0.1575 -0.1309 -0.1781 -0.3934 -0.3851 -0.0317 -0.3597 -0.1500 -0.1495
S-162	3,2 % in der 5.600-I.E.-Vitamin-D3-Gruppe . Der Anteil an Patientinnen mit
T-162	3.2 % in the Vitamin D3 5600 group through the 24-week extension .
H-162	-0.5806213617324829	3.2 % in the 5.600 IU vitamin D3 group .
D-162	-0.5806213617324829	3.2 % in the 5.600 IU vitamin D3 group .
P-162	-4.9299 -0.1614 -0.1337 -0.1852 -0.1370 -0.7682 -0.0396 -0.0851 -0.3336 -0.3395 -0.1603 -1.2282 -0.1457 -0.1942 -0.2257 -0.2227
S-515	Zum Auflösen nur das beigepackte Wasser für Injektionszwecke und das beigepackte Rekonstitutionsset verwenden .
T-515	For reconstitution only the water for injections and the reconstitution device provided in the pack should be used .
H-515	-0.4725411534309387	Use only the enclosed water for injections and the enclosed reconstitution set to disperse .
D-515	-0.4725411534309387	Use only the enclosed water for injections and the enclosed reconstitution set to disperse .
P-515	-1.3548 -0.3419 -0.1329 -2.1051 -0.0786 -0.1099 -0.1654 -0.1677 -0.8139 -0.1739 -0.1328 -0.1033 -0.0689 -1.6711 -0.0608 -1.0588 -0.4424 -0.9479 -0.0231 -0.1433 -0.1462 -0.1531
S-852	In Tierversuchen war weder Desloratadin noch die Kombination von Loratadin und Pseudoephedrin teratogen .
T-852	Neither desloratadine nor the combination of loratadine and pseudoephedrine were teratogenic in animal studies .
H-852	-0.23658928275108337	In animal experiments neither desloratadine nor the combination of loratadine and pseudoephedrine was teratogenic .
D-852	-0.23658928275108337	In animal experiments neither desloratadine nor the combination of loratadine and pseudoephedrine was teratogenic .
P-852	-0.3275 -0.0586 -0.7029 -0.1566 -1.0388 -0.1318 -0.0355 -0.1267 -0.5906 -0.1762 -0.0999 -0.1571 -0.0828 -0.1420 -0.1761 -0.1328 -0.4161 -0.2554 -0.2065 -0.1567 -0.2880 -0.1421 -0.0461 -0.1502 -0.1109 -0.1145 -0.1792 -0.0712 -0.1012 -0.7550 -0.4438 -0.1716 -0.1484 -0.1512
S-361	Die rekonstituierte Lösung durch langsames Zurückziehen des Kolbens in die Spritze aufziehen ( Abb.e ) .
T-361	Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Fig . e ) .
H-361	-0.3075307607650757	Pull the reconstituted solution into the syringe by slowly pulling the plunger back ( Fig.e ) .
D-361	-0.3075307607650757	Pull the reconstituted solution into the syringe by slowly pulling the plunger back ( Fig.e ) .
P-361	-0.6734 -0.0607 -0.6956 -0.2696 -0.0653 -0.1240 -0.1255 -0.4828 -0.1388 -0.0845 -0.0503 -0.0240 -0.1312 -0.2165 -0.4212 -1.1375 -0.0274 -0.0822 -0.0334 -0.1808 -1.5653 -0.7956 -0.1669 -0.1429 -0.1488 -0.1518
S-23	Alendronat ist ein Biphosphonat , das seit Mitte der 1990er Jahre gegen Osteoporose eingesetzt wird .
T-23	Vitamin D3 , along with other forms of vitamin D , is required for calcium absorption and normal bone formation .
H-23	-0.22617274522781372	Alendronate is a biphosphonate used to treat osteoporosis since the mid 1990s .
D-23	-0.22617274522781372	Alendronate is a biphosphonate used to treat osteoporosis since the mid 1990s .
P-23	-0.2120 -0.1661 -0.0892 -0.0819 -0.1349 -0.1280 -0.0864 -0.1060 -0.0511 -0.1452 -0.7098 -1.2382 -0.1246 -0.1207 -0.1111 -0.0956 -0.1176 -0.1047 -0.0812 -0.3041 -0.1422 -0.1555 -0.8465 -0.1508 -0.1512
S-757	Wie ADVATE angewendet wird ADVATE wird normalerweise vom Arzt in eine Vene ( intravenös ) verabreicht .
T-757	How ADVATE is given ADVATE is usually injected into a vein ( intravenously ) by your doctor or nurse .
H-757	-0.24998697638511658	How ADVATE is administered ADVATE is usually given by the doctor into a vein ( intravenously ) .
D-757	-0.24998697638511658	How ADVATE is administered ADVATE is usually given by the doctor into a vein ( intravenously ) .
P-757	-0.9081 -0.1008 -0.1879 -0.0956 -0.0783 -0.1479 -0.2710 -0.0929 -0.1303 -0.1751 -0.0898 -0.0956 -0.1107 -0.2097 -0.6771 -0.2652 -0.2817 -1.2148 -0.7980 -0.1618 -0.1545 -0.0401 -0.1325 -0.1506 -0.0900 -0.0802 -0.3108 -0.1477 -0.1480 -0.1531
S-118	Osteonekrose des Kiefers wurde auch bei Osteoporosepatienten unter oralen Bisphosphonaten berichtet .
T-118	Osteonecrosis of the jaw has also been reported in patients with osteoporosis receiving oral bisphosphonates .
H-118	-0.14936482906341553	Osteonecrosis of the jaw has also been reported with oral bisphosphonates in patients with osteoporosis .
D-118	-0.14936482906341553	Osteonecrosis of the jaw has also been reported with oral bisphosphonates in patients with osteoporosis .
P-118	-0.1677 -0.0833 -0.1240 -0.0656 -0.0371 -0.0877 -0.1398 -0.1217 -0.1226 -0.1290 -0.1211 -0.0950 -0.1502 -0.0970 -1.2519 -0.0660 -0.0862 -0.0390 -0.0557 -0.0825 -0.0874 -0.2778 -0.2050 -0.1930 -0.1231 -0.0628 -0.0971 -0.1455 -0.1089 -0.0604 -0.1445 -0.1510
S-42	Osteonekrose des Kiefers wurde auch bei Osteoporosepatienten unter oralen Bisphosphonaten berichtet .
T-42	Osteonecrosis of the jaw has also been reported in patients with osteoporosis receiving oral bisphosphonates .
H-42	-0.14936482906341553	Osteonecrosis of the jaw has also been reported with oral bisphosphonates in patients with osteoporosis .
D-42	-0.14936482906341553	Osteonecrosis of the jaw has also been reported with oral bisphosphonates in patients with osteoporosis .
P-42	-0.1677 -0.0833 -0.1240 -0.0656 -0.0371 -0.0877 -0.1398 -0.1217 -0.1226 -0.1290 -0.1211 -0.0950 -0.1502 -0.0970 -1.2519 -0.0660 -0.0862 -0.0390 -0.0557 -0.0825 -0.0874 -0.2778 -0.2050 -0.1930 -0.1231 -0.0628 -0.0971 -0.1455 -0.1089 -0.0604 -0.1445 -0.1510
S-823	Die Wirksamkeit von Aerinaze wurde in zwei Hauptstudien mit insgesamt 1 248 erwachsenen und jugendlichen Patienten untersucht .
T-823	The effectiveness of Aerinaze was assessed in two main studies involving a total of 1,248 adult and adolescent patients .
H-823	-0.23011921346187592	The effectiveness of Aerinaze has been examined in two main studies involving a total of 1,248 adult and adolescent patients .
D-823	-0.23011921346187592	The effectiveness of Aerinaze has been examined in two main studies involving a total of 1,248 adult and adolescent patients .
P-823	-0.2689 -0.6031 -0.1121 -0.1404 -0.1423 -0.1275 -0.1294 -0.1357 -0.1040 -0.3964 -0.1567 -1.7580 -0.1528 -0.1613 -0.3428 -0.1072 -0.1083 -0.1537 -0.1093 -0.1449 -0.2589 -0.1103 -0.1225 -0.1076 -0.1614 -0.3030 -0.1242 -0.2059 -0.0876 -0.1474 -0.1502
S-280	Die rekonstituierte Lösung durch langsames Zurückziehen des Kolbens in die Spritze aufziehen ( Abb.e ) .
T-280	Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Fig . e ) .
H-280	-0.3075307607650757	Pull the reconstituted solution into the syringe by slowly pulling the plunger back ( Fig.e ) .
D-280	-0.3075307607650757	Pull the reconstituted solution into the syringe by slowly pulling the plunger back ( Fig.e ) .
P-280	-0.6734 -0.0607 -0.6956 -0.2696 -0.0653 -0.1240 -0.1255 -0.4828 -0.1388 -0.0845 -0.0503 -0.0240 -0.1312 -0.2165 -0.4212 -1.1375 -0.0274 -0.0822 -0.0334 -0.1808 -1.5653 -0.7956 -0.1669 -0.1429 -0.1488 -0.1518
S-685	Die rekonstituierte Lösung durch langsames Zurückziehen des Kolbens in die Spritze aufziehen ( Abb.e ) .
T-685	Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Fig . e ) .
H-685	-0.3075307607650757	Pull the reconstituted solution into the syringe by slowly pulling the plunger back ( Fig.e ) .
D-685	-0.3075307607650757	Pull the reconstituted solution into the syringe by slowly pulling the plunger back ( Fig.e ) .
P-685	-0.6734 -0.0607 -0.6956 -0.2696 -0.0653 -0.1240 -0.1255 -0.4828 -0.1388 -0.0845 -0.0503 -0.0240 -0.1312 -0.2165 -0.4212 -1.1375 -0.0274 -0.0822 -0.0334 -0.1808 -1.5653 -0.7956 -0.1669 -0.1429 -0.1488 -0.1518
S-604	Die rekonstituierte Lösung durch langsames Zurückziehen des Kolbens in die Spritze aufziehen ( Abb.e ) .
T-604	Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Fig . e ) .
H-604	-0.3075307607650757	Pull the reconstituted solution into the syringe by slowly pulling the plunger back ( Fig.e ) .
D-604	-0.3075307607650757	Pull the reconstituted solution into the syringe by slowly pulling the plunger back ( Fig.e ) .
P-604	-0.6734 -0.0607 -0.6956 -0.2696 -0.0653 -0.1240 -0.1255 -0.4828 -0.1388 -0.0845 -0.0503 -0.0240 -0.1312 -0.2165 -0.4212 -1.1375 -0.0274 -0.0822 -0.0334 -0.1808 -1.5653 -0.7956 -0.1669 -0.1429 -0.1488 -0.1518
S-523	Die rekonstituierte Lösung durch langsames Zurückziehen des Kolbens in die Spritze aufziehen ( Abb.e ) .
T-523	Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Fig . e ) .
H-523	-0.3075307607650757	Pull the reconstituted solution into the syringe by slowly pulling the plunger back ( Fig.e ) .
D-523	-0.3075307607650757	Pull the reconstituted solution into the syringe by slowly pulling the plunger back ( Fig.e ) .
P-523	-0.6734 -0.0607 -0.6956 -0.2696 -0.0653 -0.1240 -0.1255 -0.4828 -0.1388 -0.0845 -0.0503 -0.0240 -0.1312 -0.2165 -0.4212 -1.1375 -0.0274 -0.0822 -0.0334 -0.1808 -1.5653 -0.7956 -0.1669 -0.1429 -0.1488 -0.1518
S-442	Die rekonstituierte Lösung durch langsames Zurückziehen des Kolbens in die Spritze aufziehen ( Abb.e ) .
T-442	Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Fig . e ) .
H-442	-0.3075307607650757	Pull the reconstituted solution into the syringe by slowly pulling the plunger back ( Fig.e ) .
D-442	-0.3075307607650757	Pull the reconstituted solution into the syringe by slowly pulling the plunger back ( Fig.e ) .
P-442	-0.6734 -0.0607 -0.6956 -0.2696 -0.0653 -0.1240 -0.1255 -0.4828 -0.1388 -0.0845 -0.0503 -0.0240 -0.1312 -0.2165 -0.4212 -1.1375 -0.0274 -0.0822 -0.0334 -0.1808 -1.5653 -0.7956 -0.1669 -0.1429 -0.1488 -0.1518
S-358	Wenn es Lösung und Behältnisse zulassen , sind Parenteralia vor der Verabreichung immer auf Schwebeteilchen zu überprüfen .
T-358	Parenteral medicinal products should be inspected for particulate matter prior to administration , whenever solution and container permit .
H-358	-0.3879649043083191	Always check for suspended particles before administration if the solution and containers allow .
D-358	-0.3879649043083191	Always check for suspended particles before administration if the solution and containers allow .
P-358	-0.9365 -0.0670 -0.0562 -0.5924 -1.4835 -0.6671 -0.1152 -0.5531 -0.1143 -1.2946 -0.2600 -0.0536 -0.2546 -0.0978 -0.0508 -0.1424 -0.2967 -0.1851 -0.1505
S-277	Wenn es Lösung und Behältnisse zulassen , sind Parenteralia vor der Verabreichung immer auf Schwebeteilchen zu überprüfen .
T-277	Parenteral medicinal products should be inspected for particulate matter prior to administration , whenever solution and container permit .
H-277	-0.3879649043083191	Always check for suspended particles before administration if the solution and containers allow .
D-277	-0.3879649043083191	Always check for suspended particles before administration if the solution and containers allow .
P-277	-0.9365 -0.0670 -0.0562 -0.5924 -1.4835 -0.6671 -0.1152 -0.5531 -0.1143 -1.2946 -0.2600 -0.0536 -0.2546 -0.0978 -0.0508 -0.1424 -0.2967 -0.1851 -0.1505
S-826	Die vollständige Auflistung der im Zusammenhang mit Aerinaze berichteten Nebenwirkungen ist der Packungsbeilage zu entnehmen .
T-826	For the full list of all side effects reported with Aerinaze , see the Package Leaflet .
H-826	-0.17270216345787048	For the full list of all side effects reported with Aerinaze , see the Package Leaflet .
D-826	-0.17270216345787048	For the full list of all side effects reported with Aerinaze , see the Package Leaflet .
P-826	-0.1765 -0.1954 -0.1177 -0.1459 -0.1360 -0.9964 -0.3499 -0.1003 -0.0617 -0.1181 -0.1403 -0.1277 -0.1299 -0.1251 -0.1003 -0.1259 -0.2596 -0.1419 -0.0804 -0.1242 -0.0500 -0.0523 -0.1184 -0.1919 -0.1516
S-214	Faktor VIII pro kg Körpergewicht die Faktor VIII-Aktivität im Plasma um 2 I.E.<unk> dl erhöht .
T-214	2 factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/ dl .
H-214	-0.3087306618690491	Factor VIII per kg bodyweight increases factor VIIII activity in plasma by 2 IU/ dl .
D-214	-0.3087306618690491	Factor VIII per kg bodyweight increases factor VIIII activity in plasma by 2 IU/ dl .
P-214	-0.3362 -0.1836 -0.0648 -0.1254 -0.0896 -0.5323 -0.0574 -0.3323 -1.2844 -0.4645 -1.7007 -0.0738 -0.1512 -0.1692 -0.0841 -0.0794 -0.1048 -0.1342 -0.1271 -0.1385 -0.1437 -0.0484 -0.8250 -0.1586
S-26	Die vollständige Auflistung der im Zusammenhang mit ADROVANCE berichteten Nebenwirkungen ist der Packungsbeilage zu entnehmen .
T-26	For the full list of all side effects reported with ADROVANCE , see the Package Leaflet .
H-26	-0.165723517537117	For the full list of all side effects reported with ADROVANCE , see the Package Leaflet .
D-26	-0.165723517537117	For the full list of all side effects reported with ADROVANCE , see the Package Leaflet .
P-26	-0.2165 -0.1781 -0.1317 -0.0934 -0.1382 -0.5884 -0.5995 -0.1084 -0.0873 -0.1406 -0.1087 -0.0912 -0.1496 -0.0967 -0.0500 -0.1471 -0.2657 -0.1480 -0.0725 -0.1228 -0.0539 -0.0507 -0.1223 -0.2280 -0.1535
S-520	Wenn es Lösung und Behältnisse zulassen , sind Parenteralia vor der Verabreichung immer auf Schwebeteilchen zu überprüfen .
T-520	Parenteral medicinal products should be inspected for particulate matter prior to administration , whenever solution and container permit .
H-520	-0.3879649043083191	Always check for suspended particles before administration if the solution and containers allow .
D-520	-0.3879649043083191	Always check for suspended particles before administration if the solution and containers allow .
P-520	-0.9365 -0.0670 -0.0562 -0.5924 -1.4835 -0.6671 -0.1152 -0.5531 -0.1143 -1.2946 -0.2600 -0.0536 -0.2546 -0.0978 -0.0508 -0.1424 -0.2967 -0.1851 -0.1505
S-832	Symptomatische Behandlung der saisonalen allergischen Rhinitis mit begleitender Nasenschleimhautschwellung .
T-832	Symptomatic treatment of seasonal allergic rhinitis when accompanied by nasal congestion .
H-832	-0.30271008610725403	Treatment of seasonal allergic rhinitis with associated nasal swelling .
D-832	-0.30271008610725403	Treatment of seasonal allergic rhinitis with associated nasal swelling .
P-832	-1.0288 -0.0519 -0.1167 -0.1594 -0.5082 -0.1065 -0.0537 -0.0812 -0.1184 -0.0632 -0.1113 -0.0718 -0.7791 -0.9478 -0.6489 -0.0201 -0.1938 -0.7060 -0.1295 -0.3016 -0.1591
S-809	Das Gen , welches das Virus in Advexin trägt , ist das normale ( nicht defekte ) p53-Gen .
T-809	The gene carried by the virus in Advexin is the normal ( non-defective ) p53 gene .
H-809	-0.2754017412662506	The gene that carries the virus in Advexin is the normal ( non-defective ) p53 gene .
D-809	-0.2754017412662506	The gene that carries the virus in Advexin is the normal ( non-defective ) p53 gene .
P-809	-0.1444 -0.1319 -1.4215 -0.4070 -0.1738 -0.1378 -0.2357 -0.4936 -0.1707 -0.1534 -0.1551 -0.2283 -0.0937 -0.2213 -0.9495 -0.4258 -0.2338 -0.1285 -0.1558 -0.1634 -0.0259 -0.0523 -0.1512 -0.1555
S-631	59 Dieses Arzneimittel enthält nach der Rekonstitution 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-631	After reconstitution this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-631	-0.3793463706970215	59 This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial as reconstituted .
D-631	-0.3793463706970215	59 This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial as reconstituted .
P-631	-2.0537 -0.2171 -0.0817 -0.0536 -0.1057 -0.7621 -1.2729 -0.1250 -0.1027 -0.1498 -0.1018 -0.0524 -0.0594 -0.1417 -0.1434 -0.0517 -0.1585 -0.0897 -0.0309 -0.0542 -0.9594 -2.5843 -0.0905 -0.1346 -0.1374 -0.1487
S-550	48 Dieses Arzneimittel enthält nach der Rekonstitution 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-550	After reconstitution this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-550	-0.2863351106643677	48 This medicinal product according to the reconstitution contains 0.45 mmol sodium ( 10 mg ) per vial .
D-550	-0.2863351106643677	48 This medicinal product according to the reconstitution contains 0.45 mmol sodium ( 10 mg ) per vial .
P-550	-0.3848 -0.2092 -0.0673 -0.0571 -0.1029 -2.9693 -0.1382 -0.7677 -1.1751 -0.0369 -0.1592 -0.1125 -0.1203 -0.0955 -0.1475 -0.1005 -0.0616 -0.0543 -0.1379 -0.1470 -0.0492 -0.1562 -0.0953 -0.0271 -0.0547 -0.1558 -0.1479
S-469	37 Dieses Arzneimittel enthält nach der Rekonstitution 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-469	After reconstitution this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-469	-0.3842509984970093	37 This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial as reconstituted .
D-469	-0.3842509984970093	37 This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial as reconstituted .
P-469	-1.7908 -0.1999 -0.0828 -0.0569 -0.1061 -0.9941 -1.4045 -0.1268 -0.1046 -0.1504 -0.1021 -0.0529 -0.0591 -0.1418 -0.1435 -0.0550 -0.1591 -0.0897 -0.0313 -0.0539 -1.0701 -2.5047 -0.0940 -0.1330 -0.1369 -0.1464
S-388	26 Dieses Arzneimittel enthält nach der Rekonstitution 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-388	After reconstitution this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-388	-0.31235310435295105	26 This medicinal product according to the reconstitution contains 0.45 mmol sodium ( 10 mg ) per vial .
D-388	-0.31235310435295105	26 This medicinal product according to the reconstitution contains 0.45 mmol sodium ( 10 mg ) per vial .
P-388	-0.8472 -0.2164 -0.0663 -0.0596 -0.1098 -3.3531 -0.1384 -0.5757 -1.2105 -0.0365 -0.1515 -0.1165 -0.1198 -0.0957 -0.1467 -0.1002 -0.0617 -0.0558 -0.1382 -0.1486 -0.0521 -0.1562 -0.0967 -0.0270 -0.0544 -0.1523 -0.1466
S-74	Vitamin D3 über bis zu 5 Monate nicht mit Hypercalciurie oder Hypercalcämie assoziiert .
T-74	In a clinical study of healthy adults a 4000 IU daily dose of vitamin D3 for up to five months was not associated with hypercalciuria or hypercalcaemia .
H-74	-0.16285760700702667	Vitamin D3 not associated with hypercalciuria or hypercalcaemia for up to 5 months .
D-74	-0.16285760700702667	Vitamin D3 not associated with hypercalciuria or hypercalcaemia for up to 5 months .
P-74	-0.1633 -0.0686 -0.1542 -0.1664 -0.7900 -0.2584 -0.1308 -0.0645 -0.1193 -0.1314 -0.0601 -0.1499 -0.1152 -0.0765 -0.0838 -0.1258 -0.0433 -0.1485 -0.2116 -0.0988 -0.1341 -0.1434 -0.1194 -0.3582 -0.1559
S-439	Wenn es Lösung und Behältnisse zulassen , sind Parenteralia vor der Verabreichung immer auf Schwebeteilchen zu überprüfen .
T-439	Parenteral medicinal products should be inspected for particulate matter prior to administration , whenever solution and container permit .
H-439	-0.3879649043083191	Always check for suspended particles before administration if the solution and containers allow .
D-439	-0.3879649043083191	Always check for suspended particles before administration if the solution and containers allow .
P-439	-0.9365 -0.0670 -0.0562 -0.5924 -1.4835 -0.6671 -0.1152 -0.5531 -0.1143 -1.2946 -0.2600 -0.0536 -0.2546 -0.0978 -0.0508 -0.1424 -0.2967 -0.1851 -0.1505
S-229	4 Dieses Arzneimittel enthält nach der Rekonstitution 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-229	After reconstitution this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-229	-0.3107471466064453	Following reconstitution , this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
D-229	-0.3107471466064453	Following reconstitution , this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
P-229	-4.5187 -0.5370 -0.0611 -0.3291 -0.1373 -0.1125 -0.0489 -0.0886 -0.2098 -0.1358 -0.1275 -0.1000 -0.1505 -0.1006 -0.0629 -0.0600 -0.1340 -0.1549 -0.0526 -0.1561 -0.0982 -0.0288 -0.0568 -0.1563 -0.1506
S-601	Wenn es Lösung und Behältnisse zulassen , sind Parenteralia vor der Verabreichung immer auf Schwebeteilchen zu überprüfen .
T-601	Parenteral medicinal products should be inspected for particulate matter prior to administration , whenever solution and container permit .
H-601	-0.3879649043083191	Always check for suspended particles before administration if the solution and containers allow .
D-601	-0.3879649043083191	Always check for suspended particles before administration if the solution and containers allow .
P-601	-0.9365 -0.0670 -0.0562 -0.5924 -1.4835 -0.6671 -0.1152 -0.5531 -0.1143 -1.2946 -0.2600 -0.0536 -0.2546 -0.0978 -0.0508 -0.1424 -0.2967 -0.1851 -0.1505
S-789	Norge Baxter AS Gjerdrumsvei 11 N-0486 Oslo Tlf : <unk> 47 22 58 4800
T-789	Norge Baxter AS Gjerdrumsvei 11 N-0486 Oslo Tlf : <<unk>> 47 22 58 4800
H-789	-0.11468837410211563	Norge Baxter AS Gjerdrumsvei 11 N-0486 Oslo Tlf : <unk> 47 22 58 4800
D-789	-0.11468837410211563	Norge Baxter AS Gjerdrumsvei 11 N-0486 Oslo Tlf : <unk> 47 22 58 4800
P-789	-0.0771 -0.0901 -0.1241 -0.1378 -0.1641 -0.0517 -0.1320 -0.1222 -0.0955 -0.1770 -0.1476 -0.1908 -0.1708 -0.1053 -0.1151 -0.0452 -0.0923 -0.1276 -0.1414 -0.0927 -0.1230 -0.1452 -0.0279 -0.0778 -0.0683 -0.0937 -0.1397 -0.0867 -0.1631
S-498	Da keine Kompatibilitätsstudien durchgeführt wurden , darf dieses Arzneimittel nicht mit anderen Arzneimitteln oder Lösungsmitteln gemischt werden .
T-498	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
H-498	-0.13692644238471985	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
D-498	-0.13692644238471985	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
P-498	-0.1304 -0.1463 -0.0630 -0.1425 -0.1234 -0.0825 -0.0921 -0.0640 -0.1510 -0.1278 -0.0445 -0.0627 -0.1666 -0.3105 -0.1400 -0.1207 -0.2651 -0.1474 -0.2096 -0.1390 -0.0732 -0.2163 -0.1141 -0.1919 -0.1102 -0.1040 -0.1468 -0.1485
S-150	Vitamin D3 über bis zu 5 Monate nicht mit Hypercalciurie oder Hypercalcämie assoziiert .
T-150	In a clinical study of healthy adults a 4000 IU daily dose of vitamin D3 for up to five months was not associated with hypercalciuria or hypercalcaemia .
H-150	-0.16285760700702667	Vitamin D3 not associated with hypercalciuria or hypercalcaemia for up to 5 months .
D-150	-0.16285760700702667	Vitamin D3 not associated with hypercalciuria or hypercalcaemia for up to 5 months .
P-150	-0.1633 -0.0686 -0.1542 -0.1664 -0.7900 -0.2584 -0.1308 -0.0645 -0.1193 -0.1314 -0.0601 -0.1499 -0.1152 -0.0765 -0.0838 -0.1258 -0.0433 -0.1485 -0.2116 -0.0988 -0.1341 -0.1434 -0.1194 -0.3582 -0.1559
S-790	Eesti AS Oriola Kungla 2 EE-76505 Saue Tel . : <unk> 372 6 515 100
T-790	Eesti AS Oriola Kungla 2 EE-76505 Saue Tel . : <<unk>> 372 6 515 100
H-790	-0.11436134576797485	Eesti AS Oriola Kungla 2 EE-76505 Saue Tel . : <unk> 372 6 515 100
D-790	-0.11436134576797485	Eesti AS Oriola Kungla 2 EE-76505 Saue Tel . : <unk> 372 6 515 100
P-790	-0.1143 -0.0918 -0.1371 -0.0426 -0.1032 -0.2153 -0.1284 -0.0881 -0.1283 -0.1255 -0.1172 -0.1030 -0.1076 -0.0799 -0.0774 -0.1314 -0.0414 -0.1404 -0.0700 -0.1653 -0.1408 -0.0495 -0.1393 -0.0742 -0.1425 -0.1266 -0.1522 -0.1198 -0.1635
S-824	In beiden Studien wurde Aerinaze mit Desloratadin allein und mit Pseudoephedrin allein verglichen .
T-824	In both studies , Aerinaze was compared with desloratadine alone and with pseudoephedrine alone .
H-824	-0.2454090714454651	In both studies , Aerinaze was compared to desloratadine alone and to pseudoephedrine alone .
D-824	-0.2454090714454651	In both studies , Aerinaze was compared to desloratadine alone and to pseudoephedrine alone .
P-824	-1.1916 -0.0956 -0.1680 -0.4118 -0.2694 -0.1269 -0.1206 -0.1167 -0.0938 -0.1426 -0.1106 -0.6707 -0.6455 -0.0439 -0.1244 -0.3330 -0.2598 -0.6582 -0.1467 -0.1907 -0.1440 -0.2944 -0.1520 -0.0476 -0.1548 -0.1016 -0.1020 -0.1451 -0.1502 -0.1502
S-579	Da keine Kompatibilitätsstudien durchgeführt wurden , darf dieses Arzneimittel nicht mit anderen Arzneimitteln oder Lösungsmitteln gemischt werden .
T-579	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
H-579	-0.13692644238471985	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
D-579	-0.13692644238471985	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
P-579	-0.1304 -0.1463 -0.0630 -0.1425 -0.1234 -0.0825 -0.0921 -0.0640 -0.1510 -0.1278 -0.0445 -0.0627 -0.1666 -0.3105 -0.1400 -0.1207 -0.2651 -0.1474 -0.2096 -0.1390 -0.0732 -0.2163 -0.1141 -0.1919 -0.1102 -0.1040 -0.1468 -0.1485
S-682	Wenn es Lösung und Behältnisse zulassen , sind Parenteralia vor der Verabreichung immer auf Schwebeteilchen zu überprüfen .
T-682	Parenteral medicinal products should be inspected for particulate matter prior to administration , whenever solution and container permit .
H-682	-0.3879649043083191	Always check for suspended particles before administration if the solution and containers allow .
D-682	-0.3879649043083191	Always check for suspended particles before administration if the solution and containers allow .
P-682	-0.9365 -0.0670 -0.0562 -0.5924 -1.4835 -0.6671 -0.1152 -0.5531 -0.1143 -1.2946 -0.2600 -0.0536 -0.2546 -0.0978 -0.0508 -0.1424 -0.2967 -0.1851 -0.1505
S-660	Da keine Kompatibilitätsstudien durchgeführt wurden , darf dieses Arzneimittel nicht mit anderen Arzneimitteln oder Lösungsmitteln gemischt werden .
T-660	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
H-660	-0.13692644238471985	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
D-660	-0.13692644238471985	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
P-660	-0.1304 -0.1463 -0.0630 -0.1425 -0.1234 -0.0825 -0.0921 -0.0640 -0.1510 -0.1278 -0.0445 -0.0627 -0.1666 -0.3105 -0.1400 -0.1207 -0.2651 -0.1474 -0.2096 -0.1390 -0.0732 -0.2163 -0.1141 -0.1919 -0.1102 -0.1040 -0.1468 -0.1485
S-57	Antikonvulsiva , Cimetidin und Thiazide können den Abbaustoffwechsel von Vitamin D verstärken .
T-57	Anticonvulsants , cimetidine and thiazides may increase the catabolism of vitamin D.
H-57	-0.26726454496383667	Anticonvulsants , cimetidine and thiazides may increase the metabolism of vitamin D .
D-57	-0.26726454496383667	Anticonvulsants , cimetidine and thiazides may increase the metabolism of vitamin D .
P-57	-0.2121 -0.1092 -0.0133 -0.1901 -0.1587 -0.1512 -0.2022 -0.1368 -0.1887 -0.1007 -0.1469 -0.2264 -0.0793 -0.1012 -0.0805 -0.3096 -0.2214 -0.8390 -0.3884 -2.3491 -0.0282 -0.1159 -0.1435 -0.1205 -0.1104 -0.3792 -0.2273 -0.1538
S-417	Da keine Kompatibilitätsstudien durchgeführt wurden , darf dieses Arzneimittel nicht mit anderen Arzneimitteln oder Lösungsmitteln gemischt werden .
T-417	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
H-417	-0.13692644238471985	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
D-417	-0.13692644238471985	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
P-417	-0.1304 -0.1463 -0.0630 -0.1425 -0.1234 -0.0825 -0.0921 -0.0640 -0.1510 -0.1278 -0.0445 -0.0627 -0.1666 -0.3105 -0.1400 -0.1207 -0.2651 -0.1474 -0.2096 -0.1390 -0.0732 -0.2163 -0.1141 -0.1919 -0.1102 -0.1040 -0.1468 -0.1485
S-336	Da keine Kompatibilitätsstudien durchgeführt wurden , darf dieses Arzneimittel nicht mit anderen Arzneimitteln oder Lösungsmitteln gemischt werden .
T-336	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
H-336	-0.13692644238471985	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
D-336	-0.13692644238471985	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
P-336	-0.1304 -0.1463 -0.0630 -0.1425 -0.1234 -0.0825 -0.0921 -0.0640 -0.1510 -0.1278 -0.0445 -0.0627 -0.1666 -0.3105 -0.1400 -0.1207 -0.2651 -0.1474 -0.2096 -0.1390 -0.0732 -0.2163 -0.1141 -0.1919 -0.1102 -0.1040 -0.1468 -0.1485
S-255	Da keine Kompatibilitätsstudien durchgeführt wurden , darf dieses Arzneimittel nicht mit anderen Arzneimitteln oder Lösungsmitteln gemischt werden .
T-255	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
H-255	-0.13692644238471985	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
D-255	-0.13692644238471985	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
P-255	-0.1304 -0.1463 -0.0630 -0.1425 -0.1234 -0.0825 -0.0921 -0.0640 -0.1510 -0.1278 -0.0445 -0.0627 -0.1666 -0.3105 -0.1400 -0.1207 -0.2651 -0.1474 -0.2096 -0.1390 -0.0732 -0.2163 -0.1141 -0.1919 -0.1102 -0.1040 -0.1468 -0.1485
S-133	Antikonvulsiva , Cimetidin und Thiazide können den Abbaustoffwechsel von Vitamin D verstärken .
T-133	Anticonvulsants , cimetidine and thiazides may increase the catabolism of vitamin D.
H-133	-0.26726454496383667	Anticonvulsants , cimetidine and thiazides may increase the metabolism of vitamin D .
D-133	-0.26726454496383667	Anticonvulsants , cimetidine and thiazides may increase the metabolism of vitamin D .
P-133	-0.2121 -0.1092 -0.0133 -0.1901 -0.1587 -0.1512 -0.2022 -0.1368 -0.1887 -0.1007 -0.1469 -0.2264 -0.0793 -0.1012 -0.0805 -0.3096 -0.2214 -0.8390 -0.3884 -2.3491 -0.0282 -0.1159 -0.1435 -0.1205 -0.1104 -0.3792 -0.2273 -0.1538
S-307	15 Dieses Arzneimittel enthält nach der Rekonstitution 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-307	After reconstitution this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-307	-0.3548096716403961	This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial as reconstituted .
D-307	-0.3548096716403961	This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial as reconstituted .
P-307	-1.2555 -0.0483 -0.0614 -0.1058 -0.4522 -1.4232 -0.1243 -0.1038 -0.1496 -0.1035 -0.0535 -0.0595 -0.1413 -0.1455 -0.0552 -0.1583 -0.0915 -0.0315 -0.0545 -1.0302 -2.7097 -0.0931 -0.1342 -0.1370 -0.1475
S-121	Nach Markteinführung waren diese Symptome selten schwerwiegend und<unk> oder mit Einschränkungen der Beweglichkeit verbunden ( siehe Abschnitt 4.8 ) .
T-121	In post-marketing experience , these symptoms have rarely been severe and/ or incapacitating ( see section 4.8 ) .
H-121	-0.3607610762119293	Post-marketing symptoms were rarely severe and/ or associated with mobility impairment ( see section 4.8 ) .
D-121	-0.3607610762119293	Post-marketing symptoms were rarely severe and/ or associated with mobility impairment ( see section 4.8 ) .
P-121	-1.1351 -0.1767 -0.0249 -0.9961 -0.7318 -0.2495 -0.4376 -0.1145 -0.0675 -0.1521 -0.4807 -0.1199 -1.4390 -0.1921 -1.3528 -0.0867 -0.0431 -0.3347 -0.1498 -0.2778 -0.1116 -0.1166 -0.1331 -0.1500 -0.1535 -0.1527
S-45	Nach Markteinführung waren diese Symptome selten schwerwiegend und<unk> oder mit Einschränkungen der Beweglichkeit verbunden ( siehe Abschnitt 4.8 ) .
T-45	In post-marketing experience , these symptoms have rarely been severe and/ or incapacitating ( see section 4.8 ) .
H-45	-0.3607610762119293	Post-marketing symptoms were rarely severe and/ or associated with mobility impairment ( see section 4.8 ) .
D-45	-0.3607610762119293	Post-marketing symptoms were rarely severe and/ or associated with mobility impairment ( see section 4.8 ) .
P-45	-1.1351 -0.1767 -0.0249 -0.9961 -0.7318 -0.2495 -0.4376 -0.1145 -0.0675 -0.1521 -0.4807 -0.1199 -1.4390 -0.1921 -1.3528 -0.0867 -0.0431 -0.3347 -0.1498 -0.2778 -0.1116 -0.1166 -0.1331 -0.1500 -0.1535 -0.1527
S-81	Ein Mangel steht in Verbindung mit einer negativen Calciumbilanz , Knochenverlust und einem erhöhten Risiko für Skelettfrakturen .
T-81	Insufficiency is associated with negative calcium balance , bone loss , and increased risk of skeletal fracture .
H-81	-0.23397734761238098	Deficiency is associated with negative calcium balance , bone loss , and an increased risk of skeletal fractures .
D-81	-0.23397734761238098	Deficiency is associated with negative calcium balance , bone loss , and an increased risk of skeletal fractures .
P-81	-0.0417 -0.0624 -0.1370 -0.8657 -0.1886 -0.1208 -0.5020 -0.0260 -0.0865 -0.1173 -0.5089 -0.1667 -0.0490 -0.0784 -0.6588 -0.1269 -1.0299 -0.0538 -0.1208 -0.1565 -0.0996 -0.0748 -0.0396 -0.1188 -0.7449 -0.0741 -0.1507 -0.1515
S-169	Das mittlere Steady-State-Volumen der Verteilung beträgt , den Knochen ausgenommen , mindestens 28 Liter beim Menschen .
T-169	The mean steady-state volume of distribution , exclusive of bone , is at least 28 litres in humans .
H-169	-0.3362051248550415	The mean steady state volume of distribution in man , excluding bone , is at least 28 litres .
D-169	-0.3362051248550415	The mean steady state volume of distribution in man , excluding bone , is at least 28 litres .
P-169	-0.1876 -0.3061 -0.9347 -0.1510 -0.0575 -0.1586 -0.2147 -0.2213 -0.6912 -0.4680 -1.7254 -0.1436 -0.3364 -0.2076 -0.1345 -0.1497 -0.1198 -0.0959 -0.3476 -0.6638 -0.1194 -0.1474 -0.1509
S-158	Ein Mangel steht in Verbindung mit einer negativen Calciumbilanz , Knochenverlust und einem erhöhten Risiko für Skelettfrakturen .
T-158	Insufficiency is associated with negative calcium balance , bone loss , and increased risk of skeletal fracture .
H-158	-0.23397734761238098	Deficiency is associated with negative calcium balance , bone loss , and an increased risk of skeletal fractures .
D-158	-0.23397734761238098	Deficiency is associated with negative calcium balance , bone loss , and an increased risk of skeletal fractures .
P-158	-0.0417 -0.0624 -0.1370 -0.8657 -0.1886 -0.1208 -0.5020 -0.0260 -0.0865 -0.1173 -0.5089 -0.1667 -0.0490 -0.0784 -0.6588 -0.1269 -1.0299 -0.0538 -0.1208 -0.1565 -0.0996 -0.0748 -0.0396 -0.1188 -0.7449 -0.0741 -0.1507 -0.1515
S-2	Bei der Hyperurikämie können sich Uratkristalle bilden und in den Gelenken und Nieren ablagern .
T-2	Hyperuricaemia can lead to urate crystals forming and building up in the joints and the kidneys .
H-2	-0.34612926840782166	In hyperuricaemia , urine crystals may form and deposit in the joints and kidneys .
D-2	-0.34612926840782166	In hyperuricaemia , urine crystals may form and deposit in the joints and kidneys .
P-2	-1.8749 -0.0667 -0.0830 -0.2881 -0.0317 -0.1255 -0.4082 -2.1087 -0.4410 -0.0555 -0.0328 -0.1054 -0.8166 -0.4680 -0.1385 -0.6861 -0.1635 -0.1418 -0.0820 -0.0448 -0.1437 -0.1319 -0.2264 -0.0421 -0.1427 -0.1498
S-829	Jede Tablette enthält 2,5 mg Desloratadin und 120 mg Pseudoephedrin ( als Sulfat ) .
T-829	Each tablet contains 2.5 mg desloratadine and 120 mg pseudoephedrine ( as sulphate ) .
H-829	-0.16867877542972565	Each tablet contains 2.5 mg desloratadine and 120 mg pseudoephedrine ( as sulphate ) .
D-829	-0.16867877542972565	Each tablet contains 2.5 mg desloratadine and 120 mg pseudoephedrine ( as sulphate ) .
P-829	-0.0233 -0.1332 -0.0905 -0.0776 -0.0767 -0.0746 -0.7771 -0.0575 -0.1177 -0.3896 -0.2677 -0.1446 -0.0784 -0.0477 -0.1626 -0.3413 -0.1471 -0.0517 -0.1677 -0.1333 -0.1295 -0.1317 -0.2942 -0.2346 -0.1502 -0.1442 -0.1503 -0.1447 -0.1524
S-834	Überempfindlichkeit gegen den Wirkstoff , einen der sonstigen Bestandteile , adrenergen Wirkstoffen oder Loratadin .
T-834	Hypersensitivity to the active substance , to any of the excipients , to adrenergic agents or to loratadine .
H-834	-0.22455744445323944	Hypersensitivity to the active substance , to any of the excipients , to adrenergic agents , or to loratadine .
D-834	-0.22455744445323944	Hypersensitivity to the active substance , to any of the excipients , to adrenergic agents , or to loratadine .
P-834	-0.0566 -0.0509 -0.0471 -0.0644 -0.1620 -0.2696 -0.1062 -0.0623 -0.1672 -0.2612 -0.1974 -0.1505 -0.1381 -0.0905 -0.0672 -0.0928 -0.1113 -0.1593 -1.5230 -0.2310 -0.0594 -0.1076 -0.1108 -0.2198 -0.7288 -0.0967 -0.1571 -0.0634 -0.1119 -0.4044 -1.0356 -0.1515 -0.1548
S-807	Advexin hätte zur Behandlung von Li-Fraumeni-Krebs bei Patienten ab einem Alter von 18 Jahren angewendet werden sollen .
T-807	Advexin was expected to be used to treat Li-Fraumeni cancer in patients from the age of 18 years .
H-807	-0.37469998002052307	Advexin should have been used to treat Li-Fraumeni cancer in patients from the age of 18 years .
D-807	-0.37469998002052307	Advexin should have been used to treat Li-Fraumeni cancer in patients from the age of 18 years .
P-807	-0.7151 -0.1548 -0.1458 -0.1892 -0.1277 -0.1396 -0.1299 -0.1524 -0.1327 -3.0565 -0.1349 -0.2747 -0.0240 -0.1776 -0.4057 -0.1377 -0.0907 -1.4968 -0.5194 -0.1322 -0.1488 -0.1157 -0.2163 -0.3988 -0.1504
S-8	Der in Adenuric enthaltene Wirkstoff Feboxustat vermindert die Bildung von Harnsäure .
T-8	The active substance in Adenuric , feboxustat , reduces the formation of uric acid .
H-8	-0.275533527135849	Feboxustat , the active substance in Adenuric , decreases the formation of uric acid .
D-8	-0.275533527135849	Feboxustat , the active substance in Adenuric , decreases the formation of uric acid .
P-8	-0.4030 -0.0985 -0.1501 -0.5076 -0.1122 -0.2984 -0.6000 -0.0863 -0.0783 -0.6701 -0.1527 -0.1273 -0.0689 -0.1261 -0.1584 -1.7130 -0.1010 -0.3803 -0.3964 -0.1412 -0.0416 -0.0845 -0.0866 -0.1519 -0.1538
S-89	Das mittlere Steady-State-Volumen der Verteilung beträgt , den Knochen ausgenommen , mindestens 28 Liter beim Menschen .
T-89	The mean steady-state volume of distribution , exclusive of bone , is at least 28 litres in humans .
H-89	-0.3362051248550415	The mean steady state volume of distribution in man , excluding bone , is at least 28 litres .
D-89	-0.3362051248550415	The mean steady state volume of distribution in man , excluding bone , is at least 28 litres .
P-89	-0.1876 -0.3061 -0.9347 -0.1510 -0.0575 -0.1586 -0.2147 -0.2213 -0.6912 -0.4680 -1.7254 -0.1436 -0.3364 -0.2076 -0.1345 -0.1497 -0.1198 -0.0959 -0.3476 -0.6638 -0.1194 -0.1474 -0.1509
S-220	Die Dosis und Häufigkeit der Verabreichung sollen entsprechend der klinischen Wirksamkeit des Produktes im Einzelfall angepasst werden .
T-220	The dose and frequency of administration should be adapted to the clinical response in the individual case .
H-220	-0.25603580474853516	The dose and frequency of administration should be adjusted on a case by case basis in accordance with the clinical efficacy of the product .
D-220	-0.25603580474853516	The dose and frequency of administration should be adjusted on a case by case basis in accordance with the clinical efficacy of the product .
P-220	-0.3153 -0.2707 -0.1420 -0.0637 -0.0837 -0.1382 -0.1685 -0.1226 -0.1591 -0.1138 -0.2872 -0.9232 -0.0127 -0.5640 -0.1496 -0.0680 -0.9395 -1.1929 -0.1007 -0.1459 -0.1372 -0.1254 -0.6150 -0.0635 -0.1166 -0.1393 -0.1335 -0.0877 -0.1535 -0.1482
S-597	Den weißen Dorn des BAXJECTs II durch den Gummistopfen der ADVATE-Flasche drücken .
T-597	Insert the white plastic spike through the ADVATE stopper .
H-597	-0.3025636374950409	Press the white mandrel of BAXJECT II through the rubber stopper of the ADVATE bottle .
D-597	-0.3025636374950409	Press the white mandrel of BAXJECT II through the rubber stopper of the ADVATE bottle .
P-597	-1.2412 -0.1500 -0.3171 -1.0928 -0.1200 -0.4957 -0.9315 -0.1280 -0.2182 -0.0642 -0.1366 -0.1110 -0.2241 -0.1385 -0.0892 -0.2632 -0.1119 -0.5878 -0.1399 -0.3118 -0.1803 -0.2945 -0.1024 -0.1161 -0.1461 -0.1546
S-516	Den weißen Dorn des BAXJECTs II durch den Gummistopfen der ADVATE-Flasche drücken .
T-516	Insert the white plastic spike through the ADVATE stopper .
H-516	-0.3025636374950409	Press the white mandrel of BAXJECT II through the rubber stopper of the ADVATE bottle .
D-516	-0.3025636374950409	Press the white mandrel of BAXJECT II through the rubber stopper of the ADVATE bottle .
P-516	-1.2412 -0.1500 -0.3171 -1.0928 -0.1200 -0.4957 -0.9315 -0.1280 -0.2182 -0.0642 -0.1366 -0.1110 -0.2241 -0.1385 -0.0892 -0.2632 -0.1119 -0.5878 -0.1399 -0.3118 -0.1803 -0.2945 -0.1024 -0.1161 -0.1461 -0.1546
S-298	Die Dosis und Häufigkeit der Verabreichung sollen entsprechend der klinischen Wirksamkeit des Produktes im Einzelfall angepasst werden .
T-298	The dose and frequency of administration should be adapted to the clinical response in the individual case .
H-298	-0.25603580474853516	The dose and frequency of administration should be adjusted on a case by case basis in accordance with the clinical efficacy of the product .
D-298	-0.25603580474853516	The dose and frequency of administration should be adjusted on a case by case basis in accordance with the clinical efficacy of the product .
P-298	-0.3153 -0.2707 -0.1420 -0.0637 -0.0837 -0.1382 -0.1685 -0.1226 -0.1591 -0.1138 -0.2872 -0.9232 -0.0127 -0.5640 -0.1496 -0.0680 -0.9395 -1.1929 -0.1007 -0.1459 -0.1372 -0.1254 -0.6150 -0.0635 -0.1166 -0.1393 -0.1335 -0.0877 -0.1535 -0.1482
S-270	Die Öffnung nach unten drehen und den durchsichtigen Plastikdorn durch den Gummistopfen der Lösungsmittelflasche drücken .
T-270	Turn the package over and insert the clear plastic spike through the solvent stopper .
H-270	-0.3846435844898224	Turn the opening downwards and push the transparent plastic mandrel through the rubber stopper on the solvent bottle .
D-270	-0.3846435844898224	Turn the opening downwards and push the transparent plastic mandrel through the rubber stopper on the solvent bottle .
P-270	-0.7369 -0.1313 -0.1792 -1.2614 -0.7253 -0.2943 -0.1483 -1.3270 -0.1585 -0.4754 -0.3227 -1.0168 -0.2136 -0.1984 -0.1477 -0.0918 -0.0781 -0.1121 -0.4965 -0.1441 -0.5572 -0.3964 -0.1036 -0.1480 -0.1511
S-432	Die Öffnung nach unten drehen und den durchsichtigen Plastikdorn durch den Gummistopfen der Lösungsmittelflasche drücken .
T-432	Turn the package over and insert the clear plastic spike through the solvent stopper .
H-432	-0.3846435844898224	Turn the opening downwards and push the transparent plastic mandrel through the rubber stopper on the solvent bottle .
D-432	-0.3846435844898224	Turn the opening downwards and push the transparent plastic mandrel through the rubber stopper on the solvent bottle .
P-432	-0.7369 -0.1313 -0.1792 -1.2614 -0.7253 -0.2943 -0.1483 -1.3270 -0.1585 -0.4754 -0.3227 -1.0168 -0.2136 -0.1984 -0.1477 -0.0918 -0.0781 -0.1121 -0.4965 -0.1441 -0.5572 -0.3964 -0.1036 -0.1480 -0.1511
S-678	Den weißen Dorn des BAXJECTs II durch den Gummistopfen der ADVATE-Flasche drücken .
T-678	Insert the white plastic spike through the ADVATE stopper .
H-678	-0.3025636374950409	Press the white mandrel of BAXJECT II through the rubber stopper of the ADVATE bottle .
D-678	-0.3025636374950409	Press the white mandrel of BAXJECT II through the rubber stopper of the ADVATE bottle .
P-678	-1.2412 -0.1500 -0.3171 -1.0928 -0.1200 -0.4957 -0.9315 -0.1280 -0.2182 -0.0642 -0.1366 -0.1110 -0.2241 -0.1385 -0.0892 -0.2632 -0.1119 -0.5878 -0.1399 -0.3118 -0.1803 -0.2945 -0.1024 -0.1161 -0.1461 -0.1546
S-351	Die Öffnung nach unten drehen und den durchsichtigen Plastikdorn durch den Gummistopfen der Lösungsmittelflasche drücken .
T-351	Turn the package over and insert the clear plastic spike through the solvent stopper .
H-351	-0.3846435844898224	Turn the opening downwards and push the transparent plastic mandrel through the rubber stopper on the solvent bottle .
D-351	-0.3846435844898224	Turn the opening downwards and push the transparent plastic mandrel through the rubber stopper on the solvent bottle .
P-351	-0.7369 -0.1313 -0.1792 -1.2614 -0.7253 -0.2943 -0.1483 -1.3270 -0.1585 -0.4754 -0.3227 -1.0168 -0.2136 -0.1984 -0.1477 -0.0918 -0.0781 -0.1121 -0.4965 -0.1441 -0.5572 -0.3964 -0.1036 -0.1480 -0.1511
S-435	Den weißen Dorn des BAXJECTs II durch den Gummistopfen der ADVATE-Flasche drücken .
T-435	Insert the white plastic spike through the ADVATE stopper .
H-435	-0.3025636374950409	Press the white mandrel of BAXJECT II through the rubber stopper of the ADVATE bottle .
D-435	-0.3025636374950409	Press the white mandrel of BAXJECT II through the rubber stopper of the ADVATE bottle .
P-435	-1.2412 -0.1500 -0.3171 -1.0928 -0.1200 -0.4957 -0.9315 -0.1280 -0.2182 -0.0642 -0.1366 -0.1110 -0.2241 -0.1385 -0.0892 -0.2632 -0.1119 -0.5878 -0.1399 -0.3118 -0.1803 -0.2945 -0.1024 -0.1161 -0.1461 -0.1546
S-354	Den weißen Dorn des BAXJECTs II durch den Gummistopfen der ADVATE-Flasche drücken .
T-354	Insert the white plastic spike through the ADVATE stopper .
H-354	-0.3025636374950409	Press the white mandrel of BAXJECT II through the rubber stopper of the ADVATE bottle .
D-354	-0.3025636374950409	Press the white mandrel of BAXJECT II through the rubber stopper of the ADVATE bottle .
P-354	-1.2412 -0.1500 -0.3171 -1.0928 -0.1200 -0.4957 -0.9315 -0.1280 -0.2182 -0.0642 -0.1366 -0.1110 -0.2241 -0.1385 -0.0892 -0.2632 -0.1119 -0.5878 -0.1399 -0.3118 -0.1803 -0.2945 -0.1024 -0.1161 -0.1461 -0.1546
S-273	Den weißen Dorn des BAXJECTs II durch den Gummistopfen der ADVATE-Flasche drücken .
T-273	Insert the white plastic spike through the ADVATE stopper .
H-273	-0.3025636374950409	Press the white mandrel of BAXJECT II through the rubber stopper of the ADVATE bottle .
D-273	-0.3025636374950409	Press the white mandrel of BAXJECT II through the rubber stopper of the ADVATE bottle .
P-273	-1.2412 -0.1500 -0.3171 -1.0928 -0.1200 -0.4957 -0.9315 -0.1280 -0.2182 -0.0642 -0.1366 -0.1110 -0.2241 -0.1385 -0.0892 -0.2632 -0.1119 -0.5878 -0.1399 -0.3118 -0.1803 -0.2945 -0.1024 -0.1161 -0.1461 -0.1546
S-379	Die Dosis und Häufigkeit der Verabreichung sollen entsprechend der klinischen Wirksamkeit des Produktes im Einzelfall angepasst werden .
T-379	The dose and frequency of administration should be adapted to the clinical response in the individual case .
H-379	-0.25603580474853516	The dose and frequency of administration should be adjusted on a case by case basis in accordance with the clinical efficacy of the product .
D-379	-0.25603580474853516	The dose and frequency of administration should be adjusted on a case by case basis in accordance with the clinical efficacy of the product .
P-379	-0.3153 -0.2707 -0.1420 -0.0637 -0.0837 -0.1382 -0.1685 -0.1226 -0.1591 -0.1138 -0.2872 -0.9232 -0.0127 -0.5640 -0.1496 -0.0680 -0.9395 -1.1929 -0.1007 -0.1459 -0.1372 -0.1254 -0.6150 -0.0635 -0.1166 -0.1393 -0.1335 -0.0877 -0.1535 -0.1482
S-170	Biotransformation Es gibt keine Hinweise darauf , dass Alendronat beim Tier oder beim Menschen metabolisiert wird .
T-170	Biotransformation There is no evidence that alendronate is metabolised in animals or humans .
H-170	-0.18972571194171906	Biotransformation There is no evidence that alendronate is metabolised in animals or humans .
D-170	-0.18972571194171906	Biotransformation There is no evidence that alendronate is metabolised in animals or humans .
P-170	-0.2790 -0.0944 -0.0556 -0.1188 -0.0937 -1.0804 -0.2484 -0.1448 -0.1113 -0.1300 -0.1532 -0.1356 -0.0997 -0.0713 -0.1479 -0.1007 -0.0809 -0.1246 -0.3167 -0.3805 -0.1187 -0.1708 -0.1414 -0.1551
S-154	Bei unzureichender Sonnenbestrahlung ist es essenziell , dass Vitamin D3 ein Bestandteil der Nahrung ist .
T-154	In the absence of adequate sunlight exposure , vitamin D3 is an essential dietary nutrient .
H-154	-0.45560774207115173	In case of insufficient exposure to the sun , it is essential that vitamin D3 is included in the diet .
D-154	-0.45560774207115173	In case of insufficient exposure to the sun , it is essential that vitamin D3 is included in the diet .
P-154	-0.9871 -1.0999 -0.1559 -0.0756 -1.0280 -2.2202 -0.1712 -0.2936 -0.1052 -0.3116 -0.1705 -0.1399 -0.3790 -0.2085 -0.0803 -0.0934 -0.1473 -0.1604 -0.2052 -1.5519 -0.1390 -0.7333 -0.6233 -0.1584 -0.1513
S-767	Schwere Nebenwirkungen einschließlich Atmenot , und ( Beinahe<unk> -Ohnmachten erfordern eine sofortige Notfallbehandlung .
T-767	Severe symptoms , including difficulty in breathing and ( nearly ) fainting , require prompt emergency treatment .
H-767	-0.4366338849067688	Severe side effects including difficulty breathing , and ( near ) fainting require immediate emergency treatment .
D-767	-0.4366338849067688	Severe side effects including difficulty breathing , and ( near ) fainting require immediate emergency treatment .
P-767	-0.2482 -0.1519 -0.9263 -0.0966 -0.2855 -2.5439 -0.1644 -0.4124 -0.1433 -0.3049 -0.1285 -0.6422 -0.1747 -0.4596 -0.1558 -0.7857 -0.7822 -0.2087 -0.2571 -0.1457 -0.1517
S-90	Biotransformation Es gibt keine Hinweise darauf , dass Alendronat beim Tier oder beim Menschen metabolisiert wird .
T-90	Biotransformation There is no evidence that alendronate is metabolised in animals or humans .
H-90	-0.18972571194171906	Biotransformation There is no evidence that alendronate is metabolised in animals or humans .
D-90	-0.18972571194171906	Biotransformation There is no evidence that alendronate is metabolised in animals or humans .
P-90	-0.2790 -0.0944 -0.0556 -0.1188 -0.0937 -1.0804 -0.2484 -0.1448 -0.1113 -0.1300 -0.1532 -0.1356 -0.0997 -0.0713 -0.1479 -0.1007 -0.0809 -0.1246 -0.3167 -0.3805 -0.1187 -0.1708 -0.1414 -0.1551
S-15	Die vollständige Auflistung der im Zusammenhang mit Adenuric berichteten Nebenwirkungen ist der Packungsbeilage zu entnehmen .
T-15	For the full list of all side effects reported with Adenuric , see the Package Leaflet .
H-15	-0.18295520544052124	For the full list of all side effects reported with Adenuric , see the Package Leaflet .
D-15	-0.18295520544052124	For the full list of all side effects reported with Adenuric , see the Package Leaflet .
P-15	-0.1252 -0.1623 -0.1214 -0.1133 -0.1348 -1.2415 -0.5877 -0.0969 -0.0778 -0.1094 -0.1004 -0.1583 -0.0617 -0.1137 -0.1227 -0.1986 -0.1333 -0.0462 -0.1256 -0.0610 -0.0600 -0.1141 -0.1755 -0.1496
S-513	Die Öffnung nach unten drehen und den durchsichtigen Plastikdorn durch den Gummistopfen der Lösungsmittelflasche drücken .
T-513	Turn the package over and insert the clear plastic spike through the solvent stopper .
H-513	-0.3846435844898224	Turn the opening downwards and push the transparent plastic mandrel through the rubber stopper on the solvent bottle .
D-513	-0.3846435844898224	Turn the opening downwards and push the transparent plastic mandrel through the rubber stopper on the solvent bottle .
P-513	-0.7369 -0.1313 -0.1792 -1.2614 -0.7253 -0.2943 -0.1483 -1.3270 -0.1585 -0.4754 -0.3227 -1.0168 -0.2136 -0.1984 -0.1477 -0.0918 -0.0781 -0.1121 -0.4965 -0.1441 -0.5572 -0.3964 -0.1036 -0.1480 -0.1511
S-460	Die Dosis und Häufigkeit der Verabreichung sollen entsprechend der klinischen Wirksamkeit des Produktes im Einzelfall angepasst werden .
T-460	The dose and frequency of administration should be adapted to the clinical response in the individual case .
H-460	-0.25603580474853516	The dose and frequency of administration should be adjusted on a case by case basis in accordance with the clinical efficacy of the product .
D-460	-0.25603580474853516	The dose and frequency of administration should be adjusted on a case by case basis in accordance with the clinical efficacy of the product .
P-460	-0.3153 -0.2707 -0.1420 -0.0637 -0.0837 -0.1382 -0.1685 -0.1226 -0.1591 -0.1138 -0.2872 -0.9232 -0.0127 -0.5640 -0.1496 -0.0680 -0.9395 -1.1929 -0.1007 -0.1459 -0.1372 -0.1254 -0.6150 -0.0635 -0.1166 -0.1393 -0.1335 -0.0877 -0.1535 -0.1482
S-77	Bei unzureichender Sonnenbestrahlung ist es essenziell , dass Vitamin D3 ein Bestandteil der Nahrung ist .
T-77	In the absence of adequate sunlight exposure , vitamin D3 is an essential dietary nutrient .
H-77	-0.45560774207115173	In case of insufficient exposure to the sun , it is essential that vitamin D3 is included in the diet .
D-77	-0.45560774207115173	In case of insufficient exposure to the sun , it is essential that vitamin D3 is included in the diet .
P-77	-0.9871 -1.0999 -0.1559 -0.0756 -1.0280 -2.2202 -0.1712 -0.2936 -0.1052 -0.3116 -0.1705 -0.1399 -0.3790 -0.2085 -0.0803 -0.0934 -0.1473 -0.1604 -0.2052 -1.5519 -0.1390 -0.7333 -0.6233 -0.1584 -0.1513
S-675	Die Öffnung nach unten drehen und den durchsichtigen Plastikdorn durch den Gummistopfen der Lösungsmittelflasche drücken .
T-675	Turn the package over and insert the clear plastic spike through the solvent stopper .
H-675	-0.3846435844898224	Turn the opening downwards and push the transparent plastic mandrel through the rubber stopper on the solvent bottle .
D-675	-0.3846435844898224	Turn the opening downwards and push the transparent plastic mandrel through the rubber stopper on the solvent bottle .
P-675	-0.7369 -0.1313 -0.1792 -1.2614 -0.7253 -0.2943 -0.1483 -1.3270 -0.1585 -0.4754 -0.3227 -1.0168 -0.2136 -0.1984 -0.1477 -0.0918 -0.0781 -0.1121 -0.4965 -0.1441 -0.5572 -0.3964 -0.1036 -0.1480 -0.1511
S-622	Die Dosis und Häufigkeit der Verabreichung sollen entsprechend der klinischen Wirksamkeit des Produktes im Einzelfall angepasst werden .
T-622	The dose and frequency of administration should be adapted to the clinical response in the individual case .
H-622	-0.25603580474853516	The dose and frequency of administration should be adjusted on a case by case basis in accordance with the clinical efficacy of the product .
D-622	-0.25603580474853516	The dose and frequency of administration should be adjusted on a case by case basis in accordance with the clinical efficacy of the product .
P-622	-0.3153 -0.2707 -0.1420 -0.0637 -0.0837 -0.1382 -0.1685 -0.1226 -0.1591 -0.1138 -0.2872 -0.9232 -0.0127 -0.5640 -0.1496 -0.0680 -0.9395 -1.1929 -0.1007 -0.1459 -0.1372 -0.1254 -0.6150 -0.0635 -0.1166 -0.1393 -0.1335 -0.0877 -0.1535 -0.1482
S-594	Die Öffnung nach unten drehen und den durchsichtigen Plastikdorn durch den Gummistopfen der Lösungsmittelflasche drücken .
T-594	Turn the package over and insert the clear plastic spike through the solvent stopper .
H-594	-0.3846435844898224	Turn the opening downwards and push the transparent plastic mandrel through the rubber stopper on the solvent bottle .
D-594	-0.3846435844898224	Turn the opening downwards and push the transparent plastic mandrel through the rubber stopper on the solvent bottle .
P-594	-0.7369 -0.1313 -0.1792 -1.2614 -0.7253 -0.2943 -0.1483 -1.3270 -0.1585 -0.4754 -0.3227 -1.0168 -0.2136 -0.1984 -0.1477 -0.0918 -0.0781 -0.1121 -0.4965 -0.1441 -0.5572 -0.3964 -0.1036 -0.1480 -0.1511
S-541	Die Dosis und Häufigkeit der Verabreichung sollen entsprechend der klinischen Wirksamkeit des Produktes im Einzelfall angepasst werden .
T-541	The dose and frequency of administration should be adapted to the clinical response in the individual case .
H-541	-0.25603580474853516	The dose and frequency of administration should be adjusted on a case by case basis in accordance with the clinical efficacy of the product .
D-541	-0.25603580474853516	The dose and frequency of administration should be adjusted on a case by case basis in accordance with the clinical efficacy of the product .
P-541	-0.3153 -0.2707 -0.1420 -0.0637 -0.0837 -0.1382 -0.1685 -0.1226 -0.1591 -0.1138 -0.2872 -0.9232 -0.0127 -0.5640 -0.1496 -0.0680 -0.9395 -1.1929 -0.1007 -0.1459 -0.1372 -0.1254 -0.6150 -0.0635 -0.1166 -0.1393 -0.1335 -0.0877 -0.1535 -0.1482
S-96	Es wurden keine nicht-klinischen Studien mit der Kombination von Alendronat und Colecalciferol durchgeführt .
T-96	Non-clinical studies with the combination of alendronate and colecalciferol have not been conducted .
H-96	-0.30449000000953674	No non-clinical trials with the combination of alendronate and colecalciferol have been performed .
D-96	-0.30449000000953674	No non-clinical trials with the combination of alendronate and colecalciferol have been performed .
P-96	-0.8491 -0.1836 -0.3132 -0.1178 -0.8522 -1.7879 -0.1489 -0.6195 -0.1415 -0.2231 -0.1309 -0.0944 -0.0786 -0.1624 -0.1711 -0.1221 -0.1796 -0.1060 -0.0933 -0.1338 -0.2218 -0.1108 -0.4691 -0.1455 -0.1560
S-157	Ein Vitamin-D-Mangel entsteht , wenn Sonnenbestrahlung und Aufnahme aus der Nahrung unzureichend sind .
T-157	Vitamin D insufficiency develops when both sunlight exposure and dietary intake are inadequate .
H-157	-0.3349277973175049	Vitamin D deficiency occurs when insufficient exposure to the sun and food intake .
D-157	-0.3349277973175049	Vitamin D deficiency occurs when insufficient exposure to the sun and food intake .
P-157	-0.0482 -0.1009 -0.1314 -0.0151 -0.0449 -0.1451 -0.7911 -0.0699 -0.1523 -0.2072 -0.7637 -0.6225 -0.1393 -0.3030 -0.0892 -0.1224 -2.2427 -0.1633 -0.1077 -0.6232 -0.1504
S-192	Der Wirkstoff in Advate , Octocog alfa , ist ein Protein des Blutgerinnungsfaktors .
T-192	The active substance in Advate , octocog alfa , is a blood coagulation factor protein .
H-192	-0.2336224913597107	The active substance in Advate , Octocog alfa , is a protein in the blood clotting factor .
D-192	-0.2336224913597107	The active substance in Advate , Octocog alfa , is a protein in the blood clotting factor .
P-192	-0.1559 -0.0833 -0.0684 -0.1535 -0.5364 -0.1412 -0.1568 -0.7141 -0.1017 -0.1255 -0.1484 -0.1326 -0.0785 -0.1632 -0.1255 -0.1532 -0.4042 -1.1144 -0.2091 -0.1468 -0.5591 -0.0101 -0.1163 -0.1551 -0.1702 -0.1507
S-355	Durch das Vakuum wird das Lösungsmittel in die ADVATE-Flasche gezogen ( Abb . C ) .
T-355	The vacuum will draw the solvent into the ADVATE vial ( Fig . c ) .
H-355	-0.27802833914756775	The solvent is drawn into the ADVATE bottle through the vacuum ( Fig . C ) .
D-355	-0.27802833914756775	The solvent is drawn into the ADVATE bottle through the vacuum ( Fig . C ) .
P-355	-0.3620 -0.2875 -0.3256 -0.1336 -1.0146 -0.5646 -0.1347 -0.2602 -0.1625 -0.1207 -0.1075 -0.1776 -1.1459 -0.1973 -0.0992 -0.0930 -0.1060 -0.1500 -0.5445 -0.1637 -0.2096 -0.1456 -0.1368 -0.1540 -0.1541
S-175	Es wurden keine nicht-klinischen Studien mit der Kombination von Alendronat und Colecalciferol durchgeführt .
T-175	Non-clinical studies with the combination of alendronate and colecalciferol have not been conducted .
H-175	-0.30449000000953674	No non-clinical trials with the combination of alendronate and colecalciferol have been performed .
D-175	-0.30449000000953674	No non-clinical trials with the combination of alendronate and colecalciferol have been performed .
P-175	-0.8491 -0.1836 -0.3132 -0.1178 -0.8522 -1.7879 -0.1489 -0.6195 -0.1415 -0.2231 -0.1309 -0.0944 -0.0786 -0.1624 -0.1711 -0.1221 -0.1796 -0.1060 -0.0933 -0.1338 -0.2218 -0.1108 -0.4691 -0.1455 -0.1560
S-274	Durch das Vakuum wird das Lösungsmittel in die ADVATE-Flasche gezogen ( Abb . C ) .
T-274	The vacuum will draw the solvent into the ADVATE vial ( Fig . c ) .
H-274	-0.27802833914756775	The solvent is drawn into the ADVATE bottle through the vacuum ( Fig . C ) .
D-274	-0.27802833914756775	The solvent is drawn into the ADVATE bottle through the vacuum ( Fig . C ) .
P-274	-0.3620 -0.2875 -0.3256 -0.1336 -1.0146 -0.5646 -0.1347 -0.2602 -0.1625 -0.1207 -0.1075 -0.1776 -1.1459 -0.1973 -0.0992 -0.0930 -0.1060 -0.1500 -0.5445 -0.1637 -0.2096 -0.1456 -0.1368 -0.1540 -0.1541
S-436	Durch das Vakuum wird das Lösungsmittel in die ADVATE-Flasche gezogen ( Abb . C ) .
T-436	The vacuum will draw the solvent into the ADVATE vial ( Fig . c ) .
H-436	-0.27802833914756775	The solvent is drawn into the ADVATE bottle through the vacuum ( Fig . C ) .
D-436	-0.27802833914756775	The solvent is drawn into the ADVATE bottle through the vacuum ( Fig . C ) .
P-436	-0.3620 -0.2875 -0.3256 -0.1336 -1.0146 -0.5646 -0.1347 -0.2602 -0.1625 -0.1207 -0.1075 -0.1776 -1.1459 -0.1973 -0.0992 -0.0930 -0.1060 -0.1500 -0.5445 -0.1637 -0.2096 -0.1456 -0.1368 -0.1540 -0.1541
S-80	Ein Vitamin-D-Mangel entsteht , wenn Sonnenbestrahlung und Aufnahme aus der Nahrung unzureichend sind .
T-80	Vitamin D insufficiency develops when both sunlight exposure and dietary intake are inadequate .
H-80	-0.3349277973175049	Vitamin D deficiency occurs when insufficient exposure to the sun and food intake .
D-80	-0.3349277973175049	Vitamin D deficiency occurs when insufficient exposure to the sun and food intake .
P-80	-0.0482 -0.1009 -0.1314 -0.0151 -0.0449 -0.1451 -0.7911 -0.0699 -0.1523 -0.2072 -0.7637 -0.6225 -0.1393 -0.3030 -0.0892 -0.1224 -2.2427 -0.1633 -0.1077 -0.6232 -0.1504
S-598	Durch das Vakuum wird das Lösungsmittel in die ADVATE-Flasche gezogen ( Abb . C ) .
T-598	The vacuum will draw the solvent into the ADVATE vial ( Fig . c ) .
H-598	-0.27802833914756775	The solvent is drawn into the ADVATE bottle through the vacuum ( Fig . C ) .
D-598	-0.27802833914756775	The solvent is drawn into the ADVATE bottle through the vacuum ( Fig . C ) .
P-598	-0.3620 -0.2875 -0.3256 -0.1336 -1.0146 -0.5646 -0.1347 -0.2602 -0.1625 -0.1207 -0.1075 -0.1776 -1.1459 -0.1973 -0.0992 -0.0930 -0.1060 -0.1500 -0.5445 -0.1637 -0.2096 -0.1456 -0.1368 -0.1540 -0.1541
S-658	Es liegen keine pharmakokinetischen Daten über den Einsatz von ADVATE bei bisher unbehandelten Patienten vor .
T-658	Pharmacokinetic data with ADVATE on previously untreated patients are currently not available .
H-658	-0.16547177731990814	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
D-658	-0.16547177731990814	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
P-658	-0.1752 -0.1481 -0.0916 -0.1326 -0.0712 -0.0573 -0.1614 -0.1238 -0.1899 -0.7675 -0.0772 -0.1474 -0.0931 -0.1625 -0.0711 -0.0762 -0.1382 -0.5596 -0.1180 -0.0670 -0.0785 -0.1457 -0.1526
S-577	Es liegen keine pharmakokinetischen Daten über den Einsatz von ADVATE bei bisher unbehandelten Patienten vor .
T-577	Pharmacokinetic data with ADVATE on previously untreated patients are currently not available .
H-577	-0.16547177731990814	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
D-577	-0.16547177731990814	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
P-577	-0.1752 -0.1481 -0.0916 -0.1326 -0.0712 -0.0573 -0.1614 -0.1238 -0.1899 -0.7675 -0.0772 -0.1474 -0.0931 -0.1625 -0.0711 -0.0762 -0.1382 -0.5596 -0.1180 -0.0670 -0.0785 -0.1457 -0.1526
S-496	Es liegen keine pharmakokinetischen Daten über den Einsatz von ADVATE bei bisher unbehandelten Patienten vor .
T-496	Pharmacokinetic data with ADVATE on previously untreated patients are currently not available .
H-496	-0.16547177731990814	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
D-496	-0.16547177731990814	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
P-496	-0.1752 -0.1481 -0.0916 -0.1326 -0.0712 -0.0573 -0.1614 -0.1238 -0.1899 -0.7675 -0.0772 -0.1474 -0.0931 -0.1625 -0.0711 -0.0762 -0.1382 -0.5596 -0.1180 -0.0670 -0.0785 -0.1457 -0.1526
S-415	Es liegen keine pharmakokinetischen Daten über den Einsatz von ADVATE bei bisher unbehandelten Patienten vor .
T-415	Pharmacokinetic data with ADVATE on previously untreated patients are currently not available .
H-415	-0.16547177731990814	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
D-415	-0.16547177731990814	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
P-415	-0.1752 -0.1481 -0.0916 -0.1326 -0.0712 -0.0573 -0.1614 -0.1238 -0.1899 -0.7675 -0.0772 -0.1474 -0.0931 -0.1625 -0.0711 -0.0762 -0.1382 -0.5596 -0.1180 -0.0670 -0.0785 -0.1457 -0.1526
S-334	Es liegen keine pharmakokinetischen Daten über den Einsatz von ADVATE bei bisher unbehandelten Patienten vor .
T-334	Pharmacokinetic data with ADVATE on previously untreated patients are currently not available .
H-334	-0.16547177731990814	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
D-334	-0.16547177731990814	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
P-334	-0.1752 -0.1481 -0.0916 -0.1326 -0.0712 -0.0573 -0.1614 -0.1238 -0.1899 -0.7675 -0.0772 -0.1474 -0.0931 -0.1625 -0.0711 -0.0762 -0.1382 -0.5596 -0.1180 -0.0670 -0.0785 -0.1457 -0.1526
S-253	Es liegen keine pharmakokinetischen Daten über den Einsatz von ADVATE bei bisher unbehandelten Patienten vor .
T-253	Pharmacokinetic data with ADVATE on previously untreated patients are currently not available .
H-253	-0.16547177731990814	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
D-253	-0.16547177731990814	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
P-253	-0.1752 -0.1481 -0.0916 -0.1326 -0.0712 -0.0573 -0.1614 -0.1238 -0.1899 -0.7675 -0.0772 -0.1474 -0.0931 -0.1625 -0.0711 -0.0762 -0.1382 -0.5596 -0.1180 -0.0670 -0.0785 -0.1457 -0.1526
S-190	Die Dosierung wird darüber hinaus je nach Schweregrad der Blutung und Art des chirurgischen Eingriffes angepasst .
T-190	The dose is also adjusted depending on the severity of the haemorrhage or the type of surgery .
H-190	-0.37652814388275146	Moreover , the dosage is adjusted according to the severity of the haemorrhage and the type of surgery performed .
D-190	-0.37652814388275146	Moreover , the dosage is adjusted according to the severity of the haemorrhage and the type of surgery performed .
P-190	-1.2832 -0.1646 -0.4892 -0.2671 -0.1178 -0.1066 -0.2881 -0.2169 -1.1911 -0.1400 -0.1458 -1.6475 -0.1321 -0.1463 -0.3102 -0.8675 -0.1659 -0.0264 -0.1122 -0.1338 -0.2845 -0.6768 -0.1409 -0.3780 -0.4449 -0.1393 -0.1496
S-171	Die Plasmakonzentrationen fielen um mehr als 95 % innerhalb von sechs Stunden nach intravenöser Gabe .
T-171	Plasma concentrations fell by more than 95 % within six hours following intravenous administration .
H-171	-0.22213764488697052	Plasma concentrations fell by more than 95 % within six hours after intravenous administration .
D-171	-0.22213764488697052	Plasma concentrations fell by more than 95 % within six hours after intravenous administration .
P-171	-0.2451 -0.0749 -0.0872 -0.0616 -0.1188 -0.0703 -0.6647 -0.1294 -0.2770 -0.1303 -0.0925 -0.1385 -0.5292 -0.5112 -0.1121 -0.8149 -0.2531 -0.0791 -0.0614 -0.1307 -0.2133 -0.1646 -0.1492
S-494	41 Daten einer Einmalapplikation von ADVATE bei 53 Kindern unter 6 Jahren wurden zur Aufstellung dieser Tabelle verwendet .
T-494	Data from single-dose administrations of ADVATE in 53 paediatric patients less than 6 years of age were used to obtain this table .
H-494	-0.390370637178421	Data from a single use of ADVATE in 53 children under 6 years of age were used to compile this table .
D-494	-0.390370637178421	Data from a single use of ADVATE in 53 children under 6 years of age were used to compile this table .
P-494	-0.2416 -0.1892 -0.1406 -2.9662 -1.6923 -0.2418 -0.1156 -0.1727 -0.0838 -0.0859 -0.2282 -0.0671 -0.1167 -0.2814 -0.2459 -0.1147 -0.1297 -0.1094 -0.6549 -0.1054 -0.1364 -1.4503 -0.4536 -0.1029 -0.1155 -0.1464 -0.1517
S-517	Durch das Vakuum wird das Lösungsmittel in die ADVATE-Flasche gezogen ( Abb . C ) .
T-517	The vacuum will draw the solvent into the ADVATE vial ( Fig . c ) .
H-517	-0.27802833914756775	The solvent is drawn into the ADVATE bottle through the vacuum ( Fig . C ) .
D-517	-0.27802833914756775	The solvent is drawn into the ADVATE bottle through the vacuum ( Fig . C ) .
P-517	-0.3620 -0.2875 -0.3256 -0.1336 -1.0146 -0.5646 -0.1347 -0.2602 -0.1625 -0.1207 -0.1075 -0.1776 -1.1459 -0.1973 -0.0992 -0.0930 -0.1060 -0.1500 -0.5445 -0.1637 -0.2096 -0.1456 -0.1368 -0.1540 -0.1541
S-91	Die Plasmakonzentrationen fielen um mehr als 95 % innerhalb von sechs Stunden nach intravenöser Gabe .
T-91	Plasma concentrations fell by more than 95 % within six hours following intravenous administration .
H-91	-0.22213764488697052	Plasma concentrations fell by more than 95 % within six hours after intravenous administration .
D-91	-0.22213764488697052	Plasma concentrations fell by more than 95 % within six hours after intravenous administration .
P-91	-0.2451 -0.0749 -0.0872 -0.0616 -0.1188 -0.0703 -0.6647 -0.1294 -0.2770 -0.1303 -0.0925 -0.1385 -0.5292 -0.5112 -0.1121 -0.8149 -0.2531 -0.0791 -0.0614 -0.1307 -0.2133 -0.1646 -0.1492
S-413	30 Daten einer Einmalapplikation von ADVATE bei 53 Kindern unter 6 Jahren wurden zur Aufstellung dieser Tabelle verwendet .
T-413	Data from single-dose administrations of ADVATE in 53 paediatric patients less than 6 years of age were used to obtain this table .
H-413	-0.3843010365962982	Data from a single use of ADVATE in 53 children under 6 years of age were used to compile this table .
D-413	-0.3843010365962982	Data from a single use of ADVATE in 53 children under 6 years of age were used to compile this table .
P-413	-0.4252 -0.1774 -0.1513 -2.9558 -1.7019 -0.2569 -0.1109 -0.1728 -0.0839 -0.0859 -0.1964 -0.0668 -0.1248 -0.2926 -0.2649 -0.1140 -0.1583 -0.1085 -0.5345 -0.1084 -0.1404 -1.2645 -0.3601 -0.1050 -0.1153 -0.1464 -0.1532
S-362	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren .
T-362	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren . Inject intravenously .
H-362	-0.29814964532852173	Connect the perfusion set to the syringe and intravenously inject the product .
D-362	-0.29814964532852173	Connect the perfusion set to the syringe and intravenously inject the product .
P-362	-0.6582 -0.0574 -0.1201 -0.1332 -0.4675 -0.0537 -1.2825 -0.1449 -0.1316 -0.0944 -0.0369 -0.0213 -0.1261 -0.1425 -1.0014 -0.0839 -0.1542 -0.5073 -0.0638 -0.8377 -0.4340 -0.1537 -0.1512
S-851	In einer klinisch- pharmakologischen Studie wurde bei gleichzeitiger Einnahme von Desloratadin und Alkohol die
T-851	However , in a clinical pharmacology trial desloratadine taken concomitantly with alcohol did not potentiate the performance impairing effects of alcohol .
H-851	-0.6721661686897278	In a clinical pharmacological study , concomitant administration of desloratadine and alcohol failed to significantly reduce the incidence of serious heart failure in patients with type 2 diabetes .
D-851	-0.6721661686897278	In a clinical pharmacological study , concomitant administration of desloratadine and alcohol failed to significantly reduce the incidence of serious heart failure in patients with type 2 diabetes .
P-851	-0.3235 -0.5168 -0.0457 -0.1069 -0.4074 -0.2031 -1.6192 -1.5108 -0.0218 -0.0047 -0.1380 -0.7577 -0.1566 -0.2729 -0.0395 -0.1230 -0.2545 -0.3116 -0.8873 -0.1139 -2.7550 -0.0922 -1.2378 -0.7421 -0.5643 -0.6307 -0.0433 -0.1722 -1.4392 -0.7174 -0.8235 -1.7743 -0.8264 -1.7727 -3.0546 -0.2197 -0.0401 -1.3384 -0.1555
S-686	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren .
T-686	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren . Inject intravenously .
H-686	-0.29814964532852173	Connect the perfusion set to the syringe and intravenously inject the product .
D-686	-0.29814964532852173	Connect the perfusion set to the syringe and intravenously inject the product .
P-686	-0.6582 -0.0574 -0.1201 -0.1332 -0.4675 -0.0537 -1.2825 -0.1449 -0.1316 -0.0944 -0.0369 -0.0213 -0.1261 -0.1425 -1.0014 -0.0839 -0.1542 -0.5073 -0.0638 -0.8377 -0.4340 -0.1537 -0.1512
S-656	63 Daten einer Einmalapplikation von ADVATE bei 53 Kindern unter 6 Jahren wurden zur Aufstellung dieser Tabelle verwendet .
T-656	Data from single-dose administrations of ADVATE in 53 paediatric patients less than 6 years of age were used to obtain this table .
H-656	-0.38500112295150757	Data from a single use of ADVATE in 53 children under 6 years of age were used to compile this table .
D-656	-0.38500112295150757	Data from a single use of ADVATE in 53 children under 6 years of age were used to compile this table .
P-656	-0.3149 -0.1964 -0.1573 -2.9934 -1.7235 -0.2620 -0.1126 -0.1719 -0.0839 -0.0857 -0.1979 -0.0615 -0.1225 -0.2647 -0.2533 -0.1134 -0.1479 -0.1110 -0.5505 -0.0998 -0.1387 -1.3196 -0.3982 -0.1041 -0.1122 -0.1469 -0.1513
S-605	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren .
T-605	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren . Inject intravenously .
H-605	-0.29814964532852173	Connect the perfusion set to the syringe and intravenously inject the product .
D-605	-0.29814964532852173	Connect the perfusion set to the syringe and intravenously inject the product .
P-605	-0.6582 -0.0574 -0.1201 -0.1332 -0.4675 -0.0537 -1.2825 -0.1449 -0.1316 -0.0944 -0.0369 -0.0213 -0.1261 -0.1425 -1.0014 -0.0839 -0.1542 -0.5073 -0.0638 -0.8377 -0.4340 -0.1537 -0.1512
S-575	52 Daten einer Einmalapplikation von ADVATE bei 53 Kindern unter 6 Jahren wurden zur Aufstellung dieser Tabelle verwendet .
T-575	Data from single-dose administrations of ADVATE in 53 paediatric patients less than 6 years of age were used to obtain this table .
H-575	-0.39057567715644836	Data from a single use of ADVATE in 53 children under 6 years of age were used to compile this table .
D-575	-0.39057567715644836	Data from a single use of ADVATE in 53 children under 6 years of age were used to compile this table .
P-575	-0.3701 -0.1749 -0.1497 -2.9934 -1.7838 -0.2588 -0.1151 -0.1717 -0.0843 -0.0858 -0.1980 -0.0667 -0.1212 -0.2719 -0.2544 -0.1136 -0.1392 -0.1099 -0.5977 -0.1104 -0.1371 -1.3497 -0.3734 -0.1040 -0.1119 -0.1465 -0.1526
S-524	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren .
T-524	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren . Inject intravenously .
H-524	-0.29814964532852173	Connect the perfusion set to the syringe and intravenously inject the product .
D-524	-0.29814964532852173	Connect the perfusion set to the syringe and intravenously inject the product .
P-524	-0.6582 -0.0574 -0.1201 -0.1332 -0.4675 -0.0537 -1.2825 -0.1449 -0.1316 -0.0944 -0.0369 -0.0213 -0.1261 -0.1425 -1.0014 -0.0839 -0.1542 -0.5073 -0.0638 -0.8377 -0.4340 -0.1537 -0.1512
S-443	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren .
T-443	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren . Inject intravenously .
H-443	-0.29814964532852173	Connect the perfusion set to the syringe and intravenously inject the product .
D-443	-0.29814964532852173	Connect the perfusion set to the syringe and intravenously inject the product .
P-443	-0.6582 -0.0574 -0.1201 -0.1332 -0.4675 -0.0537 -1.2825 -0.1449 -0.1316 -0.0944 -0.0369 -0.0213 -0.1261 -0.1425 -1.0014 -0.0839 -0.1542 -0.5073 -0.0638 -0.8377 -0.4340 -0.1537 -0.1512
S-679	Durch das Vakuum wird das Lösungsmittel in die ADVATE-Flasche gezogen ( Abb . C ) .
T-679	The vacuum will draw the solvent into the ADVATE vial ( Fig . c ) .
H-679	-0.27802833914756775	The solvent is drawn into the ADVATE bottle through the vacuum ( Fig . C ) .
D-679	-0.27802833914756775	The solvent is drawn into the ADVATE bottle through the vacuum ( Fig . C ) .
P-679	-0.3620 -0.2875 -0.3256 -0.1336 -1.0146 -0.5646 -0.1347 -0.2602 -0.1625 -0.1207 -0.1075 -0.1776 -1.1459 -0.1973 -0.0992 -0.0930 -0.1060 -0.1500 -0.5445 -0.1637 -0.2096 -0.1456 -0.1368 -0.1540 -0.1541
S-213	Die Berechnung der erforderlichen Faktor VIII Dosis basiert auf dem empirischen Befund , dass 1 I.E.
T-213	The calculation of the required dose of factor VIII is based on the empirical finding that 1 IU
H-213	-0.33260464668273926	The calculation of the required Factor VIII dose is based on the empirical finding that 1 IU
D-213	-0.33260464668273926	The calculation of the required Factor VIII dose is based on the empirical finding that 1 IU
P-213	-2.0272 -0.0989 -0.2012 -0.1154 -0.1469 -0.1401 -0.8884 -0.4633 -0.1563 -0.0686 -0.0299 -0.1516 -0.0965 -0.1372 -0.2230 -0.1078 -0.1572 -0.1923 -0.1138 -0.3279 -0.1362 -0.1180 -0.1126 -0.0826 -2.0222
S-332	19 Daten einer Einmalapplikation von ADVATE bei 53 Kindern unter 6 Jahren wurden zur Aufstellung dieser Tabelle verwendet .
T-332	Data from single-dose administrations of ADVATE in 53 paediatric patients less than 6 years of age were used to obtain this table .
H-332	-0.3859640955924988	Data from a single use of ADVATE in 53 children under 6 years of age were used to compile this table .
D-332	-0.3859640955924988	Data from a single use of ADVATE in 53 children under 6 years of age were used to compile this table .
P-332	-0.3388 -0.1804 -0.1556 -3.0630 -1.7425 -0.2532 -0.1128 -0.1727 -0.0829 -0.0853 -0.1983 -0.0704 -0.1232 -0.2773 -0.2651 -0.1105 -0.1596 -0.1082 -0.5203 -0.1051 -0.1384 -1.2358 -0.3913 -0.1040 -0.1218 -0.1491 -0.1554
S-281	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren .
T-281	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren . Inject intravenously .
H-281	-0.29814964532852173	Connect the perfusion set to the syringe and intravenously inject the product .
D-281	-0.29814964532852173	Connect the perfusion set to the syringe and intravenously inject the product .
P-281	-0.6582 -0.0574 -0.1201 -0.1332 -0.4675 -0.0537 -1.2825 -0.1449 -0.1316 -0.0944 -0.0369 -0.0213 -0.1261 -0.1425 -1.0014 -0.0839 -0.1542 -0.5073 -0.0638 -0.8377 -0.4340 -0.1537 -0.1512
S-251	8 Daten einer Einmalapplikation von ADVATE bei 53 Kindern unter 6 Jahren wurden zur Aufstellung dieser Tabelle verwendet .
T-251	Data from single-dose administrations of ADVATE in 53 paediatric patients less than 6 years of age were used to obtain this table .
H-251	-0.3913939297199249	Data from a single use of ADVATE in 53 children under 6 years of age were used to compile this table .
D-251	-0.3913939297199249	Data from a single use of ADVATE in 53 children under 6 years of age were used to compile this table .
P-251	-0.3015 -0.1890 -0.1421 -2.9802 -1.7761 -0.2483 -0.1161 -0.1722 -0.0834 -0.0851 -0.2073 -0.0730 -0.1216 -0.3009 -0.2510 -0.1119 -0.1413 -0.1048 -0.6109 -0.1074 -0.1383 -1.3552 -0.4270 -0.1031 -0.1188 -0.1472 -0.1538
S-30	Therapie der postmenopausalen Osteoporose bei Patienten mit Risiko für einen Vitamin-D-Mangel .
T-30	Treatment of postmenopausal osteoporosis in patients at risk of vitamin D insufficiency .
H-30	-0.1701154112815857	Treatment of post-menopausal osteoporosis in patients at risk for vitamin D deficiency .
D-30	-0.1701154112815857	Treatment of post-menopausal osteoporosis in patients at risk for vitamin D deficiency .
P-30	-0.8446 -0.0810 -0.1194 -0.1444 -0.0476 -0.5905 -0.0995 -0.1106 -0.0390 -0.1332 -0.1541 -0.1164 -0.1145 -0.1256 -0.0960 -0.0764 -0.1272 -0.0845 -0.0719 -0.0974 -0.4757 -0.0444 -0.1023 -0.1481 -0.0186 -0.0665 -0.1916 -0.4570 -0.1556
S-736	Bei Patienten mit Hämophilie A ( angeborenem Faktor VIII-Mangel ) fehlt er oder funktioniert nicht korrekt .
T-736	In patients with haemophilia A ( inborn factor VIII deficiency ) , it is missing or not working properly .
H-736	-0.36637523770332336	In patients with haemophilia A ( congenital factor VIIII deficiency ) it is missing or not functioning properly .
D-736	-0.36637523770332336	In patients with haemophilia A ( congenital factor VIIII deficiency ) it is missing or not functioning properly .
P-736	-0.7966 -0.0672 -0.1127 -0.1161 -0.0856 -0.0812 -0.0843 -0.1249 -0.1575 -0.2242 -0.1475 -0.1999 -0.3084 -0.3775 -1.6941 -0.0444 -0.1355 -0.1065 -0.1489 -0.5848 -0.1400 -0.8977 -0.1509 -1.6435 -1.1831 -0.0595 -0.6422 -0.1554 -0.1547
S-791	Kruczkowskiego 8 PL-00-380 Warszawa Tel . : <unk> 48 22 4883 777
T-791	Kruczkowskiego 8 PL-00-380 Warszawa Tel . : <<unk>> 48 22 4883 777
H-791	-0.1212676391005516	Kruczkowskiego 8 PL-00-380 Warszawa Tel . : <unk> 48 22 4883 777
D-791	-0.1212676391005516	Kruczkowskiego 8 PL-00-380 Warszawa Tel . : <unk> 48 22 4883 777
P-791	-0.2532 -0.1747 -0.2834 -0.0749 -0.0811 -0.1307 -0.0981 -0.0627 -0.1185 -0.1084 -0.0896 -0.1054 -0.0775 -0.1619 -0.2468 -0.1301 -0.0512 -0.1597 -0.1364 -0.0227 -0.0728 -0.0723 -0.1312 -0.0705 -0.1048 -0.0855 -0.1701
S-776	- Der arzneilich wirksame Bestandteil ist Octocog alfa ( Blutgerinnungsfaktor VIII vom Menschen ,
T-776	- The active substance is octocog alfa ( human coagulation Factor VIII produced by recombinant
H-776	-0.46624913811683655	- The active ingredient is Octocog alfa ( human blood clotting factor VIII ) .
D-776	-0.46624913811683655	- The active ingredient is Octocog alfa ( human blood clotting factor VIII ) .
P-776	-0.1472 -0.9069 -0.0671 -1.7456 -0.0625 -0.0540 -0.7168 -0.7053 -0.1042 -0.1086 -0.1303 -0.1260 -0.0695 -0.1553 -0.1604 -1.3009 -0.3883 -0.0080 -0.0968 -0.0604 -0.1775 -0.0632 -1.6388 -2.4946 -0.1679
S-831	Ovale Tablette mit einer blauen und einer weißen Schicht , die blaue Schicht trägt die Prägung D12 .
T-831	Blue and white bilayer oval tablet with D12 branded to blue layer .
H-831	-0.40509480237960815	Oval tablet with one blue and one white layer , the blue layer is engraved with D12 .
D-831	-0.40509480237960815	Oval tablet with one blue and one white layer , the blue layer is engraved with D12 .
P-831	-0.6188 -0.1089 -0.0899 -0.2692 -1.2515 -0.1490 -0.3261 -0.1158 -0.1215 -0.2223 -0.3712 -0.1445 -0.1114 -0.1482 -2.0046 -1.6629 -0.0564 -0.0934 -0.8793 -0.1136 -0.1559 -0.1459 -0.1566
S-285	Jede Flasche enthält nominal 500 I.E.* rekombinanter Blutgerinnungsfaktor VIII ( rDNS ) Octocog alfa<unk> * .
T-285	Each vial contains nominally 500 IU* human coagulation factor VIII ( rDNA ) , octocog alfa<<unk>> * .
H-285	-0.2599045932292938	Each bottle contains a nominal 500 IU* recombinant blood clotting factor VIII ( rDNA ) octocog alfa/ * .
D-285	-0.2599045932292938	Each bottle contains a nominal 500 IU* recombinant blood clotting factor VIII ( rDNA ) octocog alfa/ * .
P-285	-0.0143 -0.0868 -0.3193 -0.8073 -0.0742 -0.0505 -0.3921 -0.1001 -0.4215 -1.3906 -0.3156 -0.0878 -0.0798 -0.1394 -0.2743 -0.8844 -0.0117 -0.1125 -0.0579 -0.1596 -0.0635 -0.1493 -0.1262 -0.0914 -0.1466 -1.2384 -0.1090 -0.1042 -0.1581 -0.1177 -0.1333 -0.4882 -0.0857 -0.1547 -0.1504
S-609	Jede Flasche enthält nominal 3000 I.E.* rekombinanter Blutgerinnungsfaktor VIII ( rDNS ) Octocog alfa<unk> * .
T-609	Each vial contains nominally 3000 IU* human coagulation factor VIII ( rDNA ) , octocog alfa<<unk>> * .
H-609	-0.2698999047279358	Each bottle contains a nominal 3000 IU/ recombinant blood clotting factor VIII ( rDNA ) octocog alfa/ * .
D-609	-0.2698999047279358	Each bottle contains a nominal 3000 IU/ recombinant blood clotting factor VIII ( rDNA ) octocog alfa/ * .
P-609	-0.0146 -0.0860 -0.3740 -1.1543 -0.0501 -0.0456 -0.1315 -0.0973 -0.4575 -1.0170 -1.2514 -0.0893 -0.0818 -0.1428 -0.1965 -0.8520 -0.0122 -0.1108 -0.0643 -0.1559 -0.0644 -0.1496 -0.1250 -0.0888 -0.1484 -1.1410 -0.1098 -0.1049 -0.1556 -0.1170 -0.1340 -0.3318 -0.0876 -0.1525 -0.1513
S-528	Jede Flasche enthält nominal 2000 I.E.* rekombinanter Blutgerinnungsfaktor VIII ( rDNS ) Octocog alfa<unk> * .
T-528	Each vial contains nominally 2000 IU* human coagulation factor VIII ( rDNA ) , octocog alfa<<unk>> * .
H-528	-0.27101317048072815	Each bottle contains a nominal 2000 IU/ recombinant blood clotting factor VIII ( rDNA ) octocog alfa/ * .
D-528	-0.27101317048072815	Each bottle contains a nominal 2000 IU/ recombinant blood clotting factor VIII ( rDNA ) octocog alfa/ * .
P-528	-0.0157 -0.0869 -0.3982 -1.5146 -0.0534 -0.0449 -0.1812 -0.0959 -0.4866 -1.0049 -0.7991 -0.0882 -0.0814 -0.1467 -0.1973 -0.9063 -0.0119 -0.1101 -0.0619 -0.1556 -0.0638 -0.1500 -0.1251 -0.0908 -0.1490 -1.1252 -0.1100 -0.1041 -0.1568 -0.1186 -0.1326 -0.3266 -0.0869 -0.1531 -0.1523
S-447	Jede Flasche enthält nominal 1500 I.E.* rekombinanter Blutgerinnungsfaktor VIII ( rDNS ) Octocog alfa<unk> * .
T-447	Each vial contains nominally 1500 IU* human coagulation factor VIII ( rDNA ) , octocog alfa<<unk>> * .
H-447	-0.2640116512775421	Each bottle contains a nominal 1500 IU* recombinant blood clotting factor VIII ( rDNA ) octocog alfa/ * .
D-447	-0.2640116512775421	Each bottle contains a nominal 1500 IU* recombinant blood clotting factor VIII ( rDNA ) octocog alfa/ * .
P-447	-0.0177 -0.0817 -0.4405 -0.7015 -0.0616 -0.0517 -0.5414 -0.1017 -0.5758 -1.3211 -0.2617 -0.0881 -0.0797 -0.1441 -0.2664 -0.8596 -0.0117 -0.1123 -0.0589 -0.1623 -0.0632 -0.1503 -0.1246 -0.0851 -0.1468 -1.2368 -0.1097 -0.1033 -0.1576 -0.1173 -0.1359 -0.4781 -0.0855 -0.1567 -0.1501
S-366	Jede Flasche enthält nominal 1000 I.E.* rekombinanter Blutgerinnungsfaktor VIII ( rDNS ) Octocog alfa<unk> * .
T-366	Each vial contains nominally 1000 IU* human coagulation factor VIII ( rDNA ) , octocog alfa<<unk>> * .
H-366	-0.2534341812133789	Each bottle contains a nominal 1000 IU/ recombinant blood clotting factor VIII ( rDNA ) octocog alfa/ * .
D-366	-0.2534341812133789	Each bottle contains a nominal 1000 IU/ recombinant blood clotting factor VIII ( rDNA ) octocog alfa/ * .
P-366	-0.0174 -0.0872 -0.4705 -0.8295 -0.0447 -0.0486 -0.2577 -0.1041 -0.4515 -0.9781 -0.8267 -0.0884 -0.0823 -0.1450 -0.1844 -0.8522 -0.0120 -0.1093 -0.0608 -0.1552 -0.0640 -0.1495 -0.1236 -0.0907 -0.1496 -1.1583 -0.1098 -0.1055 -0.1564 -0.1171 -0.1304 -0.3231 -0.0871 -0.1481 -0.1516
S-821	Desloratadin , ein Antihistaminikum , und Pseudoephedrin , ein die Nasenschleimhaut abschwellendes Mittel .
T-821	Desloratadine works by blocking the receptors on which histamine , a substance in the body that causes allergic symptoms , normally fixes itself .
H-821	-0.18388913571834564	Desloratadine , an antihistamine , and pseudoephedrine , a nasal decongestant .
D-821	-0.18388913571834564	Desloratadine , an antihistamine , and pseudoephedrine , a nasal decongestant .
P-821	-0.5443 -0.0392 -0.1087 -0.3570 -0.1908 -0.1684 -0.1318 -0.1125 -0.0685 -0.1064 -0.1970 -0.1134 -0.3014 -0.3213 -0.1567 -0.0476 -0.1333 -0.1089 -0.0885 -0.1562 -0.2935 -0.6926 -0.0182 -0.3054 -0.1097 -0.0108 -0.2141 -0.1073 -0.1615 -0.1516
S-205	Jede Flasche enthält nominal 250 I.E.* rekombinanter Blutgerinnungsfaktor VIII ( rDNS ) Octocog alfa<unk> * .
T-205	Each vial contains nominally 250 IU* human coagulation factor VIII ( rDNA ) , octocog alfa<<unk>> * .
H-205	-0.26020756363868713	Each bottle contains a nominal 250 IU* recombinant blood clotting factor VIII ( rDNA ) octocog alfa/ * .
D-205	-0.26020756363868713	Each bottle contains a nominal 250 IU* recombinant blood clotting factor VIII ( rDNA ) octocog alfa/ * .
P-205	-0.0175 -0.0952 -0.4815 -0.5230 -0.0806 -0.0504 -0.6700 -0.1079 -0.3853 -1.3368 -0.2848 -0.0866 -0.0796 -0.1412 -0.2965 -0.8570 -0.0114 -0.1109 -0.0595 -0.1607 -0.0641 -0.1504 -0.1252 -0.0893 -0.1475 -1.1850 -0.1097 -0.1050 -0.1582 -0.1169 -0.1332 -0.4971 -0.0853 -0.1531 -0.1511
S-126	Aufgrund der Stimulation der Knochenmineralisation durch Alendronat können Abnahmen des Serum-Calciums und -Phosphats auftreten .
T-126	Due to the positive effects of alendronate in increasing bone mineral , decreases in serum calcium and phosphate may occur .
H-126	-0.23751908540725708	Decreases in serum calcium and phosphate may occur as a result of stimulation of bone mineralisation with alendronate .
D-126	-0.23751908540725708	Decreases in serum calcium and phosphate may occur as a result of stimulation of bone mineralisation with alendronate .
P-126	-1.3392 -0.2541 -0.2606 -0.2327 -0.0269 -0.0967 -0.0821 -0.0880 -0.1050 -0.1305 -0.0833 -0.0676 -0.1253 -0.1147 -0.0620 -0.1193 -0.2309 -0.4121 -0.1348 -0.7768 -0.1155 -0.1420 -0.1058 -0.0929 -0.1400 -0.6532 -1.0464 -0.1376 -0.1437 -0.1450 -0.0780 -0.1465 -0.1491
S-403	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak der Antikörperspiegel gegen murines IgG .
T-403	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-murine IgG antibody level .
H-403	-0.30746057629585266	One patient showed both a statistically significant uptrend and a sustained peak in antibody levels to murine IgG .
D-403	-0.30746057629585266	One patient showed both a statistically significant uptrend and a sustained peak in antibody levels to murine IgG .
P-403	-1.1099 -0.0661 -1.9502 -0.0959 -0.1537 -0.0126 -0.0817 -0.1000 -0.1093 -0.0781 -1.0652 -0.1281 -0.1869 -0.0832 -0.0239 -0.5064 -0.0438 -0.1912 -0.0928 -1.0696 -0.0194 -0.3335 -0.0716 -0.1165 -0.1516 -0.1528
S-484	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak der Antikörperspiegel gegen murines IgG .
T-484	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-murine IgG antibody level .
H-484	-0.30746057629585266	One patient showed both a statistically significant uptrend and a sustained peak in antibody levels to murine IgG .
D-484	-0.30746057629585266	One patient showed both a statistically significant uptrend and a sustained peak in antibody levels to murine IgG .
P-484	-1.1099 -0.0661 -1.9502 -0.0959 -0.1537 -0.0126 -0.0817 -0.1000 -0.1093 -0.0781 -1.0652 -0.1281 -0.1869 -0.0832 -0.0239 -0.5064 -0.0438 -0.1912 -0.0928 -1.0696 -0.0194 -0.3335 -0.0716 -0.1165 -0.1516 -0.1528
S-646	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak der Antikörperspiegel gegen murines IgG .
T-646	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-murine IgG antibody level .
H-646	-0.30746057629585266	One patient showed both a statistically significant uptrend and a sustained peak in antibody levels to murine IgG .
D-646	-0.30746057629585266	One patient showed both a statistically significant uptrend and a sustained peak in antibody levels to murine IgG .
P-646	-1.1099 -0.0661 -1.9502 -0.0959 -0.1537 -0.0126 -0.0817 -0.1000 -0.1093 -0.0781 -1.0652 -0.1281 -0.1869 -0.0832 -0.0239 -0.5064 -0.0438 -0.1912 -0.0928 -1.0696 -0.0194 -0.3335 -0.0716 -0.1165 -0.1516 -0.1528
S-322	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak der Antikörperspiegel gegen murines IgG .
T-322	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-murine IgG antibody level .
H-322	-0.30746057629585266	One patient showed both a statistically significant uptrend and a sustained peak in antibody levels to murine IgG .
D-322	-0.30746057629585266	One patient showed both a statistically significant uptrend and a sustained peak in antibody levels to murine IgG .
P-322	-1.1099 -0.0661 -1.9502 -0.0959 -0.1537 -0.0126 -0.0817 -0.1000 -0.1093 -0.0781 -1.0652 -0.1281 -0.1869 -0.0832 -0.0239 -0.5064 -0.0438 -0.1912 -0.0928 -1.0696 -0.0194 -0.3335 -0.0716 -0.1165 -0.1516 -0.1528
S-752	Ihr Arzt wird in regelmäßigen Abständen geeignete Labortests durchführen , um sicherzustellen , dass Sie ausreichende Faktor-VIII-Spiegel haben .
T-752	Your doctor will perform appropriate laboratory tests to make sure that you have adequate Factor VIII levels .
H-752	-0.4051256775856018	Your doctor will perform appropriate laboratory tests at regular intervals to ensure that you have adequate Factor VIIII levels .
D-752	-0.4051256775856018	Your doctor will perform appropriate laboratory tests at regular intervals to ensure that you have adequate Factor VIIII levels .
P-752	-0.2658 -0.1454 -0.1895 -2.8201 -0.2133 -0.1047 -0.0974 -0.1178 -0.6996 -0.2039 -0.0708 -0.0657 -0.1272 -0.4147 -0.3000 -0.1092 -0.1007 -0.1807 -1.1885 -0.7362 -1.1963 -0.0659 -0.1582 -0.1513
S-243	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak der Antikörperspiegel gegen murines IgG .
T-243	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-murine IgG antibody level .
H-243	-0.30746057629585266	One patient showed both a statistically significant uptrend and a sustained peak in antibody levels to murine IgG .
D-243	-0.30746057629585266	One patient showed both a statistically significant uptrend and a sustained peak in antibody levels to murine IgG .
P-243	-1.1099 -0.0661 -1.9502 -0.0959 -0.1537 -0.0126 -0.0817 -0.1000 -0.1093 -0.0781 -1.0652 -0.1281 -0.1869 -0.0832 -0.0239 -0.5064 -0.0438 -0.1912 -0.0928 -1.0696 -0.0194 -0.3335 -0.0716 -0.1165 -0.1516 -0.1528
S-178	Colecalciferol In Tierstudien wurden bei weit höheren Dosen als der therapeutischen Dosis beim Menschen reproduktionstoxische Wirkungen beobachtet .
T-178	Colecalciferol At doses far higher than the human therapeutic range , reproductive toxicity has been observed in animal studies .
H-178	-0.3272710144519806	Colecalciferol Animal studies have shown reproductive toxicity at doses much higher than the human therapeutic dose .
D-178	-0.3272710144519806	Colecalciferol Animal studies have shown reproductive toxicity at doses much higher than the human therapeutic dose .
P-178	-0.1518 -0.0999 -0.1507 -0.1152 -0.1051 -0.2007 -1.7992 -0.0847 -0.0624 -0.2072 -0.3967 -0.0788 -0.7330 -0.0685 -0.0907 -0.0950 -0.1449 -0.3060 -0.0688 -1.7928 -0.0931 -0.1599 -0.2917 -0.8829 -0.8172 -0.0982 -0.1047 -0.1413 -0.1499
S-99	Colecalciferol In Tierstudien wurden bei weit höheren Dosen als der therapeutischen Dosis beim Menschen reproduktionstoxische Wirkungen beobachtet .
T-99	Colecalciferol At doses far higher than the human therapeutic range , reproductive toxicity has been observed in animal studies .
H-99	-0.3272710144519806	Colecalciferol Animal studies have shown reproductive toxicity at doses much higher than the human therapeutic dose .
D-99	-0.3272710144519806	Colecalciferol Animal studies have shown reproductive toxicity at doses much higher than the human therapeutic dose .
P-99	-0.1518 -0.0999 -0.1507 -0.1152 -0.1051 -0.2007 -1.7992 -0.0847 -0.0624 -0.2072 -0.3967 -0.0788 -0.7330 -0.0685 -0.0907 -0.0950 -0.1449 -0.3060 -0.0688 -1.7928 -0.0931 -0.1599 -0.2917 -0.8829 -0.8172 -0.0982 -0.1047 -0.1413 -0.1499
S-86	FIT 1 : eine Drei-Jahres-Studie an 2.027 Patientinnen mit mindestens einer vorbestehenden Wirbel-<unk> Kompressions-<unk> Fraktur .
T-86	FIT 1 : eine Drei-Jahres-Studie an 2.027 Patientinnen mit mindestens einer vorbestehenden Wirbel-<<unk>> Kompressions-<<unk>> Fraktur . A three-year study of 2,027 patients who had at least one baseline vertebral ( compression ) fracture .
H-86	-0.2608417272567749	FIT 1 : a three-year trial involving 2,027 patients with at least one pre-existing spine / compression / fracture .
D-86	-0.2608417272567749	FIT 1 : a three-year trial involving 2,027 patients with at least one pre-existing spine / compression / fracture .
P-86	-0.0939 -0.1221 -0.2181 -0.2010 -0.1563 -1.2809 -0.1635 -0.0573 -0.0774 -1.1335 -0.2351 -0.2055 -0.0607 -0.0937 -0.2345 -0.1293 -0.0979 -0.1048 -0.1521 -0.1593 -0.2859 -0.0372 -0.8788 -0.4518 -0.8320 -0.0990 -0.0630 -0.1637 -0.3654 -0.0645 -0.0781 -0.1577 -0.1538
S-166	FIT 1 : eine Drei-Jahres-Studie an 2.027 Patientinnen mit mindestens einer vorbestehenden Wirbel-<unk> Kompressions-<unk> Fraktur .
T-166	FIT 1 : eine Drei-Jahres-Studie an 2.027 Patientinnen mit mindestens einer vorbestehenden Wirbel-<<unk>> Kompressions-<<unk>> Fraktur . A three-year study of 2,027 patients who had at least one baseline vertebral ( compression ) fracture .
H-166	-0.2608417272567749	FIT 1 : a three-year trial involving 2,027 patients with at least one pre-existing spine / compression / fracture .
D-166	-0.2608417272567749	FIT 1 : a three-year trial involving 2,027 patients with at least one pre-existing spine / compression / fracture .
P-166	-0.0939 -0.1221 -0.2181 -0.2010 -0.1563 -1.2809 -0.1635 -0.0573 -0.0774 -1.1335 -0.2351 -0.2055 -0.0607 -0.0937 -0.2345 -0.1293 -0.0979 -0.1048 -0.1521 -0.1593 -0.2859 -0.0372 -0.8788 -0.4518 -0.8320 -0.0990 -0.0630 -0.1637 -0.3654 -0.0645 -0.0781 -0.1577 -0.1538
S-800	Sverige Baxter Medical AB Box 63 Torshamnsgatan 35 S-164 94 Kista Tel : <unk> 46 8 6326400
T-800	Sverige Baxter Medical AB Box 63 Torshamnsgatan 35 S-164 94 Kista Tel : <<unk>> 46 8 6326400
H-800	-0.11288756132125854	Sverige Baxter Medical AB Box 63 Torshamnsgatan 35 S-164 94 Kista Tel : <unk> 46 8 6326400
D-800	-0.11288756132125854	Sverige Baxter Medical AB Box 63 Torshamnsgatan 35 S-164 94 Kista Tel : <unk> 46 8 6326400
P-800	-0.1333 -0.0978 -0.0399 -0.1190 -0.1369 -0.1614 -0.2060 -0.0352 -0.2090 -0.0633 -0.1392 -0.0308 -0.1039 -0.1245 -0.1392 -0.1226 -0.0696 -0.1794 -0.1261 -0.1041 -0.1600 -0.0698 -0.1266 -0.0639 -0.1365 -0.0578 -0.1451 -0.0146 -0.0932 -0.1268 -0.1486 -0.1469 -0.0844 -0.0753 -0.1604
S-565	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak der Antikörperspiegel gegen murines IgG .
T-565	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-murine IgG antibody level .
H-565	-0.30746057629585266	One patient showed both a statistically significant uptrend and a sustained peak in antibody levels to murine IgG .
D-565	-0.30746057629585266	One patient showed both a statistically significant uptrend and a sustained peak in antibody levels to murine IgG .
P-565	-1.1099 -0.0661 -1.9502 -0.0959 -0.1537 -0.0126 -0.0817 -0.1000 -0.1093 -0.0781 -1.0652 -0.1281 -0.1869 -0.0832 -0.0239 -0.5064 -0.0438 -0.1912 -0.0928 -1.0696 -0.0194 -0.3335 -0.0716 -0.1165 -0.1516 -0.1528
S-167	FIT 2 : eine Vier-Jahres-Studie an 4.432 Patientinnen mit einer niedrigen Knochenmasse , aber ohne vorbestehende Wirbelfraktur .
T-167	FIT 2 : eine Vier-Jahres-Studie an 4.432 Patientinnen mit einer niedrigen Knochenmasse , aber ohne vorbestehende Wirbelfraktur . A four-year study of 4,432 patients with low bone mass but without a baseline vertebral fracture .
H-167	-0.2747783064842224	FIT 2 : a four-year study involving 4,432 patients with low bone mass but no pre-existing vertebral fracture .
D-167	-0.2747783064842224	FIT 2 : a four-year study involving 4,432 patients with low bone mass but no pre-existing vertebral fracture .
P-167	-0.1342 -0.1160 -0.1823 -0.1806 -0.1348 -1.7194 -0.1214 -0.0196 -0.0831 -0.7420 -0.9085 -0.8757 -0.1305 -0.1033 -0.5536 -0.1568 -0.1402 -0.0599 -0.0934 -0.1448 -0.8216 -0.1546 -0.2672 -0.0401 -0.2988 -0.0840 -0.0351 -0.0689 -0.0397 -0.0711 -0.1590 -0.1528
S-87	FIT 2 : eine Vier-Jahres-Studie an 4.432 Patientinnen mit einer niedrigen Knochenmasse , aber ohne vorbestehende Wirbelfraktur .
T-87	FIT 2 : eine Vier-Jahres-Studie an 4.432 Patientinnen mit einer niedrigen Knochenmasse , aber ohne vorbestehende Wirbelfraktur . A four-year study of 4,432 patients with low bone mass but without a baseline vertebral fracture .
H-87	-0.2747783064842224	FIT 2 : a four-year study involving 4,432 patients with low bone mass but no pre-existing vertebral fracture .
D-87	-0.2747783064842224	FIT 2 : a four-year study involving 4,432 patients with low bone mass but no pre-existing vertebral fracture .
P-87	-0.1342 -0.1160 -0.1823 -0.1806 -0.1348 -1.7194 -0.1214 -0.0196 -0.0831 -0.7420 -0.9085 -0.8757 -0.1305 -0.1033 -0.5536 -0.1568 -0.1402 -0.0599 -0.0934 -0.1448 -0.8216 -0.1546 -0.2672 -0.0401 -0.2988 -0.0840 -0.0351 -0.0689 -0.0397 -0.0711 -0.1590 -0.1528
S-795	Ireland Baxter Healthcare Ltd Unit 7 Deansgrange Industrial Estate IRL-Blackrock , Dublin Tel : <unk> 353 1 2065500
T-795	Ireland Baxter Healthcare Ltd Unit 7 Deansgrange Industrial Estate IRL-Blackrock , Dublin Tel : <<unk>> 353 1 2065500
H-795	-0.12779799103736877	Ireland Baxter Healthcare Ltd Unit 7 Deansgrange Industrial Estate IRL-Blackrock , Dublin Tel : <unk> 353 1 2065500
D-795	-0.12779799103736877	Ireland Baxter Healthcare Ltd Unit 7 Deansgrange Industrial Estate IRL-Blackrock , Dublin Tel : <unk> 353 1 2065500
P-795	-0.0418 -0.1342 -0.1872 -0.1765 -0.0824 -0.1051 -0.1379 -0.0479 -0.2041 -0.1942 -0.1315 -0.1143 -0.0554 -0.1443 -0.0661 -0.0959 -0.1417 -0.2543 -0.1694 -0.2377 -0.1088 -0.0969 -0.1516 -0.1449 -0.0482 -0.1455 -0.0157 -0.1291 -0.0982 -0.1471 -0.1634 -0.1129 -0.0985 -0.1626
S-792	Pouet de Camilo , 2 E- 46394 Ribarroja del Turia ( Valencia ) Tel : <unk> 34 96 2722800
T-792	Pouet de Camilo , 2 E- 46394 Ribarroja del Turia ( Valencia ) Tel : <<unk>> 34 96 2722800
H-792	-0.13113819062709808	Pouet de Camilo , 2 E- 46394 Ribarroja del Turia ( Valencia ) Tel : <unk> 34 96 2722800
D-792	-0.13113819062709808	Pouet de Camilo , 2 E- 46394 Ribarroja del Turia ( Valencia ) Tel : <unk> 34 96 2722800
P-792	-0.1871 -0.0846 -0.1552 -0.1134 -0.1887 -0.0918 -0.1320 -0.1545 -0.1487 -0.4480 -0.1665 -0.0906 -0.1321 -0.0881 -0.1571 -0.2336 -0.1070 -0.0851 -0.1017 -0.0981 -0.1031 -0.1507 -0.1545 -0.1512 -0.0554 -0.1478 -0.0111 -0.0919 -0.0565 -0.0610 -0.1089 -0.1013 -0.1347 -0.1667
S-112	Bei Patienten mit einer glomerulären Filtrationsrate ( GFR ) über 35 ml<unk> min ist eine Dosisanpassung nicht erforderlich .
T-112	No dosage adjustment is necessary for patients with a glomerular filtration rate ( GFR ) greater than 35ml/ min .
H-112	-0.21303421258926392	No dosage adjustment is required in patients with a glomerular filtration rate ( GFR ) greater than 35 ml/ min .
D-112	-0.21303421258926392	No dosage adjustment is required in patients with a glomerular filtration rate ( GFR ) greater than 35 ml/ min .
P-112	-0.1439 -0.6097 -0.0472 -0.1042 -0.0759 -0.0931 -0.1068 -0.1371 -0.8547 -0.8739 -0.1253 -0.1637 -0.2236 -0.2169 -0.1272 -0.1277 -0.2477 -0.1616 -0.0713 -0.1160 -0.3433 -0.1465 -0.1696 -0.0909 -0.1427 -0.6850 -0.1264 -0.1089 -0.1139 -0.1333 -0.1456 -0.1021 -0.1578 -0.1497
S-37	Bei Patienten mit einer glomerulären Filtrationsrate ( GFR ) über 35 ml<unk> min ist eine Dosisanpassung nicht erforderlich .
T-37	No dosage adjustment is necessary for patients with a glomerular filtration rate ( GFR ) greater than 35ml/ min .
H-37	-0.21303421258926392	No dosage adjustment is required in patients with a glomerular filtration rate ( GFR ) greater than 35 ml/ min .
D-37	-0.21303421258926392	No dosage adjustment is required in patients with a glomerular filtration rate ( GFR ) greater than 35 ml/ min .
P-37	-0.1439 -0.6097 -0.0472 -0.1042 -0.0759 -0.0931 -0.1068 -0.1371 -0.8547 -0.8739 -0.1253 -0.1637 -0.2236 -0.2169 -0.1272 -0.1277 -0.2477 -0.1616 -0.0713 -0.1160 -0.3433 -0.1465 -0.1696 -0.0909 -0.1427 -0.6850 -0.1264 -0.1089 -0.1139 -0.1333 -0.1456 -0.1021 -0.1578 -0.1497
S-777	- Die sonstigen Bestandteile sind Mannitol , Natriumchlorid , Histidin , Trehalose , Calciumchlorid ,
T-777	- The other ingredients are mannitol , sodium chloride , histidine , trehalose , calcium chloride ,
H-777	-0.2491336166858673	- The other ingredients are mannitol , sodium chloride , histidine , trehalose , calcium chloride ,
D-777	-0.2491336166858673	- The other ingredients are mannitol , sodium chloride , histidine , trehalose , calcium chloride ,
P-777	-0.1207 -0.4026 -0.3257 -0.1162 -0.0974 -0.1097 -0.0890 -0.1193 -0.1431 -0.0995 -0.0579 -0.1291 -0.0985 -0.0597 -0.1053 -0.1427 -0.1348 -0.2466 -0.1425 -0.1406 -0.1999 -0.3058 -0.1691 -0.1399 -0.0805 -0.0891 -0.1447 -0.1527 -0.0751 -0.0562 -0.1075 -0.1639 -3.6563
S-13	Adenuric war bei der Senkung des Harnsäurespiegels im Blut wirksamer als Allopurinol und Placebo .
T-13	Adenuric was more effective than allopurinol and placebo in reducing blood uric acid levels .
H-13	-0.22293302416801453	Adenuric was more effective than allopurinol and placebo at lowering uric acid levels in the blood .
D-13	-0.22293302416801453	Adenuric was more effective than allopurinol and placebo at lowering uric acid levels in the blood .
P-13	-0.1801 -0.1634 -0.0703 -0.1089 -0.9296 -0.1645 -0.1073 -0.2673 -0.0783 -0.1074 -0.1283 -0.1346 -0.3487 -0.0627 -0.1392 -0.0670 -0.1222 -0.8739 -0.3861 -0.0812 -0.9932 -0.0762 -0.0665 -0.1761 -0.1508 -0.1340 -0.0506 -0.1483 -0.1485
S-217	Tabelle 1 : Dosierungsanleitung bei Blutungsereignissen und Operationen Grad der Blutung / Art des chirurgischen Eingriffes Blutung
T-217	Table 1 Guide for dosing in bleeding episodes and surgery Degree of haemorrhage/ type of surgical procedure Haemorrhage
H-217	-0.544699490070343	Table 1 : Dosage guidance for haemorrhage events and operations Bleeding degree / type of surgery Haemorrhage
D-217	-0.544699490070343	Table 1 : Dosage guidance for haemorrhage events and operations Bleeding degree / type of surgery Haemorrhage
P-217	-0.1344 -0.1764 -0.1402 -1.7141 -0.0884 -0.0980 -0.9213 -0.3941 -0.4699 -0.6312 -0.0806 -0.2443 -0.2584 -0.1455 -0.9662 -1.9872 -0.2561 -2.0351 -0.2225 -0.6448 -0.1391 -0.4245 -1.8197 -0.3448 -0.0262 -0.1778 -0.1660
S-295	Tabelle 1 : Dosierungsanleitung bei Blutungsereignissen und Operationen Grad der Blutung / Art des chirurgischen Eingriffes Blutung
T-295	Table 1 Guide for dosing in bleeding episodes and surgery Degree of haemorrhage/ type of surgical procedure Haemorrhage
H-295	-0.544699490070343	Table 1 : Dosage guidance for haemorrhage events and operations Bleeding degree / type of surgery Haemorrhage
D-295	-0.544699490070343	Table 1 : Dosage guidance for haemorrhage events and operations Bleeding degree / type of surgery Haemorrhage
P-295	-0.1344 -0.1764 -0.1402 -1.7141 -0.0884 -0.0980 -0.9213 -0.3941 -0.4699 -0.6312 -0.0806 -0.2443 -0.2584 -0.1455 -0.9662 -1.9872 -0.2561 -2.0351 -0.2225 -0.6448 -0.1391 -0.4245 -1.8197 -0.3448 -0.0262 -0.1778 -0.1660
S-536	Erforderliche Einheiten ( I.E. ) = Körpergewicht ( kg ) x gewünschter Faktor-VIII-Anstieg ( % ) x 0,5
T-536	Required units ( IU ) = body weight ( kg ) x desired factor VIII rise ( % ) x 0.5
H-536	-0.364280104637146	Required units ( IU ) = body weight ( kg ) x desired factor VIIII increase ( % ) x 0.5
D-536	-0.364280104637146	Required units ( IU ) = body weight ( kg ) x desired factor VIIII increase ( % ) x 0.5
P-536	-1.4311 -0.0426 -0.1152 -0.1748 -0.1514 -0.1340 -0.0591 -0.1531 -0.1164 -2.7013 -0.0579 -0.1481 -0.0963 -0.1455 -0.1475 -0.9102 -0.0791 -0.2879 -0.0331 -1.7806 -0.2193 -0.1511 -0.1761 -0.1464 -0.1720 -0.0477 -0.1576
S-376	Tabelle 1 : Dosierungsanleitung bei Blutungsereignissen und Operationen Grad der Blutung / Art des chirurgischen Eingriffes Blutung
T-376	Table 1 Guide for dosing in bleeding episodes and surgery Degree of haemorrhage/ type of surgical procedure Haemorrhage
H-376	-0.544699490070343	Table 1 : Dosage guidance for haemorrhage events and operations Bleeding degree / type of surgery Haemorrhage
D-376	-0.544699490070343	Table 1 : Dosage guidance for haemorrhage events and operations Bleeding degree / type of surgery Haemorrhage
P-376	-0.1344 -0.1764 -0.1402 -1.7141 -0.0884 -0.0980 -0.9213 -0.3941 -0.4699 -0.6312 -0.0806 -0.2443 -0.2584 -0.1455 -0.9662 -1.9872 -0.2561 -2.0351 -0.2225 -0.6448 -0.1391 -0.4245 -1.8197 -0.3448 -0.0262 -0.1778 -0.1660
S-457	Tabelle 1 : Dosierungsanleitung bei Blutungsereignissen und Operationen Grad der Blutung / Art des chirurgischen Eingriffes Blutung
T-457	Table 1 Guide for dosing in bleeding episodes and surgery Degree of haemorrhage/ type of surgical procedure Haemorrhage
H-457	-0.544699490070343	Table 1 : Dosage guidance for haemorrhage events and operations Bleeding degree / type of surgery Haemorrhage
D-457	-0.544699490070343	Table 1 : Dosage guidance for haemorrhage events and operations Bleeding degree / type of surgery Haemorrhage
P-457	-0.1344 -0.1764 -0.1402 -1.7141 -0.0884 -0.0980 -0.9213 -0.3941 -0.4699 -0.6312 -0.0806 -0.2443 -0.2584 -0.1455 -0.9662 -1.9872 -0.2561 -2.0351 -0.2225 -0.6448 -0.1391 -0.4245 -1.8197 -0.3448 -0.0262 -0.1778 -0.1660
S-538	Tabelle 1 : Dosierungsanleitung bei Blutungsereignissen und Operationen Grad der Blutung / Art des chirurgischen Eingriffes Blutung
T-538	Table 1 Guide for dosing in bleeding episodes and surgery Degree of haemorrhage/ type of surgical procedure Haemorrhage
H-538	-0.544699490070343	Table 1 : Dosage guidance for haemorrhage events and operations Bleeding degree / type of surgery Haemorrhage
D-538	-0.544699490070343	Table 1 : Dosage guidance for haemorrhage events and operations Bleeding degree / type of surgery Haemorrhage
P-538	-0.1344 -0.1764 -0.1402 -1.7141 -0.0884 -0.0980 -0.9213 -0.3941 -0.4699 -0.6312 -0.0806 -0.2443 -0.2584 -0.1455 -0.9662 -1.9872 -0.2561 -2.0351 -0.2225 -0.6448 -0.1391 -0.4245 -1.8197 -0.3448 -0.0262 -0.1778 -0.1660
S-617	Erforderliche Einheiten ( I.E. ) = Körpergewicht ( kg ) x gewünschter Faktor-VIII-Anstieg ( % ) x 0,5
T-617	Required units ( IU ) = body weight ( kg ) x desired factor VIII rise ( % ) x 0.5
H-617	-0.364280104637146	Required units ( IU ) = body weight ( kg ) x desired factor VIIII increase ( % ) x 0.5
D-617	-0.364280104637146	Required units ( IU ) = body weight ( kg ) x desired factor VIIII increase ( % ) x 0.5
P-617	-1.4311 -0.0426 -0.1152 -0.1748 -0.1514 -0.1340 -0.0591 -0.1531 -0.1164 -2.7013 -0.0579 -0.1481 -0.0963 -0.1455 -0.1475 -0.9102 -0.0791 -0.2879 -0.0331 -1.7806 -0.2193 -0.1511 -0.1761 -0.1464 -0.1720 -0.0477 -0.1576
S-793	103 France Baxter SAS 6 Avenue Louis PasteurF-78310 Maurepas Tél : <unk> 33 1 3461 5050
T-793	97 France Baxter SAS 6 Avenue Louis PasteurF-78310 Maurepas Tél : <<unk>> 33 1 3461 5050
H-793	-0.1479293555021286	103 France Baxter SAS 6 Avenue Louis PasteurF-78310 Maurepas Tél : <unk> 33 1 3461 5050
D-793	-0.1479293555021286	103 France Baxter SAS 6 Avenue Louis PasteurF-78310 Maurepas Tél : <unk> 33 1 3461 5050
P-793	-1.3227 -0.0744 -0.1311 -0.1430 -0.1570 -0.1452 -0.0596 -0.1364 -0.0650 -0.0884 -0.1171 -0.0806 -0.1166 -0.0786 -0.0574 -0.1151 -0.1502 -0.1017 -0.1155 -0.1211 -0.1314 -0.0613 -0.1033 -0.1497 -0.0343 -0.0968 -0.1524 -0.1359 -0.0989 -0.1364 -0.0859 -0.1520 -0.1667
S-455	Erforderliche Einheiten ( I.E. ) = Körpergewicht ( kg ) x gewünschter Faktor-VIII-Anstieg ( % ) x 0,5
T-455	Required units ( IU ) = body weight ( kg ) x desired factor VIII rise ( % ) x 0.5
H-455	-0.364280104637146	Required units ( IU ) = body weight ( kg ) x desired factor VIIII increase ( % ) x 0.5
D-455	-0.364280104637146	Required units ( IU ) = body weight ( kg ) x desired factor VIIII increase ( % ) x 0.5
P-455	-1.4311 -0.0426 -0.1152 -0.1748 -0.1514 -0.1340 -0.0591 -0.1531 -0.1164 -2.7013 -0.0579 -0.1481 -0.0963 -0.1455 -0.1475 -0.9102 -0.0791 -0.2879 -0.0331 -1.7806 -0.2193 -0.1511 -0.1761 -0.1464 -0.1720 -0.0477 -0.1576
S-374	Erforderliche Einheiten ( I.E. ) = Körpergewicht ( kg ) x gewünschter Faktor-VIII-Anstieg ( % ) x 0,5
T-374	Required units ( IU ) = body weight ( kg ) x desired factor VIII rise ( % ) x 0.5
H-374	-0.364280104637146	Required units ( IU ) = body weight ( kg ) x desired factor VIIII increase ( % ) x 0.5
D-374	-0.364280104637146	Required units ( IU ) = body weight ( kg ) x desired factor VIIII increase ( % ) x 0.5
P-374	-1.4311 -0.0426 -0.1152 -0.1748 -0.1514 -0.1340 -0.0591 -0.1531 -0.1164 -2.7013 -0.0579 -0.1481 -0.0963 -0.1455 -0.1475 -0.9102 -0.0791 -0.2879 -0.0331 -1.7806 -0.2193 -0.1511 -0.1761 -0.1464 -0.1720 -0.0477 -0.1576
S-293	Erforderliche Einheiten ( I.E. ) = Körpergewicht ( kg ) x gewünschter Faktor-VIII-Anstieg ( % ) x 0,5
T-293	Required units ( IU ) = body weight ( kg ) x desired factor VIII rise ( % ) x 0.5
H-293	-0.364280104637146	Required units ( IU ) = body weight ( kg ) x desired factor VIIII increase ( % ) x 0.5
D-293	-0.364280104637146	Required units ( IU ) = body weight ( kg ) x desired factor VIIII increase ( % ) x 0.5
P-293	-1.4311 -0.0426 -0.1152 -0.1748 -0.1514 -0.1340 -0.0591 -0.1531 -0.1164 -2.7013 -0.0579 -0.1481 -0.0963 -0.1455 -0.1475 -0.9102 -0.0791 -0.2879 -0.0331 -1.7806 -0.2193 -0.1511 -0.1761 -0.1464 -0.1720 -0.0477 -0.1576
S-215	Erforderliche Einheiten ( I.E. ) = Körpergewicht ( kg ) x gewünschter Faktor-VIII-Anstieg ( % ) x 0,5
T-215	Required units ( IU ) = body weight ( kg ) x desired factor VIII rise ( % ) x 0.5
H-215	-0.364280104637146	Required units ( IU ) = body weight ( kg ) x desired factor VIIII increase ( % ) x 0.5
D-215	-0.364280104637146	Required units ( IU ) = body weight ( kg ) x desired factor VIIII increase ( % ) x 0.5
P-215	-1.4311 -0.0426 -0.1152 -0.1748 -0.1514 -0.1340 -0.0591 -0.1531 -0.1164 -2.7013 -0.0579 -0.1481 -0.0963 -0.1455 -0.1475 -0.9102 -0.0791 -0.2879 -0.0331 -1.7806 -0.2193 -0.1511 -0.1761 -0.1464 -0.1720 -0.0477 -0.1576
S-155	Vitamin D3 wird in der Leber zu 25-Hydroxyvitamin D3 umgewandelt und gespeichert , bis es gebraucht wird .
T-155	Vitamin D3 is converted to 25-hydroxyvitamin D3 in the liver , and stored until needed .
H-155	-0.22580696642398834	Vitamin D3 is converted by the liver to 25-hydroxy vitamin D3 and stored until it is needed .
D-155	-0.22580696642398834	Vitamin D3 is converted by the liver to 25-hydroxy vitamin D3 and stored until it is needed .
P-155	-0.1490 -0.0815 -0.1480 -0.1509 -0.1307 -0.1584 -0.5954 -0.1302 -0.0878 -0.6250 -0.1659 -0.0847 -0.0733 -0.5649 -0.0644 -0.1034 -0.1412 -0.1630 -0.2238 -0.3394 -0.1298 -0.0980 -0.5778 -0.1642 -0.6408 -0.1512 -0.1541
S-78	Vitamin D3 wird in der Leber zu 25-Hydroxyvitamin D3 umgewandelt und gespeichert , bis es gebraucht wird .
T-78	Vitamin D3 is converted to 25-hydroxyvitamin D3 in the liver , and stored until needed .
H-78	-0.22580696642398834	Vitamin D3 is converted by the liver to 25-hydroxy vitamin D3 and stored until it is needed .
D-78	-0.22580696642398834	Vitamin D3 is converted by the liver to 25-hydroxy vitamin D3 and stored until it is needed .
P-78	-0.1490 -0.0815 -0.1480 -0.1509 -0.1307 -0.1584 -0.5954 -0.1302 -0.0878 -0.6250 -0.1659 -0.0847 -0.0733 -0.5649 -0.0644 -0.1034 -0.1412 -0.1630 -0.2238 -0.3394 -0.1298 -0.0980 -0.5778 -0.1642 -0.6408 -0.1512 -0.1541
S-653	Hämophilie A ist eine geschlechtsgebundene , erbliche Störung der Blutgerinnung aufgrund erniedrigter Faktor VIII-Spiegel .
T-653	Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII activity and results in profuse bleeding into joints , muscles or internal organs , either
H-653	-0.5005825161933899	Haemophilia A is a gender related , hereditary blood clotting disorder caused by decreased Factor VIII levels .
D-653	-0.5005825161933899	Haemophilia A is a gender related , hereditary blood clotting disorder caused by decreased Factor VIII levels .
P-653	-0.4892 -0.0766 -0.0772 -0.1075 -0.1163 -0.1272 -0.1604 -0.6096 -1.8602 -1.1082 -0.3574 -0.0341 -0.0907 -0.4113 -0.1012 -0.0167 -0.1128 -0.2186 -2.1454 -0.1199 -1.4095 -0.0682 -1.0916 -0.5535 -1.0415 -1.5869 -0.1113 -0.1630 -0.1511
S-619	Tabelle 1 : Dosierungsanleitung bei Blutungsereignissen und Operationen Grad der Blutung / Art des chirurgischen Eingriffes Blutung
T-619	Table 1 Guide for dosing in bleeding episodes and surgery Degree of haemorrhage/ type of surgical procedure Haemorrhage
H-619	-0.544699490070343	Table 1 : Dosage guidance for haemorrhage events and operations Bleeding degree / type of surgery Haemorrhage
D-619	-0.544699490070343	Table 1 : Dosage guidance for haemorrhage events and operations Bleeding degree / type of surgery Haemorrhage
P-619	-0.1344 -0.1764 -0.1402 -1.7141 -0.0884 -0.0980 -0.9213 -0.3941 -0.4699 -0.6312 -0.0806 -0.2443 -0.2584 -0.1455 -0.9662 -1.9872 -0.2561 -2.0351 -0.2225 -0.6448 -0.1391 -0.4245 -1.8197 -0.3448 -0.0262 -0.1778 -0.1660
S-40	Alendronat Alendronat kann lokale Irritationen der Schleimhäute des oberen Gastrointestinaltraktes verursachen .
T-40	Alendronate Alendronate can cause local irritation of the upper gastrointestinal mucosa .
H-40	-0.22770248353481293	Alendronate Alendronate may cause local irritation of the mucosal membranes of the upper gastrointestinal tract .
D-40	-0.22770248353481293	Alendronate Alendronate may cause local irritation of the mucosal membranes of the upper gastrointestinal tract .
P-40	-0.2184 -0.1433 -0.1311 -0.1477 -0.2029 -0.1433 -0.1136 -0.0900 -0.1412 -0.0919 -0.6305 -0.0742 -0.1832 -0.2606 -0.1363 -0.9929 -0.5112 -1.4946 -0.0839 -0.0338 -0.1502 -0.1734 -0.1240 -0.2498 -0.0918 -0.0495 -0.1083 -0.1019 -0.0996 -0.1556 -0.0644 -0.1664 -0.1546
S-249	Hämophilie A ist eine geschlechtsgebundene , erbliche Störung der Blutgerinnung aufgrund erniedrigter Faktor VIII-Spiegel .
T-249	Hämophilie A ist eine geschlechtsgebundene , erbliche Störung der Blutgerinnung aufgrund erniedrigter Faktor VIII-Spiegel . The plasma levels of factor VIII are
H-249	-0.5005825161933899	Haemophilia A is a gender related , hereditary blood clotting disorder caused by decreased Factor VIII levels .
D-249	-0.5005825161933899	Haemophilia A is a gender related , hereditary blood clotting disorder caused by decreased Factor VIII levels .
P-249	-0.4892 -0.0766 -0.0772 -0.1075 -0.1163 -0.1272 -0.1604 -0.6096 -1.8602 -1.1082 -0.3574 -0.0341 -0.0907 -0.4113 -0.1012 -0.0167 -0.1128 -0.2186 -2.1454 -0.1199 -1.4095 -0.0682 -1.0916 -0.5535 -1.0415 -1.5869 -0.1113 -0.1630 -0.1511
S-556	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) .
T-556	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) . ( see section 4.4 ) .
H-556	-0.24536943435668945	As with any protein administered intravenously , allergic type hypersensitivity reactions may occur ( see section 4.4 ) .
D-556	-0.24536943435668945	As with any protein administered intravenously , allergic type hypersensitivity reactions may occur ( see section 4.4 ) .
P-556	-0.3889 -0.2065 -0.0877 -0.8562 -1.4007 -0.1093 -0.1182 -0.0927 -0.0840 -0.1119 -0.1583 -0.0781 -0.0691 -0.5188 -0.2131 -0.0549 -0.0480 -0.0952 -0.0834 -1.0755 -0.0899 -0.1411 -0.1989 -0.1161 -0.1210 -0.1496 -0.1500 -0.1483 -0.1504
S-768	100 Anschwellen von Füßen und Beinen , erhöhte Leberenzyme , Hämatokritabfall und Schmerzen im Oberbauch oder unteren Brustbereich
T-768	94 itching , increased sweating , unusual taste in the mouth , hot flushes , migraines , memory impairment , chills , diarrhoea , nausea , vomiting , shortness of breath , sore throat , infection of the lymphatic vessels , whitening of skin , eye inflammation , rashes , excessive sweating , foot and leg swelling , increase in enzymes that track liver function , reduced percentage of red blood cells and pain in the upper abdomen or lower chest .
H-768	-0.4270802438259125	foot and leg swelling , increased liver enzymes , haematocrit loss , and upper abdominal or lower chest pain
D-768	-0.4270802438259125	foot and leg swelling , increased liver enzymes , haematocrit loss , and upper abdominal or lower chest pain
P-768	-3.1717 -0.1676 -0.2297 -0.2169 -0.1468 -0.1549 -0.1737 -0.0871 -0.0504 -0.0596 -0.1420 -0.1404 -0.5245 -0.0606 -0.1108 -0.0872 -0.0422 -0.4969 -2.9713 -0.5464 -0.2512 -0.8753 -0.8319 -0.0235 -0.1460 -0.4916 -0.1679 -0.2184 -0.0439 -0.1822
S-572	Hämophilie A ist eine geschlechtsgebundene , erbliche Störung der Blutgerinnung aufgrund erniedrigter Faktor VIII-Spiegel .
T-572	Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII activity and results in profuse bleeding into joints , muscles or internal organs , either
H-572	-0.5005825161933899	Haemophilia A is a gender related , hereditary blood clotting disorder caused by decreased Factor VIII levels .
D-572	-0.5005825161933899	Haemophilia A is a gender related , hereditary blood clotting disorder caused by decreased Factor VIII levels .
P-572	-0.4892 -0.0766 -0.0772 -0.1075 -0.1163 -0.1272 -0.1604 -0.6096 -1.8602 -1.1082 -0.3574 -0.0341 -0.0907 -0.4113 -0.1012 -0.0167 -0.1128 -0.2186 -2.1454 -0.1199 -1.4095 -0.0682 -1.0916 -0.5535 -1.0415 -1.5869 -0.1113 -0.1630 -0.1511
S-491	Hämophilie A ist eine geschlechtsgebundene , erbliche Störung der Blutgerinnung aufgrund erniedrigter Faktor VIII-Spiegel .
T-491	Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII activity and results in profuse bleeding into joints , muscles or internal organs , either
H-491	-0.5005825161933899	Haemophilia A is a gender related , hereditary blood clotting disorder caused by decreased Factor VIII levels .
D-491	-0.5005825161933899	Haemophilia A is a gender related , hereditary blood clotting disorder caused by decreased Factor VIII levels .
P-491	-0.4892 -0.0766 -0.0772 -0.1075 -0.1163 -0.1272 -0.1604 -0.6096 -1.8602 -1.1082 -0.3574 -0.0341 -0.0907 -0.4113 -0.1012 -0.0167 -0.1128 -0.2186 -2.1454 -0.1199 -1.4095 -0.0682 -1.0916 -0.5535 -1.0415 -1.5869 -0.1113 -0.1630 -0.1511
S-410	Hämophilie A ist eine geschlechtsgebundene , erbliche Störung der Blutgerinnung aufgrund erniedrigter Faktor VIII-Spiegel .
T-410	Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII activity and results in profuse bleeding into joints , muscles or internal organs , either
H-410	-0.5005825161933899	Haemophilia A is a gender related , hereditary blood clotting disorder caused by decreased Factor VIII levels .
D-410	-0.5005825161933899	Haemophilia A is a gender related , hereditary blood clotting disorder caused by decreased Factor VIII levels .
P-410	-0.4892 -0.0766 -0.0772 -0.1075 -0.1163 -0.1272 -0.1604 -0.6096 -1.8602 -1.1082 -0.3574 -0.0341 -0.0907 -0.4113 -0.1012 -0.0167 -0.1128 -0.2186 -2.1454 -0.1199 -1.4095 -0.0682 -1.0916 -0.5535 -1.0415 -1.5869 -0.1113 -0.1630 -0.1511
S-329	Hämophilie A ist eine geschlechtsgebundene , erbliche Störung der Blutgerinnung aufgrund erniedrigter Faktor VIII-Spiegel .
T-329	Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII activity and results in profuse bleeding into joints , muscles or internal organs , either
H-329	-0.5005825161933899	Haemophilia A is a gender related , hereditary blood clotting disorder caused by decreased Factor VIII levels .
D-329	-0.5005825161933899	Haemophilia A is a gender related , hereditary blood clotting disorder caused by decreased Factor VIII levels .
P-329	-0.4892 -0.0766 -0.0772 -0.1075 -0.1163 -0.1272 -0.1604 -0.6096 -1.8602 -1.1082 -0.3574 -0.0341 -0.0907 -0.4113 -0.1012 -0.0167 -0.1128 -0.2186 -2.1454 -0.1199 -1.4095 -0.0682 -1.0916 -0.5535 -1.0415 -1.5869 -0.1113 -0.1630 -0.1511
S-54	In klinischen Studien erhielten mehrere Patientinnen Östrogen ( intravaginal , transdermal oder oral ) gemeinsam mit Alendronat .
T-54	A number of patients in the clinical trials received oestrogen ( intravaginal , transdermal , or oral ) while taking alendronate .
H-54	-0.21952061355113983	In clinical trials , multiple patients were receiving oestrogen ( intravaginal , transdermal or oral ) concomitantly with alendronate .
D-54	-0.21952061355113983	In clinical trials , multiple patients were receiving oestrogen ( intravaginal , transdermal or oral ) concomitantly with alendronate .
P-54	-0.1431 -0.1051 -0.1771 -0.2170 -0.6513 -0.3535 -1.1095 -0.1668 -0.3925 -0.0689 -0.0713 -0.1167 -0.1225 -0.1756 -0.2435 -0.1381 -0.1004 -0.1471 -0.0665 -0.2094 -0.1344 -0.2789 -0.0932 -0.1437 -0.8759 -0.0043 -0.0082 -0.4130 -0.1071 -0.1844 -0.1385 -0.1431 -0.0739 -0.1598 -0.1488
S-637	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) .
T-637	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) . ( see section 4.4 ) .
H-637	-0.24536943435668945	As with any protein administered intravenously , allergic type hypersensitivity reactions may occur ( see section 4.4 ) .
D-637	-0.24536943435668945	As with any protein administered intravenously , allergic type hypersensitivity reactions may occur ( see section 4.4 ) .
P-637	-0.3889 -0.2065 -0.0877 -0.8562 -1.4007 -0.1093 -0.1182 -0.0927 -0.0840 -0.1119 -0.1583 -0.0781 -0.0691 -0.5188 -0.2131 -0.0549 -0.0480 -0.0952 -0.0834 -1.0755 -0.0899 -0.1411 -0.1989 -0.1161 -0.1210 -0.1496 -0.1500 -0.1483 -0.1504
S-130	In klinischen Studien erhielten mehrere Patientinnen Östrogen ( intravaginal , transdermal oder oral ) gemeinsam mit Alendronat .
T-130	A number of patients in the clinical trials received oestrogen ( intravaginal , transdermal , or oral ) while taking alendronate .
H-130	-0.21952061355113983	In clinical trials , multiple patients were receiving oestrogen ( intravaginal , transdermal or oral ) concomitantly with alendronate .
D-130	-0.21952061355113983	In clinical trials , multiple patients were receiving oestrogen ( intravaginal , transdermal or oral ) concomitantly with alendronate .
P-130	-0.1431 -0.1051 -0.1771 -0.2170 -0.6513 -0.3535 -1.1095 -0.1668 -0.3925 -0.0689 -0.0713 -0.1167 -0.1225 -0.1756 -0.2435 -0.1381 -0.1004 -0.1471 -0.0665 -0.2094 -0.1344 -0.2789 -0.0932 -0.1437 -0.8759 -0.0043 -0.0082 -0.4130 -0.1071 -0.1844 -0.1385 -0.1431 -0.0739 -0.1598 -0.1488
S-475	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) .
T-475	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) . ( see section 4.4 ) .
H-475	-0.24536943435668945	As with any protein administered intravenously , allergic type hypersensitivity reactions may occur ( see section 4.4 ) .
D-475	-0.24536943435668945	As with any protein administered intravenously , allergic type hypersensitivity reactions may occur ( see section 4.4 ) .
P-475	-0.3889 -0.2065 -0.0877 -0.8562 -1.4007 -0.1093 -0.1182 -0.0927 -0.0840 -0.1119 -0.1583 -0.0781 -0.0691 -0.5188 -0.2131 -0.0549 -0.0480 -0.0952 -0.0834 -1.0755 -0.0899 -0.1411 -0.1989 -0.1161 -0.1210 -0.1496 -0.1500 -0.1483 -0.1504
S-394	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) .
T-394	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) . ( see section 4.4 ) .
H-394	-0.24536943435668945	As with any protein administered intravenously , allergic type hypersensitivity reactions may occur ( see section 4.4 ) .
D-394	-0.24536943435668945	As with any protein administered intravenously , allergic type hypersensitivity reactions may occur ( see section 4.4 ) .
P-394	-0.3889 -0.2065 -0.0877 -0.8562 -1.4007 -0.1093 -0.1182 -0.0927 -0.0840 -0.1119 -0.1583 -0.0781 -0.0691 -0.5188 -0.2131 -0.0549 -0.0480 -0.0952 -0.0834 -1.0755 -0.0899 -0.1411 -0.1989 -0.1161 -0.1210 -0.1496 -0.1500 -0.1483 -0.1504
S-313	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) .
T-313	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) . ( see section 4.4 ) .
H-313	-0.24536943435668945	As with any protein administered intravenously , allergic type hypersensitivity reactions may occur ( see section 4.4 ) .
D-313	-0.24536943435668945	As with any protein administered intravenously , allergic type hypersensitivity reactions may occur ( see section 4.4 ) .
P-313	-0.3889 -0.2065 -0.0877 -0.8562 -1.4007 -0.1093 -0.1182 -0.0927 -0.0840 -0.1119 -0.1583 -0.0781 -0.0691 -0.5188 -0.2131 -0.0549 -0.0480 -0.0952 -0.0834 -1.0755 -0.0899 -0.1411 -0.1989 -0.1161 -0.1210 -0.1496 -0.1500 -0.1483 -0.1504
S-235	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) .
T-235	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) . ( see section 4.4 ) .
H-235	-0.24536943435668945	As with any protein administered intravenously , allergic type hypersensitivity reactions may occur ( see section 4.4 ) .
D-235	-0.24536943435668945	As with any protein administered intravenously , allergic type hypersensitivity reactions may occur ( see section 4.4 ) .
P-235	-0.3889 -0.2065 -0.0877 -0.8562 -1.4007 -0.1093 -0.1182 -0.0927 -0.0840 -0.1119 -0.1583 -0.0781 -0.0691 -0.5188 -0.2131 -0.0549 -0.0480 -0.0952 -0.0834 -1.0755 -0.0899 -0.1411 -0.1989 -0.1161 -0.1210 -0.1496 -0.1500 -0.1483 -0.1504
S-95	Es wurden keine Hinweise auf eine Sättigung der Aufnahmefähigkeit des Knochens nach Langzeitdosierung von kumulativen intravenösen Dosen bis zu
T-95	No evidence of saturation of bone uptake was found after chronic dosing with cumulative intravenous doses up to 35 mg/ kg in animals .
H-95	-0.42704206705093384	No evidence exists that indicates saturation of bone absorption capacity at long term doses ranging from cumulative intravenous doses up to
D-95	-0.42704206705093384	No evidence exists that indicates saturation of bone absorption capacity at long term doses ranging from cumulative intravenous doses up to
P-95	-0.3057 -0.0572 -1.5477 -0.1372 -0.0517 -0.1324 -1.2493 -0.1066 -0.1906 -0.1583 -0.6895 -0.4858 -0.1932 -1.3579 -0.9553 -1.1303 -1.5993 -0.0294 -0.3266 -0.5518 -0.1630 -0.0870 -0.0490 -0.1050 -0.1898 -0.1030 -0.0699 -0.1171 -0.1069 -0.0692 -0.6576 -0.1254 -0.9940
S-115	Alendronat Alendronat kann lokale Irritationen der Schleimhäute des oberen Gastrointestinaltraktes verursachen .
T-115	Alendronate Alendronate can cause local irritation of the upper gastrointestinal mucosa .
H-115	-0.22770248353481293	Alendronate Alendronate may cause local irritation of the mucosal membranes of the upper gastrointestinal tract .
D-115	-0.22770248353481293	Alendronate Alendronate may cause local irritation of the mucosal membranes of the upper gastrointestinal tract .
P-115	-0.2184 -0.1433 -0.1311 -0.1477 -0.2029 -0.1433 -0.1136 -0.0900 -0.1412 -0.0919 -0.6305 -0.0742 -0.1832 -0.2606 -0.1363 -0.9929 -0.5112 -1.4946 -0.0839 -0.0338 -0.1502 -0.1734 -0.1240 -0.2498 -0.0918 -0.0495 -0.1083 -0.1019 -0.0996 -0.1556 -0.0644 -0.1664 -0.1546
S-185	Succursale belge Tél : <unk> 32 ( 0 ) 800 38693 MSDBelgium<unk> info<unk> merck.com
T-185	Succursale belge/ Belgisch bijhuis Tél/ Tel : <<unk>> 32 ( 0 ) 800 38693 MSDBelgium<<unk>> info<<unk>> merck . com
H-185	-0.13894791901111603	Succursale belge Tél : <unk> 32 ( 0 ) 800 38693 MSDBelgium<unk> info<unk> merck.com
D-185	-0.13894791901111603	Succursale belge Tél : <unk> 32 ( 0 ) 800 38693 MSDBelgium<unk> info<unk> merck.com
P-185	-0.1743 -0.0432 -0.0503 -0.0803 -0.1475 -0.1073 -0.1174 -0.0731 -0.1090 -0.1465 -0.0431 -0.0804 -0.1317 -0.1167 -0.1466 -0.0682 -0.0702 -0.1340 -0.0988 -0.1132 -0.1522 -0.1497 -0.0156 -0.0882 -0.7911 -0.1545 -0.0944 -0.4187 -0.1390 -0.0931 -0.1186 -0.1794
S-186	Succursale belge Tél : <unk> 32 ( 0 ) 800 38693 MSDBelgium<unk> info<unk> merck.com
T-186	Succursale belge/ Belgisch bijhuis Tél/ Tel : <<unk>> 32 ( 0 ) 800 38693 MSDBelgium<<unk>> info<<unk>> merck . com
H-186	-0.13894791901111603	Succursale belge Tél : <unk> 32 ( 0 ) 800 38693 MSDBelgium<unk> info<unk> merck.com
D-186	-0.13894791901111603	Succursale belge Tél : <unk> 32 ( 0 ) 800 38693 MSDBelgium<unk> info<unk> merck.com
P-186	-0.1743 -0.0432 -0.0503 -0.0803 -0.1475 -0.1073 -0.1174 -0.0731 -0.1090 -0.1465 -0.0431 -0.0804 -0.1317 -0.1167 -0.1466 -0.0682 -0.0702 -0.1340 -0.0988 -0.1132 -0.1522 -0.1497 -0.0156 -0.0882 -0.7911 -0.1545 -0.0944 -0.4187 -0.1390 -0.0931 -0.1186 -0.1794
S-38	ADROVANCE wird für Patienten mit eingeschränkter Nierenfunktion mit einer GFR unter 35 ml<unk> min aufgrund mangelnder Erfahrung nicht empfohlen .
T-38	ADROVANCE is not recommended for patients with renal impairment where GFR is less than 35ml/ min , due to lack of experience .
H-38	-0.233970507979393	ADROVANCE is not recommended for patients with renal impairment with GFR less than 35 ml/ min due to lack of experience .
D-38	-0.233970507979393	ADROVANCE is not recommended for patients with renal impairment with GFR less than 35 ml/ min due to lack of experience .
P-38	-0.3473 -0.0734 -0.1427 -0.0950 -0.0814 -0.1675 -0.1748 -0.0733 -0.2409 -0.5079 -0.1118 -0.8881 -0.1416 -0.0569 -0.0381 -0.0383 -0.1141 -0.2559 -0.4519 -0.0973 -0.8842 -0.1385 -0.1058 -0.1179 -0.1311 -0.1465 -0.1465 -0.1479 -0.1394 -1.3505 -0.1403 -0.0893 -0.1655 -0.1534
S-113	ADROVANCE wird für Patienten mit eingeschränkter Nierenfunktion mit einer GFR unter 35 ml<unk> min aufgrund mangelnder Erfahrung nicht empfohlen .
T-113	ADROVANCE is not recommended for patients with renal impairment where GFR is less than 35ml/ min , due to lack of experience .
H-113	-0.233970507979393	ADROVANCE is not recommended for patients with renal impairment with GFR less than 35 ml/ min due to lack of experience .
D-113	-0.233970507979393	ADROVANCE is not recommended for patients with renal impairment with GFR less than 35 ml/ min due to lack of experience .
P-113	-0.3473 -0.0734 -0.1427 -0.0950 -0.0814 -0.1675 -0.1748 -0.0733 -0.2409 -0.5079 -0.1118 -0.8881 -0.1416 -0.0569 -0.0381 -0.0383 -0.1141 -0.2559 -0.4519 -0.0973 -0.8842 -0.1385 -0.1058 -0.1179 -0.1311 -0.1465 -0.1465 -0.1479 -0.1394 -1.3505 -0.1403 -0.0893 -0.1655 -0.1534
S-35	In klinischen Studien gab es keinen altersabhängigen Unterschied bei dem Wirksamkeits- oder Sicherheitsprofil von Alendronat .
T-35	In clinical studies there was no age-related difference in the efficacy or safety profiles of alendronate .
H-35	-0.18905329704284668	In clinical trials there was no age related difference in the efficacy or safety profile of alendronate .
D-35	-0.18905329704284668	In clinical trials there was no age related difference in the efficacy or safety profile of alendronate .
P-35	-0.0945 -0.0772 -0.0990 -0.8548 -0.4350 -0.1170 -0.1273 -0.4555 -0.2879 -0.1530 -0.2653 -0.1191 -0.0595 -0.1267 -0.1267 -0.0957 -0.0899 -0.1434 -0.2065 -0.1451 -0.1073 -0.0530 -0.1467 -0.1511
S-152	Die Aktivität der Osteoklasten wird gehemmt , Rekrutierung und Anbindung der Osteoklasten sind jedoch nicht betroffen .
T-152	Activity of osteoclasts is inhibited , but recruitment or attachment of osteoclasts is not affected .
H-152	-0.35778212547302246	Osteoclastic activity is inhibited but osteoclastic recruiting and binding are not affected .
D-152	-0.35778212547302246	Osteoclastic activity is inhibited but osteoclastic recruiting and binding are not affected .
P-152	-0.4177 -0.1337 -0.1525 -0.0128 -1.7061 -0.1408 -0.1469 -0.3134 -0.0790 -0.0973 -1.3335 -0.2430 -0.1102 -0.1556 -0.0148 -0.6362 -0.7528 -0.1990 -0.1223 -1.2943 -0.1173 -0.2750 -0.4521 -0.1006 -0.1436 -0.1519
S-849	Die Resorptionsrate von Pseudoephedrinsulfat wird durch Antazida erhöht und durch Kaolin gemindert .
T-849	Antacids increase the rate of pseudoephedrine sulphate absorption , kaolin decreases it .
H-849	-0.18179400265216827	The rate of absorption of pseudoephedrine sulphate is increased by antacids and decreased by kaolin .
D-849	-0.18179400265216827	The rate of absorption of pseudoephedrine sulphate is increased by antacids and decreased by kaolin .
P-849	-0.9184 -0.0313 -0.1471 -0.0855 -0.1026 -0.1437 -0.2279 -0.2075 -0.1481 -0.1004 -0.1300 -0.1445 -0.1623 -0.1215 -0.2204 -0.1305 -0.1394 -0.0364 -0.2564 -0.1167 -0.0960 -0.1906 -0.1606 -0.6386 -0.0861 -0.1071 -0.2448 -0.1176 -0.1302 -0.1414 -0.1521
S-110	In klinischen Studien gab es keinen altersabhängigen Unterschied bei dem Wirksamkeits- oder Sicherheitsprofil von Alendronat .
T-110	In clinical studies there was no age-related difference in the efficacy or safety profiles of alendronate .
H-110	-0.18905329704284668	In clinical trials there was no age related difference in the efficacy or safety profile of alendronate .
D-110	-0.18905329704284668	In clinical trials there was no age related difference in the efficacy or safety profile of alendronate .
P-110	-0.0945 -0.0772 -0.0990 -0.8548 -0.4350 -0.1170 -0.1273 -0.4555 -0.2879 -0.1530 -0.2653 -0.1191 -0.0595 -0.1267 -0.1267 -0.0957 -0.0899 -0.1434 -0.2065 -0.1451 -0.1073 -0.0530 -0.1467 -0.1511
S-12	Die Wirksamkeit von Adenuric wurde in zwei Hauptstudien an insgesamt 1 834 Patienten mit Hyperurikämie und Gicht untersucht .
T-12	The effectiveness of Adenuric has been studied in two main studies involving a total of 1,834 patients with hyperuricaemia and gout .
H-12	-0.22201666235923767	The effectiveness of Adenuric has been examined in two main studies involving a total of 1,834 patients with hyperuricaemia and gout .
D-12	-0.22201666235923767	The effectiveness of Adenuric has been examined in two main studies involving a total of 1,834 patients with hyperuricaemia and gout .
P-12	-0.1421 -0.9239 -0.1093 -0.1387 -0.1183 -0.1918 -0.0683 -0.1148 -0.7061 -0.1628 -1.5961 -0.1625 -0.2749 -0.2887 -0.0986 -0.1656 -0.1726 -0.0861 -0.1425 -0.2068 -0.1079 -0.0737 -0.2381 -0.1242 -0.0665 -0.0759 -0.3030 -0.0267 -0.1266 -0.1337 -0.0616 -0.0503 -0.1417 -0.1483
S-856	In klinischen Studien zur Beurteilung der Verkehrstüchtigkeit wurde bei Patienten , die Desloratadin erhielten , keine Beeinträchtigung festgestellt .
T-856	In clinical trials that assessed the driving ability , no impairment occurred in patients receiving desloratadine .
H-856	-0.32030266523361206	In clinical trials assessing ability to drive , no impairment was observed in patients receiving desloratadine .
D-856	-0.32030266523361206	In clinical trials assessing ability to drive , no impairment was observed in patients receiving desloratadine .
P-856	-1.7953 -0.1010 -0.2852 -1.2948 -0.1186 -1.0182 -0.1305 -0.0426 -0.1237 -0.3397 -0.1567 -0.1365 -0.0339 -0.1119 -0.1025 -0.7628 -0.2634 -0.1108 -0.1656 -0.2251 -0.0468 -0.1059 -0.3184 -0.2427 -0.1464 -0.1491
S-239	Nach Beendigung der kontinuierlichen Infusion wurden Tests auf Faktor VIII-Inhibitoren durchgeführt und waren am Ende der Studie negativ .
T-239	Factor VIII inhibitor assays performed after completion of continuous infusion and at study termination were negative .
H-239	-0.42077428102493286	Following continuous infusion , tests for Factor VIII inhibitors were performed and negative at the end of the study .
D-239	-0.42077428102493286	Following continuous infusion , tests for Factor VIII inhibitors were performed and negative at the end of the study .
P-239	-1.5315 -1.1577 -0.1540 -0.4629 -0.1815 -0.2474 -0.3631 -0.4748 -1.1850 -1.1809 -0.1246 -0.1221 -0.0449 -0.0910 -0.1429 -0.1527 -0.3177 -0.1261 -1.7020 -0.2139 -0.1395 -0.1645 -0.1376 -0.1571 -0.4901 -0.1474 -0.1479
S-399	Nach Beendigung der kontinuierlichen Infusion wurden Tests auf Faktor VIII-Inhibitoren durchgeführt und waren am Ende der Studie negativ .
T-399	Factor VIII inhibitor assays performed after completion of continuous infusion and at study termination were negative .
H-399	-0.42077428102493286	Following continuous infusion , tests for Factor VIII inhibitors were performed and negative at the end of the study .
D-399	-0.42077428102493286	Following continuous infusion , tests for Factor VIII inhibitors were performed and negative at the end of the study .
P-399	-1.5315 -1.1577 -0.1540 -0.4629 -0.1815 -0.2474 -0.3631 -0.4748 -1.1850 -1.1809 -0.1246 -0.1221 -0.0449 -0.0910 -0.1429 -0.1527 -0.3177 -0.1261 -1.7020 -0.2139 -0.1395 -0.1645 -0.1376 -0.1571 -0.4901 -0.1474 -0.1479
S-654	Die Auswertung der Plasmaproben fand in einem Zentrallabor unter Verwendung eines Einstufen- Gerinnungstests statt .
T-654	The analysis of plasma samples was conducted in a central laboratory using a one-stage clotting assay .
H-654	-0.32287076115608215	Evaluation of plasma samples was performed in a central laboratory using a single-stage clotting test .
D-654	-0.32287076115608215	Evaluation of plasma samples was performed in a central laboratory using a single-stage clotting test .
P-654	-2.2718 -0.2314 -0.1405 -0.2516 -0.0727 -0.2207 -0.0828 -0.2824 -0.6526 -0.1732 -0.1204 -0.1641 -0.1713 -0.0553 -0.1902 -0.1280 -0.4586 -0.0227 -0.3629 -1.1881 -0.5845 -0.0191 -0.1384 -0.1126 -0.1493 -0.1495
S-224	Überempfindlichkeit gegen den arzneilich wirksamen Bestandteil oder einen der sonstigen Bestandteile oder gegen Maus- oder Hamsterproteinen .
T-224	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
H-224	-0.15497951209545135	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
D-224	-0.15497951209545135	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
P-224	-0.0503 -0.0451 -0.0494 -0.0858 -0.1631 -0.2712 -0.0869 -0.7303 -0.3305 -0.2611 -0.0738 -0.1485 -0.1409 -0.0574 -0.0208 -0.1088 -0.1141 -0.3453 -0.1411 -0.2451 -0.0735 -0.1351 -0.1283 -0.0504 -0.1038 -0.0616 -0.1647 -0.1525
S-318	Nach Beendigung der kontinuierlichen Infusion wurden Tests auf Faktor VIII-Inhibitoren durchgeführt und waren am Ende der Studie negativ .
T-318	Factor VIII inhibitor assays performed after completion of continuous infusion and at study termination were negative .
H-318	-0.42077428102493286	Following continuous infusion , tests for Factor VIII inhibitors were performed and negative at the end of the study .
D-318	-0.42077428102493286	Following continuous infusion , tests for Factor VIII inhibitors were performed and negative at the end of the study .
P-318	-1.5315 -1.1577 -0.1540 -0.4629 -0.1815 -0.2474 -0.3631 -0.4748 -1.1850 -1.1809 -0.1246 -0.1221 -0.0449 -0.0910 -0.1429 -0.1527 -0.3177 -0.1261 -1.7020 -0.2139 -0.1395 -0.1645 -0.1376 -0.1571 -0.4901 -0.1474 -0.1479
S-492	Die Auswertung der Plasmaproben fand in einem Zentrallabor unter Verwendung eines Einstufen- Gerinnungstests statt .
T-492	The analysis of plasma samples was conducted in a central laboratory using a one-stage clotting assay .
H-492	-0.32287076115608215	Evaluation of plasma samples was performed in a central laboratory using a single-stage clotting test .
D-492	-0.32287076115608215	Evaluation of plasma samples was performed in a central laboratory using a single-stage clotting test .
P-492	-2.2718 -0.2314 -0.1405 -0.2516 -0.0727 -0.2207 -0.0828 -0.2824 -0.6526 -0.1732 -0.1204 -0.1641 -0.1713 -0.0553 -0.1902 -0.1280 -0.4586 -0.0227 -0.3629 -1.1881 -0.5845 -0.0191 -0.1384 -0.1126 -0.1493 -0.1495
S-480	Nach Beendigung der kontinuierlichen Infusion wurden Tests auf Faktor VIII-Inhibitoren durchgeführt und waren am Ende der Studie negativ .
T-480	Factor VIII inhibitor assays performed after completion of continuous infusion and at study termination were negative .
H-480	-0.42077428102493286	Following continuous infusion , tests for Factor VIII inhibitors were performed and negative at the end of the study .
D-480	-0.42077428102493286	Following continuous infusion , tests for Factor VIII inhibitors were performed and negative at the end of the study .
P-480	-1.5315 -1.1577 -0.1540 -0.4629 -0.1815 -0.2474 -0.3631 -0.4748 -1.1850 -1.1809 -0.1246 -0.1221 -0.0449 -0.0910 -0.1429 -0.1527 -0.3177 -0.1261 -1.7020 -0.2139 -0.1395 -0.1645 -0.1376 -0.1571 -0.4901 -0.1474 -0.1479
S-561	Nach Beendigung der kontinuierlichen Infusion wurden Tests auf Faktor VIII-Inhibitoren durchgeführt und waren am Ende der Studie negativ .
T-561	Factor VIII inhibitor assays performed after completion of continuous infusion and at study termination were negative .
H-561	-0.42077428102493286	Following continuous infusion , tests for Factor VIII inhibitors were performed and negative at the end of the study .
D-561	-0.42077428102493286	Following continuous infusion , tests for Factor VIII inhibitors were performed and negative at the end of the study .
P-561	-1.5315 -1.1577 -0.1540 -0.4629 -0.1815 -0.2474 -0.3631 -0.4748 -1.1850 -1.1809 -0.1246 -0.1221 -0.0449 -0.0910 -0.1429 -0.1527 -0.3177 -0.1261 -1.7020 -0.2139 -0.1395 -0.1645 -0.1376 -0.1571 -0.4901 -0.1474 -0.1479
S-642	Nach Beendigung der kontinuierlichen Infusion wurden Tests auf Faktor VIII-Inhibitoren durchgeführt und waren am Ende der Studie negativ .
T-642	Factor VIII inhibitor assays performed after completion of continuous infusion and at study termination were negative .
H-642	-0.42077428102493286	Following continuous infusion , tests for Factor VIII inhibitors were performed and negative at the end of the study .
D-642	-0.42077428102493286	Following continuous infusion , tests for Factor VIII inhibitors were performed and negative at the end of the study .
P-642	-1.5315 -1.1577 -0.1540 -0.4629 -0.1815 -0.2474 -0.3631 -0.4748 -1.1850 -1.1809 -0.1246 -0.1221 -0.0449 -0.0910 -0.1429 -0.1527 -0.3177 -0.1261 -1.7020 -0.2139 -0.1395 -0.1645 -0.1376 -0.1571 -0.4901 -0.1474 -0.1479
S-250	Die Auswertung der Plasmaproben fand in einem Zentrallabor unter Verwendung eines Einstufen- Gerinnungstests statt .
T-250	The analysis of plasma samples was conducted in a central laboratory using a one-stage clotting assay .
H-250	-0.32287076115608215	Evaluation of plasma samples was performed in a central laboratory using a single-stage clotting test .
D-250	-0.32287076115608215	Evaluation of plasma samples was performed in a central laboratory using a single-stage clotting test .
P-250	-2.2718 -0.2314 -0.1405 -0.2516 -0.0727 -0.2207 -0.0828 -0.2824 -0.6526 -0.1732 -0.1204 -0.1641 -0.1713 -0.0553 -0.1902 -0.1280 -0.4586 -0.0227 -0.3629 -1.1881 -0.5845 -0.0191 -0.1384 -0.1126 -0.1493 -0.1495
S-302	Überempfindlichkeit gegen den arzneilich wirksamen Bestandteil oder einen der sonstigen Bestandteile oder gegen Maus- oder Hamsterproteinen .
T-302	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
H-302	-0.15497951209545135	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
D-302	-0.15497951209545135	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
P-302	-0.0503 -0.0451 -0.0494 -0.0858 -0.1631 -0.2712 -0.0869 -0.7303 -0.3305 -0.2611 -0.0738 -0.1485 -0.1409 -0.0574 -0.0208 -0.1088 -0.1141 -0.3453 -0.1411 -0.2451 -0.0735 -0.1351 -0.1283 -0.0504 -0.1038 -0.0616 -0.1647 -0.1525
S-573	Die Auswertung der Plasmaproben fand in einem Zentrallabor unter Verwendung eines Einstufen- Gerinnungstests statt .
T-573	The analysis of plasma samples was conducted in a central laboratory using a one-stage clotting assay .
H-573	-0.32287076115608215	Evaluation of plasma samples was performed in a central laboratory using a single-stage clotting test .
D-573	-0.32287076115608215	Evaluation of plasma samples was performed in a central laboratory using a single-stage clotting test .
P-573	-2.2718 -0.2314 -0.1405 -0.2516 -0.0727 -0.2207 -0.0828 -0.2824 -0.6526 -0.1732 -0.1204 -0.1641 -0.1713 -0.0553 -0.1902 -0.1280 -0.4586 -0.0227 -0.3629 -1.1881 -0.5845 -0.0191 -0.1384 -0.1126 -0.1493 -0.1495
S-464	Überempfindlichkeit gegen den arzneilich wirksamen Bestandteil oder einen der sonstigen Bestandteile oder gegen Maus- oder Hamsterproteinen .
T-464	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
H-464	-0.15497951209545135	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
D-464	-0.15497951209545135	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
P-464	-0.0503 -0.0451 -0.0494 -0.0858 -0.1631 -0.2712 -0.0869 -0.7303 -0.3305 -0.2611 -0.0738 -0.1485 -0.1409 -0.0574 -0.0208 -0.1088 -0.1141 -0.3453 -0.1411 -0.2451 -0.0735 -0.1351 -0.1283 -0.0504 -0.1038 -0.0616 -0.1647 -0.1525
S-242	Die bisherige Häufigkeit der Erkennung von FVIII-Inhibitoren entspricht den Erwartungen und liegt im bereits beobachteten Bereich .
T-242	The frequency of FVIII inhibitors detected so far is within the expected and previously observed range .
H-242	-0.3441970944404602	The frequency of detection of FVIIII inhibitors to date is in line with expectations and in the range already observed .
D-242	-0.3441970944404602	The frequency of detection of FVIIII inhibitors to date is in line with expectations and in the range already observed .
P-242	-0.1740 -1.6470 -0.0736 -0.8323 -0.1970 -0.1383 -0.2430 -0.2004 -0.1457 -1.4186 -0.1114 -0.0363 -0.0829 -0.1497 -0.6066 -0.1041 -0.6285 -0.4197 -0.2952 -0.1242 -0.1193 -0.1326 -0.9509 -0.1451 -0.1009 -0.4676 -0.1394 -0.1444 -0.1532
S-402	Die bisherige Häufigkeit der Erkennung von FVIII-Inhibitoren entspricht den Erwartungen und liegt im bereits beobachteten Bereich .
T-402	The frequency of FVIII inhibitors detected so far is within the expected and previously observed range .
H-402	-0.3441970944404602	The frequency of detection of FVIIII inhibitors to date is in line with expectations and in the range already observed .
D-402	-0.3441970944404602	The frequency of detection of FVIIII inhibitors to date is in line with expectations and in the range already observed .
P-402	-0.1740 -1.6470 -0.0736 -0.8323 -0.1970 -0.1383 -0.2430 -0.2004 -0.1457 -1.4186 -0.1114 -0.0363 -0.0829 -0.1497 -0.6066 -0.1041 -0.6285 -0.4197 -0.2952 -0.1242 -0.1193 -0.1326 -0.9509 -0.1451 -0.1009 -0.4676 -0.1394 -0.1444 -0.1532
S-737	WAS MÜSSEN SIE VOR DER ANWENDUNG VON ADVATE BEACHTEN ?
T-737	BEFORE YOU USE ADVATE
H-737	-0.11254989355802536	BEFORE YOU USE ADVATE
D-737	-0.11254989355802536	BEFORE YOU USE ADVATE
P-737	-0.0733 -0.0187 -0.0201 -0.0767 -0.0761 -0.0613 -0.2462 -0.0522 -0.2224 -0.2033 -0.1032 -0.0918 -0.2182
S-745	Verkehrstüchtigkeit und das Bedienen von Maschinen ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und das Bedienen von Maschinen .
T-745	Driving and using machines ADVATE has no influence on your ability to drive or to use machines .
H-745	-0.2467310130596161	Driving and using machines ADVATE has no effect on the ability to drive and use machines .
D-745	-0.2467310130596161	Driving and using machines ADVATE has no effect on the ability to drive and use machines .
P-745	-0.9344 -0.2399 -0.1344 -0.1612 -0.0822 -0.0892 -0.1667 -0.0752 -0.0792 -0.2003 -0.1586 -0.9724 -0.1304 -0.8900 -0.2404 -0.1367 -0.0744 -0.1793 -0.1131 -0.0630 -0.1502 -0.1568
S-88	Die gemeinsame Einnahme von Alendronat mit Kaffee oder Orangensaft reduzierte die Bioverfügbarkeit um etwa 60 <unk> .
T-88	Concomitant administration of alendronate with coffee or orange juice reduced bioavailability by approximately 60 % .
H-88	-0.269905686378479	Alendronate concomitant administration with coffee or orange juice reduced bioavailability by approximately 60 % .
D-88	-0.269905686378479	Alendronate concomitant administration with coffee or orange juice reduced bioavailability by approximately 60 % .
P-88	-1.2607 -0.1733 -0.1073 -0.0921 -0.5807 -0.0081 -0.0048 -0.2884 -0.9919 -0.2969 -0.2673 -0.1169 -0.1048 -0.1564 -0.2461 -0.0500 -0.0837 -0.1256 -0.6283 -0.1930 -0.1380 -0.1430 -0.1507
S-168	Die gemeinsame Einnahme von Alendronat mit Kaffee oder Orangensaft reduzierte die Bioverfügbarkeit um etwa 60 <unk> .
T-168	Concomitant administration of alendronate with coffee or orange juice reduced bioavailability by approximately 60 % .
H-168	-0.269905686378479	Alendronate concomitant administration with coffee or orange juice reduced bioavailability by approximately 60 % .
D-168	-0.269905686378479	Alendronate concomitant administration with coffee or orange juice reduced bioavailability by approximately 60 % .
P-168	-1.2607 -0.1733 -0.1073 -0.0921 -0.5807 -0.0081 -0.0048 -0.2884 -0.9919 -0.2969 -0.2673 -0.1169 -0.1048 -0.1564 -0.2461 -0.0500 -0.0837 -0.1256 -0.6283 -0.1930 -0.1380 -0.1430 -0.1507
S-411	Die Auswertung der Plasmaproben fand in einem Zentrallabor unter Verwendung eines Einstufen- Gerinnungstests statt .
T-411	The analysis of plasma samples was conducted in a central laboratory using a one-stage clotting assay .
H-411	-0.32287076115608215	Evaluation of plasma samples was performed in a central laboratory using a single-stage clotting test .
D-411	-0.32287076115608215	Evaluation of plasma samples was performed in a central laboratory using a single-stage clotting test .
P-411	-2.2718 -0.2314 -0.1405 -0.2516 -0.0727 -0.2207 -0.0828 -0.2824 -0.6526 -0.1732 -0.1204 -0.1641 -0.1713 -0.0553 -0.1902 -0.1280 -0.4586 -0.0227 -0.3629 -1.1881 -0.5845 -0.0191 -0.1384 -0.1126 -0.1493 -0.1495
S-321	Die bisherige Häufigkeit der Erkennung von FVIII-Inhibitoren entspricht den Erwartungen und liegt im bereits beobachteten Bereich .
T-321	The frequency of FVIII inhibitors detected so far is within the expected and previously observed range .
H-321	-0.3441970944404602	The frequency of detection of FVIIII inhibitors to date is in line with expectations and in the range already observed .
D-321	-0.3441970944404602	The frequency of detection of FVIIII inhibitors to date is in line with expectations and in the range already observed .
P-321	-0.1740 -1.6470 -0.0736 -0.8323 -0.1970 -0.1383 -0.2430 -0.2004 -0.1457 -1.4186 -0.1114 -0.0363 -0.0829 -0.1497 -0.6066 -0.1041 -0.6285 -0.4197 -0.2952 -0.1242 -0.1193 -0.1326 -0.9509 -0.1451 -0.1009 -0.4676 -0.1394 -0.1444 -0.1532
S-330	Die Auswertung der Plasmaproben fand in einem Zentrallabor unter Verwendung eines Einstufen- Gerinnungstests statt .
T-330	The analysis of plasma samples was conducted in a central laboratory using a one-stage clotting assay .
H-330	-0.32287076115608215	Evaluation of plasma samples was performed in a central laboratory using a single-stage clotting test .
D-330	-0.32287076115608215	Evaluation of plasma samples was performed in a central laboratory using a single-stage clotting test .
P-330	-2.2718 -0.2314 -0.1405 -0.2516 -0.0727 -0.2207 -0.0828 -0.2824 -0.6526 -0.1732 -0.1204 -0.1641 -0.1713 -0.0553 -0.1902 -0.1280 -0.4586 -0.0227 -0.3629 -1.1881 -0.5845 -0.0191 -0.1384 -0.1126 -0.1493 -0.1495
S-483	Die bisherige Häufigkeit der Erkennung von FVIII-Inhibitoren entspricht den Erwartungen und liegt im bereits beobachteten Bereich .
T-483	The frequency of FVIII inhibitors detected so far is within the expected and previously observed range .
H-483	-0.3441970944404602	The frequency of detection of FVIIII inhibitors to date is in line with expectations and in the range already observed .
D-483	-0.3441970944404602	The frequency of detection of FVIIII inhibitors to date is in line with expectations and in the range already observed .
P-483	-0.1740 -1.6470 -0.0736 -0.8323 -0.1970 -0.1383 -0.2430 -0.2004 -0.1457 -1.4186 -0.1114 -0.0363 -0.0829 -0.1497 -0.6066 -0.1041 -0.6285 -0.4197 -0.2952 -0.1242 -0.1193 -0.1326 -0.9509 -0.1451 -0.1009 -0.4676 -0.1394 -0.1444 -0.1532
S-564	Die bisherige Häufigkeit der Erkennung von FVIII-Inhibitoren entspricht den Erwartungen und liegt im bereits beobachteten Bereich .
T-564	The frequency of FVIII inhibitors detected so far is within the expected and previously observed range .
H-564	-0.3441970944404602	The frequency of detection of FVIIII inhibitors to date is in line with expectations and in the range already observed .
D-564	-0.3441970944404602	The frequency of detection of FVIIII inhibitors to date is in line with expectations and in the range already observed .
P-564	-0.1740 -1.6470 -0.0736 -0.8323 -0.1970 -0.1383 -0.2430 -0.2004 -0.1457 -1.4186 -0.1114 -0.0363 -0.0829 -0.1497 -0.6066 -0.1041 -0.6285 -0.4197 -0.2952 -0.1242 -0.1193 -0.1326 -0.9509 -0.1451 -0.1009 -0.4676 -0.1394 -0.1444 -0.1532
S-645	Die bisherige Häufigkeit der Erkennung von FVIII-Inhibitoren entspricht den Erwartungen und liegt im bereits beobachteten Bereich .
T-645	The frequency of FVIII inhibitors detected so far is within the expected and previously observed range .
H-645	-0.3441970944404602	The frequency of detection of FVIIII inhibitors to date is in line with expectations and in the range already observed .
D-645	-0.3441970944404602	The frequency of detection of FVIIII inhibitors to date is in line with expectations and in the range already observed .
P-645	-0.1740 -1.6470 -0.0736 -0.8323 -0.1970 -0.1383 -0.2430 -0.2004 -0.1457 -1.4186 -0.1114 -0.0363 -0.0829 -0.1497 -0.6066 -0.1041 -0.6285 -0.4197 -0.2952 -0.1242 -0.1193 -0.1326 -0.9509 -0.1451 -0.1009 -0.4676 -0.1394 -0.1444 -0.1532
S-149	Bei einer Überdosis mit ADROVANCE sollten Milch oder Antazida gegeben werden , um Alendronat zu binden .
T-149	In case of overdose with ADROVANCE , milk or antacids should be given to bind alendronate .
H-149	-0.21366223692893982	In case of overdose with ADROVANCE , milk or antacids should be given to bind alendronate .
D-149	-0.21366223692893982	In case of overdose with ADROVANCE , milk or antacids should be given to bind alendronate .
P-149	-0.3876 -0.3642 -0.1473 -0.9239 -0.1307 -0.1554 -0.0890 -0.0785 -0.1463 -0.1084 -0.0751 -0.1386 -0.1346 -0.1077 -0.0731 -0.1232 -0.1155 -0.1090 -0.1385 -0.9609 -0.1845 -0.1051 -0.0460 -0.7101 -0.1307 -0.1199 -0.0645 -0.1758 -0.1519
S-383	Überempfindlichkeit gegen den arzneilich wirksamen Bestandteil oder einen der sonstigen Bestandteile oder gegen Maus- oder Hamsterproteinen .
T-383	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
H-383	-0.15497951209545135	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
D-383	-0.15497951209545135	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
P-383	-0.0503 -0.0451 -0.0494 -0.0858 -0.1631 -0.2712 -0.0869 -0.7303 -0.3305 -0.2611 -0.0738 -0.1485 -0.1409 -0.0574 -0.0208 -0.1088 -0.1141 -0.3453 -0.1411 -0.2451 -0.0735 -0.1351 -0.1283 -0.0504 -0.1038 -0.0616 -0.1647 -0.1525
S-143	Selten : starke muskuloskelettale ( Knochen- , Muskel- oder Gelenk- ) Schmerzen ( siehe Abschnitt 4.4 ) .
T-143	Metabolism and nutrition disorders :
H-143	-0.17870421707630157	Rare : severe musculoskeletal ( bone , muscle or joint ) pain ( see section 4.4 ) .
D-143	-0.17870421707630157	Rare : severe musculoskeletal ( bone , muscle or joint ) pain ( see section 4.4 ) .
P-143	-0.6470 -0.1152 -0.1724 -0.1011 -0.0988 -0.4512 -0.0891 -0.0702 -0.2360 -0.1090 -0.3407 -0.0819 -0.1551 -0.1336 -0.2395 -0.0605 -0.1657 -0.0689 -0.1457 -0.2895 -0.1369 -0.1179 -0.1510 -0.1494 -0.1592 -0.1609
S-545	Überempfindlichkeit gegen den arzneilich wirksamen Bestandteil oder einen der sonstigen Bestandteile oder gegen Maus- oder Hamsterproteinen .
T-545	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
H-545	-0.15497951209545135	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
D-545	-0.15497951209545135	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
P-545	-0.0503 -0.0451 -0.0494 -0.0858 -0.1631 -0.2712 -0.0869 -0.7303 -0.3305 -0.2611 -0.0738 -0.1485 -0.1409 -0.0574 -0.0208 -0.1088 -0.1141 -0.3453 -0.1411 -0.2451 -0.0735 -0.1351 -0.1283 -0.0504 -0.1038 -0.0616 -0.1647 -0.1525
S-495	Tabelle 4 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 53 Kindern mit schwerer bis mäßiger Hämophilie A
T-495	Table 4 Summary of pharmacokinetic parameters for ADVATE in 53 paediatric patients with severe to moderately severe haemophilia A
H-495	-0.1742004007101059	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
D-495	-0.1742004007101059	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
P-495	-0.0675 -0.1661 -0.0626 -0.0646 -0.1464 -1.1088 -0.1841 -0.0777 -0.0785 -0.4987 -0.0762 -0.0521 -0.1775 -0.1394 -0.0606 -0.1280 -0.2085 -0.0865 -0.3807 -0.1081 -0.0626 -0.2337 -0.0480 -0.3182 -0.0866 -0.0762 -0.0716 -0.1163 -0.1662
S-576	Tabelle 4 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 53 Kindern mit schwerer bis mäßiger Hämophilie A
T-576	Table 4 Summary of pharmacokinetic parameters for ADVATE in 53 paediatric patients with severe to moderately severe haemophilia A
H-576	-0.1742004007101059	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
D-576	-0.1742004007101059	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
P-576	-0.0675 -0.1661 -0.0626 -0.0646 -0.1464 -1.1088 -0.1841 -0.0777 -0.0785 -0.4987 -0.0762 -0.0521 -0.1775 -0.1394 -0.0606 -0.1280 -0.2085 -0.0865 -0.3807 -0.1081 -0.0626 -0.2337 -0.0480 -0.3182 -0.0866 -0.0762 -0.0716 -0.1163 -0.1662
S-613	Behandlung und Prophylaxe von Blutungen bei Patienten mit Hämophilie A ( angeborener Faktor VIII- Mangel ) .
T-613	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
H-613	-0.18959304690361023	Treatment and prophylaxis of haemorrhage in patients with haemophilia A ( congenital factor VIII deficiency ) .
D-613	-0.18959304690361023	Treatment and prophylaxis of haemorrhage in patients with haemophilia A ( congenital factor VIII deficiency ) .
P-613	-0.0547 -0.0991 -0.1208 -0.1244 -0.1565 -0.0836 -0.1336 -0.0962 -0.0829 -0.1438 -0.6243 -0.4126 -0.0538 -0.5301 -0.1514 -0.0874 -0.1409 -0.1077 -0.0681 -0.0828 -0.0860 -0.1270 -0.1552 -0.3642 -0.1037 -0.1758 -0.1123 -0.5477 -0.8663 -0.0118 -0.0543 -0.1026 -0.1491 -0.2686 -0.1563
S-252	Tabelle 4 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 53 Kindern mit schwerer bis mäßiger Hämophilie A
T-252	Table 4 Summary of pharmacokinetic parameters for ADVATE in 53 paediatric patients with severe to moderately severe haemophilia A
H-252	-0.1742004007101059	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
D-252	-0.1742004007101059	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
P-252	-0.0675 -0.1661 -0.0626 -0.0646 -0.1464 -1.1088 -0.1841 -0.0777 -0.0785 -0.4987 -0.0762 -0.0521 -0.1775 -0.1394 -0.0606 -0.1280 -0.2085 -0.0865 -0.3807 -0.1081 -0.0626 -0.2337 -0.0480 -0.3182 -0.0866 -0.0762 -0.0716 -0.1163 -0.1662
S-333	Tabelle 4 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 53 Kindern mit schwerer bis mäßiger Hämophilie A
T-333	Table 4 Summary of pharmacokinetic parameters for ADVATE in 53 paediatric patients with severe to moderately severe haemophilia A
H-333	-0.1742004007101059	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
D-333	-0.1742004007101059	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
P-333	-0.0675 -0.1661 -0.0626 -0.0646 -0.1464 -1.1088 -0.1841 -0.0777 -0.0785 -0.4987 -0.0762 -0.0521 -0.1775 -0.1394 -0.0606 -0.1280 -0.2085 -0.0865 -0.3807 -0.1081 -0.0626 -0.2337 -0.0480 -0.3182 -0.0866 -0.0762 -0.0716 -0.1163 -0.1662
S-414	Tabelle 4 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 53 Kindern mit schwerer bis mäßiger Hämophilie A
T-414	Table 4 Summary of pharmacokinetic parameters for ADVATE in 53 paediatric patients with severe to moderately severe haemophilia A
H-414	-0.1742004007101059	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
D-414	-0.1742004007101059	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
P-414	-0.0675 -0.1661 -0.0626 -0.0646 -0.1464 -1.1088 -0.1841 -0.0777 -0.0785 -0.4987 -0.0762 -0.0521 -0.1775 -0.1394 -0.0606 -0.1280 -0.2085 -0.0865 -0.3807 -0.1081 -0.0626 -0.2337 -0.0480 -0.3182 -0.0866 -0.0762 -0.0716 -0.1163 -0.1662
S-451	Behandlung und Prophylaxe von Blutungen bei Patienten mit Hämophilie A ( angeborener Faktor VIII- Mangel ) .
T-451	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
H-451	-0.18959304690361023	Treatment and prophylaxis of haemorrhage in patients with haemophilia A ( congenital factor VIII deficiency ) .
D-451	-0.18959304690361023	Treatment and prophylaxis of haemorrhage in patients with haemophilia A ( congenital factor VIII deficiency ) .
P-451	-0.0547 -0.0991 -0.1208 -0.1244 -0.1565 -0.0836 -0.1336 -0.0962 -0.0829 -0.1438 -0.6243 -0.4126 -0.0538 -0.5301 -0.1514 -0.0874 -0.1409 -0.1077 -0.0681 -0.0828 -0.0860 -0.1270 -0.1552 -0.3642 -0.1037 -0.1758 -0.1123 -0.5477 -0.8663 -0.0118 -0.0543 -0.1026 -0.1491 -0.2686 -0.1563
S-289	Behandlung und Prophylaxe von Blutungen bei Patienten mit Hämophilie A ( angeborener Faktor VIII- Mangel ) .
T-289	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
H-289	-0.18959304690361023	Treatment and prophylaxis of haemorrhage in patients with haemophilia A ( congenital factor VIII deficiency ) .
D-289	-0.18959304690361023	Treatment and prophylaxis of haemorrhage in patients with haemophilia A ( congenital factor VIII deficiency ) .
P-289	-0.0547 -0.0991 -0.1208 -0.1244 -0.1565 -0.0836 -0.1336 -0.0962 -0.0829 -0.1438 -0.6243 -0.4126 -0.0538 -0.5301 -0.1514 -0.0874 -0.1409 -0.1077 -0.0681 -0.0828 -0.0860 -0.1270 -0.1552 -0.3642 -0.1037 -0.1758 -0.1123 -0.5477 -0.8663 -0.0118 -0.0543 -0.1026 -0.1491 -0.2686 -0.1563
S-657	Tabelle 4 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 53 Kindern mit schwerer bis mäßiger Hämophilie A
T-657	Table 4 Summary of pharmacokinetic parameters for ADVATE in 53 paediatric patients with severe to moderately severe haemophilia A
H-657	-0.1742004007101059	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
D-657	-0.1742004007101059	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
P-657	-0.0675 -0.1661 -0.0626 -0.0646 -0.1464 -1.1088 -0.1841 -0.0777 -0.0785 -0.4987 -0.0762 -0.0521 -0.1775 -0.1394 -0.0606 -0.1280 -0.2085 -0.0865 -0.3807 -0.1081 -0.0626 -0.2337 -0.0480 -0.3182 -0.0866 -0.0762 -0.0716 -0.1163 -0.1662
S-840	Bei der Anwendung bei Patienten mit stenosierenden Magengeschwüren und pyloroduodenaler Obstruktion ist Vorsicht geboten .
T-840	Use with caution in patients with stenosing peptic ulcer , pyloroduodenal obstruction , and obstruction of the vesical cervix .
H-840	-0.34218528866767883	Caution should be used in patients with stenosising stomach ulcers and pyloroduodenal obstruction .
D-840	-0.34218528866767883	Caution should be used in patients with stenosising stomach ulcers and pyloroduodenal obstruction .
P-840	-0.1642 -0.0733 -1.5015 -0.1692 -0.8276 -0.1413 -0.1612 -0.1939 -0.0136 -0.1962 -0.8364 -1.1755 -1.0788 -0.1128 -1.3110 -0.1225 -0.1548 -0.0364 -0.0385 -0.1412 -0.1326 -0.0797 -0.0576 -0.2254 -0.1808 -0.1513 -0.1540 -0.1501
S-68	Selten : symptomatische Hypocalcämie , meist bei Patienten mit entsprechenden prädisponierenden Faktoren ( siehe Abschnitt 4.4 ) .
T-68	Common : musculoskeletal ( bone , muscle or joint ) pain Rare : severe musculoskeletal ( bone , muscle or joint ) pain ( see section 4.4 ) Rare : symptomatic hypocalcaemia , often in association with predisposing conditions .
H-68	-0.19057141244411469	Rare : symptomatic hypocalcaemia , usually in patients with corresponding predisposing factors ( see section 4.4 ) .
D-68	-0.19057141244411469	Rare : symptomatic hypocalcaemia , usually in patients with corresponding predisposing factors ( see section 4.4 ) .
P-68	-0.1373 -0.0929 -0.1170 -0.0699 -0.0792 -0.1127 -0.0239 -0.0777 -0.2606 -0.0785 -0.1254 -0.1985 -1.6050 -0.2609 -0.0893 -0.1257 -0.2269 -0.1150 -0.2658 -0.1427 -0.1207 -0.1696 -0.1466 -0.2325 -0.1134 -0.1181 -0.1526 -0.1489 -0.1556 -0.1542
S-144	Selten : symptomatische Hypocalcämie , meist bei Patienten mit entsprechenden prädisponierenden Faktoren ( siehe Abschnitt 4.4 ) .
T-144	Common : musculoskeletal ( bone , muscle or joint ) pain Rare : severe musculoskeletal ( bone , muscle or joint ) pain ( see section 4.4 ) Rare : symptomatic hypocalcaemia , often in association with predisposing conditions .
H-144	-0.19057141244411469	Rare : symptomatic hypocalcaemia , usually in patients with corresponding predisposing factors ( see section 4.4 ) .
D-144	-0.19057141244411469	Rare : symptomatic hypocalcaemia , usually in patients with corresponding predisposing factors ( see section 4.4 ) .
P-144	-0.1373 -0.0929 -0.1170 -0.0699 -0.0792 -0.1127 -0.0239 -0.0777 -0.2606 -0.0785 -0.1254 -0.1985 -1.6050 -0.2609 -0.0893 -0.1257 -0.2269 -0.1150 -0.2658 -0.1427 -0.1207 -0.1696 -0.1466 -0.2325 -0.1134 -0.1181 -0.1526 -0.1489 -0.1556 -0.1542
S-532	Behandlung und Prophylaxe von Blutungen bei Patienten mit Hämophilie A ( angeborener Faktor VIII- Mangel ) .
T-532	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
H-532	-0.18959304690361023	Treatment and prophylaxis of haemorrhage in patients with haemophilia A ( congenital factor VIII deficiency ) .
D-532	-0.18959304690361023	Treatment and prophylaxis of haemorrhage in patients with haemophilia A ( congenital factor VIII deficiency ) .
P-532	-0.0547 -0.0991 -0.1208 -0.1244 -0.1565 -0.0836 -0.1336 -0.0962 -0.0829 -0.1438 -0.6243 -0.4126 -0.0538 -0.5301 -0.1514 -0.0874 -0.1409 -0.1077 -0.0681 -0.0828 -0.0860 -0.1270 -0.1552 -0.3642 -0.1037 -0.1758 -0.1123 -0.5477 -0.8663 -0.0118 -0.0543 -0.1026 -0.1491 -0.2686 -0.1563
S-626	Überempfindlichkeit gegen den arzneilich wirksamen Bestandteil oder einen der sonstigen Bestandteile oder gegen Maus- oder Hamsterproteinen .
T-626	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
H-626	-0.15497951209545135	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
D-626	-0.15497951209545135	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
P-626	-0.0503 -0.0451 -0.0494 -0.0858 -0.1631 -0.2712 -0.0869 -0.7303 -0.3305 -0.2611 -0.0738 -0.1485 -0.1409 -0.0574 -0.0208 -0.1088 -0.1141 -0.3453 -0.1411 -0.2451 -0.0735 -0.1351 -0.1283 -0.0504 -0.1038 -0.0616 -0.1647 -0.1525
S-370	Behandlung und Prophylaxe von Blutungen bei Patienten mit Hämophilie A ( angeborener Faktor VIII- Mangel ) .
T-370	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
H-370	-0.18959304690361023	Treatment and prophylaxis of haemorrhage in patients with haemophilia A ( congenital factor VIII deficiency ) .
D-370	-0.18959304690361023	Treatment and prophylaxis of haemorrhage in patients with haemophilia A ( congenital factor VIII deficiency ) .
P-370	-0.0547 -0.0991 -0.1208 -0.1244 -0.1565 -0.0836 -0.1336 -0.0962 -0.0829 -0.1438 -0.6243 -0.4126 -0.0538 -0.5301 -0.1514 -0.0874 -0.1409 -0.1077 -0.0681 -0.0828 -0.0860 -0.1270 -0.1552 -0.3642 -0.1037 -0.1758 -0.1123 -0.5477 -0.8663 -0.0118 -0.0543 -0.1026 -0.1491 -0.2686 -0.1563
S-454	35 Eine I.E. der Faktor VIII-Aktivität entspricht der Menge an Faktor VIII in einem ml normalem menschlichen Plasma .
T-454	32 One IU of factor VIII activity is equivalent to that quantity of factor VIII in one ml of normal human plasma .
H-454	-0.27127960324287415	35 IU of factor VIIII activity corresponds to the amount of factor VIII in one ml of normal human plasma .
D-454	-0.27127960324287415	35 IU of factor VIIII activity corresponds to the amount of factor VIII in one ml of normal human plasma .
P-454	-0.3478 -0.4686 -0.0501 -0.1460 -0.2969 -0.2057 -1.7138 -0.0973 -1.1029 -0.1344 -0.1361 -0.1432 -0.1316 -0.1500 -0.1712 -0.1986 -0.0619 -0.1645 -0.7305 -0.1412 -0.1642 -0.1254 -0.1203 -0.1040 -0.0734 -0.1192 -0.1482 -0.1490
S-535	46 Eine I.E. der Faktor VIII-Aktivität entspricht der Menge an Faktor VIII in einem ml normalem menschlichen Plasma .
T-535	42 One IU of factor VIII activity is equivalent to that quantity of factor VIII in one ml of normal human plasma .
H-535	-0.28236839175224304	46 IU of factor VIIII activity corresponds to the amount of factor VIII in one ml of normal human plasma .
D-535	-0.28236839175224304	46 IU of factor VIIII activity corresponds to the amount of factor VIII in one ml of normal human plasma .
P-535	-0.7379 -0.3697 -0.0486 -0.1468 -0.3327 -0.1939 -1.6257 -0.1004 -1.1353 -0.1364 -0.1358 -0.1443 -0.1391 -0.1508 -0.1695 -0.2013 -0.0634 -0.1674 -0.7542 -0.1467 -0.1686 -0.1261 -0.1207 -0.1029 -0.0715 -0.1196 -0.1475 -0.1495
S-212	2 Eine I.E. der Faktor VIII-Aktivität entspricht der Menge an Faktor VIII in einem ml normalem menschlichen Plasma .
T-212	One IU of factor VIII activity is equivalent to that quantity of factor VIII in one ml of normal human plasma .
H-212	-0.28472885489463806	2 IU of factor VIIII activity corresponds to the amount of factor VIII in one ml of normal human plasma .
D-212	-0.28472885489463806	2 IU of factor VIIII activity corresponds to the amount of factor VIII in one ml of normal human plasma .
P-212	-0.5694 -0.6894 -0.0549 -0.1478 -0.3319 -0.1799 -1.7351 -0.0932 -0.9784 -0.1423 -0.1358 -0.1452 -0.1290 -0.1521 -0.1693 -0.2002 -0.0653 -0.1667 -0.7263 -0.1444 -0.1713 -0.1273 -0.1208 -0.1043 -0.0728 -0.1199 -0.1489 -0.1505
S-779	101 Wie ADVATE aussieht und Inhalt der Packung ADVATE liegt als weiße bis gelbliche , pulvrige Substanz vor .
T-779	What ADVATE looks like and contents of the pack ADVATE is a white to off-white friable powder .
H-779	-0.24813465774059296	What ADVATE looks like and contents of the pack ADVATE are presented as white to yellowish , powdery substance .
D-779	-0.24813465774059296	What ADVATE looks like and contents of the pack ADVATE are presented as white to yellowish , powdery substance .
P-779	-0.4505 -0.1240 -0.1725 -0.0923 -0.0848 -0.0919 -0.1240 -0.1391 -0.0673 -0.1169 -0.1376 -0.1290 -0.6565 -0.2108 -0.1674 -0.0830 -0.0813 -1.3080 -1.4869 -0.1397 -0.2515 -0.1415 -0.4195 -0.0309 -0.1322 -0.0359 -0.2735 -0.2023 -0.1472 -0.1972 -0.1742 -0.1615 -0.1575
S-292	13 Eine I.E. der Faktor VIII-Aktivität entspricht der Menge an Faktor VIII in einem ml normalem menschlichen Plasma .
T-292	12 One IU of factor VIII activity is equivalent to that quantity of factor VIII in one ml of normal human plasma .
H-292	-0.3153092563152313	13 IU of factor VIIII activity corresponds to the amount of factor VIII in one ml of normal human plasma .
D-292	-0.3153092563152313	13 IU of factor VIIII activity corresponds to the amount of factor VIII in one ml of normal human plasma .
P-292	-1.6175 -0.4683 -0.0523 -0.1454 -0.2939 -0.2089 -1.6842 -0.0959 -1.0486 -0.1369 -0.1355 -0.1442 -0.1390 -0.1503 -0.1710 -0.1997 -0.0621 -0.1665 -0.7604 -0.1460 -0.1649 -0.1234 -0.1193 -0.1040 -0.0728 -0.1205 -0.1480 -0.1492
S-373	24 Eine I.E. der Faktor VIII-Aktivität entspricht der Menge an Faktor VIII in einem ml normalem menschlichen Plasma .
T-373	22 One IU of factor VIII activity is equivalent to that quantity of factor VIII in one ml of normal human plasma .
H-373	-0.28498661518096924	24 IU of factor VIIII activity corresponds to the amount of factor VIII in one ml of normal human plasma .
D-373	-0.28498661518096924	24 IU of factor VIIII activity corresponds to the amount of factor VIII in one ml of normal human plasma .
P-373	-0.7949 -0.4802 -0.0530 -0.1465 -0.3253 -0.1925 -1.6133 -0.0952 -0.9744 -0.1344 -0.1375 -0.1446 -0.1397 -0.1502 -0.1727 -0.2021 -0.0608 -0.1670 -0.8485 -0.1483 -0.1664 -0.1197 -0.1203 -0.1035 -0.0725 -0.1188 -0.1482 -0.1490
S-73	Bei einer Überdosis mit ADROVANCE sollten Milch oder Antazida gegeben werden , um Alendronat zu binden .
T-73	In case of overdose with ADROVANCE , milk or antacids should be given to bind alendronate .
H-73	-0.21366223692893982	In case of overdose with ADROVANCE , milk or antacids should be given to bind alendronate .
D-73	-0.21366223692893982	In case of overdose with ADROVANCE , milk or antacids should be given to bind alendronate .
P-73	-0.3876 -0.3642 -0.1473 -0.9239 -0.1307 -0.1554 -0.0890 -0.0785 -0.1463 -0.1084 -0.0751 -0.1386 -0.1346 -0.1077 -0.0731 -0.1232 -0.1155 -0.1090 -0.1385 -0.9609 -0.1845 -0.1051 -0.0460 -0.7101 -0.1307 -0.1199 -0.0645 -0.1758 -0.1519
S-209	Behandlung und Prophylaxe von Blutungen bei Patienten mit Hämophilie A ( angeborener Faktor VIII- Mangel ) .
T-209	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
H-209	-0.18959304690361023	Treatment and prophylaxis of haemorrhage in patients with haemophilia A ( congenital factor VIII deficiency ) .
D-209	-0.18959304690361023	Treatment and prophylaxis of haemorrhage in patients with haemophilia A ( congenital factor VIII deficiency ) .
P-209	-0.0547 -0.0991 -0.1208 -0.1244 -0.1565 -0.0836 -0.1336 -0.0962 -0.0829 -0.1438 -0.6243 -0.4126 -0.0538 -0.5301 -0.1514 -0.0874 -0.1409 -0.1077 -0.0681 -0.0828 -0.0860 -0.1270 -0.1552 -0.3642 -0.1037 -0.1758 -0.1123 -0.5477 -0.8663 -0.0118 -0.0543 -0.1026 -0.1491 -0.2686 -0.1563
S-616	57 Eine I.E. der Faktor VIII-Aktivität entspricht der Menge an Faktor VIII in einem ml normalem menschlichen Plasma .
T-616	52 One IU of factor VIII activity is equivalent to that quantity of factor VIII in one ml of normal human plasma .
H-616	-0.3145284354686737	57 IU of factor VIIII activity corresponds to the amount of factor VIII in one ml of normal human plasma .
D-616	-0.3145284354686737	57 IU of factor VIIII activity corresponds to the amount of factor VIII in one ml of normal human plasma .
P-616	-1.4067 -0.5889 -0.0522 -0.1458 -0.2929 -0.2033 -1.7389 -0.0994 -1.1237 -0.1351 -0.1348 -0.1446 -0.1374 -0.1501 -0.1649 -0.2008 -0.0634 -0.1667 -0.7139 -0.1428 -0.1627 -0.1225 -0.1199 -0.1036 -0.0733 -0.1203 -0.1486 -0.1496
S-691	Baxter BioScience Manufacturing Sàrl Route de Pierre-à-Bot 111 CH-2000 Neuchâtel Schweiz
T-691	Baxter BioScience Manufacturing Sàrl Route de Pierre-à-Bot 111 CH-2000 Neuchâtel Switzerland
H-691	-0.15998601913452148	Baxter BioScience Manufacturing Sàrl Route de Pierre-à-Bot 111 CH-2000 Neuchâtel Switzerland
D-691	-0.15998601913452148	Baxter BioScience Manufacturing Sàrl Route de Pierre-à-Bot 111 CH-2000 Neuchâtel Switzerland
P-691	-0.1724 -0.1616 -0.1543 -0.0948 -0.0717 -0.0821 -0.0737 -0.2078 -0.1588 -0.2090 -0.1014 -0.1032 -0.0791 -0.1380 -0.1284 -0.1202 -0.0754 -1.0678 -0.0630 -0.1321 -0.1369 -0.0646 -0.0691 -0.0830 -0.1181 -0.1893 -0.1358 -0.1024 -0.0866 -0.4196 -0.1593
S-787	Danmark Baxter A<unk> S Gydevang 43 DK-3450 Allerød Tlf : <unk> 45 48 16 64 00
T-787	Danmark Baxter A/ S Gydevang 43 DK-3450 Allerød Tlf : <<unk>> 45 48 16 64 00
H-787	-0.12547768652439117	Danmark Baxter A/ S Gydevang 43 DK-3450 Allerød Tlf : <unk> 45 48 16 64 00
D-787	-0.12547768652439117	Danmark Baxter A/ S Gydevang 43 DK-3450 Allerød Tlf : <unk> 45 48 16 64 00
P-787	-0.4337 -0.0823 -0.1240 -0.1401 -0.1694 -0.1221 -0.1666 -0.1131 -0.0785 -0.0514 -0.1067 -0.1065 -0.1507 -0.1338 -0.0994 -0.0624 -0.1322 -0.1564 -0.1524 -0.0887 -0.1209 -0.0939 -0.1270 -0.1424 -0.0716 -0.0819 -0.0920 -0.1273 -0.0664 -0.1211 -0.1752
S-797	Dúbravská cesta 2 SK-841 04 Bratislava Tel : <unk> 421 2 59418455
T-797	Dúbravská cesta 2 SK-841 04 Bratislava Tel : <<unk>> 421 2 59418455
H-797	-0.11841393262147903	Dúbravská cesta 2 SK-841 04 Bratislava Tel : <unk> 421 2 59418455
D-797	-0.11841393262147903	Dúbravská cesta 2 SK-841 04 Bratislava Tel : <unk> 421 2 59418455
P-797	-0.1881 -0.1560 -0.0650 -0.1355 -0.1339 -0.0439 -0.1190 -0.0932 -0.1306 -0.1349 -0.2160 -0.0925 -0.1473 -0.0878 -0.1080 -0.1074 -0.1111 -0.1232 -0.0716 -0.0700 -0.1441 -0.0229 -0.1657 -0.1294 -0.1256 -0.0415 -0.1494 -0.1097 -0.1554 -0.1199 -0.1722
S-67	Selten : starke muskuloskelettale ( Knochen- , Muskel- oder Gelenk- ) Schmerzen ( siehe Abschnitt 4.4 ) .
T-67	Metabolism and nutrition disorders :
H-67	-0.17870421707630157	Rare : severe musculoskeletal ( bone , muscle or joint ) pain ( see section 4.4 ) .
D-67	-0.17870421707630157	Rare : severe musculoskeletal ( bone , muscle or joint ) pain ( see section 4.4 ) .
P-67	-0.6470 -0.1152 -0.1724 -0.1011 -0.0988 -0.4512 -0.0891 -0.0702 -0.2360 -0.1090 -0.3407 -0.0819 -0.1551 -0.1336 -0.2395 -0.0605 -0.1657 -0.0689 -0.1457 -0.2895 -0.1369 -0.1179 -0.1510 -0.1494 -0.1592 -0.1609
S-725	GEGEBENENFALLS BESONDERE VORSICHTSMASSNAHMEN FÜR DIE BESEITIGUNG VON NICHT VERWENDETEN ARZNEIMITTELN ODER DAVON STAMMENDEN ABFALLMATERIALIEN
T-725	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
H-725	-0.06490688771009445	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
D-725	-0.06490688771009445	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
P-725	-0.1052 -0.0149 -0.0472 -0.0783 -0.0635 -0.0199 -0.0128 -0.0310 -0.0477 -0.0829 -0.0720 -0.0967 -0.1138 -0.0048 -0.0285 -0.0650 -0.1425 -0.0777 -0.0841 -0.0488 -0.0565 -0.0745 -0.0522 -0.0605 -0.0270 -0.0786 -0.0975 -0.0479 -0.0695 -0.0705 -0.0685 -0.0866 -0.0868 -0.0781 -0.0994 -0.0420 -0.0337 -0.1219 -0.1138 -0.1244 -0.1272 -0.0724 -0.1118 -0.0628 -0.0407 -0.0046 -0.1260 -0.0374 -0.0177 -0.0745 -0.0170 -0.0105 -0.0201 -0.1590 -0.0805 -0.0307 -0.0468 -0.0924 -0.0585 -0.0739 -0.0486 -0.0626 -0.1184 -0.0370 -0.0238 -0.0312 -0.1083 -0.0289 -0.0172 -0.0477 -0.0080 -0.0625 -0.1521
S-720	GEGEBENENFALLS BESONDERE VORSICHTSMASSNAHMEN FÜR DIE BESEITIGUNG VON NICHT VERWENDETEN ARZNEIMITTELN ODER DAVON STAMMENDEN ABFALLMATERIALIEN
T-720	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
H-720	-0.06490688771009445	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
D-720	-0.06490688771009445	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
P-720	-0.1052 -0.0149 -0.0472 -0.0783 -0.0635 -0.0199 -0.0128 -0.0310 -0.0477 -0.0829 -0.0720 -0.0967 -0.1138 -0.0048 -0.0285 -0.0650 -0.1425 -0.0777 -0.0841 -0.0488 -0.0565 -0.0745 -0.0522 -0.0605 -0.0270 -0.0786 -0.0975 -0.0479 -0.0695 -0.0705 -0.0685 -0.0866 -0.0868 -0.0781 -0.0994 -0.0420 -0.0337 -0.1219 -0.1138 -0.1244 -0.1272 -0.0724 -0.1118 -0.0628 -0.0407 -0.0046 -0.1260 -0.0374 -0.0177 -0.0745 -0.0170 -0.0105 -0.0201 -0.1590 -0.0805 -0.0307 -0.0468 -0.0924 -0.0585 -0.0739 -0.0486 -0.0626 -0.1184 -0.0370 -0.0238 -0.0312 -0.1083 -0.0289 -0.0172 -0.0477 -0.0080 -0.0625 -0.1521
S-715	GEGEBENENFALLS BESONDERE VORSICHTSMASSNAHMEN FÜR DIE BESEITIGUNG VON NICHT VERWENDETEN ARZNEIMITTELN ODER DAVON STAMMENDEN ABFALLMATERIALIEN
T-715	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
H-715	-0.06490688771009445	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
D-715	-0.06490688771009445	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
P-715	-0.1052 -0.0149 -0.0472 -0.0783 -0.0635 -0.0199 -0.0128 -0.0310 -0.0477 -0.0829 -0.0720 -0.0967 -0.1138 -0.0048 -0.0285 -0.0650 -0.1425 -0.0777 -0.0841 -0.0488 -0.0565 -0.0745 -0.0522 -0.0605 -0.0270 -0.0786 -0.0975 -0.0479 -0.0695 -0.0705 -0.0685 -0.0866 -0.0868 -0.0781 -0.0994 -0.0420 -0.0337 -0.1219 -0.1138 -0.1244 -0.1272 -0.0724 -0.1118 -0.0628 -0.0407 -0.0046 -0.1260 -0.0374 -0.0177 -0.0745 -0.0170 -0.0105 -0.0201 -0.1590 -0.0805 -0.0307 -0.0468 -0.0924 -0.0585 -0.0739 -0.0486 -0.0626 -0.1184 -0.0370 -0.0238 -0.0312 -0.1083 -0.0289 -0.0172 -0.0477 -0.0080 -0.0625 -0.1521
S-710	GEGEBENENFALLS BESONDERE VORSICHTSMASSNAHMEN FÜR DIE BESEITIGUNG VON NICHT VERWENDETEN ARZNEIMITTELN ODER DAVON STAMMENDEN ABFALLMATERIALIEN
T-710	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
H-710	-0.06490688771009445	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
D-710	-0.06490688771009445	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
P-710	-0.1052 -0.0149 -0.0472 -0.0783 -0.0635 -0.0199 -0.0128 -0.0310 -0.0477 -0.0829 -0.0720 -0.0967 -0.1138 -0.0048 -0.0285 -0.0650 -0.1425 -0.0777 -0.0841 -0.0488 -0.0565 -0.0745 -0.0522 -0.0605 -0.0270 -0.0786 -0.0975 -0.0479 -0.0695 -0.0705 -0.0685 -0.0866 -0.0868 -0.0781 -0.0994 -0.0420 -0.0337 -0.1219 -0.1138 -0.1244 -0.1272 -0.0724 -0.1118 -0.0628 -0.0407 -0.0046 -0.1260 -0.0374 -0.0177 -0.0745 -0.0170 -0.0105 -0.0201 -0.1590 -0.0805 -0.0307 -0.0468 -0.0924 -0.0585 -0.0739 -0.0486 -0.0626 -0.1184 -0.0370 -0.0238 -0.0312 -0.1083 -0.0289 -0.0172 -0.0477 -0.0080 -0.0625 -0.1521
S-704	GEGEBENENFALLS BESONDERE VORSICHTSMASSNAHMEN FÜR DIE BESEITIGUNG VON NICHT VERWENDETEN ARZNEIMITTELN ODER DAVON STAMMENDEN ABFALLMATERIALIEN
T-704	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
H-704	-0.06490688771009445	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
D-704	-0.06490688771009445	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
P-704	-0.1052 -0.0149 -0.0472 -0.0783 -0.0635 -0.0199 -0.0128 -0.0310 -0.0477 -0.0829 -0.0720 -0.0967 -0.1138 -0.0048 -0.0285 -0.0650 -0.1425 -0.0777 -0.0841 -0.0488 -0.0565 -0.0745 -0.0522 -0.0605 -0.0270 -0.0786 -0.0975 -0.0479 -0.0695 -0.0705 -0.0685 -0.0866 -0.0868 -0.0781 -0.0994 -0.0420 -0.0337 -0.1219 -0.1138 -0.1244 -0.1272 -0.0724 -0.1118 -0.0628 -0.0407 -0.0046 -0.1260 -0.0374 -0.0177 -0.0745 -0.0170 -0.0105 -0.0201 -0.1590 -0.0805 -0.0307 -0.0468 -0.0924 -0.0585 -0.0739 -0.0486 -0.0626 -0.1184 -0.0370 -0.0238 -0.0312 -0.1083 -0.0289 -0.0172 -0.0477 -0.0080 -0.0625 -0.1521
S-699	GEGEBENENFALLS BESONDERE VORSICHTSMASSNAHMEN FÜR DIE BESEITIGUNG VON NICHT VERWENDETEN ARZNEIMITTELN ODER DAVON STAMMENDEN ABFALLMATERIALIEN
T-699	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
H-699	-0.06490688771009445	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
D-699	-0.06490688771009445	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
P-699	-0.1052 -0.0149 -0.0472 -0.0783 -0.0635 -0.0199 -0.0128 -0.0310 -0.0477 -0.0829 -0.0720 -0.0967 -0.1138 -0.0048 -0.0285 -0.0650 -0.1425 -0.0777 -0.0841 -0.0488 -0.0565 -0.0745 -0.0522 -0.0605 -0.0270 -0.0786 -0.0975 -0.0479 -0.0695 -0.0705 -0.0685 -0.0866 -0.0868 -0.0781 -0.0994 -0.0420 -0.0337 -0.1219 -0.1138 -0.1244 -0.1272 -0.0724 -0.1118 -0.0628 -0.0407 -0.0046 -0.1260 -0.0374 -0.0177 -0.0745 -0.0170 -0.0105 -0.0201 -0.1590 -0.0805 -0.0307 -0.0468 -0.0924 -0.0585 -0.0739 -0.0486 -0.0626 -0.1184 -0.0370 -0.0238 -0.0312 -0.1083 -0.0289 -0.0172 -0.0477 -0.0080 -0.0625 -0.1521
S-102	EU<unk> 1<unk> 06<unk> 364<unk> 001 2 Tabletten EU<unk> 1<unk> 06<unk> 364<unk> 002 4 Tabletten EU<unk> 1<unk> 06<unk> 364<unk> 003 6 Tabletten EU<unk> 1<unk> 06<unk> 364<unk> 004 12 Tabletten EU<unk> 1<unk> 06<unk> 364<unk> 005 40 Tabletten
T-102	EU/ 1/ 06/ 364/ 001 2 tablets EU/ 1/ 06/ 364/ 002 4 tablets EU/ 1/ 06/ 364/ 003 6 tablets EU/ 1/ 06/ 364/ 004 12 tablets EU/ 1/ 06/ 364/ 005 40 tablets
H-102	-0.1253909021615982	EU/ 1/ 06/ 364/ 001 2 tablets EU/ 1/ 06/ 364/ 002 4 tablets EU/ 1/ 06/ 364/ 003 6 tablets EU/ 1/ 06/ 364/ 004 12 tablets EU/ 1/ 06/ 364/ 005 40 tablets
D-102	-0.1253909021615982	EU/ 1/ 06/ 364/ 001 2 tablets EU/ 1/ 06/ 364/ 002 4 tablets EU/ 1/ 06/ 364/ 003 6 tablets EU/ 1/ 06/ 364/ 004 12 tablets EU/ 1/ 06/ 364/ 005 40 tablets
P-102	-0.0693 -0.1187 -0.1087 -0.1168 -0.0846 -0.1555 -0.0724 -0.1405 -0.1472 -0.1126 -0.2112 -0.1080 -0.0859 -0.1382 -0.1124 -0.1701 -0.1360 -0.1432 -0.0816 -0.1420 -0.0657 -0.1457 -0.1489 -0.1004 -0.1520 -0.1465 -0.0921 -0.1353 -0.1408 -0.1706 -0.1420 -0.1424 -0.0723 -0.1242 -0.0657 -0.1349 -0.1501 -0.0995 -0.1413 -0.1250 -0.0674 -0.1123 -0.1280 -0.1633 -0.1476 -0.1429 -0.0708 -0.1354 -0.0620 -0.1375 -0.1524 -0.1099 -0.1524 -0.1410 -0.0791 -0.1171 -0.1348 -0.1549 -0.1798 -0.1299 -0.0855 -0.1320 -0.0640 -0.1568 -0.1391 -0.0886 -0.3389 -0.0882 -0.0688 -0.1183 -0.1540
S-690	68 A. HERSTELLER DES WIRKSTOFFS BIOLOGISCHEN URSPRUNGS UND INHABER DER HERSTELLUNGSERLAUBNIS , DER FÜR DIE CHARGENFREIGABE VERANTWORTLICH IST
T-690	62 A MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
H-690	-0.19827920198440552	68 A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
D-690	-0.19827920198440552	68 A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
P-690	-2.2693 -0.0994 -0.0696 -0.0503 -0.0575 -0.0432 -0.0080 -0.0835 -0.0422 -0.2720 -0.1136 -0.1306 -0.2146 -0.3905 -0.1687 -0.0656 -0.1152 -0.1138 -0.1877 -0.0813 -1.5888 -0.1253 -0.0562 -0.0636 -2.9671 -0.2170 -0.0071 -0.0124 -0.3973 -0.0974 -0.0920 -0.0210 -0.1079 -0.0303 -0.0169 -0.0517 -0.1022 -0.0637 -0.0366 -0.0177 -0.1175 -0.0202 -0.0081 -0.0664 -0.0760 -0.0371 -0.0922 -0.0812 -0.0493 -0.0385 -0.1242 -0.0197 -0.0704 -0.0477 -0.0696 -0.0593 -0.1350 -0.1268 -0.3660 -0.0336 -0.0147 -0.0431 -0.1463
S-689	HERSTELLER DES WIRKSTOFFS BIOLOGISCHEN URSPRUNGS UND INHABER DER HERSTELLUNGSERLAUBNIS , DER FÜR DIE CHARGENFREIGABE VERANTWORTLICH IST
T-689	MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
H-689	-0.13648393750190735	MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
D-689	-0.13648393750190735	MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
P-689	-0.1121 -0.0461 -0.0473 -0.0239 -0.0051 -0.0974 -0.0416 -0.2750 -0.1461 -0.1186 -0.3371 -0.2755 -0.1697 -0.0707 -0.1285 -0.1196 -0.1738 -0.0918 -0.9175 -0.1470 -0.0607 -0.0807 -1.5967 -0.2368 -0.0067 -0.0126 -0.4341 -0.0987 -0.1148 -0.0174 -0.1026 -0.0233 -0.0165 -0.0591 -0.1112 -0.0561 -0.0425 -0.0258 -0.1138 -0.0182 -0.0082 -0.0681 -0.0708 -0.0300 -0.0956 -0.0958 -0.0581 -0.0395 -0.1264 -0.0207 -0.0732 -0.0395 -0.0679 -0.0720 -0.0730 -0.2375 -0.3440 -0.0226 -0.0141 -0.0405 -0.1550
S-181	EU<unk> 1<unk> 06<unk> 364<unk> 006 2 Tabletten EU<unk> 1<unk> 06<unk> 364<unk> 007 4 Tabletten EU<unk> 1<unk> 06<unk> 364<unk> 008 12 Tabletten EU<unk> 1<unk> 06<unk> 364<unk> 009 40 Tabletten
T-181	EU/ 1/ 06/ 364/ 006 2 tablets EU/ 1/ 06/ 364/ 007 4 tablets EU/ 1/ 06/ 364/ 008 12 tablets EU/ 1/ 06/ 364/ 009 40 tablets
H-181	-0.12189345806837082	EU/ 1/ 06/ 364/ 006 2 tablets EU/ 1/ 06/ 364/ 007 4 tablets EU/ 1/ 06/ 364/ 008 12 tablets EU/ 1/ 06/ 364/ 009 40 tablets
D-181	-0.12189345806837082	EU/ 1/ 06/ 364/ 006 2 tablets EU/ 1/ 06/ 364/ 007 4 tablets EU/ 1/ 06/ 364/ 008 12 tablets EU/ 1/ 06/ 364/ 009 40 tablets
P-181	-0.1063 -0.1167 -0.1067 -0.1157 -0.0870 -0.1539 -0.0709 -0.1380 -0.1468 -0.1057 -0.2244 -0.1120 -0.0953 -0.1342 -0.1091 -0.1663 -0.1405 -0.1455 -0.0802 -0.1405 -0.0688 -0.1434 -0.1470 -0.0894 -0.1356 -0.1525 -0.0830 -0.1268 -0.1327 -0.1718 -0.1437 -0.1449 -0.0676 -0.1295 -0.0609 -0.1351 -0.1531 -0.0931 -0.1468 -0.1403 -0.0716 -0.1113 -0.1103 -0.1585 -0.1495 -0.1432 -0.0761 -0.1409 -0.0636 -0.1573 -0.1468 -0.0849 -0.1300 -0.0983 -0.0660 -0.1275 -0.1503
S-712	WARNHINWEIS , DASS DAS ARZNEIMITTEL FÜR KINDER UNERREICHBAR UND NICHT SICHTBAR AUFZUBEWAHREN IST
T-712	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
H-712	-0.06819183379411697	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
D-712	-0.06819183379411697	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
P-712	-0.0317 -0.0518 -0.0493 -0.0811 -0.0555 -0.0342 -0.0302 -0.0411 -0.0410 -0.0521 -0.0739 -0.0231 -0.0774 -0.0542 -0.0424 -0.0711 -0.1098 -0.1058 -0.0857 -0.0845 -0.1057 -0.0580 -0.0298 -0.1047 -0.1816 -0.0440 -0.0431 -0.0272 -0.0950 -0.0775 -0.1490 -0.0693 -0.0321 -0.0564 -0.0227 -0.0056 -0.0624 -0.0967 -0.0272 -0.0605 -0.1150 -0.2920 -0.0453 -0.0392 -0.0337 -0.0980 -0.0056 -0.0125 -0.1558
S-695	BEDINGUNGEN ODER EINSCHRÄNKUNGEN BEZÜGLICH DER SICHEREN UND WIRKSAMEN ANWENDUNG DES ARZNEIMITTELS
T-695	CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
H-695	-0.09352460503578186	CONDITIONS OR RESTRICTIONS REGARDING THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
D-695	-0.09352460503578186	CONDITIONS OR RESTRICTIONS REGARDING THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
P-695	-0.1671 -0.0860 -0.0127 -0.0271 -0.0460 -0.1495 -0.1109 -0.1000 -0.1414 -0.0415 -0.0312 -0.0216 -0.0252 -0.0661 -0.1418 -0.2429 -0.1136 -0.0254 -0.0638 -0.0412 -0.1488 -0.2261 -0.0582 -0.0550 -0.1215 -0.0872 -0.0108 -0.0514 -0.1130 -0.0240 -0.0790 -0.1648 -0.0519 -0.4704 -0.0777 -0.1180 -0.0211 -0.0734 -0.0588 -0.0368 -0.0568 -0.1189 -0.1474 -0.0858 -0.0609 -0.0880 -0.1348
S-696	WARNHINWEIS , DASS DAS ARZNEIMITTEL FÜR KINDER UNERREICHBAR UND NICHT SICHTBAR AUFZUBEWAHREN IST
T-696	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
H-696	-0.06819183379411697	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
D-696	-0.06819183379411697	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
P-696	-0.0317 -0.0518 -0.0493 -0.0811 -0.0555 -0.0342 -0.0302 -0.0411 -0.0410 -0.0521 -0.0739 -0.0231 -0.0774 -0.0542 -0.0424 -0.0711 -0.1098 -0.1058 -0.0857 -0.0845 -0.1057 -0.0580 -0.0298 -0.1047 -0.1816 -0.0440 -0.0431 -0.0272 -0.0950 -0.0775 -0.1490 -0.0693 -0.0321 -0.0564 -0.0227 -0.0056 -0.0624 -0.0967 -0.0272 -0.0605 -0.1150 -0.2920 -0.0453 -0.0392 -0.0337 -0.0980 -0.0056 -0.0125 -0.1558
S-722	WARNHINWEIS , DASS DAS ARZNEIMITTEL FÜR KINDER UNERREICHBAR UND NICHT SICHTBAR AUFZUBEWAHREN IST
T-722	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
H-722	-0.06819183379411697	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
D-722	-0.06819183379411697	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
P-722	-0.0317 -0.0518 -0.0493 -0.0811 -0.0555 -0.0342 -0.0302 -0.0411 -0.0410 -0.0521 -0.0739 -0.0231 -0.0774 -0.0542 -0.0424 -0.0711 -0.1098 -0.1058 -0.0857 -0.0845 -0.1057 -0.0580 -0.0298 -0.1047 -0.1816 -0.0440 -0.0431 -0.0272 -0.0950 -0.0775 -0.1490 -0.0693 -0.0321 -0.0564 -0.0227 -0.0056 -0.0624 -0.0967 -0.0272 -0.0605 -0.1150 -0.2920 -0.0453 -0.0392 -0.0337 -0.0980 -0.0056 -0.0125 -0.1558
S-707	WARNHINWEIS , DASS DAS ARZNEIMITTEL FÜR KINDER UNERREICHBAR UND NICHT SICHTBAR AUFZUBEWAHREN IST
T-707	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
H-707	-0.06819183379411697	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
D-707	-0.06819183379411697	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
P-707	-0.0317 -0.0518 -0.0493 -0.0811 -0.0555 -0.0342 -0.0302 -0.0411 -0.0410 -0.0521 -0.0739 -0.0231 -0.0774 -0.0542 -0.0424 -0.0711 -0.1098 -0.1058 -0.0857 -0.0845 -0.1057 -0.0580 -0.0298 -0.1047 -0.1816 -0.0440 -0.0431 -0.0272 -0.0950 -0.0775 -0.1490 -0.0693 -0.0321 -0.0564 -0.0227 -0.0056 -0.0624 -0.0967 -0.0272 -0.0605 -0.1150 -0.2920 -0.0453 -0.0392 -0.0337 -0.0980 -0.0056 -0.0125 -0.1558
S-701	WARNHINWEIS , DASS DAS ARZNEIMITTEL FÜR KINDER UNERREICHBAR UND NICHT SICHTBAR AUFZUBEWAHREN IST
T-701	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
H-701	-0.06819183379411697	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
D-701	-0.06819183379411697	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
P-701	-0.0317 -0.0518 -0.0493 -0.0811 -0.0555 -0.0342 -0.0302 -0.0411 -0.0410 -0.0521 -0.0739 -0.0231 -0.0774 -0.0542 -0.0424 -0.0711 -0.1098 -0.1058 -0.0857 -0.0845 -0.1057 -0.0580 -0.0298 -0.1047 -0.1816 -0.0440 -0.0431 -0.0272 -0.0950 -0.0775 -0.1490 -0.0693 -0.0321 -0.0564 -0.0227 -0.0056 -0.0624 -0.0967 -0.0272 -0.0605 -0.1150 -0.2920 -0.0453 -0.0392 -0.0337 -0.0980 -0.0056 -0.0125 -0.1558
S-717	WARNHINWEIS , DASS DAS ARZNEIMITTEL FÜR KINDER UNERREICHBAR UND NICHT SICHTBAR AUFZUBEWAHREN IST
T-717	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
H-717	-0.06819183379411697	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
D-717	-0.06819183379411697	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
P-717	-0.0317 -0.0518 -0.0493 -0.0811 -0.0555 -0.0342 -0.0302 -0.0411 -0.0410 -0.0521 -0.0739 -0.0231 -0.0774 -0.0542 -0.0424 -0.0711 -0.1098 -0.1058 -0.0857 -0.0845 -0.1057 -0.0580 -0.0298 -0.1047 -0.1816 -0.0440 -0.0431 -0.0272 -0.0950 -0.0775 -0.1490 -0.0693 -0.0321 -0.0564 -0.0227 -0.0056 -0.0624 -0.0967 -0.0272 -0.0605 -0.1150 -0.2920 -0.0453 -0.0392 -0.0337 -0.0980 -0.0056 -0.0125 -0.1558
S-784	België<unk> Belgique<unk> Belgien Baxter Belgium SPRL Bd. de la Plaine<unk> Pleinlaan 5 B-1050 Brussel<unk> Bruxelles<unk> Brüssel Tél<unk> Tel : <unk> 32 2 650 1711
T-784	België/ Belgique/ Belgien Baxter Belgium SPRL Bd . de la Plaine/ Pleinlaan 5 B-1050 Brussel/ Bruxelles/ Brüssel Tél/ Tel : <<unk>> 32 2 650 1711
H-784	-0.1496707797050476	België/ Belgique/ Belgien Baxter Belgium SPRL Bd. de la Plaine/ Pleinlaan 5 B-1050 Brussel/ Bruxelles/ Brüssel Tél/ Tel : <unk> 32 2 650 1711
D-784	-0.1496707797050476	België/ Belgique/ Belgien Baxter Belgium SPRL Bd. de la Plaine/ Pleinlaan 5 B-1050 Brussel/ Bruxelles/ Brüssel Tél/ Tel : <unk> 32 2 650 1711
P-784	-0.0317 -0.0146 -0.0947 -0.0226 -0.1404 -0.1266 -0.1674 -0.0241 -0.1059 -0.1493 -0.1642 -0.1661 -0.0666 -0.1704 -0.1155 -0.1468 -0.1537 -0.1422 -0.0856 -0.1300 -0.0312 -0.1246 -0.1881 -0.0699 -0.1293 -0.1268 -0.1275 -0.1396 -0.1625 -0.1282 -0.1414 -0.1267 -0.1113 -0.1912 -0.3246 -0.1377 -0.1153 -0.0764 -0.2837 -1.5250 -0.1055 -0.0766 -0.1191 -0.2033 -0.0424 -0.1468 -0.0361 -0.0773 -0.1193 -0.0966 -0.1042 -0.1625 -0.1637
S-183	INHABER DER HERSTELLUNGSERLAUBNIS , DER ( DIE ) FÜR DIE CHARGENFREIGABE VERANTWORTLICH IST ( SIND )
T-183	MANUFACTURING AUTHORISATION HOLDER<<unk>> S ) RESPONSIBLE FOR BATCH RELEASE
H-183	-0.12599530816078186	MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE ( ARE )
D-183	-0.12599530816078186	MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE ( ARE )
P-183	-0.1290 -0.0293 -0.0868 -0.0346 -0.0190 -0.0260 -0.0461 -0.0653 -0.0161 -0.0177 -0.0689 -0.0200 -0.0243 -0.0727 -0.0751 -0.0353 -0.4277 -0.7346 -0.0395 -0.0412 -0.0765 -0.0175 -0.0543 -0.0831 -0.0626 -0.0799 -0.0510 -0.2805 -0.2368 -0.0160 -0.0137 -0.0533 -0.1577 -0.8167 -0.1488 -0.1590 -0.3453
S-163	19 Vitamin-D-Mangel war 0,3 % in der 2.800-I.E.-Vitamin-D3-Gruppe vs . 0 % in der 5.600-I.E.-Vitamin- D3-Gruppe .
T-163	The percentage of patients with vitamin D deficiency was 0.3 % in the Vitamin D3 2800 group vs. zero in the Vitamin D3 5600 group .
H-163	-0.22778424620628357	Vitamin D deficiency was 0.3 % in the 2.800 IU vitamin D3 group vs. 0 % in the 5.600 IU vitamin D3 group .
D-163	-0.22778424620628357	Vitamin D deficiency was 0.3 % in the 2.800 IU vitamin D3 group vs. 0 % in the 5.600 IU vitamin D3 group .
P-163	-1.7983 -0.0843 -0.1246 -0.0155 -0.0523 -0.1199 -0.2648 -0.1492 -0.1423 -0.1179 -0.1493 -0.1390 -0.7312 -0.0737 -0.0985 -0.3700 -0.5041 -0.1109 -0.3028 -0.1238 -0.1419 -0.3372 -0.1051 -0.1179 -0.1368 -0.1272 -0.4663 -0.0304 -0.1248 -0.3948 -0.1507 -0.1943 -0.1608 -0.1079 -0.0608 -0.1430 -0.1562
S-182	INHABER DER HERSTELLUNGSERLAUBNIS , DER ( DIE ) FÜR DIE CHARGENFREIGABE VERANTWORTLICH IST ( SIND
T-182	MANUFACTURING AUTHORISATION HOLDER<<unk>> S ) RESPONSIBLE FOR BATCH RELEASE
H-182	-0.12428347766399384	MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE ( ARE )
D-182	-0.12428347766399384	MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE ( ARE )
P-182	-0.1402 -0.0282 -0.0884 -0.0344 -0.0203 -0.0237 -0.0449 -0.0613 -0.0158 -0.0162 -0.0816 -0.0185 -0.0242 -0.0709 -0.0797 -0.0340 -0.5074 -0.4956 -0.0407 -0.0421 -0.0756 -0.0169 -0.0555 -0.0481 -0.0597 -0.0741 -0.0507 -0.2598 -0.2833 -0.0151 -0.0139 -0.0513 -0.1530 -0.9598 -0.1272 -0.1901 -0.2962
S-161	Der Anteil an Patientinnen mit Vitamin-D-Insuffizienz betrug während der 24-wöchigen Verlängerungsstudie 5,4 % in der 2.800-I.E.- Vitamin-D3-Gruppe vs .
T-161	The percentage of patients with vitamin D insufficiency was 5.4 % in the Vitamin D3 2800 group vs.
H-161	-0.4304841458797455	The proportion of patients with vitamin D deficiency during the 24 week extension study was 5.4 % in the 2,800 IU vitamin D3 group vs.
D-161	-0.4304841458797455	The proportion of patients with vitamin D deficiency during the 24 week extension study was 5.4 % in the 2,800 IU vitamin D3 group vs.
P-161	-0.3522 -0.4820 -0.1556 -0.3780 -0.1357 -0.2064 -0.0951 -0.1251 -0.7518 -0.0562 -0.1285 -0.8929 -0.1259 -0.4696 -0.1725 -0.2108 -0.8401 -0.1235 -0.0969 -0.1645 -0.1259 -0.1922 -0.1160 -0.9996 -0.0704 -0.1294 -0.2692 -0.1868 -0.1203 -0.5301 -0.1290 -1.1830 -0.8549 -3.7663
S-842	Diese beinhalten : Dekongestiva Anorektika oder Psychostimulanzien vom Amphetamintyp 3 Antihypertensiva trizyklische Antidepressiva und andere Antihistaminika .
T-842	These include : decongestants anorexogenics or amphetamine-type psychostimulants antihypertensive agents tricyclic antidepressants and other antihistamines .
H-842	-0.30379951000213623	These include : decongestants , anorectics or amphetamine type 3 psychostimulants , antihypertensives , tricyclic antidepressants and other antihistamines .
D-842	-0.30379951000213623	These include : decongestants , anorectics or amphetamine type 3 psychostimulants , antihypertensives , tricyclic antidepressants and other antihistamines .
P-842	-0.4895 -1.2026 -0.3448 -0.2637 -0.1157 -0.9844 -0.1128 -0.8161 -0.1286 -0.1008 -0.1778 -0.4709 -0.1681 -0.7705 -0.1692 -0.0823 -0.3027 -0.2455 -0.1286 -1.0267 -0.0492 -0.0584 -0.1008 -0.7662 -0.2222 -0.0434 -0.0827 -1.8877 -0.1522 -0.1220 -0.0240 -0.2310 -0.1082 -0.0269 -0.1429 -0.0949 -0.1847 -0.1399 -0.0613 -0.1059 -0.2131 -0.1444 -0.1513 -0.1523
S-848	Sympathomimetika können die antihypertensive Wirkung von -Methyldopa , Mecamylamin , Reserpin , Veratrum-Alkaloiden und Guanethidin mindern .
T-848	Sympathomimetic medicines reduce the antihypertensive effect of -methyldopa , mecamylamine , reserpine , veratrum alkaloids , and guanethidine .
H-848	-0.24231772124767303	Sympathomimetics may reduce the antihypertensive effect of -methyldopa , mecamylamine , reserpine , veratrum alkaloids , and guanethidine .
D-848	-0.24231772124767303	Sympathomimetics may reduce the antihypertensive effect of -methyldopa , mecamylamine , reserpine , veratrum alkaloids , and guanethidine .
P-848	-0.4645 -0.0685 -0.0695 -0.0902 -0.1863 -0.3786 -0.1685 -0.1073 -0.0521 -0.1125 -0.0754 -1.7056 -0.1369 -0.5738 -0.0420 -0.3123 -0.3519 -0.2266 -0.1183 -0.1425 -0.2562 -0.0943 -0.1580 -0.2363 -0.0729 -0.1379 -0.2816 -0.4499 -0.1888 -0.1370 -0.4763 -0.0446 -1.6853 -0.0976 -0.0768 -0.0730 -0.1105 -0.2721 -0.1085 -0.0818 -0.1071 -0.1193 -0.0900 -0.1123 -0.1413 -0.1540
S-452	ADVATE enthält keine pharmakologisch wirksamen Mengen des von-Willebrand-Faktors und ist daher nicht für die Behandlung des von-Willebrand-Jürgens-Syndroms geeignet .
T-452	ADVATE does not contain von Willebrand Factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand disease .
H-452	-0.3476666510105133	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not suitable for the treatment of von Willebrand Jürgen s syndrome .
D-452	-0.3476666510105133	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not suitable for the treatment of von Willebrand Jürgen s syndrome .
P-452	-0.2656 -0.1751 -0.0864 -0.0876 -1.0597 -0.1709 -0.2450 -0.0862 -0.1113 -0.3097 -1.5713 -0.1470 -0.1609 -0.9152 -0.3078 -0.1176 -0.5246 -0.2280 -0.1764 -0.1886 -0.1566 -0.2269 -0.2184 -0.1654 -0.1407 -0.1169 -0.1434 -1.1372 -0.1838 -0.1113 -0.6396 -0.2614 -0.9088 -0.5233 -0.9887 -0.0524 -0.1496 -0.1521
S-290	ADVATE enthält keine pharmakologisch wirksamen Mengen des von-Willebrand-Faktors und ist daher nicht für die Behandlung des von-Willebrand-Jürgens-Syndroms geeignet .
T-290	ADVATE does not contain von Willebrand Factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand disease .
H-290	-0.3476666510105133	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not suitable for the treatment of von Willebrand Jürgen s syndrome .
D-290	-0.3476666510105133	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not suitable for the treatment of von Willebrand Jürgen s syndrome .
P-290	-0.2656 -0.1751 -0.0864 -0.0876 -1.0597 -0.1709 -0.2450 -0.0862 -0.1113 -0.3097 -1.5713 -0.1470 -0.1609 -0.9152 -0.3078 -0.1176 -0.5246 -0.2280 -0.1764 -0.1886 -0.1566 -0.2269 -0.2184 -0.1654 -0.1407 -0.1169 -0.1434 -1.1372 -0.1838 -0.1113 -0.6396 -0.2614 -0.9088 -0.5233 -0.9887 -0.0524 -0.1496 -0.1521
S-371	ADVATE enthält keine pharmakologisch wirksamen Mengen des von-Willebrand-Faktors und ist daher nicht für die Behandlung des von-Willebrand-Jürgens-Syndroms geeignet .
T-371	ADVATE does not contain von Willebrand Factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand disease .
H-371	-0.3476666510105133	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not suitable for the treatment of von Willebrand Jürgen s syndrome .
D-371	-0.3476666510105133	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not suitable for the treatment of von Willebrand Jürgen s syndrome .
P-371	-0.2656 -0.1751 -0.0864 -0.0876 -1.0597 -0.1709 -0.2450 -0.0862 -0.1113 -0.3097 -1.5713 -0.1470 -0.1609 -0.9152 -0.3078 -0.1176 -0.5246 -0.2280 -0.1764 -0.1886 -0.1566 -0.2269 -0.2184 -0.1654 -0.1407 -0.1169 -0.1434 -1.1372 -0.1838 -0.1113 -0.6396 -0.2614 -0.9088 -0.5233 -0.9887 -0.0524 -0.1496 -0.1521
S-210	ADVATE enthält keine pharmakologisch wirksamen Mengen des von-Willebrand-Faktors und ist daher nicht für die Behandlung des von-Willebrand-Jürgens-Syndroms geeignet .
T-210	ADVATE does not contain von Willebrand factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand disease .
H-210	-0.3476666510105133	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not suitable for the treatment of von Willebrand Jürgen s syndrome .
D-210	-0.3476666510105133	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not suitable for the treatment of von Willebrand Jürgen s syndrome .
P-210	-0.2656 -0.1751 -0.0864 -0.0876 -1.0597 -0.1709 -0.2450 -0.0862 -0.1113 -0.3097 -1.5713 -0.1470 -0.1609 -0.9152 -0.3078 -0.1176 -0.5246 -0.2280 -0.1764 -0.1886 -0.1566 -0.2269 -0.2184 -0.1654 -0.1407 -0.1169 -0.1434 -1.1372 -0.1838 -0.1113 -0.6396 -0.2614 -0.9088 -0.5233 -0.9887 -0.0524 -0.1496 -0.1521
S-533	ADVATE enthält keine pharmakologisch wirksamen Mengen des von-Willebrand-Faktors und ist daher nicht für die Behandlung des von-Willebrand-Jürgens-Syndroms geeignet .
T-533	ADVATE does not contain von Willebrand Factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand disease .
H-533	-0.3476666510105133	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not suitable for the treatment of von Willebrand Jürgen s syndrome .
D-533	-0.3476666510105133	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not suitable for the treatment of von Willebrand Jürgen s syndrome .
P-533	-0.2656 -0.1751 -0.0864 -0.0876 -1.0597 -0.1709 -0.2450 -0.0862 -0.1113 -0.3097 -1.5713 -0.1470 -0.1609 -0.9152 -0.3078 -0.1176 -0.5246 -0.2280 -0.1764 -0.1886 -0.1566 -0.2269 -0.2184 -0.1654 -0.1407 -0.1169 -0.1434 -1.1372 -0.1838 -0.1113 -0.6396 -0.2614 -0.9088 -0.5233 -0.9887 -0.0524 -0.1496 -0.1521
S-614	ADVATE enthält keine pharmakologisch wirksamen Mengen des von-Willebrand-Faktors und ist daher nicht für die Behandlung des von-Willebrand-Jürgens-Syndroms geeignet .
T-614	ADVATE does not contain von Willebrand Factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand disease .
H-614	-0.3476666510105133	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not suitable for the treatment of von Willebrand Jürgen s syndrome .
D-614	-0.3476666510105133	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not suitable for the treatment of von Willebrand Jürgen s syndrome .
P-614	-0.2656 -0.1751 -0.0864 -0.0876 -1.0597 -0.1709 -0.2450 -0.0862 -0.1113 -0.3097 -1.5713 -0.1470 -0.1609 -0.9152 -0.3078 -0.1176 -0.5246 -0.2280 -0.1764 -0.1886 -0.1566 -0.2269 -0.2184 -0.1654 -0.1407 -0.1169 -0.1434 -1.1372 -0.1838 -0.1113 -0.6396 -0.2614 -0.9088 -0.5233 -0.9887 -0.0524 -0.1496 -0.1521
S-785	Luxembourg<unk> Luxemburg Baxter Belgium SPRL Bd. de la Plaine<unk> Pleinlaan 5 B-1050 Bruxelles<unk> Brüssel Tél<unk> Tel : <unk> 32 2 650 1711
T-785	Luxembourg/ Luxemburg Baxter Belgium SPRL Bd . de la Plaine/ Pleinlaan 5 B-1050 Bruxelles/ Brüssel Tél/ Tel : <<unk>> 32 2 650 1711
H-785	-0.15336726605892181	Luxembourg/ Luxemburg Baxter Belgium SPRL Bd. de la Plaine/ Pleinlaan 5 B-1050 Bruxelles/ Brussels Tél/ Tel : <unk> 32 2 650 1711
D-785	-0.15336726605892181	Luxembourg/ Luxemburg Baxter Belgium SPRL Bd. de la Plaine/ Pleinlaan 5 B-1050 Bruxelles/ Brussels Tél/ Tel : <unk> 32 2 650 1711
P-785	-0.1341 -0.0411 -0.1712 -0.1402 -0.0978 -0.1196 -0.1461 -0.1769 -0.1191 -0.0758 -0.1759 -0.1197 -0.1488 -0.0670 -0.1392 -0.0915 -0.1201 -0.0306 -0.1346 -0.1985 -0.0731 -0.1370 -0.1263 -0.1298 -0.1379 -0.1487 -0.1277 -0.1543 -0.2531 -0.1243 -0.1121 -0.0707 -0.1690 -1.5085 -0.1055 -0.0881 -0.1195 -0.1895 -0.0452 -0.1463 -0.0327 -0.0833 -0.1238 -0.1112 -0.1103 -0.1705 -0.1621
S-486	Der Faktor-VIII<unk> von-Willebrand-Faktor-Komplex besteht aus zwei Proteinen ( Faktor VIII und von- Willebrand-Faktor ) mit unterschiedlichen , physiologischen Funktionen .
T-486	The factor VIII/ von Willebrand Factor complex consists of two molecules ( factor VIII and von Willebrand factor ) with different physiological functions .
H-486	-0.29658401012420654	The factor VIII/ von-Willebrand factor complex consists of two proteins ( factor VIII and von- Willebrand factor ) with different physiological functions .
D-486	-0.29658401012420654	The factor VIII/ von-Willebrand factor complex consists of two proteins ( factor VIII and von- Willebrand factor ) with different physiological functions .
P-486	-0.2892 -0.7792 -0.2613 -0.1828 -0.5951 -0.1984 -2.2795 -0.1541 -0.1262 -0.1402 -0.4593 -0.4084 -0.0887 -0.1713 -0.1014 -0.1575 -0.1299 -0.0454 -0.1172 -0.1408 -0.3102 -0.2005 -0.0927 -0.2018 -0.0798 -0.9066 -0.1113 -0.1259 -0.3142 -0.1209 -0.1576 -0.1667 -0.9347 -0.1203 -0.1076 -0.1810 -0.1588 -0.1537
S-324	Der Faktor-VIII<unk> von-Willebrand-Faktor-Komplex besteht aus zwei Proteinen ( Faktor VIII und von- Willebrand-Faktor ) mit unterschiedlichen , physiologischen Funktionen .
T-324	The factor VIII/ von Willebrand Factor complex consists of two molecules ( factor VIII and von Willebrand factor ) with different physiological functions .
H-324	-0.29658401012420654	The factor VIII/ von-Willebrand factor complex consists of two proteins ( factor VIII and von- Willebrand factor ) with different physiological functions .
D-324	-0.29658401012420654	The factor VIII/ von-Willebrand factor complex consists of two proteins ( factor VIII and von- Willebrand factor ) with different physiological functions .
P-324	-0.2892 -0.7792 -0.2613 -0.1828 -0.5951 -0.1984 -2.2795 -0.1541 -0.1262 -0.1402 -0.4593 -0.4084 -0.0887 -0.1713 -0.1014 -0.1575 -0.1299 -0.0454 -0.1172 -0.1408 -0.3102 -0.2005 -0.0927 -0.2018 -0.0798 -0.9066 -0.1113 -0.1259 -0.3142 -0.1209 -0.1576 -0.1667 -0.9347 -0.1203 -0.1076 -0.1810 -0.1588 -0.1537
S-567	Der Faktor-VIII<unk> von-Willebrand-Faktor-Komplex besteht aus zwei Proteinen ( Faktor VIII und von- Willebrand-Faktor ) mit unterschiedlichen , physiologischen Funktionen .
T-567	The factor VIII/ von Willebrand Factor complex consists of two molecules ( factor VIII and von Willebrand factor ) with different physiological functions .
H-567	-0.29658401012420654	The factor VIII/ von-Willebrand factor complex consists of two proteins ( factor VIII and von- Willebrand factor ) with different physiological functions .
D-567	-0.29658401012420654	The factor VIII/ von-Willebrand factor complex consists of two proteins ( factor VIII and von- Willebrand factor ) with different physiological functions .
P-567	-0.2892 -0.7792 -0.2613 -0.1828 -0.5951 -0.1984 -2.2795 -0.1541 -0.1262 -0.1402 -0.4593 -0.4084 -0.0887 -0.1713 -0.1014 -0.1575 -0.1299 -0.0454 -0.1172 -0.1408 -0.3102 -0.2005 -0.0927 -0.2018 -0.0798 -0.9066 -0.1113 -0.1259 -0.3142 -0.1209 -0.1576 -0.1667 -0.9347 -0.1203 -0.1076 -0.1810 -0.1588 -0.1537
S-648	Der Faktor-VIII<unk> von-Willebrand-Faktor-Komplex besteht aus zwei Proteinen ( Faktor VIII und von- Willebrand-Faktor ) mit unterschiedlichen , physiologischen Funktionen .
T-648	The factor VIII/ von Willebrand Factor complex consists of two molecules ( factor VIII and von Willebrand factor ) with different physiological functions .
H-648	-0.29658401012420654	The factor VIII/ von-Willebrand factor complex consists of two proteins ( factor VIII and von- Willebrand factor ) with different physiological functions .
D-648	-0.29658401012420654	The factor VIII/ von-Willebrand factor complex consists of two proteins ( factor VIII and von- Willebrand factor ) with different physiological functions .
P-648	-0.2892 -0.7792 -0.2613 -0.1828 -0.5951 -0.1984 -2.2795 -0.1541 -0.1262 -0.1402 -0.4593 -0.4084 -0.0887 -0.1713 -0.1014 -0.1575 -0.1299 -0.0454 -0.1172 -0.1408 -0.3102 -0.2005 -0.0927 -0.2018 -0.0798 -0.9066 -0.1113 -0.1259 -0.3142 -0.1209 -0.1576 -0.1667 -0.9347 -0.1203 -0.1076 -0.1810 -0.1588 -0.1537
S-405	Der Faktor-VIII<unk> von-Willebrand-Faktor-Komplex besteht aus zwei Proteinen ( Faktor VIII und von- Willebrand-Faktor ) mit unterschiedlichen , physiologischen Funktionen .
T-405	The factor VIII/ von Willebrand Factor complex consists of two molecules ( factor VIII and von Willebrand factor ) with different physiological functions .
H-405	-0.29658401012420654	The factor VIII/ von-Willebrand factor complex consists of two proteins ( factor VIII and von- Willebrand factor ) with different physiological functions .
D-405	-0.29658401012420654	The factor VIII/ von-Willebrand factor complex consists of two proteins ( factor VIII and von- Willebrand factor ) with different physiological functions .
P-405	-0.2892 -0.7792 -0.2613 -0.1828 -0.5951 -0.1984 -2.2795 -0.1541 -0.1262 -0.1402 -0.4593 -0.4084 -0.0887 -0.1713 -0.1014 -0.1575 -0.1299 -0.0454 -0.1172 -0.1408 -0.3102 -0.2005 -0.0927 -0.2018 -0.0798 -0.9066 -0.1113 -0.1259 -0.3142 -0.1209 -0.1576 -0.1667 -0.9347 -0.1203 -0.1076 -0.1810 -0.1588 -0.1537
S-488	Wird einem Hämophilie-A-Patienten Octocog alfa injiziert , so bindet sich dieser im Blutkreislauf an den endogenen von-Willebrand-Faktor .
T-488	When infused into a haemophilia patient , octocog alfa binds to endogenous von Willebrand Factor in the patient s circulation .
H-488	-0.30415451526641846	When octocog alfa is injected into a patient with haemophilia A , it binds to the endogenous von Willebrand factor in the blood stream .
D-488	-0.30415451526641846	When octocog alfa is injected into a patient with haemophilia A , it binds to the endogenous von Willebrand factor in the blood stream .
P-488	-0.5065 -0.8212 -0.1370 -0.1203 -0.1875 -0.1401 -0.0650 -0.1179 -0.7204 -0.1063 -0.2674 -0.1732 -0.7521 -0.2236 -0.0914 -0.0951 -0.0717 -0.2528 -0.0929 -0.1840 -1.0933 -1.2039 -0.1315 -1.2438 -0.2011 -0.0404 -0.0991 -0.0855 -0.6094 -0.1913 -0.1163 -0.6096 -0.2926 -0.1402 -0.1339 -0.2266 -0.0126 -0.1545 -0.1501
S-407	Wird einem Hämophilie-A-Patienten Octocog alfa injiziert , so bindet sich dieser im Blutkreislauf an den endogenen von-Willebrand-Faktor .
T-407	When infused into a haemophilia patient , octocog alfa binds to endogenous von Willebrand Factor in the patient s circulation .
H-407	-0.30415451526641846	When octocog alfa is injected into a patient with haemophilia A , it binds to the endogenous von Willebrand factor in the blood stream .
D-407	-0.30415451526641846	When octocog alfa is injected into a patient with haemophilia A , it binds to the endogenous von Willebrand factor in the blood stream .
P-407	-0.5065 -0.8212 -0.1370 -0.1203 -0.1875 -0.1401 -0.0650 -0.1179 -0.7204 -0.1063 -0.2674 -0.1732 -0.7521 -0.2236 -0.0914 -0.0951 -0.0717 -0.2528 -0.0929 -0.1840 -1.0933 -1.2039 -0.1315 -1.2438 -0.2011 -0.0404 -0.0991 -0.0855 -0.6094 -0.1913 -0.1163 -0.6096 -0.2926 -0.1402 -0.1339 -0.2266 -0.0126 -0.1545 -0.1501
S-246	Wird einem Hämophilie-A-Patienten Octocog alfa injiziert , so bindet sich dieser im Blutkreislauf an den endogenen von-Willebrand-Faktor .
T-246	When infused into a haemophilia patient , octocog alfa binds to endogenous von Willebrand Factor in the patient s circulation .
H-246	-0.30415451526641846	When octocog alfa is injected into a patient with haemophilia A , it binds to the endogenous von Willebrand factor in the blood stream .
D-246	-0.30415451526641846	When octocog alfa is injected into a patient with haemophilia A , it binds to the endogenous von Willebrand factor in the blood stream .
P-246	-0.5065 -0.8212 -0.1370 -0.1203 -0.1875 -0.1401 -0.0650 -0.1179 -0.7204 -0.1063 -0.2674 -0.1732 -0.7521 -0.2236 -0.0914 -0.0951 -0.0717 -0.2528 -0.0929 -0.1840 -1.0933 -1.2039 -0.1315 -1.2438 -0.2011 -0.0404 -0.0991 -0.0855 -0.6094 -0.1913 -0.1163 -0.6096 -0.2926 -0.1402 -0.1339 -0.2266 -0.0126 -0.1545 -0.1501
S-569	Wird einem Hämophilie-A-Patienten Octocog alfa injiziert , so bindet sich dieser im Blutkreislauf an den endogenen von-Willebrand-Faktor .
T-569	When infused into a haemophilia patient , octocog alfa binds to endogenous von Willebrand Factor in the patient s circulation .
H-569	-0.30415451526641846	When octocog alfa is injected into a patient with haemophilia A , it binds to the endogenous von Willebrand factor in the blood stream .
D-569	-0.30415451526641846	When octocog alfa is injected into a patient with haemophilia A , it binds to the endogenous von Willebrand factor in the blood stream .
P-569	-0.5065 -0.8212 -0.1370 -0.1203 -0.1875 -0.1401 -0.0650 -0.1179 -0.7204 -0.1063 -0.2674 -0.1732 -0.7521 -0.2236 -0.0914 -0.0951 -0.0717 -0.2528 -0.0929 -0.1840 -1.0933 -1.2039 -0.1315 -1.2438 -0.2011 -0.0404 -0.0991 -0.0855 -0.6094 -0.1913 -0.1163 -0.6096 -0.2926 -0.1402 -0.1339 -0.2266 -0.0126 -0.1545 -0.1501
S-650	Wird einem Hämophilie-A-Patienten Octocog alfa injiziert , so bindet sich dieser im Blutkreislauf an den endogenen von-Willebrand-Faktor .
T-650	When infused into a haemophilia patient , octocog alfa binds to endogenous von Willebrand Factor in the patient s circulation .
H-650	-0.30415451526641846	When octocog alfa is injected into a patient with haemophilia A , it binds to the endogenous von Willebrand factor in the blood stream .
D-650	-0.30415451526641846	When octocog alfa is injected into a patient with haemophilia A , it binds to the endogenous von Willebrand factor in the blood stream .
P-650	-0.5065 -0.8212 -0.1370 -0.1203 -0.1875 -0.1401 -0.0650 -0.1179 -0.7204 -0.1063 -0.2674 -0.1732 -0.7521 -0.2236 -0.0914 -0.0951 -0.0717 -0.2528 -0.0929 -0.1840 -1.0933 -1.2039 -0.1315 -1.2438 -0.2011 -0.0404 -0.0991 -0.0855 -0.6094 -0.1913 -0.1163 -0.6096 -0.2926 -0.1402 -0.1339 -0.2266 -0.0126 -0.1545 -0.1501
S-727	ADVATE 250 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung Octocog alfa ( rekombinanter Blutgerinnungsfaktor VIII vom Menschen )
T-727	ADVATE 250 IU powder and solvent for solution for injection Octocog alfa ( recombinant human coagulation factor VIII )
H-727	-0.23988240957260132	ADVATE 250 IU powder and solvent for the preparation of solution for injection Octocog alfa ( human recombinant blood clotting factor VIII )
D-727	-0.23988240957260132	ADVATE 250 IU powder and solvent for the preparation of solution for injection Octocog alfa ( human recombinant blood clotting factor VIII )
P-727	-0.0916 -0.1641 -0.0795 -0.0851 -0.0813 -0.1036 -0.1247 -0.4318 -0.1387 -0.1342 -0.9164 -0.3076 -1.5310 -0.7568 -0.1437 -0.4778 -0.1262 -0.0789 -0.0840 -0.1243 -0.1067 -0.1303 -0.1377 -0.1321 -0.0672 -0.1455 -0.1969 -0.1170 -0.0896 -0.0826 -0.1412 -0.4804 -0.9969 -0.0143 -0.1029 -0.0692 -0.1745 -0.0726 -0.1512 -0.2050
S-326	Wird einem Hämophilie-A-Patienten Octocog alfa injiziert , so bindet sich dieser im Blutkreislauf an den endogenen von-Willebrand-Faktor .
T-326	When infused into a haemophilia patient , octocog alfa binds to endogenous von Willebrand Factor in the patient s circulation .
H-326	-0.30415451526641846	When octocog alfa is injected into a patient with haemophilia A , it binds to the endogenous von Willebrand factor in the blood stream .
D-326	-0.30415451526641846	When octocog alfa is injected into a patient with haemophilia A , it binds to the endogenous von Willebrand factor in the blood stream .
P-326	-0.5065 -0.8212 -0.1370 -0.1203 -0.1875 -0.1401 -0.0650 -0.1179 -0.7204 -0.1063 -0.2674 -0.1732 -0.7521 -0.2236 -0.0914 -0.0951 -0.0717 -0.2528 -0.0929 -0.1840 -1.0933 -1.2039 -0.1315 -1.2438 -0.2011 -0.0404 -0.0991 -0.0855 -0.6094 -0.1913 -0.1163 -0.6096 -0.2926 -0.1402 -0.1339 -0.2266 -0.0126 -0.1545 -0.1501
S-197	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail<unk> emea.europa.eu http<unk> <unk> <unk> www.emea.europa.eu
T-197	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail<<unk>> emea . europa . eu http : / <<unk>> www . emea . europa . eu
H-197	-0.11844879388809204	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail<unk> emea . europa . eu http : / <unk> www . emea . europa . eu
D-197	-0.11844879388809204	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail<unk> emea . europa . eu http : / <unk> www . emea . europa . eu
P-197	-0.1503 -0.0736 -0.0913 -0.1313 -0.1532 -0.0777 -0.1037 -0.0544 -0.1093 -0.0491 -0.1361 -0.0616 -0.0682 -0.1197 -0.1442 -0.0547 -0.0995 -0.0425 -0.1285 -0.0839 -0.1254 -0.1142 -0.1492 -0.0688 -0.0288 -0.0383 -0.1280 -0.1438 -0.0253 -0.1390 -0.4114 -0.1022 -0.1108 -0.1384 -0.1804 -0.0174 -0.1389 -0.0635 -0.1460 -0.0349 -0.1078 -0.1672 -0.0251 -0.1516 -0.5340 -0.1081 -0.2358
S-813	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 75 23 71 29 E-mail : mail<unk> emea.europa.eu http<unk> <unk> <unk> www.emea.europa.eu
T-813	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 75 23 71 29 E-mail : mail<<unk>> emea . europa . eu http : / <<unk>> www . emea . europa . eu
H-813	-0.1179300919175148	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 75 23 71 29 E-mail : mail<unk> emea . europa . eu http : / <unk> www . emea . europa . eu
D-813	-0.1179300919175148	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 75 23 71 29 E-mail : mail<unk> emea . europa . eu http : / <unk> www . emea . europa . eu
P-813	-0.1525 -0.0732 -0.0904 -0.1297 -0.1526 -0.0767 -0.1039 -0.0498 -0.0958 -0.0497 -0.1352 -0.0561 -0.0661 -0.1197 -0.1436 -0.0751 -0.0582 -0.0715 -0.0781 -0.0805 -0.1211 -0.1101 -0.1497 -0.0675 -0.0290 -0.0376 -0.1272 -0.1434 -0.0258 -0.1396 -0.4191 -0.1047 -0.1157 -0.1391 -0.1801 -0.0185 -0.1565 -0.0624 -0.1461 -0.0344 -0.1077 -0.1647 -0.0256 -0.1529 -0.5676 -0.1090 -0.2292
S-10	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 86 68 E-mail : mail<unk> emea.europa.eu http<unk> <unk> <unk> www.emea.europa.eu
T-10	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 86 68 E-mail : mail<<unk>> emea . europa . eu http : / <<unk>> www . emea . europa . eu
H-10	-0.11799786239862442	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 86 68 E-mail : mail<unk> emea . europa . eu http : / <unk> www . emea . europa . eu
D-10	-0.11799786239862442	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 86 68 E-mail : mail<unk> emea . europa . eu http : / <unk> www . emea . europa . eu
P-10	-0.1484 -0.0738 -0.0914 -0.1304 -0.1522 -0.0760 -0.1052 -0.0516 -0.1096 -0.0493 -0.1356 -0.0613 -0.0684 -0.1205 -0.1436 -0.0521 -0.1007 -0.0477 -0.0326 -0.0822 -0.1160 -0.1067 -0.1501 -0.0678 -0.0304 -0.0383 -0.1256 -0.1438 -0.0259 -0.1421 -0.4385 -0.1013 -0.1115 -0.1388 -0.1813 -0.0181 -0.1682 -0.0635 -0.1472 -0.0344 -0.1084 -0.1655 -0.0252 -0.1527 -0.5780 -0.1084 -0.2257
S-105	Therapie der postmenopausalen Osteoporose bei Patienten mit Risiko für einen Vitamin-D-Mangel , die keine zusätzliche Vitamin-D-Supplementierung erhalten .
T-105	Treatment of postmenopausal osteoporosis in patients who are not receiving vitamin D supplementation and are at risk of vitamin D insufficiency .
H-105	-0.20831942558288574	Treatment of post-menopausal osteoporosis in patients at risk for vitamin D deficiency who are not receiving additional vitamin D supplementation .
D-105	-0.20831942558288574	Treatment of post-menopausal osteoporosis in patients at risk for vitamin D deficiency who are not receiving additional vitamin D supplementation .
P-105	-1.2984 -0.0749 -0.1207 -0.1422 -0.0428 -0.6144 -0.0969 -0.1052 -0.0379 -0.1307 -0.1541 -0.1142 -0.1105 -0.1252 -0.0985 -0.0749 -0.1231 -0.0581 -0.0666 -0.0845 -0.4023 -0.0496 -0.1011 -0.1572 -0.0178 -0.0889 -0.1754 -0.3842 -1.1913 -0.2155 -0.1735 -0.7021 -0.1993 -0.0908 -0.1248 -0.0415 -0.0770 -0.1166 -0.1987 -0.1516
S-34	Eine zusätzliche Ergänzung mit Vitamin D sollte individuell unter Berücksichtung der Vitamin-D-Aufnahme durch Vitaminpräparate und Nahrungsergänzungsmittel erwogen werden .
T-34	Additional supplementation with vitamin D should be considered on an individual basis taking into account any vitamin D intake from vitamins and dietary supplements .
H-34	-0.3599984645843506	Additional vitamin D supplementation should be considered on an individual basis with consideration for vitamin D intake from vitamin D supplements and supplements .
D-34	-0.3599984645843506	Additional vitamin D supplementation should be considered on an individual basis with consideration for vitamin D intake from vitamin D supplements and supplements .
P-34	-1.6180 -1.1767 -0.0860 -0.1088 -0.0614 -0.2146 -0.1207 -0.1468 -0.1403 -0.3560 -0.3234 -0.1192 -0.0975 -0.2166 -0.7719 -1.3309 -0.1790 -0.2152 -0.1248 -0.1265 -0.9110 -0.1359 -0.5866 -0.1238 -0.2423 -0.9705 -0.0115 -0.0909 -0.1270 -0.8120 -0.0600 -0.1257 -0.1484
S-734	ADVATE enthält als arzneilich wirksamen Bestandteil Octocog alfa , Blutgerinnungsfaktor VIII vom Menschen , hergestellt mittels rekombinanter DNS-Technologie .
T-734	ADVATE contains the active substance octocog alfa , human coagulation factor VIII produced by recombinant DNA technology .
H-734	-0.35814177989959717	As a medicinal product , ADVATE contains Octocog alfa , a human coagulation factor VIII produced by recombinant DNA technology .
D-734	-0.35814177989959717	As a medicinal product , ADVATE contains Octocog alfa , a human coagulation factor VIII produced by recombinant DNA technology .
P-734	-1.1965 -1.4610 -0.2820 -0.0227 -0.7974 -0.2280 -0.1052 -0.1655 -0.0877 -0.0892 -0.0890 -1.3018 -0.1007 -0.1204 -0.1479 -0.1290 -0.0651 -0.1593 -1.8783 -0.1235 -1.4906 -0.1746 -0.1935 -0.0456 -0.1763 -0.0670 -0.7014 -0.6860 -0.1225 -0.0817 -0.0730 -0.1297 -0.0284 -0.0741 -0.1480 -0.1504
S-828	Blister ( PCTFE<unk> PVC<unk> Alu ) 20 Tabletten 2.5 mg Desloratadin<unk> 120 mg Pseudoephedrinsulphat 1<unk> 1
T-828	1/ 1
H-828	-0.15433178842067719	Blister ( PCTFE/ PVC/ alu ) 20 tablets 2.5 mg desloratadin/ 120 mg pseudoephedrine sulphate 1/ 1
D-828	-0.15433178842067719	Blister ( PCTFE/ PVC/ alu ) 20 tablets 2.5 mg desloratadin/ 120 mg pseudoephedrine sulphate 1/ 1
P-828	-0.1153 -0.1414 -0.1480 -0.1702 -0.1345 -0.1485 -0.1058 -0.3061 -0.1342 -0.1407 -0.1544 -0.1874 -0.1971 -0.1540 -0.1428 -0.1060 -0.0998 -0.1002 -0.0630 -0.0343 -0.4942 -0.0438 -0.1296 -0.1285 -0.2332 -0.1957 -0.1091 -0.0505 -0.0818 -0.3003 -0.1459 -0.0555 -0.1278 -0.1097 -0.1652 -0.0828 -0.3743 -0.1461 -0.1287 -0.2614 -0.1830 -0.1511
S-416	Pulver Mannitol Natriumchlorid Histidin Trehalose Calciumchlorid Trometamol Polysorbat 80 Glutathion ( reduziert ) .
T-416	Powder Mannitol Sodium chloride Histidine Trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced )
H-416	-0.19141361117362976	powder mannitol sodium chloride histidine trehalose calcium chloride trometamol polysorbate 80 glutathione ( reduced ) .
D-416	-0.19141361117362976	powder mannitol sodium chloride histidine trehalose calcium chloride trometamol polysorbate 80 glutathione ( reduced ) .
P-416	-2.3260 -0.4044 -0.0877 -0.1093 -0.1511 -0.0470 -0.1205 -0.1067 -0.0632 -0.1209 -0.1324 -0.1233 -0.1210 -0.1441 -0.0673 -0.0475 -0.0568 -0.0643 -0.1243 -0.1314 -0.0912 -0.1042 -0.1059 -0.1433 -0.1035 -0.2095 -0.0891 -0.0936 -0.0253 -0.1266 -0.1395 -0.0904 -0.1267 -0.0796 -0.0685 -0.1322 -0.2130 -0.1432 -0.0910 -0.1476 -0.9928 -0.1735
S-18	EU<unk> 1<unk> 08<unk> 447<unk> 002 ADENURIC 80 mg Filmtablette Zum Einnehmen Blisterpackung ( Aclar<unk> PVC<unk> Aluminium )
T-18	Adenuric Adenuric Adenuric Adenuric
H-18	-0.221690833568573	EU/ 1/ 08/ 447/ 002 ADENURIC 80 mg oral film tablet Blister ( Aclar/ PVC/ aluminium )
D-18	-0.221690833568573	EU/ 1/ 08/ 447/ 002 ADENURIC 80 mg oral film tablet Blister ( Aclar/ PVC/ aluminium )
P-18	-0.0973 -0.1345 -0.1012 -0.1125 -0.0785 -0.1385 -0.1137 -0.2020 -0.1326 -0.1181 -0.1376 -0.0895 -0.1319 -0.0914 -0.1382 -0.0709 -0.0400 -0.4322 -2.3968 -0.7967 -0.1181 -0.1276 -0.1220 -0.1524 -0.1411 -0.2289 -0.1271 -0.2012 -0.1360 -0.1504 -0.1624 -0.1633 -0.1080 -0.0450 -0.1510 -0.2922
S-335	Pulver Mannitol Natriumchlorid Histidin Trehalose Calciumchlorid Trometamol Polysorbat 80 Glutathion ( reduziert ) .
T-335	Powder Mannitol Sodium chloride Histidine Trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced )
H-335	-0.19141361117362976	powder mannitol sodium chloride histidine trehalose calcium chloride trometamol polysorbate 80 glutathione ( reduced ) .
D-335	-0.19141361117362976	powder mannitol sodium chloride histidine trehalose calcium chloride trometamol polysorbate 80 glutathione ( reduced ) .
P-335	-2.3260 -0.4044 -0.0877 -0.1093 -0.1511 -0.0470 -0.1205 -0.1067 -0.0632 -0.1209 -0.1324 -0.1233 -0.1210 -0.1441 -0.0673 -0.0475 -0.0568 -0.0643 -0.1243 -0.1314 -0.0912 -0.1042 -0.1059 -0.1433 -0.1035 -0.2095 -0.0891 -0.0936 -0.0253 -0.1266 -0.1395 -0.0904 -0.1267 -0.0796 -0.0685 -0.1322 -0.2130 -0.1432 -0.0910 -0.1476 -0.9928 -0.1735
S-254	Pulver Mannitol Natriumchlorid Histidin Trehalose Calciumchlorid Trometamol Polysorbat 80 Glutathion ( reduziert ) .
T-254	Powder Mannitol Sodium chloride Histidine Trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced )
H-254	-0.19141361117362976	powder mannitol sodium chloride histidine trehalose calcium chloride trometamol polysorbate 80 glutathione ( reduced ) .
D-254	-0.19141361117362976	powder mannitol sodium chloride histidine trehalose calcium chloride trometamol polysorbate 80 glutathione ( reduced ) .
P-254	-2.3260 -0.4044 -0.0877 -0.1093 -0.1511 -0.0470 -0.1205 -0.1067 -0.0632 -0.1209 -0.1324 -0.1233 -0.1210 -0.1441 -0.0673 -0.0475 -0.0568 -0.0643 -0.1243 -0.1314 -0.0912 -0.1042 -0.1059 -0.1433 -0.1035 -0.2095 -0.0891 -0.0936 -0.0253 -0.1266 -0.1395 -0.0904 -0.1267 -0.0796 -0.0685 -0.1322 -0.2130 -0.1432 -0.0910 -0.1476 -0.9928 -0.1735
S-497	Pulver Mannitol Natriumchlorid Histidin Trehalose Calciumchlorid Trometamol Polysorbat 80 Glutathion ( reduziert ) .
T-497	Powder Mannitol Sodium chloride Histidine Trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced )
H-497	-0.19141361117362976	powder mannitol sodium chloride histidine trehalose calcium chloride trometamol polysorbate 80 glutathione ( reduced ) .
D-497	-0.19141361117362976	powder mannitol sodium chloride histidine trehalose calcium chloride trometamol polysorbate 80 glutathione ( reduced ) .
P-497	-2.3260 -0.4044 -0.0877 -0.1093 -0.1511 -0.0470 -0.1205 -0.1067 -0.0632 -0.1209 -0.1324 -0.1233 -0.1210 -0.1441 -0.0673 -0.0475 -0.0568 -0.0643 -0.1243 -0.1314 -0.0912 -0.1042 -0.1059 -0.1433 -0.1035 -0.2095 -0.0891 -0.0936 -0.0253 -0.1266 -0.1395 -0.0904 -0.1267 -0.0796 -0.0685 -0.1322 -0.2130 -0.1432 -0.0910 -0.1476 -0.9928 -0.1735
S-659	Pulver Mannitol Natriumchlorid Histidin Trehalose Calciumchlorid Trometamol Polysorbat 80 Glutathion ( reduziert ) .
T-659	Powder Mannitol Sodium chloride Histidine Trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced )
H-659	-0.19141361117362976	powder mannitol sodium chloride histidine trehalose calcium chloride trometamol polysorbate 80 glutathione ( reduced ) .
D-659	-0.19141361117362976	powder mannitol sodium chloride histidine trehalose calcium chloride trometamol polysorbate 80 glutathione ( reduced ) .
P-659	-2.3260 -0.4044 -0.0877 -0.1093 -0.1511 -0.0470 -0.1205 -0.1067 -0.0632 -0.1209 -0.1324 -0.1233 -0.1210 -0.1441 -0.0673 -0.0475 -0.0568 -0.0643 -0.1243 -0.1314 -0.0912 -0.1042 -0.1059 -0.1433 -0.1035 -0.2095 -0.0891 -0.0936 -0.0253 -0.1266 -0.1395 -0.0904 -0.1267 -0.0796 -0.0685 -0.1322 -0.2130 -0.1432 -0.0910 -0.1476 -0.9928 -0.1735
S-578	Pulver Mannitol Natriumchlorid Histidin Trehalose Calciumchlorid Trometamol Polysorbat 80 Glutathion ( reduziert ) .
T-578	Powder Mannitol Sodium chloride Histidine Trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced )
H-578	-0.19141361117362976	powder mannitol sodium chloride histidine trehalose calcium chloride trometamol polysorbate 80 glutathione ( reduced ) .
D-578	-0.19141361117362976	powder mannitol sodium chloride histidine trehalose calcium chloride trometamol polysorbate 80 glutathione ( reduced ) .
P-578	-2.3260 -0.4044 -0.0877 -0.1093 -0.1511 -0.0470 -0.1205 -0.1067 -0.0632 -0.1209 -0.1324 -0.1233 -0.1210 -0.1441 -0.0673 -0.0475 -0.0568 -0.0643 -0.1243 -0.1314 -0.0912 -0.1042 -0.1059 -0.1433 -0.1035 -0.2095 -0.0891 -0.0936 -0.0253 -0.1266 -0.1395 -0.0904 -0.1267 -0.0796 -0.0685 -0.1322 -0.2130 -0.1432 -0.0910 -0.1476 -0.9928 -0.1735
S-505	ADVATE wird nach dem Auflösen des lyophilisierten Produktes mit dem mitgelieferten sterilisierten Wasser für Injektionszwecke intravenös verabreicht .
T-505	ADVATE is to be administered intravenously after reconstitution of the lyophilized product with the provided sterilised water for injections .
H-505	-0.27172040939331055	ADVATE is administered intravenously after the lyophilised product has been dissolved using the sterilised water provided .
D-505	-0.27172040939331055	ADVATE is administered intravenously after the lyophilised product has been dissolved using the sterilised water provided .
P-505	-0.5643 -0.1726 -0.0811 -0.0868 -0.1196 -1.0204 -0.0919 -0.2074 -0.0785 -0.0919 -0.1201 -0.3482 -0.7001 -0.2551 -0.1325 -0.1033 -0.0937 -0.0813 -0.1617 -0.7365 -0.2749 -0.0527 -0.0953 -0.6700 -0.1455 -1.0527 -0.1466 -0.0914 -0.1713 -0.3790 -0.2226 -0.1459
S-262	ADVATE wird nach dem Auflösen des lyophilisierten Produktes mit dem mitgelieferten sterilisierten Wasser für Injektionszwecke intravenös verabreicht .
T-262	Advate is to be administered intravenously after reconstitution of the lyophilized product with the provided sterilised water for injections .
H-262	-0.27172040939331055	ADVATE is administered intravenously after the lyophilised product has been dissolved using the sterilised water provided .
D-262	-0.27172040939331055	ADVATE is administered intravenously after the lyophilised product has been dissolved using the sterilised water provided .
P-262	-0.5643 -0.1726 -0.0811 -0.0868 -0.1196 -1.0204 -0.0919 -0.2074 -0.0785 -0.0919 -0.1201 -0.3482 -0.7001 -0.2551 -0.1325 -0.1033 -0.0937 -0.0813 -0.1617 -0.7365 -0.2749 -0.0527 -0.0953 -0.6700 -0.1455 -1.0527 -0.1466 -0.0914 -0.1713 -0.3790 -0.2226 -0.1459
S-343	ADVATE wird nach dem Auflösen des lyophilisierten Produktes mit dem mitgelieferten sterilisierten Wasser für Injektionszwecke intravenös verabreicht .
T-343	ADVATE is to be administered intravenously after reconstitution of the lyophilized product with the provided sterilised water for injections .
H-343	-0.27172040939331055	ADVATE is administered intravenously after the lyophilised product has been dissolved using the sterilised water provided .
D-343	-0.27172040939331055	ADVATE is administered intravenously after the lyophilised product has been dissolved using the sterilised water provided .
P-343	-0.5643 -0.1726 -0.0811 -0.0868 -0.1196 -1.0204 -0.0919 -0.2074 -0.0785 -0.0919 -0.1201 -0.3482 -0.7001 -0.2551 -0.1325 -0.1033 -0.0937 -0.0813 -0.1617 -0.7365 -0.2749 -0.0527 -0.0953 -0.6700 -0.1455 -1.0527 -0.1466 -0.0914 -0.1713 -0.3790 -0.2226 -0.1459
S-424	ADVATE wird nach dem Auflösen des lyophilisierten Produktes mit dem mitgelieferten sterilisierten Wasser für Injektionszwecke intravenös verabreicht .
T-424	ADVATE is to be administered intravenously after reconstitution of the lyophilized product with the provided sterilised water for injections .
H-424	-0.27172040939331055	ADVATE is administered intravenously after the lyophilised product has been dissolved using the sterilised water provided .
D-424	-0.27172040939331055	ADVATE is administered intravenously after the lyophilised product has been dissolved using the sterilised water provided .
P-424	-0.5643 -0.1726 -0.0811 -0.0868 -0.1196 -1.0204 -0.0919 -0.2074 -0.0785 -0.0919 -0.1201 -0.3482 -0.7001 -0.2551 -0.1325 -0.1033 -0.0937 -0.0813 -0.1617 -0.7365 -0.2749 -0.0527 -0.0953 -0.6700 -0.1455 -1.0527 -0.1466 -0.0914 -0.1713 -0.3790 -0.2226 -0.1459
S-667	ADVATE wird nach dem Auflösen des lyophilisierten Produktes mit dem mitgelieferten sterilisierten Wasser für Injektionszwecke intravenös verabreicht .
T-667	ADVATE is to be administered intravenously after reconstitution of the lyophilized product with the provided sterilised water for injections .
H-667	-0.27172040939331055	ADVATE is administered intravenously after the lyophilised product has been dissolved using the sterilised water provided .
D-667	-0.27172040939331055	ADVATE is administered intravenously after the lyophilised product has been dissolved using the sterilised water provided .
P-667	-0.5643 -0.1726 -0.0811 -0.0868 -0.1196 -1.0204 -0.0919 -0.2074 -0.0785 -0.0919 -0.1201 -0.3482 -0.7001 -0.2551 -0.1325 -0.1033 -0.0937 -0.0813 -0.1617 -0.7365 -0.2749 -0.0527 -0.0953 -0.6700 -0.1455 -1.0527 -0.1466 -0.0914 -0.1713 -0.3790 -0.2226 -0.1459
S-79	Die Konversion zum aktiven calciummobilisierenden Hormon 1,25-Dihydroxyvitamin D3 ( Calcitriol ) in der Niere ist streng reguliert .
T-79	Conversion to the active calcium-mobilizing hormone 1,25-dihydroxyvitamin D3 ( calcitriol ) in the kidney is tightly regulated .
H-79	-0.21813681721687317	Conversion to the active calcium mobilising hormone 1,25 dihydroxy vitamin D3 ( calcitriol ) in the kidney is strictly regulated .
D-79	-0.21813681721687317	Conversion to the active calcium mobilising hormone 1,25 dihydroxy vitamin D3 ( calcitriol ) in the kidney is strictly regulated .
P-79	-1.3791 -0.1854 -0.4347 -0.1646 -0.1260 -0.0337 -0.0784 -0.1768 -0.2730 -0.2916 -0.0966 -0.0567 -0.1552 -0.8441 -0.3564 -0.0609 -0.5483 -0.0947 -0.1268 -0.1407 -0.1484 -0.1457 -0.1076 -0.0628 -0.1373 -0.1066 -0.1444 -0.2015 -0.1330 -0.0954 -0.1191 -0.1214 -0.3492 -0.0783 -0.2852 -0.1295 -0.1492 -0.1513
S-586	ADVATE wird nach dem Auflösen des lyophilisierten Produktes mit dem mitgelieferten sterilisierten Wasser für Injektionszwecke intravenös verabreicht .
T-586	ADVATE is to be administered intravenously after reconstitution of the lyophilized product with the provided sterilised water for injections .
H-586	-0.27172040939331055	ADVATE is administered intravenously after the lyophilised product has been dissolved using the sterilised water provided .
D-586	-0.27172040939331055	ADVATE is administered intravenously after the lyophilised product has been dissolved using the sterilised water provided .
P-586	-0.5643 -0.1726 -0.0811 -0.0868 -0.1196 -1.0204 -0.0919 -0.2074 -0.0785 -0.0919 -0.1201 -0.3482 -0.7001 -0.2551 -0.1325 -0.1033 -0.0937 -0.0813 -0.1617 -0.7365 -0.2749 -0.0527 -0.0953 -0.6700 -0.1455 -1.0527 -0.1466 -0.0914 -0.1713 -0.3790 -0.2226 -0.1459
S-156	Die Konversion zum aktiven calciummobilisierenden Hormon 1,25-Dihydroxyvitamin D3 ( Calcitriol ) in der Niere ist streng reguliert .
T-156	Conversion to the active calcium-mobilizing hormone 1,25-dihydroxyvitamin D3 ( calcitriol ) in the kidney is tightly regulated .
H-156	-0.21813681721687317	Conversion to the active calcium mobilising hormone 1,25 dihydroxy vitamin D3 ( calcitriol ) in the kidney is strictly regulated .
D-156	-0.21813681721687317	Conversion to the active calcium mobilising hormone 1,25 dihydroxy vitamin D3 ( calcitriol ) in the kidney is strictly regulated .
P-156	-1.3791 -0.1854 -0.4347 -0.1646 -0.1260 -0.0337 -0.0784 -0.1768 -0.2730 -0.2916 -0.0966 -0.0567 -0.1552 -0.8441 -0.3564 -0.0609 -0.5483 -0.0947 -0.1268 -0.1407 -0.1484 -0.1457 -0.1076 -0.0628 -0.1373 -0.1066 -0.1444 -0.2015 -0.1330 -0.0954 -0.1191 -0.1214 -0.3492 -0.0783 -0.2852 -0.1295 -0.1492 -0.1513
S-847	Dihydroergotamin , Ergotamin , Methylergometrin : Risiko für das Auftreten einer Gefäßverengung und einer Hypertonie .
T-847	Dihydroergotamine , ergotamine , methylergometrine : risk of vasoconstriction and increase in blood pressure .
H-847	-0.3592635691165924	Dihydroergotamine , ergotamine , methylergometrine : risk for vasoconstriction and hypertension .
D-847	-0.3592635691165924	Dihydroergotamine , ergotamine , methylergometrine : risk for vasoconstriction and hypertension .
P-847	-0.1697 -0.0830 -0.2305 -0.1234 -0.1696 -0.1457 -0.6149 -0.1476 -0.1656 -0.1452 -0.0989 -0.2589 -1.2188 -0.1902 -0.0801 -1.9058 -0.1532 -0.1374 -0.2083 -0.5141 -1.4100 -0.0218 -1.8406 -0.0529 -0.3103 -0.1888 -0.1301 -0.0601 -0.0657 -0.1396 -0.1566
S-799	Suomi<unk> Finland Baxter Oy Valimotie 15 A FIN-00380 Helsinki Puh<unk> Tel : <unk> 358 9 8621111
T-799	Suomi/ Finland Baxter Oy Valimotie 15 A FIN-00380 Helsinki Puh/ Tel : <<unk>> 358 9 8621111
H-799	-0.1264544576406479	Suomi/ Finland Baxter Oy Valimotie 15 A FIN-00380 Helsinki Puh/ Tel : <unk> 358 9 8621111
D-799	-0.1264544576406479	Suomi/ Finland Baxter Oy Valimotie 15 A FIN-00380 Helsinki Puh/ Tel : <unk> 358 9 8621111
P-799	-0.1477 -0.0296 -0.1603 -0.0916 -0.1132 -0.1121 -0.1393 -0.1675 -0.1326 -0.2070 -0.1101 -0.1143 -0.1356 -0.1764 -0.1354 -0.1354 -0.1228 -0.2007 -0.0992 -0.0955 -0.1164 -0.1118 -0.0655 -0.1332 -0.1241 -0.1637 -0.2094 -0.0598 -0.1474 -0.0558 -0.1352 -0.0985 -0.1056 -0.1549 -0.1243 -0.1117 -0.0760 -0.1499 -0.1623
S-325	Octocog alfa ist ein Glycoprotein , das aus 2332 Aminosäuren mit einem Molekulargewicht von ca. 280 kD besteht .
T-325	Octocog alfa is a glycoprotein consisting of 2332 amino acids with an approximate molecular mass of 280 kD .
H-325	-0.17028126120567322	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of about 280 kD .
D-325	-0.17028126120567322	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of about 280 kD .
P-325	-0.0900 -0.0988 -0.1157 -0.1488 -0.1282 -0.0650 -0.1405 -0.1360 -0.1272 -0.0989 -0.0806 -0.0437 -0.0722 -1.4115 -0.1540 -0.1431 -0.0752 -0.1246 -0.0937 -0.0801 -0.2612 -0.0940 -0.1725 -0.2305 -0.2716 -0.0927 -0.0830 -0.1313 -0.1341 -0.4803 -0.0515 -0.0923 -0.1426 -0.1494 -0.1452
S-839	Sympathomimetische Amine können eine Stimulation des Zentralnervensystems mit Krampfanfällen oder einen Herz-Kreislauf-Kollaps mit Hypotonie verursachen .
T-839	Central nervous system stimulation with convulsions or cardiovascular collapse with accompanying hypotension may be produced by sympathomimetic amines .
H-839	-0.18504279851913452	Sympathomimetic amines may cause central nervous system stimulation with seizures or cardiovascular collapse with hypotension .
D-839	-0.18504279851913452	Sympathomimetic amines may cause central nervous system stimulation with seizures or cardiovascular collapse with hypotension .
P-839	-0.1805 -0.0623 -0.0953 -0.0976 -1.0434 -0.2122 -0.2587 -0.0613 -0.6860 -0.1037 -0.0630 -0.1180 -0.0987 -0.1537 -0.6178 -0.2417 -0.0863 -0.1970 -0.0292 -0.0748 -0.1042 -0.0715 -0.1942 -0.1138 -0.1015 -0.0694 -0.0826 -0.0342 -0.1445 -0.1543
S-406	Octocog alfa ist ein Glycoprotein , das aus 2332 Aminosäuren mit einem Molekulargewicht von ca. 280 kD besteht .
T-406	Octocog alfa is a glycoprotein consisting of 2332 amino acids with an approximate molecular mass of 280 kD .
H-406	-0.17028126120567322	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of about 280 kD .
D-406	-0.17028126120567322	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of about 280 kD .
P-406	-0.0900 -0.0988 -0.1157 -0.1488 -0.1282 -0.0650 -0.1405 -0.1360 -0.1272 -0.0989 -0.0806 -0.0437 -0.0722 -1.4115 -0.1540 -0.1431 -0.0752 -0.1246 -0.0937 -0.0801 -0.2612 -0.0940 -0.1725 -0.2305 -0.2716 -0.0927 -0.0830 -0.1313 -0.1341 -0.4803 -0.0515 -0.0923 -0.1426 -0.1494 -0.1452
S-245	Octocog alfa ist ein Glycoprotein , das aus 2332 Aminosäuren mit einem Molekulargewicht von ca. 280 kD besteht .
T-245	Octocog alfa is a glycoprotein consisting of 2332 amino acids with an approximate molecular mass of 280 kD .
H-245	-0.17028126120567322	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of about 280 kD .
D-245	-0.17028126120567322	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of about 280 kD .
P-245	-0.0900 -0.0988 -0.1157 -0.1488 -0.1282 -0.0650 -0.1405 -0.1360 -0.1272 -0.0989 -0.0806 -0.0437 -0.0722 -1.4115 -0.1540 -0.1431 -0.0752 -0.1246 -0.0937 -0.0801 -0.2612 -0.0940 -0.1725 -0.2305 -0.2716 -0.0927 -0.0830 -0.1313 -0.1341 -0.4803 -0.0515 -0.0923 -0.1426 -0.1494 -0.1452
S-568	Octocog alfa ist ein Glycoprotein , das aus 2332 Aminosäuren mit einem Molekulargewicht von ca. 280 kD besteht .
T-568	Octocog alfa is a glycoprotein consisting of 2332 amino acids with an approximate molecular mass of 280 kD .
H-568	-0.17028126120567322	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of about 280 kD .
D-568	-0.17028126120567322	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of about 280 kD .
P-568	-0.0900 -0.0988 -0.1157 -0.1488 -0.1282 -0.0650 -0.1405 -0.1360 -0.1272 -0.0989 -0.0806 -0.0437 -0.0722 -1.4115 -0.1540 -0.1431 -0.0752 -0.1246 -0.0937 -0.0801 -0.2612 -0.0940 -0.1725 -0.2305 -0.2716 -0.0927 -0.0830 -0.1313 -0.1341 -0.4803 -0.0515 -0.0923 -0.1426 -0.1494 -0.1452
S-147	Osteonekrose des Kiefers steht üblicherweise im Zusammenhang mit einer Zahnextraktion und<unk> oder einer lokalen Infektion ( einschließlich Osteomyelitis ) .
T-147	Osteonecrosis of the jaw is generally associated with tooth extraction and / or local infection ( including osteomyelitis ) .
H-147	-0.1532530039548874	Osteonecrosis of the jaw is usually associated with tooth extraction and/ or local infection ( including osteomyelitis ) .
D-147	-0.1532530039548874	Osteonecrosis of the jaw is usually associated with tooth extraction and/ or local infection ( including osteomyelitis ) .
P-147	-0.0983 -0.0904 -0.1395 -0.0934 -0.0203 -0.0854 -0.1459 -0.1235 -0.1282 -0.1255 -0.1136 -0.5426 -0.1079 -0.1338 -0.0954 -0.0355 -0.1797 -0.1920 -0.0493 -0.0764 -0.1505 -1.0232 -0.0825 -0.2048 -0.1023 -0.1280 -0.1007 -0.1107 -0.1666 -0.0422 -0.0712 -0.1460 -0.1506 -0.1549
S-71	Osteonekrose des Kiefers steht üblicherweise im Zusammenhang mit einer Zahnextraktion und<unk> oder einer lokalen Infektion ( einschließlich Osteomyelitis ) .
T-71	Osteonecrosis of the jaw is generally associated with tooth extraction and / or local infection ( including osteomyelitis ) .
H-71	-0.1532530039548874	Osteonecrosis of the jaw is usually associated with tooth extraction and/ or local infection ( including osteomyelitis ) .
D-71	-0.1532530039548874	Osteonecrosis of the jaw is usually associated with tooth extraction and/ or local infection ( including osteomyelitis ) .
P-71	-0.0983 -0.0904 -0.1395 -0.0934 -0.0203 -0.0854 -0.1459 -0.1235 -0.1282 -0.1255 -0.1136 -0.5426 -0.1079 -0.1338 -0.0954 -0.0355 -0.1797 -0.1920 -0.0493 -0.0764 -0.1505 -1.0232 -0.0825 -0.2048 -0.1023 -0.1280 -0.1007 -0.1107 -0.1666 -0.0422 -0.0712 -0.1460 -0.1506 -0.1549
S-136	In Tierstudien wurde unter hohen Vitamin-D-Dosen Hypercalcämie und Reproduktionstoxizität ( siehe Abschnitt 5.3 ) nachgewiesen .
T-136	Studies in animals have shown hypercalcaemia and reproductive toxicity with high doses of vitamin D ( see section 5.3 ) .
H-136	-0.32188963890075684	Hypercalcaemia and toxicity to reproduction ( see section 5.3 ) have been demonstrated in animal studies at high doses of vitamin D .
D-136	-0.32188963890075684	Hypercalcaemia and toxicity to reproduction ( see section 5.3 ) have been demonstrated in animal studies at high doses of vitamin D .
P-136	-0.2383 -0.0621 -0.0708 -0.0394 -0.0465 -0.1281 -0.1357 -1.5218 -0.1141 -0.1526 -0.1627 -0.1269 -0.0924 -0.3023 -0.1936 -0.1275 -0.1144 -0.1395 -0.1450 -0.8652 -0.1931 -1.6447 -0.7065 -0.0411 -0.0478 -0.2747 -1.0425 -0.0912 -0.0786 -0.1595 -0.1464 -0.8817 -0.5955 -0.4374 -0.1466
S-60	In Tierstudien wurde unter hohen Vitamin-D-Dosen Hypercalcämie und Reproduktionstoxizität ( siehe Abschnitt 5.3 ) nachgewiesen .
T-60	Studies in animals have shown hypercalcaemia and reproductive toxicity with high doses of vitamin D ( see section 5.3 ) .
H-60	-0.32188963890075684	Hypercalcaemia and toxicity to reproduction ( see section 5.3 ) have been demonstrated in animal studies at high doses of vitamin D .
D-60	-0.32188963890075684	Hypercalcaemia and toxicity to reproduction ( see section 5.3 ) have been demonstrated in animal studies at high doses of vitamin D .
P-60	-0.2383 -0.0621 -0.0708 -0.0394 -0.0465 -0.1281 -0.1357 -1.5218 -0.1141 -0.1526 -0.1627 -0.1269 -0.0924 -0.3023 -0.1936 -0.1275 -0.1144 -0.1395 -0.1450 -0.8652 -0.1931 -1.6447 -0.7065 -0.0411 -0.0478 -0.2747 -1.0425 -0.0912 -0.0786 -0.1595 -0.1464 -0.8817 -0.5955 -0.4374 -0.1466
S-487	Octocog alfa ist ein Glycoprotein , das aus 2332 Aminosäuren mit einem Molekulargewicht von ca. 280 kD besteht .
T-487	Octocog alfa is a glycoprotein consisting of 2332 amino acids with an approximate molecular mass of 280 kD .
H-487	-0.17028126120567322	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of about 280 kD .
D-487	-0.17028126120567322	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of about 280 kD .
P-487	-0.0900 -0.0988 -0.1157 -0.1488 -0.1282 -0.0650 -0.1405 -0.1360 -0.1272 -0.0989 -0.0806 -0.0437 -0.0722 -1.4115 -0.1540 -0.1431 -0.0752 -0.1246 -0.0937 -0.0801 -0.2612 -0.0940 -0.1725 -0.2305 -0.2716 -0.0927 -0.0830 -0.1313 -0.1341 -0.4803 -0.0515 -0.0923 -0.1426 -0.1494 -0.1452
S-83	Hinsichtlich der Mittelwerte von Serum-Calcium , Phosphat oder Calcium im 24-Stunden-Harn gab es keine Unterschiede zwischen den Behandlungsgruppen .
T-83	There were no differences in mean serum calcium , phosphate , or 24-hour urine calcium between treatment groups .
H-83	-0.25438928604125977	There were no differences between treatment groups with regard to the mean values of serum calcium , phosphate or calcium in 24 hour urine .
D-83	-0.25438928604125977	There were no differences between treatment groups with regard to the mean values of serum calcium , phosphate or calcium in 24 hour urine .
P-83	-0.1583 -0.2022 -0.0972 -0.0946 -0.2280 -0.3164 -0.0952 -1.1438 -0.2994 -0.1413 -0.9469 -0.9822 -0.1355 -0.1943 -0.0287 -0.1219 -0.1689 -0.0841 -0.1115 -0.1424 -0.0957 -0.0588 -0.1151 -0.1608 -0.0487 -0.0777 -0.1172 -0.1708 -0.7494 -0.7334 -0.1043 -0.2084 -0.1655 -0.1508
S-688	Ausführliche Informationen zu diesem Arzneimittel sind auf der Website der Europäischen Arzneimittel-Agentur ( EMEA ) http<unk> <unk> <unk> www.emea.europa.eu / verfügbar .
T-688	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http : / <<unk>> www . emea . europa . eu/
H-688	-0.17205683887004852	Detailed information on this product is available on the European Medicines Agency ( EMEA ) web site : http : / <unk> www . emea . europa . eu/
D-688	-0.17205683887004852	Detailed information on this product is available on the European Medicines Agency ( EMEA ) web site : http : / <unk> www . emea . europa . eu/
P-688	-0.3384 -0.0574 -0.1227 -0.1378 -0.1197 -1.0655 -0.1535 -0.1348 -0.1189 -0.1422 -0.7489 -0.1597 -0.0772 -0.0844 -0.1835 -0.1230 -0.0844 -0.1125 -0.1483 -0.4725 -0.1180 -0.1368 -0.0444 -0.1453 -0.1712 -0.0340 -0.0963 -0.0534 -0.1515 -0.0407 -0.1236 -0.1449 -0.0179 -0.1310 -0.0338 -0.1230 -0.2151
S-607	Ausführliche Informationen zu diesem Arzneimittel sind auf der Website der Europäischen Arzneimittel-Agentur ( EMEA ) http<unk> <unk> <unk> www.emea.europa.eu / verfügbar .
T-607	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http : / <<unk>> www . emea . europa . eu/
H-607	-0.17205683887004852	Detailed information on this product is available on the European Medicines Agency ( EMEA ) web site : http : / <unk> www . emea . europa . eu/
D-607	-0.17205683887004852	Detailed information on this product is available on the European Medicines Agency ( EMEA ) web site : http : / <unk> www . emea . europa . eu/
P-607	-0.3384 -0.0574 -0.1227 -0.1378 -0.1197 -1.0655 -0.1535 -0.1348 -0.1189 -0.1422 -0.7489 -0.1597 -0.0772 -0.0844 -0.1835 -0.1230 -0.0844 -0.1125 -0.1483 -0.4725 -0.1180 -0.1368 -0.0444 -0.1453 -0.1712 -0.0340 -0.0963 -0.0534 -0.1515 -0.0407 -0.1236 -0.1449 -0.0179 -0.1310 -0.0338 -0.1230 -0.2151
S-145	Selten : vorübergehende Symptome einer Akute-Phase-Reaktion ( Myalgie , Unwohlsein und selten Fieber ) , üblicherweise bei Therapiebeginn .
T-145	( see section 4.4 ) Rare : transient symptoms as in an acute-phase response ( myalgia , malaise and rarely , fever ) , typically in association with initiation of treatment .
H-145	-0.275214284658432	Rare : transient symptoms of acute phase reaction ( myalgia , malaise , and rarely fever ) , usually at the start of therapy .
D-145	-0.275214284658432	Rare : transient symptoms of acute phase reaction ( myalgia , malaise , and rarely fever ) , usually at the start of therapy .
P-145	-0.2201 -0.1195 -0.1420 -0.1061 -0.0559 -0.8175 -0.1729 -0.1506 -0.4137 -0.0682 -0.0526 -0.1592 -0.1364 -0.1251 -0.1022 -0.0503 -0.1477 -0.2926 -0.0675 -0.9216 -0.1546 -1.3743 -0.0711 -0.0630 -0.1444 -0.3464 -0.2469 -1.1862 -0.1381 -0.6168 -0.1410 -0.2292 -0.1700 -0.1537
S-69	Selten : vorübergehende Symptome einer Akute-Phase-Reaktion ( Myalgie , Unwohlsein und selten Fieber ) , üblicherweise bei Therapiebeginn .
T-69	( see section 4.4 ) Rare : transient symptoms as in an acute-phase response ( myalgia , malaise and rarely , fever ) , typically in association with initiation of treatment .
H-69	-0.275214284658432	Rare : transient symptoms of acute phase reaction ( myalgia , malaise , and rarely fever ) , usually at the start of therapy .
D-69	-0.275214284658432	Rare : transient symptoms of acute phase reaction ( myalgia , malaise , and rarely fever ) , usually at the start of therapy .
P-69	-0.2201 -0.1195 -0.1420 -0.1061 -0.0559 -0.8175 -0.1729 -0.1506 -0.4137 -0.0682 -0.0526 -0.1592 -0.1364 -0.1251 -0.1022 -0.0503 -0.1477 -0.2926 -0.0675 -0.9216 -0.1546 -1.3743 -0.0711 -0.0630 -0.1444 -0.3464 -0.2469 -1.1862 -0.1381 -0.6168 -0.1410 -0.2292 -0.1700 -0.1537
S-802	Ausführliche Informationen zu diesem Arzneimittel sind auf der Website der Europäischen Arzneimittel-Agentur ( EMEA ) http<unk> <unk> <unk> www.emea.europa.eu / verfügbar .
T-802	Detailed information on this medicine is available on the European Medicines Agency ( EMEA ) web site : http : / <<unk>> www . emea . europa . eu/
H-802	-0.17205683887004852	Detailed information on this product is available on the European Medicines Agency ( EMEA ) web site : http : / <unk> www . emea . europa . eu/
D-802	-0.17205683887004852	Detailed information on this product is available on the European Medicines Agency ( EMEA ) web site : http : / <unk> www . emea . europa . eu/
P-802	-0.3384 -0.0574 -0.1227 -0.1378 -0.1197 -1.0655 -0.1535 -0.1348 -0.1189 -0.1422 -0.7489 -0.1597 -0.0772 -0.0844 -0.1835 -0.1230 -0.0844 -0.1125 -0.1483 -0.4725 -0.1180 -0.1368 -0.0444 -0.1453 -0.1712 -0.0340 -0.0963 -0.0534 -0.1515 -0.0407 -0.1236 -0.1449 -0.0179 -0.1310 -0.0338 -0.1230 -0.2151
S-649	Octocog alfa ist ein Glycoprotein , das aus 2332 Aminosäuren mit einem Molekulargewicht von ca. 280 kD besteht .
T-649	Octocog alfa is a glycoprotein consisting of 2332 amino acids with an approximate molecular mass of 280 kD .
H-649	-0.17028126120567322	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of about 280 kD .
D-649	-0.17028126120567322	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of about 280 kD .
P-649	-0.0900 -0.0988 -0.1157 -0.1488 -0.1282 -0.0650 -0.1405 -0.1360 -0.1272 -0.0989 -0.0806 -0.0437 -0.0722 -1.4115 -0.1540 -0.1431 -0.0752 -0.1246 -0.0937 -0.0801 -0.2612 -0.0940 -0.1725 -0.2305 -0.2716 -0.0927 -0.0830 -0.1313 -0.1341 -0.4803 -0.0515 -0.0923 -0.1426 -0.1494 -0.1452
S-283	Ausführliche Informationen zu diesem Arzneimittel sind auf der Website der Europäischen Arzneimittel-Agentur ( EMEA ) http<unk> <unk> <unk> www.emea.europa.eu / verfügbar .
T-283	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http : / <<unk>> www . emea . europa . eu/
H-283	-0.17205683887004852	Detailed information on this product is available on the European Medicines Agency ( EMEA ) web site : http : / <unk> www . emea . europa . eu/
D-283	-0.17205683887004852	Detailed information on this product is available on the European Medicines Agency ( EMEA ) web site : http : / <unk> www . emea . europa . eu/
P-283	-0.3384 -0.0574 -0.1227 -0.1378 -0.1197 -1.0655 -0.1535 -0.1348 -0.1189 -0.1422 -0.7489 -0.1597 -0.0772 -0.0844 -0.1835 -0.1230 -0.0844 -0.1125 -0.1483 -0.4725 -0.1180 -0.1368 -0.0444 -0.1453 -0.1712 -0.0340 -0.0963 -0.0534 -0.1515 -0.0407 -0.1236 -0.1449 -0.0179 -0.1310 -0.0338 -0.1230 -0.2151
S-526	Ausführliche Informationen zu diesem Arzneimittel sind auf der Website der Europäischen Arzneimittel-Agentur ( EMEA ) http<unk> <unk> <unk> www.emea.europa.eu / verfügbar .
T-526	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http : / <<unk>> www . emea . europa . eu/
H-526	-0.17205683887004852	Detailed information on this product is available on the European Medicines Agency ( EMEA ) web site : http : / <unk> www . emea . europa . eu/
D-526	-0.17205683887004852	Detailed information on this product is available on the European Medicines Agency ( EMEA ) web site : http : / <unk> www . emea . europa . eu/
P-526	-0.3384 -0.0574 -0.1227 -0.1378 -0.1197 -1.0655 -0.1535 -0.1348 -0.1189 -0.1422 -0.7489 -0.1597 -0.0772 -0.0844 -0.1835 -0.1230 -0.0844 -0.1125 -0.1483 -0.4725 -0.1180 -0.1368 -0.0444 -0.1453 -0.1712 -0.0340 -0.0963 -0.0534 -0.1515 -0.0407 -0.1236 -0.1449 -0.0179 -0.1310 -0.0338 -0.1230 -0.2151
S-445	Ausführliche Informationen zu diesem Arzneimittel sind auf der Website der Europäischen Arzneimittel-Agentur ( EMEA ) http<unk> <unk> <unk> www.emea.europa.eu / verfügbar .
T-445	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http : / <<unk>> www . emea . europa . eu/
H-445	-0.17205683887004852	Detailed information on this product is available on the European Medicines Agency ( EMEA ) web site : http : / <unk> www . emea . europa . eu/
D-445	-0.17205683887004852	Detailed information on this product is available on the European Medicines Agency ( EMEA ) web site : http : / <unk> www . emea . europa . eu/
P-445	-0.3384 -0.0574 -0.1227 -0.1378 -0.1197 -1.0655 -0.1535 -0.1348 -0.1189 -0.1422 -0.7489 -0.1597 -0.0772 -0.0844 -0.1835 -0.1230 -0.0844 -0.1125 -0.1483 -0.4725 -0.1180 -0.1368 -0.0444 -0.1453 -0.1712 -0.0340 -0.0963 -0.0534 -0.1515 -0.0407 -0.1236 -0.1449 -0.0179 -0.1310 -0.0338 -0.1230 -0.2151
S-364	Ausführliche Informationen zu diesem Arzneimittel sind auf der Website der Europäischen Arzneimittel-Agentur ( EMEA ) http<unk> <unk> <unk> www.emea.europa.eu / verfügbar .
T-364	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http : / <<unk>> www . emea . europa . eu/
H-364	-0.17205683887004852	Detailed information on this product is available on the European Medicines Agency ( EMEA ) web site : http : / <unk> www . emea . europa . eu/
D-364	-0.17205683887004852	Detailed information on this product is available on the European Medicines Agency ( EMEA ) web site : http : / <unk> www . emea . europa . eu/
P-364	-0.3384 -0.0574 -0.1227 -0.1378 -0.1197 -1.0655 -0.1535 -0.1348 -0.1189 -0.1422 -0.7489 -0.1597 -0.0772 -0.0844 -0.1835 -0.1230 -0.0844 -0.1125 -0.1483 -0.4725 -0.1180 -0.1368 -0.0444 -0.1453 -0.1712 -0.0340 -0.0963 -0.0534 -0.1515 -0.0407 -0.1236 -0.1449 -0.0179 -0.1310 -0.0338 -0.1230 -0.2151
S-160	Hinsichtlich der Mittelwerte von Serum-Calcium , Phosphat oder Calcium im 24-Stunden-Harn gab es keine Unterschiede zwischen den Behandlungsgruppen .
T-160	There were no differences in mean serum calcium , phosphate , or 24-hour urine calcium between treatment groups .
H-160	-0.25438928604125977	There were no differences between treatment groups with regard to the mean values of serum calcium , phosphate or calcium in 24 hour urine .
D-160	-0.25438928604125977	There were no differences between treatment groups with regard to the mean values of serum calcium , phosphate or calcium in 24 hour urine .
P-160	-0.1583 -0.2022 -0.0972 -0.0946 -0.2280 -0.3164 -0.0952 -1.1438 -0.2994 -0.1413 -0.9469 -0.9822 -0.1355 -0.1943 -0.0287 -0.1219 -0.1689 -0.0841 -0.1115 -0.1424 -0.0957 -0.0588 -0.1151 -0.1608 -0.0487 -0.0777 -0.1172 -0.1708 -0.7494 -0.7334 -0.1043 -0.2084 -0.1655 -0.1508
S-50	4 Aufgrund der Stimulation der Knochenmineralisation durch Alendronat können Abnahmen des Serum-Calciums und -Phosphats auftreten .
T-50	Due to the positive effects of alendronate in increasing bone mineral , decreases in serum calcium and phosphate may occur .
H-50	-0.2232208549976349	Decreases in serum calcium and phosphate may occur as a result of stimulation of bone mineralisation with alendronate .
D-50	-0.2232208549976349	Decreases in serum calcium and phosphate may occur as a result of stimulation of bone mineralisation with alendronate .
P-50	-1.1112 -0.2597 -0.2471 -0.2060 -0.0280 -0.0954 -0.0837 -0.0904 -0.1051 -0.1296 -0.0847 -0.0693 -0.1235 -0.1088 -0.0629 -0.0989 -0.2291 -0.4470 -0.1353 -0.4514 -0.1093 -0.1399 -0.1016 -0.1007 -0.1407 -0.5647 -1.2480 -0.1406 -0.1456 -0.1398 -0.0726 -0.1440 -0.1517
S-845	Reversible und irreversible MAO-Hemmer können das Risiko für das Auftreten einer Gefäßverengung und einer Hypertonie erhöhen .
T-845	Reversible and irreversible MAO inhibitor<<unk>> s ) may cause : risk of vasoconstriction and increased blood pressure .
H-845	-0.21214556694030762	Reversible and irreversible MAO inhibitors may increase the risk of vessel narrowing and hypertension .
D-845	-0.21214556694030762	Reversible and irreversible MAO inhibitors may increase the risk of vessel narrowing and hypertension .
P-845	-0.1585 -0.0752 -0.1028 -0.1963 -0.0785 -0.1326 -0.0698 -0.0917 -0.1359 -0.5803 -0.1258 -0.0368 -0.0712 -0.1288 -0.0440 -0.0723 -0.1399 -0.1937 -0.2849 -0.8967 -1.4904 -0.0870 -0.1363 -0.0388 -0.0627 -0.1452 -0.1519
2021-01-24 03:25:02 | INFO | fairseq_cli.generate | NOTE: hypothesis and token scores are output in base 2
2021-01-24 03:25:02 | INFO | fairseq_cli.generate | Translated 859 sentences (20462 tokens) in 6.0s (142.30 sentences/s, 3389.66 tokens/s)
2021-01-24 03:25:02 | WARNING | root | That's 100 lines that end in a tokenized period ('.')
2021-01-24 03:25:02 | WARNING | root | It looks like you forgot to detokenize your test data, which may hurt your score.
2021-01-24 03:25:02 | WARNING | root | If you insist your data is detokenized, or don't care, you can suppress this message with '--force'.
Generate test with beam=5: BLEU = 48.08 75.0/55.9/44.2/35.5 (BP = 0.949 ratio = 0.951 hyp_len = 13490 ref_len = 14192)
